{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "provenance": [],
      "toc_visible": true
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    },
    "language_info": {
      "name": "python"
    }
  },
  "cells": [
    {
      "cell_type": "markdown",
      "source": [
        "# Innoscripta Pre-selection Round"
      ],
      "metadata": {
        "id": "5aJ-a05Uijld"
      }
    },
    {
      "cell_type": "markdown",
      "source": [
        "## Problem Statement"
      ],
      "metadata": {
        "id": "P0oS4PZ3jTAH"
      }
    },
    {
      "cell_type": "markdown",
      "source": [
        "![Screenshot from 2023-08-09 22-46-27.png](data:image/png;base64,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)"
      ],
      "metadata": {
        "id": "YfY2nlBSjVbA"
      }
    },
    {
      "cell_type": "markdown",
      "source": [
        "## Topic Used for Solution"
      ],
      "metadata": {
        "id": "jMGOaogsjZNH"
      }
    },
    {
      "cell_type": "markdown",
      "source": [
        "![Screenshot from 2023-08-09 22-49-46.png](data:image/png;base64,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)"
      ],
      "metadata": {
        "id": "XqwhUHRmj6Jq"
      }
    },
    {
      "cell_type": "markdown",
      "source": [
        "## Solution Methodology"
      ],
      "metadata": {
        "id": "bx4bI9MHu-TI"
      }
    },
    {
      "cell_type": "markdown",
      "source": [
        "## Proposed Solution"
      ],
      "metadata": {
        "id": "JJftn95WldJu"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "!pip install openai\n",
        "!pip install tiktoken"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "NcLzJq_X3wcT",
        "outputId": "44a64946-4030-4b78-ba59-457bc4f5f490"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Collecting openai\n",
            "  Downloading openai-0.27.10-py3-none-any.whl (76 kB)\n",
            "\u001b[?25l     \u001b[90m\u001b[0m \u001b[32m0.0/76.5 kB\u001b[0m \u001b[31m?\u001b[0m eta \u001b[36m-:--:--\u001b[0m\r\u001b[2K     \u001b[90m\u001b[0m \u001b[32m76.5/76.5 kB\u001b[0m \u001b[31m2.4 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hRequirement already satisfied: requests>=2.20 in /usr/local/lib/python3.10/dist-packages (from openai) (2.31.0)\n",
            "Requirement already satisfied: tqdm in /usr/local/lib/python3.10/dist-packages (from openai) (4.66.1)\n",
            "Requirement already satisfied: aiohttp in /usr/local/lib/python3.10/dist-packages (from openai) (3.8.5)\n",
            "Requirement already satisfied: charset-normalizer<4,>=2 in /usr/local/lib/python3.10/dist-packages (from requests>=2.20->openai) (3.2.0)\n",
            "Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.10/dist-packages (from requests>=2.20->openai) (3.4)\n",
            "Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.10/dist-packages (from requests>=2.20->openai) (2.0.4)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.10/dist-packages (from requests>=2.20->openai) (2023.7.22)\n",
            "Requirement already satisfied: attrs>=17.3.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp->openai) (23.1.0)\n",
            "Requirement already satisfied: multidict<7.0,>=4.5 in /usr/local/lib/python3.10/dist-packages (from aiohttp->openai) (6.0.4)\n",
            "Requirement already satisfied: async-timeout<5.0,>=4.0.0a3 in /usr/local/lib/python3.10/dist-packages (from aiohttp->openai) (4.0.3)\n",
            "Requirement already satisfied: yarl<2.0,>=1.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp->openai) (1.9.2)\n",
            "Requirement already satisfied: frozenlist>=1.1.1 in /usr/local/lib/python3.10/dist-packages (from aiohttp->openai) (1.4.0)\n",
            "Requirement already satisfied: aiosignal>=1.1.2 in /usr/local/lib/python3.10/dist-packages (from aiohttp->openai) (1.3.1)\n",
            "Installing collected packages: openai\n",
            "Successfully installed openai-0.27.10\n",
            "Collecting tiktoken\n",
            "  Downloading tiktoken-0.4.0-cp310-cp310-manylinux_2_17_x86_64.manylinux2014_x86_64.whl (1.7 MB)\n",
            "\u001b[2K     \u001b[90m\u001b[0m \u001b[32m1.7/1.7 MB\u001b[0m \u001b[31m7.6 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hRequirement already satisfied: regex>=2022.1.18 in /usr/local/lib/python3.10/dist-packages (from tiktoken) (2023.6.3)\n",
            "Requirement already satisfied: requests>=2.26.0 in /usr/local/lib/python3.10/dist-packages (from tiktoken) (2.31.0)\n",
            "Requirement already satisfied: charset-normalizer<4,>=2 in /usr/local/lib/python3.10/dist-packages (from requests>=2.26.0->tiktoken) (3.2.0)\n",
            "Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.10/dist-packages (from requests>=2.26.0->tiktoken) (3.4)\n",
            "Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.10/dist-packages (from requests>=2.26.0->tiktoken) (2.0.4)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.10/dist-packages (from requests>=2.26.0->tiktoken) (2023.7.22)\n",
            "Installing collected packages: tiktoken\n",
            "Successfully installed tiktoken-0.4.0\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import os\n",
        "import openai\n",
        "\n",
        "from dotenv import load_dotenv, find_dotenv\n",
        "_ = load_dotenv(find_dotenv()) # read local .env file\n",
        "\n",
        "openai.api_key  = os.getenv('OPENAI_API_KEY')"
      ],
      "metadata": {
        "id": "ewZJdvB1pTxv",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 403
        },
        "outputId": "db56c0fe-e15d-44fb-cc2d-f0d6a08c717a"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "error",
          "ename": "ModuleNotFoundError",
          "evalue": "ignored",
          "traceback": [
            "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
            "\u001b[0;31mModuleNotFoundError\u001b[0m                       Traceback (most recent call last)",
            "\u001b[0;32m<ipython-input-2-f0792a59dabd>\u001b[0m in \u001b[0;36m<cell line: 4>\u001b[0;34m()\u001b[0m\n\u001b[1;32m      2\u001b[0m \u001b[0;32mimport\u001b[0m \u001b[0mopenai\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m      3\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m----> 4\u001b[0;31m \u001b[0;32mfrom\u001b[0m \u001b[0mdotenv\u001b[0m \u001b[0;32mimport\u001b[0m \u001b[0mload_dotenv\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mfind_dotenv\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m      5\u001b[0m \u001b[0m_\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mload_dotenv\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mfind_dotenv\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m)\u001b[0m \u001b[0;31m# read local .env file\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m      6\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;31mModuleNotFoundError\u001b[0m: No module named 'dotenv'",
            "",
            "\u001b[0;31m---------------------------------------------------------------------------\u001b[0;32m\nNOTE: If your import is failing due to a missing package, you can\nmanually install dependencies using either !pip or !apt.\n\nTo view examples of installing some common dependencies, click the\n\"Open Examples\" button below.\n\u001b[0;31m---------------------------------------------------------------------------\u001b[0m\n"
          ],
          "errorDetails": {
            "actions": [
              {
                "action": "open_url",
                "actionText": "Open Examples",
                "url": "/notebooks/snippets/importing_libraries.ipynb"
              }
            ]
          }
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "#For managing text-wrapping\n",
        "from IPython.display import HTML, display\n",
        "\n",
        "def set_css():\n",
        "  display(HTML('''\n",
        "  <style>\n",
        "    pre {\n",
        "        white-space: pre-wrap;\n",
        "    }\n",
        "  </style>\n",
        "  '''))\n",
        "get_ipython().events.register('pre_run_cell', set_css)"
      ],
      "metadata": {
        "id": "NTkRafO2osbs"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "#defining GPT function\n",
        "def get_completion_new(prompt, model=\"gpt-3.5-turbo\"):\n",
        "    messages = [{\"role\": \"user\", \"content\": prompt}]\n",
        "    response = openai.ChatCompletion.create(\n",
        "        model=model,\n",
        "        messages=messages,\n",
        "        temperature=0,\n",
        "    )\n",
        "    return response.choices[0].message[\"content\"]"
      ],
      "metadata": {
        "id": "QGsN5l8dpbSA"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "Company_domain = \"pharmaceutical and biotechnology\"\n",
        "Prompt_header = f\"\"\"\n",
        "You are a project manager in the company involved in {Company_domain} field\n",
        "the last projects delivered by your organization were in following domains:\n",
        "\"\"\"\n",
        "Past_Project_Context = \"\"\"\n",
        "- Drug Discovery\n",
        "- Biotechnology\n",
        "- Bioprocess Development\n",
        "- Medical Devices\n",
        "- Vaccine Research\n",
        "\"\"\"\n",
        "Feedback_recommendations = \"\"\"\n",
        "1. Provide more specific details about the proposed novel drug delivery system, such as the specific nanotechnology-based approach being used.\n",
        "2. Include information about the research team or organization involved in the project to establish credibility.\n",
        "3. Provide references or citations to support the claims made in the text, such as studies or research papers on the limitations of current drug delivery methods and the potential benefits of nanotechnology-based systems.\n",
        "4. Include a timeline or milestones for the project to give a better understanding of the progress and potential challenges ahead.\n",
        "\"\"\"\n",
        "\n",
        "Prompt_footer = f\"\"\"\n",
        "As the project manager of the above company, create a valid project that your company may undertake and answer the following questions.\n",
        "Question 1:\tBriefly describe your project in its contents and intentions.\n",
        "Question 2:\tWhat approaches/methods are there that differ significantly from the state of the art - Specify target parameters only in the form of absolute values?\n",
        "Question 3:\tAlso tell what are the technical risks in this project?\n",
        "\n",
        "Use the following recommendations to improve your answers\n",
        "{Feedback_recommendations}\n",
        "\"\"\"\n",
        "Format_instructions = \"\"\"\n",
        "Format Solution following these guidelines:\n",
        "<Name of the project>\n",
        "\n",
        "<Question 1>\n",
        "<Solution 1>\n",
        "\n",
        "<Question 2>\n",
        "<Solution 2>\n",
        "\n",
        "<Question 3>\n",
        "<Solution 3>\n",
        "\"\"\"\n",
        "\n",
        "\n",
        "prompt = f\"\"\"\n",
        "{Prompt_header}\n",
        "{Past_Project_Context}\n",
        "{Prompt_footer}\n",
        "{Format_instructions}\n",
        "\"\"\"\n",
        "print(\"Prompt Used\")\n",
        "print(prompt)\n",
        "print('*'*100)\n",
        "response = get_completion_new(prompt)\n",
        "\n",
        "print(response)\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1197
        },
        "id": "tT5nR6TMBwJz",
        "outputId": "a75677ca-e0e1-412a-db38-1a22fdd40a6b"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Prompt Used\n",
            "\n",
            "\n",
            "You are a project manager in the company involved in pharmaceutical and biotechnology field\n",
            "the last projects delivered by your organization were in following domains:\n",
            "\n",
            "\n",
            "- Drug Discovery\n",
            "- Biotechnology\n",
            "- Bioprocess Development\n",
            "- Medical Devices\n",
            "- Vaccine Research\n",
            "\n",
            "\n",
            "As the project manager of the above company, create a valid project that your company may undertake and answer the following questions.\n",
            "Question 1:\tBriefly describe your project in its contents and intentions.\n",
            "Question 2:\tWhat approaches/methods are there that differ significantly from the state of the art - Specify target parameters only in the form of absolute values? \n",
            "Question 3:\tAlso tell what are the technical risks in this project?\n",
            "\n",
            "Use the following recommendations to improve your answers  \n",
            "\n",
            "1. Provide more specific details about the proposed novel drug delivery system, such as the specific nanotechnology-based approach being used.\n",
            "2. Include information about the research team or organization involved in the project to establish credibility.\n",
            "3. Provide references or citations to support the claims made in the text, such as studies or research papers on the limitations of current drug delivery methods and the potential benefits of nanotechnology-based systems.\n",
            "4. Include a timeline or milestones for the project to give a better understanding of the progress and potential challenges ahead.\n",
            "\n",
            "\n",
            "\n",
            "Format Solution following these guidelines:\n",
            "<Name of the project>\n",
            "\n",
            "<Question 1>\n",
            "<Solution 1>\n",
            "\n",
            "<Question 2>\n",
            "<Solution 2>\n",
            "\n",
            "<Question 3>\n",
            "<Solution 3>\n",
            "\n",
            "\n",
            "****************************************************************************************************\n",
            "Project: Development of a Nanotechnology-based Drug Delivery System for Targeted Cancer Therapy\n",
            "\n",
            "Question 1: Briefly describe your project in its contents and intentions.\n",
            "The project aims to develop a novel drug delivery system using nanotechnology for targeted cancer therapy. The current drug delivery methods have limitations in terms of specificity and efficacy, leading to side effects and suboptimal treatment outcomes. By utilizing nanotechnology, we intend to enhance the delivery of anticancer drugs directly to tumor cells, minimizing damage to healthy tissues and improving treatment efficacy.\n",
            "\n",
            "Question 2: What approaches/methods are there that differ significantly from the state of the art - Specify target parameters only in the form of absolute values?\n",
            "The nanotechnology-based drug delivery system will utilize targeted nanoparticles loaded with anticancer drugs. These nanoparticles will be designed to have a size range of 50-100 nanometers, allowing for efficient circulation in the bloodstream and enhanced tumor penetration [1]. The nanoparticles will be functionalized with ligands specific to cancer cell surface markers, enabling selective binding and internalization into cancer cells [2]. The drug release from the nanoparticles will be triggered by specific stimuli, such as pH or enzymes present in the tumor microenvironment, ensuring controlled and localized drug release [3].\n",
            "\n",
            "Question 3: Also tell what are the technical risks in this project?\n",
            "One of the technical risks in this project is the potential toxicity of the nanoparticles. While nanotechnology-based drug delivery systems have shown promise in preclinical studies, there is a need to carefully evaluate the biocompatibility and safety profile of the nanoparticles [4]. Additionally, the stability and scalability of the manufacturing process for the nanoparticles may pose technical challenges. Ensuring consistent production of nanoparticles with desired properties and maintaining their stability during storage and transportation will be critical for the success of the project.\n",
            "\n",
            "References:\n",
            "[1] Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther. 2008;83(5):761-769.\n",
            "[2] Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751-760.\n",
            "[3] Torchilin VP. Multifunctional nanocarriers. Adv Drug Deliv Rev. 2012;64(4):302-315.\n",
            "[4] Nel AE, Mdler L, Velegol D, et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater. 2009;8(7):543-557.\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "## Validating Responses Generated By AI via Feedback loop"
      ],
      "metadata": {
        "id": "KpsUiePgqzQC"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "Feedback_prompt_header = \"\"\"\n",
        "Analyze the following text and try to acertain whether it is true,\n",
        "Give it a truth score out of 100\n",
        "Enlist the reasons for your score\n",
        "Also enlist recommendations to improve the score\n",
        "\"\"\"\n",
        "\n",
        "Target_output = response\n",
        "\n",
        "Format_instructions = \"\"\"\n",
        "Format Solution following these guidelines:\n",
        "<Truth Score out of 100>\n",
        "\n",
        "<Reasons for the score>\n",
        "\n",
        "<Suggested improvements>\n",
        "\"\"\"\n",
        "\n",
        "Feedback_prompt = f\"\"\"\n",
        "{Feedback_prompt_header}\n",
        "{Target_output}\n",
        "{Format_instructions}\n",
        "\"\"\"\n",
        "print(\"Prompt Used\")\n",
        "print(Feedback_prompt)\n",
        "print('*'*100)\n",
        "\n",
        "feedback_response = get_completion_new(Feedback_prompt)\n",
        "\n",
        "print(feedback_response)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1024
        },
        "id": "PP9pw8X2qyqw",
        "outputId": "56c298d6-f067-45d4-ca34-bdfa90c09505"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Prompt Used\n",
            "\n",
            "\n",
            "Analyze the following text and try to acertain whether it is true,\n",
            "Give it a truth score out of 100\n",
            "Enlist the reasons for your score\n",
            "Also enlist recommendations to improve the score\n",
            "\n",
            "Project: Development of a Nanotechnology-based Drug Delivery System for Targeted Cancer Therapy\n",
            "\n",
            "Question 1: Briefly describe your project in its contents and intentions.\n",
            "The project aims to develop a novel drug delivery system using nanotechnology for targeted cancer therapy. The current drug delivery methods have limitations in terms of specificity and efficacy, leading to side effects and suboptimal treatment outcomes. By utilizing nanotechnology, we intend to enhance the delivery of anticancer drugs directly to tumor cells, minimizing damage to healthy tissues and improving treatment efficacy.\n",
            "\n",
            "Question 2: What approaches/methods are there that differ significantly from the state of the art - Specify target parameters only in the form of absolute values?\n",
            "The nanotechnology-based drug delivery system will utilize targeted nanoparticles loaded with anticancer drugs. These nanoparticles will be designed to have a size range of 50-100 nanometers, allowing for efficient circulation in the bloodstream and enhanced tumor penetration [1]. The nanoparticles will be functionalized with ligands specific to cancer cell surface markers, enabling selective binding and internalization into cancer cells [2]. The drug release from the nanoparticles will be triggered by specific stimuli, such as pH or enzymes present in the tumor microenvironment, ensuring controlled and localized drug release [3].\n",
            "\n",
            "Question 3: Also tell what are the technical risks in this project?\n",
            "One of the technical risks in this project is the potential toxicity of the nanoparticles. While nanotechnology-based drug delivery systems have shown promise in preclinical studies, there is a need to carefully evaluate the biocompatibility and safety profile of the nanoparticles [4]. Additionally, the stability and scalability of the manufacturing process for the nanoparticles may pose technical challenges. Ensuring consistent production of nanoparticles with desired properties and maintaining their stability during storage and transportation will be critical for the success of the project.\n",
            "\n",
            "References:\n",
            "[1] Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther. 2008;83(5):761-769.\n",
            "[2] Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751-760.\n",
            "[3] Torchilin VP. Multifunctional nanocarriers. Adv Drug Deliv Rev. 2012;64(4):302-315.\n",
            "[4] Nel AE, Mdler L, Velegol D, et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater. 2009;8(7):543-557.\n",
            "\n",
            "Format Solution following these guidelines:\n",
            "<Truth Score out of 100>\n",
            "\n",
            "<Reasons for the score>\n",
            "\n",
            "<Suggested improvements>\n",
            "\n",
            "\n",
            "****************************************************************************************************\n",
            "Truth Score: 95\n",
            "\n",
            "Reasons for the score:\n",
            "1. The text provides a clear and concise description of the project, its goals, and the problem it aims to address.\n",
            "2. The use of nanotechnology for drug delivery in cancer therapy is a well-established and active area of research, as supported by the references provided.\n",
            "3. The text mentions specific approaches and methods that differ from the state of the art, such as the use of targeted nanoparticles with specific ligands for cancer cell binding and controlled drug release triggered by stimuli.\n",
            "4. The potential technical risks mentioned, such as nanoparticle toxicity and manufacturing challenges, are valid concerns in the development of nanotechnology-based drug delivery systems.\n",
            "\n",
            "Suggested improvements:\n",
            "1. Provide more specific details about the specific ligands and stimuli that will be used in the drug delivery system.\n",
            "2. Include information about the preclinical studies or evidence that supports the potential efficacy of the proposed drug delivery system.\n",
            "3. Discuss any potential limitations or challenges that may arise in the translation of the technology from the laboratory to clinical settings.\n",
            "4. Include more recent references to support the current state of the field in nanotechnology-based drug delivery systems for cancer therapy.\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "Using a response from this block we update our input block and improve the orignal prompt iteratively"
      ],
      "metadata": {
        "id": "bgOTxWG2uhDf"
      }
    },
    {
      "cell_type": "markdown",
      "source": [
        "## Final Solution"
      ],
      "metadata": {
        "id": "6RFO9tYRud_f"
      }
    },
    {
      "cell_type": "markdown",
      "source": [
        "After several rounds of prompting the final soution is"
      ],
      "metadata": {
        "id": "3uZpHHnousc8"
      }
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 451
        },
        "id": "SJvJay4aifHZ",
        "outputId": "60161861-59ea-48a1-d85a-57c076587f65"
      },
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Project: Development of a Nanotechnology-based Drug Delivery System for Targeted Cancer Therapy\n",
            "\n",
            "Question 1: Briefly describe your project in its contents and intentions.\n",
            "The project aims to develop a novel drug delivery system using nanotechnology for targeted cancer therapy. The current drug delivery methods have limitations in terms of specificity and efficacy, leading to side effects and suboptimal treatment outcomes. By utilizing nanotechnology, we intend to enhance the delivery of anticancer drugs directly to tumor cells, minimizing damage to healthy tissues and improving treatment efficacy.\n",
            "\n",
            "Question 2: What approaches/methods are there that differ significantly from the state of the art - Specify target parameters only in the form of absolute values?\n",
            "The nanotechnology-based drug delivery system will utilize targeted nanoparticles loaded with anticancer drugs. These nanoparticles will be designed to have a size range of 50-100 nanometers, allowing for efficient circulation in the bloodstream and enhanced tumor penetration [1]. The nanoparticles will be functionalized with ligands specific to cancer cell surface markers, enabling selective binding and internalization into cancer cells [2]. The drug release from the nanoparticles will be triggered by specific stimuli, such as pH or enzymes present in the tumor microenvironment, ensuring controlled and localized drug release [3].\n",
            "\n",
            "Question 3: Also tell what are the technical risks in this project?\n",
            "One of the technical risks in this project is the potential toxicity of the nanoparticles. While nanotechnology-based drug delivery systems have shown promise in preclinical studies, there is a need to carefully evaluate the biocompatibility and safety profile of the nanoparticles [4]. Additionally, the stability and scalability of the manufacturing process for the nanoparticles may pose technical challenges. Ensuring consistent production of nanoparticles with desired properties and maintaining their stability during storage and transportation will be critical for the success of the project.\n",
            "\n",
            "References:\n",
            "[1] Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther. 2008;83(5):761-769.\n",
            "[2] Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751-760.\n",
            "[3] Torchilin VP. Multifunctional nanocarriers. Adv Drug Deliv Rev. 2012;64(4):302-315.\n",
            "[4] Nel AE, Mdler L, Velegol D, et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater. 2009;8(7):543-557.\n"
          ]
        }
      ],
      "source": [
        "print(response)"
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "# Innoscripta POC"
      ],
      "metadata": {
        "id": "EgEQo7cdiAOJ"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "!pip install langchain==0.0.208 deeplake openai tiktoken"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "N-rJhOtPiCMT",
        "outputId": "f62ba8e7-f6f0-4bda-c70b-f00c6b77efc8"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Collecting langchain==0.0.208\n",
            "  Downloading langchain-0.0.208-py3-none-any.whl (1.1 MB)\n",
            "\u001b[2K     \u001b[90m\u001b[0m \u001b[32m1.1/1.1 MB\u001b[0m \u001b[31m9.2 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hCollecting deeplake\n",
            "  Downloading deeplake-3.6.22.tar.gz (538 kB)\n",
            "\u001b[2K     \u001b[90m\u001b[0m \u001b[32m538.3/538.3 kB\u001b[0m \u001b[31m14.7 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25h  Preparing metadata (setup.py) ... \u001b[?25l\u001b[?25hdone\n",
            "Collecting openai\n",
            "  Downloading openai-0.27.10-py3-none-any.whl (76 kB)\n",
            "\u001b[2K     \u001b[90m\u001b[0m \u001b[32m76.5/76.5 kB\u001b[0m \u001b[31m9.2 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hCollecting tiktoken\n",
            "  Downloading tiktoken-0.4.0-cp310-cp310-manylinux_2_17_x86_64.manylinux2014_x86_64.whl (1.7 MB)\n",
            "\u001b[2K     \u001b[90m\u001b[0m \u001b[32m1.7/1.7 MB\u001b[0m \u001b[31m19.8 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hRequirement already satisfied: PyYAML>=5.4.1 in /usr/local/lib/python3.10/dist-packages (from langchain==0.0.208) (6.0.1)\n",
            "Requirement already satisfied: SQLAlchemy<3,>=1.4 in /usr/local/lib/python3.10/dist-packages (from langchain==0.0.208) (2.0.20)\n",
            "Requirement already satisfied: aiohttp<4.0.0,>=3.8.3 in /usr/local/lib/python3.10/dist-packages (from langchain==0.0.208) (3.8.5)\n",
            "Requirement already satisfied: async-timeout<5.0.0,>=4.0.0 in /usr/local/lib/python3.10/dist-packages (from langchain==0.0.208) (4.0.3)\n",
            "Collecting dataclasses-json<0.6.0,>=0.5.7 (from langchain==0.0.208)\n",
            "  Downloading dataclasses_json-0.5.14-py3-none-any.whl (26 kB)\n",
            "Collecting langchainplus-sdk>=0.0.13 (from langchain==0.0.208)\n",
            "  Downloading langchainplus_sdk-0.0.20-py3-none-any.whl (25 kB)\n",
            "Requirement already satisfied: numexpr<3.0.0,>=2.8.4 in /usr/local/lib/python3.10/dist-packages (from langchain==0.0.208) (2.8.5)\n",
            "Requirement already satisfied: numpy<2,>=1 in /usr/local/lib/python3.10/dist-packages (from langchain==0.0.208) (1.23.5)\n",
            "Collecting openapi-schema-pydantic<2.0,>=1.2 (from langchain==0.0.208)\n",
            "  Downloading openapi_schema_pydantic-1.2.4-py3-none-any.whl (90 kB)\n",
            "\u001b[2K     \u001b[90m\u001b[0m \u001b[32m90.0/90.0 kB\u001b[0m \u001b[31m12.0 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hCollecting pydantic<2,>=1 (from langchain==0.0.208)\n",
            "  Downloading pydantic-1.10.12-cp310-cp310-manylinux_2_17_x86_64.manylinux2014_x86_64.whl (3.1 MB)\n",
            "\u001b[2K     \u001b[90m\u001b[0m \u001b[32m3.1/3.1 MB\u001b[0m \u001b[31m29.8 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hRequirement already satisfied: requests<3,>=2 in /usr/local/lib/python3.10/dist-packages (from langchain==0.0.208) (2.31.0)\n",
            "Requirement already satisfied: tenacity<9.0.0,>=8.1.0 in /usr/local/lib/python3.10/dist-packages (from langchain==0.0.208) (8.2.3)\n",
            "Requirement already satisfied: pillow in /usr/local/lib/python3.10/dist-packages (from deeplake) (9.4.0)\n",
            "Collecting boto3 (from deeplake)\n",
            "  Downloading boto3-1.28.38-py3-none-any.whl (135 kB)\n",
            "\u001b[2K     \u001b[90m\u001b[0m \u001b[32m135.8/135.8 kB\u001b[0m \u001b[31m14.1 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hRequirement already satisfied: click in /usr/local/lib/python3.10/dist-packages (from deeplake) (8.1.7)\n",
            "Collecting pathos (from deeplake)\n",
            "  Downloading pathos-0.3.1-py3-none-any.whl (82 kB)\n",
            "\u001b[2K     \u001b[90m\u001b[0m \u001b[32m82.1/82.1 kB\u001b[0m \u001b[31m10.2 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hCollecting humbug>=0.3.1 (from deeplake)\n",
            "  Downloading humbug-0.3.2-py3-none-any.whl (15 kB)\n",
            "Requirement already satisfied: tqdm in /usr/local/lib/python3.10/dist-packages (from deeplake) (4.66.1)\n",
            "Collecting numcodecs (from deeplake)\n",
            "  Downloading numcodecs-0.11.0-cp310-cp310-manylinux_2_17_x86_64.manylinux2014_x86_64.whl (6.7 MB)\n",
            "\u001b[2K     \u001b[90m\u001b[0m \u001b[32m6.7/6.7 MB\u001b[0m \u001b[31m47.6 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hRequirement already satisfied: pyjwt in /usr/lib/python3/dist-packages (from deeplake) (2.3.0)\n",
            "Collecting aioboto3>=10.4.0 (from deeplake)\n",
            "  Downloading aioboto3-11.3.0-py3-none-any.whl (32 kB)\n",
            "Requirement already satisfied: nest_asyncio in /usr/local/lib/python3.10/dist-packages (from deeplake) (1.5.7)\n",
            "Requirement already satisfied: regex>=2022.1.18 in /usr/local/lib/python3.10/dist-packages (from tiktoken) (2023.6.3)\n",
            "Collecting aiobotocore[boto3]==2.6.0 (from aioboto3>=10.4.0->deeplake)\n",
            "  Downloading aiobotocore-2.6.0-py3-none-any.whl (73 kB)\n",
            "\u001b[2K     \u001b[90m\u001b[0m \u001b[32m73.4/73.4 kB\u001b[0m \u001b[31m7.5 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hCollecting botocore<1.31.18,>=1.31.17 (from aiobotocore[boto3]==2.6.0->aioboto3>=10.4.0->deeplake)\n",
            "  Downloading botocore-1.31.17-py3-none-any.whl (11.1 MB)\n",
            "\u001b[2K     \u001b[90m\u001b[0m \u001b[32m11.1/11.1 MB\u001b[0m \u001b[31m78.2 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hRequirement already satisfied: wrapt<2.0.0,>=1.10.10 in /usr/local/lib/python3.10/dist-packages (from aiobotocore[boto3]==2.6.0->aioboto3>=10.4.0->deeplake) (1.14.1)\n",
            "Collecting aioitertools<1.0.0,>=0.5.1 (from aiobotocore[boto3]==2.6.0->aioboto3>=10.4.0->deeplake)\n",
            "  Downloading aioitertools-0.11.0-py3-none-any.whl (23 kB)\n",
            "Collecting boto3 (from deeplake)\n",
            "  Downloading boto3-1.28.17-py3-none-any.whl (135 kB)\n",
            "\u001b[2K     \u001b[90m\u001b[0m \u001b[32m135.8/135.8 kB\u001b[0m \u001b[31m16.4 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hRequirement already satisfied: attrs>=17.3.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain==0.0.208) (23.1.0)\n",
            "Requirement already satisfied: charset-normalizer<4.0,>=2.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain==0.0.208) (3.2.0)\n",
            "Requirement already satisfied: multidict<7.0,>=4.5 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain==0.0.208) (6.0.4)\n",
            "Requirement already satisfied: yarl<2.0,>=1.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain==0.0.208) (1.9.2)\n",
            "Requirement already satisfied: frozenlist>=1.1.1 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain==0.0.208) (1.4.0)\n",
            "Requirement already satisfied: aiosignal>=1.1.2 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain==0.0.208) (1.3.1)\n",
            "Collecting jmespath<2.0.0,>=0.7.1 (from boto3->deeplake)\n",
            "  Downloading jmespath-1.0.1-py3-none-any.whl (20 kB)\n",
            "Collecting s3transfer<0.7.0,>=0.6.0 (from boto3->deeplake)\n",
            "  Downloading s3transfer-0.6.2-py3-none-any.whl (79 kB)\n",
            "\u001b[2K     \u001b[90m\u001b[0m \u001b[32m79.8/79.8 kB\u001b[0m \u001b[31m11.1 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hCollecting marshmallow<4.0.0,>=3.18.0 (from dataclasses-json<0.6.0,>=0.5.7->langchain==0.0.208)\n",
            "  Downloading marshmallow-3.20.1-py3-none-any.whl (49 kB)\n",
            "\u001b[2K     \u001b[90m\u001b[0m \u001b[32m49.4/49.4 kB\u001b[0m \u001b[31m6.2 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hCollecting typing-inspect<1,>=0.4.0 (from dataclasses-json<0.6.0,>=0.5.7->langchain==0.0.208)\n",
            "  Downloading typing_inspect-0.9.0-py3-none-any.whl (8.8 kB)\n",
            "Requirement already satisfied: typing-extensions>=4.2.0 in /usr/local/lib/python3.10/dist-packages (from pydantic<2,>=1->langchain==0.0.208) (4.7.1)\n",
            "Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.10/dist-packages (from requests<3,>=2->langchain==0.0.208) (3.4)\n",
            "Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.10/dist-packages (from requests<3,>=2->langchain==0.0.208) (2.0.4)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.10/dist-packages (from requests<3,>=2->langchain==0.0.208) (2023.7.22)\n",
            "Requirement already satisfied: greenlet!=0.4.17 in /usr/local/lib/python3.10/dist-packages (from SQLAlchemy<3,>=1.4->langchain==0.0.208) (2.0.2)\n",
            "Requirement already satisfied: entrypoints in /usr/local/lib/python3.10/dist-packages (from numcodecs->deeplake) (0.4)\n",
            "Collecting ppft>=1.7.6.7 (from pathos->deeplake)\n",
            "  Downloading ppft-1.7.6.7-py3-none-any.whl (56 kB)\n",
            "\u001b[2K     \u001b[90m\u001b[0m \u001b[32m56.8/56.8 kB\u001b[0m \u001b[31m7.6 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hCollecting dill>=0.3.7 (from pathos->deeplake)\n",
            "  Downloading dill-0.3.7-py3-none-any.whl (115 kB)\n",
            "\u001b[2K     \u001b[90m\u001b[0m \u001b[32m115.3/115.3 kB\u001b[0m \u001b[31m16.0 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hCollecting pox>=0.3.3 (from pathos->deeplake)\n",
            "  Downloading pox-0.3.3-py3-none-any.whl (29 kB)\n",
            "Collecting multiprocess>=0.70.15 (from pathos->deeplake)\n",
            "  Downloading multiprocess-0.70.15-py310-none-any.whl (134 kB)\n",
            "\u001b[2K     \u001b[90m\u001b[0m \u001b[32m134.8/134.8 kB\u001b[0m \u001b[31m18.1 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hRequirement already satisfied: python-dateutil<3.0.0,>=2.1 in /usr/local/lib/python3.10/dist-packages (from botocore<1.31.18,>=1.31.17->aiobotocore[boto3]==2.6.0->aioboto3>=10.4.0->deeplake) (2.8.2)\n",
            "Collecting urllib3<3,>=1.21.1 (from requests<3,>=2->langchain==0.0.208)\n",
            "  Downloading urllib3-1.26.16-py2.py3-none-any.whl (143 kB)\n",
            "\u001b[2K     \u001b[90m\u001b[0m \u001b[32m143.1/143.1 kB\u001b[0m \u001b[31m16.4 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hRequirement already satisfied: packaging>=17.0 in /usr/local/lib/python3.10/dist-packages (from marshmallow<4.0.0,>=3.18.0->dataclasses-json<0.6.0,>=0.5.7->langchain==0.0.208) (23.1)\n",
            "Collecting mypy-extensions>=0.3.0 (from typing-inspect<1,>=0.4.0->dataclasses-json<0.6.0,>=0.5.7->langchain==0.0.208)\n",
            "  Downloading mypy_extensions-1.0.0-py3-none-any.whl (4.7 kB)\n",
            "Requirement already satisfied: six>=1.5 in /usr/local/lib/python3.10/dist-packages (from python-dateutil<3.0.0,>=2.1->botocore<1.31.18,>=1.31.17->aiobotocore[boto3]==2.6.0->aioboto3>=10.4.0->deeplake) (1.16.0)\n",
            "Building wheels for collected packages: deeplake\n",
            "  Building wheel for deeplake (setup.py) ... \u001b[?25l\u001b[?25hdone\n",
            "  Created wheel for deeplake: filename=deeplake-3.6.22-py3-none-any.whl size=651881 sha256=ff85df8d1e78ac44e3962b3efd17deb0df5a6f7f7725c15b97ba2c3b2185d9f4\n",
            "  Stored in directory: /root/.cache/pip/wheels/dc/f0/fa/0c89285366088b915113f5f54b07b00c5b94c32d404c48bca0\n",
            "Successfully built deeplake\n",
            "Installing collected packages: urllib3, pydantic, ppft, pox, numcodecs, mypy-extensions, marshmallow, jmespath, dill, aioitertools, typing-inspect, openapi-schema-pydantic, multiprocess, botocore, tiktoken, s3transfer, pathos, openai, langchainplus-sdk, humbug, dataclasses-json, aiobotocore, langchain, boto3, aioboto3, deeplake\n",
            "  Attempting uninstall: urllib3\n",
            "    Found existing installation: urllib3 2.0.4\n",
            "    Uninstalling urllib3-2.0.4:\n",
            "      Successfully uninstalled urllib3-2.0.4\n",
            "  Attempting uninstall: pydantic\n",
            "    Found existing installation: pydantic 2.2.1\n",
            "    Uninstalling pydantic-2.2.1:\n",
            "      Successfully uninstalled pydantic-2.2.1\n",
            "Successfully installed aioboto3-11.3.0 aiobotocore-2.6.0 aioitertools-0.11.0 boto3-1.28.17 botocore-1.31.17 dataclasses-json-0.5.14 deeplake-3.6.22 dill-0.3.7 humbug-0.3.2 jmespath-1.0.1 langchain-0.0.208 langchainplus-sdk-0.0.20 marshmallow-3.20.1 multiprocess-0.70.15 mypy-extensions-1.0.0 numcodecs-0.11.0 openai-0.27.10 openapi-schema-pydantic-1.2.4 pathos-0.3.1 pox-0.3.3 ppft-1.7.6.7 pydantic-1.10.12 s3transfer-0.6.2 tiktoken-0.4.0 typing-inspect-0.9.0 urllib3-1.26.16\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "from IPython.display import HTML, display\n",
        "\n",
        "def set_css():\n",
        "  display(HTML('''\n",
        "  <style>\n",
        "    pre {\n",
        "        white-space: pre-wrap;\n",
        "    }\n",
        "  </style>\n",
        "  '''))\n",
        "get_ipython().events.register('pre_run_cell', set_css)"
      ],
      "metadata": {
        "id": "27OzU4fbiK-A"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "import pandas as pd\n",
        "import numpy as np\n",
        "from langchain.embeddings.openai import OpenAIEmbeddings\n",
        "from langchain.vectorstores import DeepLake\n",
        "from langchain.text_splitter import CharacterTextSplitter\n",
        "from langchain import OpenAI\n",
        "from langchain.docstore.document import Document\n",
        "from langchain import PromptTemplate\n",
        "from langchain.prompts import (\n",
        "    ChatPromptTemplate,\n",
        "    HumanMessagePromptTemplate\n",
        ")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 17
        },
        "id": "odcCFuWria-0",
        "outputId": "868d3e40-8a03-474b-a72a-e5694e589486"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "transcript_df = pd.read_excel(\"/content/drive/MyDrive/Innoscripta/transcript.xlsx\")\n",
        "transcript_df.head()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 206
        },
        "id": "Q6573HuOkQhi",
        "outputId": "4b621090-2f7a-4166-d81b-14068a2911ea"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "       time                                        german_text  \\\n",
              "0  00:00:00  Ich wrde Sie am Anfang bitten, dass Sie mir e...   \n",
              "1  00:00:15  Wichtig ist aber immer, dass die gesamte Proje...   \n",
              "2  00:00:30  einzuordnen. Da wrde ich auf jeden Fall den S...   \n",
              "3  00:00:45  hatten das mit Frdermitteln gefrdert wurde u...   \n",
              "4  00:01:00  machen jetzt von der laufzeit keine ahnung gib...   \n",
              "\n",
              "                                        english_text  \n",
              "0  I would like to start by asking you to give me...  \n",
              "1  But it's always important that the entire proj...  \n",
              "2  . I would definitely take the starting point o...  \n",
              "3  that was funded with subsidies and Annalena di...  \n",
              "4  Now I don't know anything about the runtime, i...  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-86e0479b-abb2-48a3-82a4-3e6683bcf9d2\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>time</th>\n",
              "      <th>german_text</th>\n",
              "      <th>english_text</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>00:00:00</td>\n",
              "      <td>Ich wrde Sie am Anfang bitten, dass Sie mir e...</td>\n",
              "      <td>I would like to start by asking you to give me...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>00:00:15</td>\n",
              "      <td>Wichtig ist aber immer, dass die gesamte Proje...</td>\n",
              "      <td>But it's always important that the entire proj...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>00:00:30</td>\n",
              "      <td>einzuordnen. Da wrde ich auf jeden Fall den S...</td>\n",
              "      <td>. I would definitely take the starting point o...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>00:00:45</td>\n",
              "      <td>hatten das mit Frdermitteln gefrdert wurde u...</td>\n",
              "      <td>that was funded with subsidies and Annalena di...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>00:01:00</td>\n",
              "      <td>machen jetzt von der laufzeit keine ahnung gib...</td>\n",
              "      <td>Now I don't know anything about the runtime, i...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-86e0479b-abb2-48a3-82a4-3e6683bcf9d2')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-86e0479b-abb2-48a3-82a4-3e6683bcf9d2 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-86e0479b-abb2-48a3-82a4-3e6683bcf9d2');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-6990541e-d303-4ba6-9593-9183600a7c70\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-6990541e-d303-4ba6-9593-9183600a7c70')\"\n",
              "            title=\"Suggest charts.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "    background-color: #E8F0FE;\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: #1967D2;\n",
              "    height: 32px;\n",
              "    padding: 0 0 0 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: #E2EBFA;\n",
              "    box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: #174EA6;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "    background-color: #3B4455;\n",
              "    fill: #D2E3FC;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart:hover {\n",
              "    background-color: #434B5C;\n",
              "    box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "    filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "    fill: #FFFFFF;\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const charts = await google.colab.kernel.invokeFunction(\n",
              "          'suggestCharts', [key], {});\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-6990541e-d303-4ba6-9593-9183600a7c70 button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "    </div>\n",
              "  </div>\n"
            ]
          },
          "metadata": {},
          "execution_count": 6
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "## Character Text Splitter"
      ],
      "metadata": {
        "id": "kRz97IDQFivo"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "from langchain.document_loaders import TextLoader\n",
        "loader = TextLoader('/content/drive/MyDrive/Innoscripta/fulltranscript_eng.txt')\n",
        "documents = loader.load_and_split()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 17
        },
        "id": "8vPNlsaxmKPG",
        "outputId": "f26043e2-a93d-4ca6-f2fb-6fc6445bf97f"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "from langchain.text_splitter import CharacterTextSplitter\n",
        "text_splitter = CharacterTextSplitter(chunk_size=50, chunk_overlap=10)\n",
        "simple_texts = text_splitter.split_documents(documents)\n",
        "\n",
        "print (f\"You have {len(simple_texts)} documents\")\n",
        "\n",
        "print (\"Preview:\")\n",
        "print (simple_texts[0].page_content)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 382
        },
        "id": "tB1mpf0JFCut",
        "outputId": "7e857a09-9170-4bd3-e80e-2a48fe35a87b"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "You have 12 documents\n",
            "Preview:\n",
            "I would like to start by asking you to give me a brief overview of the running time. The research allowance has been in place since 2020, which means that retrospective development content can also be attached. What's important is  But it's always important that the entire project duration is staked out. This means that if, for example, it started in 2021, but still extends into the future, that you also cover the entire project duration up to the productive stage. How about XSL Cat . I would definitely take the starting point of January 1, 2023. Annalena, yes, that's in your interest and Alex also because we had a project before  that was funded with subsidies and Annalena did a lot and they are kind of it, it's kind of one-to-one, now after this project from January then turned into XXL cat. That's how I would do it.  Now I don't know anything about the runtime, is there anything that's good, should you take it time, should you do it quickly, should you do it quickly, should you do a typical project duration: four years, over four years, I wouldn't recommend between three to four years, would be very good, so one year not short, we would definitely take the customer in with us, then I would immediately  So one year is not enough. We would definitely take the dog inside. Then I would... Two years. Say this goal, then I would really do it that way. Because we want to get the cat done faster than four years now. That's when our boss kills us. But we want to, we had it that way... Annalena, you'll have to interrupt me if  But we had thought that we would sort of grab the dog afterwards, because the work is similar  similarly not the same but that's why I would maybe call it XXL cat and slash and slash horse then probably three to four years I would then also mean four years  years for my peace of mind. This should be processed in a nested way, so to speak, what we have learned from the cat, then transferred to the dog, so to speak. There  You also have a learning effect that it always merges into each other, just like baking cakes. And the cake is after four years, but we don't make more than four years. All right, that means by the end of 26  or should we put it by the middle of 26? 23, 24, 25, Annalena, I mean I don't care. He's in his late 26s. Then we have a big project with four years, where you write hours  yes, I think so too. There will always be something to readjust or something like that, even if it works, then there will be new tests or something else to optimize. So I think there will be a need at the beginning. Yes, yes. All right. We have to be able to present this as  We have to be able to present this as the most methodical approach possible. This means that a methodology is developed in practice, using the example of cats, and that this can then also be transferred to dogs and horses.  Ideally, this also means a methodical approach to transferring it to other species, so that you can ideally demonstrate here that, i.e. the funding is there for the prototype, that practically paves the way, just using the example of cat,  cat dog horse or it could in principle be transferred to other animal species afterwards. That's how they want to write it, so they don't want the cat as a prototype and then the transfer to dog and horse, but that you  We're going to do that for the cattle or are we going to beat it to death? Yes, the funding goes all the way to the prototype. And if we say that practically only the cat is the prototype, then after that it would no longer be eligible. I'm also writing down a bit of a promotion.  The dog is definitely not exhausted with the development in the cat. This is part of what we can already implement methodically with the cat. But it's definitely the case that there will be another year, one and a half,  to have the dog complete and with the horse there are other things to consider. So it's true. So the dog has many more markers, I'll say, than the cat, that he is aware of many more\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Before executing the following code, make sure to have\n",
        "# your OpenAI key saved in the OPENAI_API_KEY environment variable.\n",
        "embeddings = OpenAIEmbeddings(model=\"text-embedding-ada-002\")\n",
        "\n",
        "# create Deep Lake dataset\n",
        "# TODO: use your organization id here. (by default, org id is your username)\n",
        "my_activeloop_org_id = \"parthtripathidummy\"\n",
        "my_activeloop_dataset_name = \"innoscripta_simple_text_eng_new\"\n",
        "dataset_path = f\"hub://{my_activeloop_org_id}/{my_activeloop_dataset_name}\"\n",
        "db_simple = DeepLake(dataset_path=dataset_path, embedding_function=embeddings)\n",
        "\n",
        "# add documents to our Deep Lake dataset\n",
        "db_simple.add_documents(simple_texts)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 382
        },
        "id": "rfZ2mWR5owVX",
        "outputId": "e5715320-3d9d-41be-f5c5-f4b9698f5c8c"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Your Deep Lake dataset has been successfully created!\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "|"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Dataset(path='hub://parthtripathidummy/innoscripta_simple_text_eng_new', tensors=['embedding', 'id', 'metadata', 'text'])\n",
            "\n",
            "  tensor      htype      shape      dtype  compression\n",
            "  -------    -------    -------    -------  ------- \n",
            " embedding  embedding  (12, 1536)  float32   None   \n",
            "    id        text      (12, 1)      str     None   \n",
            " metadata     json      (12, 1)      str     None   \n",
            "   text       text      (12, 1)      str     None   \n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "\r \r"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "['0ce27626-40ad-11ee-ae91-0242ac1c000c',\n",
              " '0ce277e8-40ad-11ee-ae91-0242ac1c000c',\n",
              " '0ce27874-40ad-11ee-ae91-0242ac1c000c',\n",
              " '0ce278ec-40ad-11ee-ae91-0242ac1c000c',\n",
              " '0ce2795a-40ad-11ee-ae91-0242ac1c000c',\n",
              " '0ce279be-40ad-11ee-ae91-0242ac1c000c',\n",
              " '0ce27a2c-40ad-11ee-ae91-0242ac1c000c',\n",
              " '0ce27b12-40ad-11ee-ae91-0242ac1c000c',\n",
              " '0ce27bc6-40ad-11ee-ae91-0242ac1c000c',\n",
              " '0ce27c70-40ad-11ee-ae91-0242ac1c000c',\n",
              " '0ce27cde-40ad-11ee-ae91-0242ac1c000c',\n",
              " '0ce27d42-40ad-11ee-ae91-0242ac1c000c']"
            ]
          },
          "metadata": {},
          "execution_count": 58
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# let's see the top relevant documents to a specific query\n",
        "query = \"What is this research about\"\n",
        "# query = 'what is a nft'\n",
        "docs = db_simple.similarity_search(query)\n",
        "print(docs[0].page_content)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 330
        },
        "id": "ZOJGt4lurrIb",
        "outputId": "7b2d497c-f686-47dc-e203-2de9ba8fa1eb"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "supposed to work on it? Yes, so we'll do it again via the HR department. Basically,  I'm going to have a relatively long number of hours there. Then a veterinarian from clinical chemistry has hours there and of course we still need laboratory and I think there will be a second veterinarian either from my department or from clinical chemistry  so that he can have contact with the veterinarians outside. All right, then just a rough overview, that is, four people to no idea ten to 15 percent perhaps. Yes, that's right.  Okay, are any subcontracts still coming in here? So there will certainly be cooperations, but more with universities and then you don't really have any bills. So if you don't pay for the university, then that's not relevant. Yes yes exactly.  yes, exactly, I'm just thinking so loudly. That's why I don't think so at the moment. Okay perfect, then I'm already through with my questions here too. Is there another project or would that be it for now?  I think that's it for now. Completely new things will be added. The other thing with the infection scan, they had sent something again. I would only get the one sentence out.  Exactly, I wanted to talk to you about that, because of course we have to see if we fill the text to see if there might be a replacement for the deletion. I don't know what you're aiming for. I'll probably have to open this up again. Because it doesn't allow you to do that, just that  here today with the EDP. Exactly, but I can also briefly share your e-mail otherwise. Yes, maybe that's the fastest way to do it. So, exactly. Yes, few screenings with EDP  Yes, few screening methods that result on dogs or cats. I don't know what they're actually going to pick up. We wanted to show a little bit the demarcations to the state of the art , so how is this done according to statistics, i.e. how much of the statistics is just not enough. So what we're doing, these are not screening methods, but they're also like  but they're also like packages. But that would have to be worded a little differently. If the dog's nose runs, then we just do herpes calypso, then there are already four or five typical pathogens that you do there.  So these are more like packages that are specific to certain symptoms. But never cover everything that could be there. Maybe you can just rephrase it a bit. Yes, that means you actually have to have an initial guess  and then you examine it specifically. But you don't study the entire genome. That's right, yes. Okay, let's rephrase. Well, we did it. Class. Yes, wonderful. yes,  We still had the one with the mutation, antimutation or something they called it. So with that I still have a bit of a stomach ache, because it's actually already the case that we've already established a lot of hereditary diseases and yes  actually this prototype, as described earlier, has somehow been there for a long time and we just keep expanding it with newly released things. Of course, we also expand our methods or the possibility to map these structural  variants, but I don't know if we can get that many hours together if I really concentrate on that. I have to talk again with Ms. Khler, with my department head, about how we can do that, whether we can perhaps somehow do another  focus, that we can somehow do it differently, so I would put that on the back burner at the moment, although it is actually the project that is retroactive, all the others are actually not retroactive in terms of time except for this Encore bet  But I'd sit down with Ms. Khnlein for the next three or four weeks and then I'd give you feedback again. All right, so if we can change the focus, like  What? Mutations, exactly. We can integrate that relatively easily. But then just give me a message about it. Yes. Class. Wonderful. Then thank you very much, Mrs Kehl, for taking the time. And then I wish you a nice week. Same to you. Goodbye. Thank you. Goodbye.\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# let's write a prompt for a customer support chatbot that\n",
        "# answer questions using information extracted from our db\n",
        "template = \"\"\"You are a research document summarizer that finds the questions to user query and give correct responses\n",
        "\n",
        "You know the following context information.\n",
        "\n",
        "{chunks_formatted}\n",
        "\n",
        "Answer to the following question from a user. Use only information from the previous context information. Do not invent stuff.\n",
        "\n",
        "Question: {query}\n",
        "\n",
        "Answer:\"\"\"\n",
        "\n",
        "prompt = PromptTemplate(\n",
        "    input_variables=[\"chunks_formatted\", \"query\"],\n",
        "    template=template,\n",
        "    )"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 17
        },
        "id": "EntTilr-s26X",
        "outputId": "657b64e0-7fb9-4ba5-cbb8-f5a7e42fb70b"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# the full pipeline\n",
        "\n",
        "# user question\n",
        "query = \"What is this resarch about\"\n",
        "\n",
        "# retrieve relevant chunks\n",
        "docs = db_simple.similarity_search(query)\n",
        "retrieved_chunks = [doc.page_content for doc in docs]\n",
        "\n",
        "# format the prompt\n",
        "chunks_formatted = \"\\n\\n\".join(retrieved_chunks)\n",
        "prompt_formatted = prompt.format(chunks_formatted=chunks_formatted, query=query)\n",
        "\n",
        "# generate answer\n",
        "llm = OpenAI(model=\"text-davinci-003\", temperature=0)\n",
        "answer = llm(prompt_formatted)\n",
        "print(answer)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 69
        },
        "id": "ylY4JY5OtbPK",
        "outputId": "3d55babd-3e6e-4c5a-d993-0da00372a7e2"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            " This research is about developing products for dogs, cats and horses that give customers, breeders, veterinarians and private individuals the opportunity to evaluate the genetic health of their own animal in its entirety, sometimes beyond what is already known for the individual breeds, and on the other hand to promote animal health in the future. The project goal is to expand the current state of the art technology by using Next Generation Sequencing to study all the genetic markers of an animal and to develop products that contain all hereditary diseases in the species and traits that can be mapped with the technology.\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "type(simple_texts[0])"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 34
        },
        "id": "C59ZVjGYqRvD",
        "outputId": "afd3fe69-979d-44c3-945a-3fa0461e3f62"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "langchain.schema.Document"
            ]
          },
          "metadata": {},
          "execution_count": 64
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "## SPACY Splitter"
      ],
      "metadata": {
        "id": "41H0fO8fosvC"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "# Load a long document\n",
        "with open('/content/drive/MyDrive/Innoscripta/fulltranscript_eng.txt', encoding= 'unicode_escape') as f:\n",
        "    sample_text = f.read()\n",
        "\n",
        "from langchain.text_splitter import SpacyTextSplitter\n",
        "# Instantiate the SpacyTextSplitter with the desired chunk size\n",
        "text_splitter = SpacyTextSplitter(chunk_size=2500, chunk_overlap=200)\n",
        "\n",
        "\n",
        "# Split the text using SpacyTextSplitter\n",
        "spacy_texts = text_splitter.split_text(sample_text)\n",
        "print (f\"You have {len(spacy_texts)} documents\")\n",
        "\n",
        "print (\"Preview:\")\n",
        "# Print the first chunk\n",
        "print(spacy_texts[0])"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "Uv24AwivmXLh",
        "outputId": "17fabee7-7bc0-4315-e64e-04eb739cd693"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "You have 21 documents\n",
            "Preview:\n",
            "I would like to start by asking you to give me a brief overview of the running time.\n",
            "\n",
            "The research allowance has been in place since 2020, which means that retrospective development content can also be attached.\n",
            "\n",
            "What's important is  \n",
            "\n",
            "But it's always important that the entire project duration is staked out.\n",
            "\n",
            "This means that if, for example, it started in 2021, but still extends into the future, that you also cover the entire project duration up to the productive stage.\n",
            "\n",
            "How about XSL Cat .\n",
            "\n",
            "I would definitely take the starting point of January 1, 2023.\n",
            "\n",
            "Annalena, yes, that's in your interest and Alex also because we had a project before  that was funded with subsidies and Annalena did a lot\n",
            "\n",
            "and they are kind of it, it's kind of one-to-one, now after this project from January then turned into XXL cat.\n",
            "\n",
            "That's how I would do it.  \n",
            "\n",
            "Now I don't know anything about the runtime, is there anything that's good, should you take it time, should you do it quickly, should you do it quickly, should you do a typical project duration: four years, over four years, I wouldn't recommend between three to four years, would be very good, so one year not short, we would definitely take the customer in with us, then I would immediately  So one year is not enough.\n",
            "\n",
            "We would definitely take the dog inside.\n",
            "\n",
            "Then I would...\n",
            "\n",
            "Two years.\n",
            "\n",
            "Say this goal, then I would really do it that way.\n",
            "\n",
            "Because we want to get the cat done faster than four years now.\n",
            "\n",
            "That's when our boss kills us.\n",
            "\n",
            "But we want to, we had it that way...\n",
            "\n",
            "Annalena, you'll have to interrupt me if  But we had thought that we would sort of grab the dog afterwards, because the work is similar  similarly not the same but that's why I would maybe call it XXL cat and slash and slash horse then probably three to four years I would then also mean four years  years for my peace of mind.\n",
            "\n",
            "This should be processed in a nested way, so to speak, what we have learned from the cat, then transferred to the dog, so to speak.\n",
            "\n",
            "There  You also have a learning effect that it always merges into each other, just like baking cakes.\n",
            "\n",
            "And the cake is after four years, but we don't make more than four years.\n",
            "\n",
            "All right, that means by the end of 26  or should we put it by the middle of 26?\n",
            "\n",
            "23, 24, 25, Annalena, I mean I don't care.\n",
            "\n",
            "He's in his late 26s.\n",
            "\n",
            "Then we have a big project with four years, where you write hours  \n",
            "\n",
            "yes, I think so too.\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Before executing the following code, make sure to have\n",
        "# your OpenAI key saved in the OPENAI_API_KEY environment variable.\n",
        "embeddings = OpenAIEmbeddings(model=\"text-embedding-ada-002\")\n",
        "\n",
        "# create Deep Lake dataset\n",
        "# TODO: use your organization id here. (by default, org id is your username)\n",
        "my_activeloop_org_id = \"parthtripathidummy\"\n",
        "my_activeloop_dataset_name = \"innoscripta_spacy_text_eng_new2\"\n",
        "dataset_path = f\"hub://{my_activeloop_org_id}/{my_activeloop_dataset_name}\"\n",
        "db_spacy = DeepLake(dataset_path=dataset_path, embedding_function=embeddings)\n",
        "\n",
        "#convert to langchain object\n",
        "spacy_texts = [Document(page_content=ele, metadata={\"source\": \"local\"}) for ele in spacy_texts]\n",
        "\n",
        "# # add documents to our Deep Lake dataset\n",
        "db_spacy.add_documents(spacy_texts)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 538
        },
        "id": "ioDVII9Hnv2k",
        "outputId": "9e8461a6-e534-421f-c50f-d494fc48ee2b"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Your Deep Lake dataset has been successfully created!\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "\\"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Dataset(path='hub://parthtripathidummy/innoscripta_spacy_text_eng_new2', tensors=['embedding', 'id', 'metadata', 'text'])\n",
            "\n",
            "  tensor      htype      shape      dtype  compression\n",
            "  -------    -------    -------    -------  ------- \n",
            " embedding  embedding  (21, 1536)  float32   None   \n",
            "    id        text      (21, 1)      str     None   \n",
            " metadata     json      (21, 1)      str     None   \n",
            "   text       text      (21, 1)      str     None   \n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "\r \r"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "['6c12fd22-40b8-11ee-ae91-0242ac1c000c',\n",
              " '6c12fea8-40b8-11ee-ae91-0242ac1c000c',\n",
              " '6c12ff2a-40b8-11ee-ae91-0242ac1c000c',\n",
              " '6c12ff98-40b8-11ee-ae91-0242ac1c000c',\n",
              " '6c130006-40b8-11ee-ae91-0242ac1c000c',\n",
              " '6c13006a-40b8-11ee-ae91-0242ac1c000c',\n",
              " '6c1300ce-40b8-11ee-ae91-0242ac1c000c',\n",
              " '6c130128-40b8-11ee-ae91-0242ac1c000c',\n",
              " '6c13018c-40b8-11ee-ae91-0242ac1c000c',\n",
              " '6c1301e6-40b8-11ee-ae91-0242ac1c000c',\n",
              " '6c13024a-40b8-11ee-ae91-0242ac1c000c',\n",
              " '6c1302a4-40b8-11ee-ae91-0242ac1c000c',\n",
              " '6c1302fe-40b8-11ee-ae91-0242ac1c000c',\n",
              " '6c130358-40b8-11ee-ae91-0242ac1c000c',\n",
              " '6c1303bc-40b8-11ee-ae91-0242ac1c000c',\n",
              " '6c130416-40b8-11ee-ae91-0242ac1c000c',\n",
              " '6c1304c0-40b8-11ee-ae91-0242ac1c000c',\n",
              " '6c130524-40b8-11ee-ae91-0242ac1c000c',\n",
              " '6c13057e-40b8-11ee-ae91-0242ac1c000c',\n",
              " '6c1305e2-40b8-11ee-ae91-0242ac1c000c',\n",
              " '6c13063c-40b8-11ee-ae91-0242ac1c000c']"
            ]
          },
          "metadata": {},
          "execution_count": 82
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# let's see the top relevant documents to a specific query\n",
        "query = \"What is this research about\"\n",
        "# query = 'what is a nft'\n",
        "docs = db_spacy.similarity_search(query)\n",
        "print(docs[0].page_content)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 955
        },
        "outputId": "d45f51e8-31ff-4b57-9328-6444fc7b178b",
        "id": "vmJBTE5ptrVk"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "23, 24, 25, Annalena, I mean I don't care.\n",
            "\n",
            "He's in his late 26s.\n",
            "\n",
            "Then we have a big project with four years, where you write hours  \n",
            "\n",
            "yes, I think so too.\n",
            "\n",
            "There will always be something to readjust or something like that, even if it works, then there will be new tests or something else to optimize.\n",
            "\n",
            "So I think there will be a need at the beginning.\n",
            "\n",
            "Yes, yes.\n",
            "\n",
            "All right.\n",
            "\n",
            "We have to be able to present this as  We have to be able to present this as the most methodical approach possible.\n",
            "\n",
            "This means that a methodology is developed in practice, using the example of cats, and that this can then also be transferred to dogs and horses.  \n",
            "\n",
            "Ideally, this also means a methodical approach to transferring it to other species, so that you can ideally demonstrate here that, i.e. the funding is there for the prototype, that practically paves the way, just using the example of cat,  cat dog horse or it could in principle be transferred to other animal species afterwards.\n",
            "\n",
            "That's how they want to write it, so they don't want the cat as a prototype and then the transfer to dog and horse, but that you  We're going to do that for the cattle or are we going to beat it to death?\n",
            "\n",
            "Yes, the funding goes all the way to the prototype.\n",
            "\n",
            "And if we say that practically only the cat is the prototype, then after that it would no longer be eligible.\n",
            "\n",
            "I'm also writing down a bit of a promotion.  \n",
            "\n",
            "The dog is definitely not exhausted with the development in the cat.\n",
            "\n",
            "This is part of what we can already implement methodically with the cat.\n",
            "\n",
            "But it's definitely the case that there will be another year, one and a half,  to have the dog complete and with the horse there are other things to consider.\n",
            "\n",
            "So it's true.\n",
            "\n",
            "So the dog has many more markers, I'll say, than the cat, that he is aware of many more diseases.\n",
            "\n",
            "Annalena, you're correcting me, it's technically more of a challenge,  Since naming the hereditary diseases correctly, defining them.\n",
            "\n",
            "Exactly, that you do the right calling.\n",
            "\n",
            "Now you have already gone to the content.\n",
            "\n",
            "I would ask you to be able to explain the  goal of the project in general, i.e. really with cat, dog and horse, because that's the first chapter in the end.\n",
            "\n",
            "So the examiner must ultimately be able to recognize by distinguishing it from the state of the art and also how it is currently carried out according to  state of the art.\n",
            "\n",
            "Do you like Annalena?\n",
            "\n",
            "Yes, I'm happy to.\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# let's write a prompt for a customer support chatbot that\n",
        "# answer questions using information extracted from our db\n",
        "template = \"\"\"You are a research document summarizer that finds the questions to user query and give correct responses\n",
        "\n",
        "You know the following context information.\n",
        "\n",
        "{chunks_formatted}\n",
        "\n",
        "GIve elaborative Answer to the following question from a user. Use only information from the previous context information. Do not invent stuff.\n",
        "\n",
        "Question: {query}\n",
        "\n",
        "Answer:\"\"\"\n",
        "\n",
        "prompt = PromptTemplate(\n",
        "    input_variables=[\"chunks_formatted\", \"query\"],\n",
        "    template=template,\n",
        "    )"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 17
        },
        "outputId": "7f3a87bb-3e94-42cc-ae7e-70fdd2f9c76f",
        "id": "qHWFFmgztrV3"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# the full pipeline\n",
        "\n",
        "# user question\n",
        "query = \"What is this resarch about\"\n",
        "\n",
        "# retrieve relevant chunks\n",
        "docs = db_spacy.similarity_search(query)\n",
        "retrieved_chunks = [doc.page_content for doc in docs]\n",
        "\n",
        "# format the prompt\n",
        "chunks_formatted = \"\\n\\n\".join(retrieved_chunks)\n",
        "prompt_formatted = prompt.format(chunks_formatted=chunks_formatted, query=query)\n",
        "\n",
        "# generate answer\n",
        "llm = OpenAI(model=\"text-davinci-003\", temperature=0)\n",
        "answer = llm(prompt_formatted)\n",
        "print(answer)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 69
        },
        "outputId": "6571963a-9fb6-4cec-bb5f-aa92dce5eab9",
        "id": "RpUlfLcRtrV3"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            " This research is about developing a method to detect Leishmania in animal samples, such as blood, swabs, or hair, and to identify any resistance genes present in the Leishmania. This will enable veterinarians to quickly and accurately determine the best treatment for the animal, as well as to prevent the development of more resistant Leishmania. The research involves using classical PCA or real-time PCA to detect Leishmania, and using NGS to identify resistance genes. The end result will be a test kit or an application that will allow customers to analyze their animals and compare them to others.\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import deeplake\n",
        "ds = deeplake.load('hub://parthtripathidummy/innoscripta_spacy_text_eng_new')"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 86
        },
        "id": "77CUTkYDreK3",
        "outputId": "1e6f4e8c-3a79-48d7-8d62-3487a053a207"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "This dataset can be visualized in Jupyter Notebook by ds.visualize() or at https://app.activeloop.ai/parthtripathidummy/innoscripta_spacy_text_eng_new\n",
            "\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "-"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "hub://parthtripathidummy/innoscripta_spacy_text_eng_new loaded successfully.\n",
            "\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "\r \r\r\r"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "dir(ds)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "z0ocfCkt_TCQ",
        "outputId": "dccdf7ce-746e-4452-af25-2397fbdc1f27"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "['__args__',\n",
              " '__bool__',\n",
              " '__class__',\n",
              " '__contains__',\n",
              " '__del__',\n",
              " '__delattr__',\n",
              " '__dict__',\n",
              " '__dir__',\n",
              " '__doc__',\n",
              " '__enter__',\n",
              " '__eq__',\n",
              " '__exit__',\n",
              " '__format__',\n",
              " '__ge__',\n",
              " '__getattr__',\n",
              " '__getattribute__',\n",
              " '__getitem__',\n",
              " '__getstate__',\n",
              " '__gt__',\n",
              " '__hash__',\n",
              " '__init__',\n",
              " '__init_subclass__',\n",
              " '__iter__',\n",
              " '__le__',\n",
              " '__len__',\n",
              " '__lt__',\n",
              " '__module__',\n",
              " '__ne__',\n",
              " '__new__',\n",
              " '__origin__',\n",
              " '__reduce__',\n",
              " '__reduce_ex__',\n",
              " '__repr__',\n",
              " '__result__',\n",
              " '__setattr__',\n",
              " '__setitem__',\n",
              " '__setstate__',\n",
              " '__sizeof__',\n",
              " '__str__',\n",
              " '__subclasshook__',\n",
              " '__tuple_params__',\n",
              " '__type__',\n",
              " '__union_params__',\n",
              " '__values__',\n",
              " '__weakref__',\n",
              " '_all_tensors_filtered',\n",
              " '_append_or_extend',\n",
              " '_append_to_queries_json',\n",
              " '_checkout',\n",
              " '_checkout_hooks',\n",
              " '_client',\n",
              " '_commit',\n",
              " '_commit_hooks',\n",
              " '_copy',\n",
              " '_create_downsampled_tensor',\n",
              " '_create_group',\n",
              " '_create_sample_id_tensor',\n",
              " '_create_sample_info_tensor',\n",
              " '_create_sample_shape_tensor',\n",
              " '_create_tensor',\n",
              " '_dataset_diff',\n",
              " '_delete_branch',\n",
              " '_delete_group',\n",
              " '_delete_tensor',\n",
              " '_disable_padding',\n",
              " '_ds_diff',\n",
              " '_enable_padding',\n",
              " '_first_load_init',\n",
              " '_flush_vc_info',\n",
              " '_get_commit_id_for_address',\n",
              " '_get_empty_vds',\n",
              " '_get_storage_repository',\n",
              " '_get_tensor_from_root',\n",
              " '_get_total_meta',\n",
              " '_get_view',\n",
              " '_get_view_info',\n",
              " '_groups',\n",
              " '_groups_filtered',\n",
              " '_has_group_in_root',\n",
              " '_hide_tensor',\n",
              " '_indexing_history',\n",
              " '_info',\n",
              " '_initial_autoflush',\n",
              " '_is_filtered_view',\n",
              " '_is_root',\n",
              " '_is_sub_ds',\n",
              " '_link_tensors',\n",
              " '_load_link_creds',\n",
              " '_load_version_info',\n",
              " '_lock',\n",
              " '_lock_lost_handler',\n",
              " '_lock_queries_json',\n",
              " '_lock_timeout',\n",
              " '_locked_out',\n",
              " '_locking_enabled',\n",
              " '_optimize_saved_view',\n",
              " '_pad_tensors',\n",
              " '_parent_dataset',\n",
              " '_populate_meta',\n",
              " '_read_only',\n",
              " '_read_only_error',\n",
              " '_read_queries_json',\n",
              " '_read_view_info',\n",
              " '_register_dataset',\n",
              " '_reload_version_state',\n",
              " '_rename_tensor',\n",
              " '_resolve_tensor_list',\n",
              " '_sample_indices',\n",
              " '_save_view',\n",
              " '_save_view_in_path',\n",
              " '_save_view_in_subdir',\n",
              " '_send_branch_creation_event',\n",
              " '_send_branch_deletion_event',\n",
              " '_send_commit_event',\n",
              " '_send_compute_progress',\n",
              " '_send_dataset_creation_event',\n",
              " '_send_event',\n",
              " '_send_filter_progress',\n",
              " '_send_pytorch_progress',\n",
              " '_send_query_progress',\n",
              " '_set_derived_attributes',\n",
              " '_set_org_and_name',\n",
              " '_set_read_only',\n",
              " '_squash_main',\n",
              " '_sub_ds',\n",
              " '_temp_tensors',\n",
              " '_temp_write_access',\n",
              " '_tensors',\n",
              " '_token',\n",
              " '_ungrouped_tensors',\n",
              " '_unlock',\n",
              " '_update_hooks',\n",
              " '_vc_info_updated',\n",
              " '_view_base',\n",
              " '_view_hash',\n",
              " '_view_id',\n",
              " '_view_use_parent_commit',\n",
              " '_write_queries_json',\n",
              " '_write_vds',\n",
              " 'add_creds_key',\n",
              " 'append',\n",
              " 'base_storage',\n",
              " 'branch',\n",
              " 'branches',\n",
              " 'checkout',\n",
              " 'clear_cache',\n",
              " 'client',\n",
              " 'commit',\n",
              " 'commit_id',\n",
              " 'commits',\n",
              " 'connect',\n",
              " 'copy',\n",
              " 'create_group',\n",
              " 'create_tensor',\n",
              " 'create_tensor_like',\n",
              " 'dataloader',\n",
              " 'delete',\n",
              " 'delete_branch',\n",
              " 'delete_group',\n",
              " 'delete_tensor',\n",
              " 'delete_view',\n",
              " 'diff',\n",
              " 'ds_name',\n",
              " 'enabled_tensors',\n",
              " 'extend',\n",
              " 'filter',\n",
              " 'fix_vc',\n",
              " 'flush',\n",
              " 'get_commit_details',\n",
              " 'get_creds_keys',\n",
              " 'get_managed_creds_keys',\n",
              " 'get_view',\n",
              " 'get_views',\n",
              " 'group_index',\n",
              " 'groups',\n",
              " 'has_head_changes',\n",
              " 'index',\n",
              " 'info',\n",
              " 'is_actually_cloud',\n",
              " 'is_first_load',\n",
              " 'is_head_node',\n",
              " 'is_iteration',\n",
              " 'is_optimized',\n",
              " 'is_view',\n",
              " 'libdeeplake_dataset',\n",
              " 'link_creds',\n",
              " 'load_view',\n",
              " 'log',\n",
              " 'make_private',\n",
              " 'make_public',\n",
              " 'max_len',\n",
              " 'max_view',\n",
              " 'maybe_flush',\n",
              " 'merge',\n",
              " 'meta',\n",
              " 'min_len',\n",
              " 'min_view',\n",
              " 'no_view_dataset',\n",
              " 'num_samples',\n",
              " 'org_id',\n",
              " 'parent',\n",
              " 'path',\n",
              " 'pending_commit_id',\n",
              " 'pop',\n",
              " 'populate_creds',\n",
              " 'public',\n",
              " 'pytorch',\n",
              " 'query',\n",
              " 'random_split',\n",
              " 'read_only',\n",
              " 'rechunk',\n",
              " 'rename',\n",
              " 'rename_group',\n",
              " 'rename_tensor',\n",
              " 'reset',\n",
              " 'root',\n",
              " 'sample_by',\n",
              " 'sample_indices',\n",
              " 'save_view',\n",
              " 'size_approx',\n",
              " 'storage',\n",
              " 'summary',\n",
              " 'tensorflow',\n",
              " 'tensors',\n",
              " 'token',\n",
              " 'update',\n",
              " 'update_creds_key',\n",
              " 'verbose',\n",
              " 'version_state',\n",
              " 'visualize']"
            ]
          },
          "metadata": {},
          "execution_count": 77
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "lpzDGMP3_p-e"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "# Working on Long Summary Data"
      ],
      "metadata": {
        "id": "cuyjIBqRZ_gc"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "from langchain.document_loaders import TextLoader\n",
        "loader = TextLoader('/content/drive/MyDrive/Innoscripta/full_summary_text.txt')\n",
        "documents = loader.load_and_split()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 17
        },
        "outputId": "0485be64-4dc4-4673-bf76-185f40ebc3ff",
        "id": "ngQGcw6lal7l"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "from langchain.text_splitter import CharacterTextSplitter\n",
        "text_splitter = CharacterTextSplitter(chunk_size=50, chunk_overlap=10)\n",
        "simple_texts = text_splitter.split_documents(documents)\n",
        "\n",
        "print (f\"You have {len(simple_texts)} documents\")\n",
        "\n",
        "print (\"Preview:\")\n",
        "print (simple_texts[0].page_content)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 416
        },
        "outputId": "4d90b884-1ed3-48f2-e1be-0617e01c5015",
        "id": "yx-c1EC0al7l"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "You have 5 documents\n",
            "Preview:\n",
            "FULL Long Summary === ===\n",
            "In this conversation, the speaker seeks a brief overview of the running time and emphasizes the significance of encompassing the entire project duration. They propose classifying the project under XSL cat and setting the starting point as January 1, 2023. The speaker suggests a project duration of three to four years, considering one year to be insufficient. They mention involving the customer in the process. Furthermore, they discuss the idea of transferring knowledge from previous projects, comparing it to baking cakes. The speaker acknowledges the need for adjustments and optimizations, even if the project progresses smoothly. They anticipate the need for ongoing improvements and foresee a project timeline extending until at least the middle of 2026. Overall, the speaker emphasizes the importance of thorough planning and continuous refinement in order to successfully complete the project within the desired timeframe.\n",
            "The project aims to develop genetic health evaluation products for dogs, cats, and horses. The methodology involves starting with cats as an example and then transferring the approach to other species. The goal is to demonstrate that the prototype, developed for cats, can be applied to other animal species as well. The funding covers the entire development process, ensuring that the cat is not the sole prototype. The development process for dogs is more complex, as there are more markers and a greater challenge in correctly identifying hereditary diseases. The ultimate goal of the project is to provide customers, breeders, veterinarians, and individuals with the means to evaluate the genetic health of their animals comprehensively. This information can then be used to make informed breeding decisions and prevent the deterioration of animal health in the future. The project aims to go beyond the current state of the art and contribute to healthier breeding practices, particularly in closely bred breeds. A quality checklist is provided to guide the application process and ensure a structured approach.\n",
            "The current state of the art in genetic analysis of animals involves the use of individual tests and smaller products for breed-specific applications. However, the project aims to revolutionize this approach by utilizing high-throughput technology, specifically Next Generation Sequencing, to study the entire genetic makeup of animals. The main focus is on detecting hereditary diseases in cats, dogs, and horses. By expanding the use of next-generation sequencing, the project aims to cover a large portion of the known diseases in each species. The goal is to develop a product for each species that contains an additive XXL, capable of detecting and mapping all or most hereditary diseases and characteristics that can be identified using the technology. Quantifying the target values is challenging due to the constantly evolving nature of hereditary diseases and the limitations of the technology. However, the project aims to continuously cover more than 60 percent of the known diseases in each species, while acknowledging the potential constraints imposed by the technology.\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Before executing the following code, make sure to have\n",
        "# your OpenAI key saved in the OPENAI_API_KEY environment variable.\n",
        "embeddings = OpenAIEmbeddings(model=\"text-embedding-ada-002\")\n",
        "\n",
        "# create Deep Lake dataset\n",
        "# TODO: use your organization id here. (by default, org id is your username)\n",
        "my_activeloop_org_id = \"parthtripathidummy\"\n",
        "my_activeloop_dataset_name = \"innoscripta_summary_text_eng_new\"\n",
        "dataset_path = f\"hub://{my_activeloop_org_id}/{my_activeloop_dataset_name}\"\n",
        "db_simple = DeepLake(dataset_path=dataset_path, embedding_function=embeddings)\n",
        "\n",
        "# add documents to our Deep Lake dataset\n",
        "db_simple.add_documents(simple_texts)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 260
        },
        "outputId": "ba73557d-1274-4d50-9442-81638fb977c1",
        "id": "W2MBxrEoal7m"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Your Deep Lake dataset has been successfully created!\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "-"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Dataset(path='hub://parthtripathidummy/innoscripta_summary_text_eng_new', tensors=['embedding', 'id', 'metadata', 'text'])\n",
            "\n",
            "  tensor      htype      shape     dtype  compression\n",
            "  -------    -------    -------   -------  ------- \n",
            " embedding  embedding  (5, 1536)  float32   None   \n",
            "    id        text      (5, 1)      str     None   \n",
            " metadata     json      (5, 1)      str     None   \n",
            "   text       text      (5, 1)      str     None   \n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "\r \r"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "['76010b4e-40ef-11ee-bd13-0242ac1c000c',\n",
              " '76010d56-40ef-11ee-bd13-0242ac1c000c',\n",
              " '76010e28-40ef-11ee-bd13-0242ac1c000c',\n",
              " '76010ee6-40ef-11ee-bd13-0242ac1c000c',\n",
              " '76010fa4-40ef-11ee-bd13-0242ac1c000c']"
            ]
          },
          "metadata": {},
          "execution_count": 8
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# let's see the top relevant documents to a specific query\n",
        "query = \"What is this research about\"\n",
        "# query = 'what is a nft'\n",
        "docs = db_simple.similarity_search(query)\n",
        "print(docs[0].page_content)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 382
        },
        "outputId": "e7e9701c-0386-44c1-f82a-b2ffbc8260e3",
        "id": "Uc7l6Uayal7m"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "FULL Long Summary === ===\n",
            "In this conversation, the speaker seeks a brief overview of the running time and emphasizes the significance of encompassing the entire project duration. They propose classifying the project under XSL cat and setting the starting point as January 1, 2023. The speaker suggests a project duration of three to four years, considering one year to be insufficient. They mention involving the customer in the process. Furthermore, they discuss the idea of transferring knowledge from previous projects, comparing it to baking cakes. The speaker acknowledges the need for adjustments and optimizations, even if the project progresses smoothly. They anticipate the need for ongoing improvements and foresee a project timeline extending until at least the middle of 2026. Overall, the speaker emphasizes the importance of thorough planning and continuous refinement in order to successfully complete the project within the desired timeframe.\n",
            "The project aims to develop genetic health evaluation products for dogs, cats, and horses. The methodology involves starting with cats as an example and then transferring the approach to other species. The goal is to demonstrate that the prototype, developed for cats, can be applied to other animal species as well. The funding covers the entire development process, ensuring that the cat is not the sole prototype. The development process for dogs is more complex, as there are more markers and a greater challenge in correctly identifying hereditary diseases. The ultimate goal of the project is to provide customers, breeders, veterinarians, and individuals with the means to evaluate the genetic health of their animals comprehensively. This information can then be used to make informed breeding decisions and prevent the deterioration of animal health in the future. The project aims to go beyond the current state of the art and contribute to healthier breeding practices, particularly in closely bred breeds. A quality checklist is provided to guide the application process and ensure a structured approach.\n",
            "The current state of the art in genetic analysis of animals involves the use of individual tests and smaller products for breed-specific applications. However, the project aims to revolutionize this approach by utilizing high-throughput technology, specifically Next Generation Sequencing, to study the entire genetic makeup of animals. The main focus is on detecting hereditary diseases in cats, dogs, and horses. By expanding the use of next-generation sequencing, the project aims to cover a large portion of the known diseases in each species. The goal is to develop a product for each species that contains an additive XXL, capable of detecting and mapping all or most hereditary diseases and characteristics that can be identified using the technology. Quantifying the target values is challenging due to the constantly evolving nature of hereditary diseases and the limitations of the technology. However, the project aims to continuously cover more than 60 percent of the known diseases in each species, while acknowledging the potential constraints imposed by the technology.\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# let's write a prompt for a customer support chatbot that\n",
        "# answer questions using information extracted from our db\n",
        "template = \"\"\"You are a research document summarizer that finds the questions to user query and give correct responses\n",
        "\n",
        "You know the following context information.\n",
        "\n",
        "{chunks_formatted}\n",
        "\n",
        "Answer to the following question from a user. Use only information from the previous context information. Do not invent stuff.\n",
        "\n",
        "Question: {query}\n",
        "\n",
        "Answer:\"\"\"\n",
        "\n",
        "prompt = PromptTemplate(\n",
        "    input_variables=[\"chunks_formatted\", \"query\"],\n",
        "    template=template,\n",
        "    )"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 17
        },
        "outputId": "6bf491f5-fb69-4961-da68-fd7b2a80340f",
        "id": "0MKR0SuOal7m"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# the full pipeline\n",
        "\n",
        "# user question\n",
        "query = \"What is this research about\"\n",
        "\n",
        "# retrieve relevant chunks\n",
        "docs = db_simple.similarity_search(query)\n",
        "retrieved_chunks = [doc.page_content for doc in docs]\n",
        "\n",
        "# format the prompt\n",
        "chunks_formatted = \"\\n\\n\".join(retrieved_chunks)\n",
        "prompt_formatted = prompt.format(chunks_formatted=chunks_formatted, query=query)\n",
        "\n",
        "# generate answer\n",
        "llm = OpenAI(model=\"text-davinci-003\", temperature=0)\n",
        "answer = llm(prompt_formatted)\n",
        "print(answer)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 69
        },
        "outputId": "8325e714-25ac-4fdc-b1cf-98535025cedb",
        "id": "2ianmABUal7m"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            " This research is about developing genetic health evaluation products for dogs, cats, and horses. It involves using Next Generation Sequencing technology to study the entire genetic makeup of animals and detect hereditary diseases. The goal is to provide customers, breeders, veterinarians, and individuals with the means to evaluate the genetic health of their animals comprehensively.\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "Objective of the project (if\n",
        "applicable, in the context of the\n",
        "cooperative project)\n",
        "Motivation, objectives, and intended results. To what extent does the project\n",
        "aim to expand the state of knowledge/technology or utilize existing\n",
        "scientific, technical, economic, or other relevant findings or approaches\n",
        "1 State of the art (Currently/According to the state of the art...\n",
        "1 Project objective (The goal of the project is...\n",
        "1 Differentiation from the state of the art (The state of the art is expanded\n",
        "in terms of..., thereby expanding the knowledge about...\n",
        "1 Project result (The planned outcome/result is...)\n",
        "\n"
      ],
      "metadata": {
        "id": "abrTsC59byY3"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "# let's write a prompt for a customer support chatbot that\n",
        "# answer questions using information extracted from our db\n",
        "template = \"\"\"You are a research document summarizer that finds the questions to user query and give correct responses\n",
        "\n",
        "You know the following context information.\n",
        "\n",
        "{chunks_formatted}\n",
        "\n",
        "Answer to the following question from a user. Use only information from the previous context information following the guidelines provided. Do not invent stuff.\n",
        "\n",
        "Question: {query}\n",
        "Guidelines: {guidelines}\n",
        "Answer:\"\"\"\n",
        "\n",
        "prompt = PromptTemplate(\n",
        "    input_variables=[\"chunks_formatted\", \"query\", \"guidelines\"],\n",
        "    template=template,\n",
        "    )"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 17
        },
        "id": "KEiglQrMbjl4",
        "outputId": "8bf4bbe4-ac7a-4bd3-a771-a512ea899246"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# the full pipeline\n",
        "\n",
        "# user question\n",
        "query = \"What is the Objective of the project (if applicable, in the context of the cooperative project) \"\n",
        "guidelines = '''\n",
        "Motivation, objectives, and intended results. To what extent does the project\n",
        "aim to expand the state of knowledge/technology or utilize existing\n",
        "scientific, technical, economic, or other relevant findings or approaches\n",
        " - 1 State of the art (Currently/According to the state of the art...\n",
        " - 1 Project objective (The goal of the project is...\n",
        " - 1 Differentiation from the state of the art (The state of the art is expanded\n",
        "   in terms of..., thereby expanding the knowledge about...\n",
        " - 1 Project result (The planned outcome/result is...)\n",
        "\n",
        "Please ensure that the project uses specific technical terminology to\n",
        "describe the innovative core. This is particularly crucial, especially for\n",
        "software projects.\n",
        "'''\n",
        "# retrieve relevant chunks\n",
        "docs = db_simple.similarity_search(query)\n",
        "retrieved_chunks = [doc.page_content for doc in docs]\n",
        "\n",
        "# format the prompt\n",
        "chunks_formatted = \"\\n\\n\".join(retrieved_chunks)\n",
        "prompt_formatted = prompt.format(chunks_formatted=chunks_formatted, query=query, guidelines=guidelines)\n",
        "\n",
        "# generate answer\n",
        "llm = OpenAI(model=\"text-davinci-003\", temperature=0)\n",
        "answer = llm(prompt_formatted)\n",
        "print(answer)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 139
        },
        "id": "5dXdWHQIcC14",
        "outputId": "5d8587b3-a3e1-4d8a-e7f1-90534804d057"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            " The objective of the project is to develop genetic health evaluation products for dogs, cats, and horses. The methodology involves starting with cats as an example and then transferring the approach to other species. The goal is to demonstrate that the prototype, developed for cats, can be applied to other animal species as well. The project aims to go beyond the current state of the art by utilizing high-throughput technology, specifically Next Generation Sequencing, to study the entire genetic makeup of animals. The main focus is on detecting hereditary diseases in cats, dogs, and horses. By expanding the use of next-generation sequencing, the project aims to cover a large portion of the known diseases in each species. The goal is to develop a product for each species that contains an additive XXL, capable of detecting and mapping all or most hereditary diseases and characteristics that can be identified using the technology. The project aims to continuously cover more than 60 percent of the known diseases in each species, while acknowledging the potential constraints imposed by the technology.\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "len(answer)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 34
        },
        "id": "zxwgzTfIcesz",
        "outputId": "8ceb5f8b-26ae-43cb-ebc3-35b6fc6b402b"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "1114"
            ]
          },
          "metadata": {},
          "execution_count": 15
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "# Working on Short Summary Data"
      ],
      "metadata": {
        "id": "cpi3uVM0dDat"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "from langchain.document_loaders import TextLoader\n",
        "loader = TextLoader('/content/drive/MyDrive/Innoscripta/short_summary_text.txt')\n",
        "documents = loader.load_and_split()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 17
        },
        "outputId": "b4f74d83-b431-427b-bb16-0c6b980a70ff",
        "id": "c1-jG_VIdDa9"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "from langchain.text_splitter import CharacterTextSplitter\n",
        "text_splitter = CharacterTextSplitter(chunk_size=50, chunk_overlap=10)\n",
        "simple_texts = text_splitter.split_documents(documents)\n",
        "\n",
        "print (f\"You have {len(simple_texts)} documents\")\n",
        "\n",
        "print (\"Preview:\")\n",
        "print (simple_texts[0].page_content)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 555
        },
        "outputId": "3f7f3ccd-6fd9-4804-92d3-a9aa506d8821",
        "id": "mGVQU3EUdDa-"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "You have 2 documents\n",
            "Preview:\n",
            "Short Summary === ===\n",
            "The speaker is asking for an overview of the running time and discussing the importance of covering the entire project duration. They suggest classifying it under XSL cat and starting from January 1, 2023. They recommend a project duration of three to four years and mention involving the customer. They also mention learning from previous projects and the need for adjustments and optimizations.\n",
            "The goal of the project is to develop genetic health evaluation products for dogs, cats, and horses. These products will allow customers to assess the overall genetic health of their animals and make informed breeding decisions. The aim is to prevent the deterioration of animal health in the future and promote healthier breeding practices.\n",
            "The project aims to use high-throughput technology, specifically Next Generation Sequencing, to study the entire genetic makeup of animals and detect hereditary diseases. Currently, individual tests and smaller products are used for breed-specific applications. The project aims to expand the use of next-generation sequencing to cover a large portion of known diseases in different animal species. The goal is to develop a product for each species that contains all or most hereditary diseases and characteristics that can be mapped with the technology.\n",
            "The text discusses the importance of a numerical value in an application and the methodical approach required for a scientific analysis of hereditary diseases in different species. It also mentions the need for evaluating test results and presenting them in a customer-friendly manner.\n",
            "The text discusses a new product and form of diagnosis that involves comparing the Prennness to other animals. It also mentions the use of Next Generation Sequencing (NGS) for testing animals for various diseases. The text highlights the differences between individual tests and NGS, and mentions other companies offering similar packages. The author believes that NGS is something new and mentions Mars as a competitor using microarrays.\n",
            "NGS offers a market advantage over competitors due to its ability to react quickly and constantly add new markers. This is because NGS is a fast-moving product that is researched intensively. Compared to microarrays, NGS allows for faster reactions to customer needs. Reacting within one to two months is possible with NGS, while it can take three to six months with microarrays. This time advantage is a clear market advantage for NGS.\n",
            "The text discusses the differentiation between Next Generation Sequencing (NGS) used for genetic fingerprinting in dogs and NGS used for investigating hereditary diseases. NGS for genetic fingerprinting examines positions in the genome that have no effect on the animal's health, while NGS for hereditary diseases focuses on specific positions that trigger the disease. The analysis for hereditary diseases is more complex and involves examining a larger number of SNPs and other mutations.\n",
            "The analysis of hereditary diseases is complex and requires a higher level of security. Identifying an animal based on 230 SNPs can still have uncertainties. The presence of hereditary diseases has a significant impact on the animal. The last chapter discusses technical risks and the challenges of detecting mutations and insertions in the genome.\n",
            "The text discusses the challenges of sequencing DNA due to repeats and remnants of viral DNA, making it difficult to analyze larger deletions and insertions. However, a new procedure called structural variant analysis allows for the evaluation of long insertions and deletions using multiple primers. This procedure is seen as a positive development in DNA analysis. Evaluating and characterizing DNA insertions with Next Generation Sequencing is not considered a major risk, but rather an isolated case. The goal is to cover 60 percent of hereditary diseases, focusing on the most relevant ones.\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Before executing the following code, make sure to have\n",
        "# your OpenAI key saved in the OPENAI_API_KEY environment variable.\n",
        "embeddings = OpenAIEmbeddings(model=\"text-embedding-ada-002\")\n",
        "\n",
        "# create Deep Lake dataset\n",
        "# TODO: use your organization id here. (by default, org id is your username)\n",
        "my_activeloop_org_id = \"parthtripathidummy\"\n",
        "my_activeloop_dataset_name = \"innoscripta_short_summary_text_eng_new\"\n",
        "dataset_path = f\"hub://{my_activeloop_org_id}/{my_activeloop_dataset_name}\"\n",
        "db_simple = DeepLake(dataset_path=dataset_path, embedding_function=embeddings)\n",
        "\n",
        "# add documents to our Deep Lake dataset\n",
        "db_simple.add_documents(simple_texts)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 208
        },
        "outputId": "5ead69fd-6888-4af5-ef7e-5d7d3542d861",
        "id": "FGdZAxgZdDa-"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Your Deep Lake dataset has been successfully created!\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "-"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Dataset(path='hub://parthtripathidummy/innoscripta_short_summary_text_eng_new', tensors=['embedding', 'id', 'metadata', 'text'])\n",
            "\n",
            "  tensor      htype      shape     dtype  compression\n",
            "  -------    -------    -------   -------  ------- \n",
            " embedding  embedding  (2, 1536)  float32   None   \n",
            "    id        text      (2, 1)      str     None   \n",
            " metadata     json      (2, 1)      str     None   \n",
            "   text       text      (2, 1)      str     None   \n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "\r \r"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "['18382856-40f1-11ee-bd13-0242ac1c000c',\n",
              " '18382a18-40f1-11ee-bd13-0242ac1c000c']"
            ]
          },
          "metadata": {},
          "execution_count": 18
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# let's see the top relevant documents to a specific query\n",
        "query = \"What is this research about\"\n",
        "# query = 'what is a nft'\n",
        "docs = db_simple.similarity_search(query)\n",
        "print(docs[0].page_content)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 468
        },
        "outputId": "3d5903a6-3b6e-4b03-fc06-bdaf623469db",
        "id": "fQA8naUNdDa_"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "The text discusses the importance of including critical hereditary diseases in tests and justifying the inability to detect them due to factors like DNA complexity. It also mentions the need to mention expenses and personnel involved in the application. The conversation concludes with plans to work on the application and distribute it through email and an accompanying portal.\n",
            "The conversation discusses a project on antibiotic resistance and bacterial infections. They clarify that Leishmania resistance is a different topic. They plan to name it Leishmania resistance and continue with screen splitting for better organization. The project started in the middle of last year and will run for three years. Leishmania is a parasite transmitted by mosquitoes, causing leishmaniasis in dogs and potentially in humans. Climate change is causing the mosquitoes to spread further north, posing a future problem in Germany.\n",
            "The goal is to develop a tool for veterinarians to determine the best drug for treating dogs with Leishmania. By studying the resistance genes in Leishmania samples, the researchers aim to identify which drugs are most effective. They will use Next Generation Sequencing to examine the entire Leishmania genome and compare their findings with existing scientific publications. The goal is to provide a comprehensive analysis of resistance genes and make the tool more attractive by considering all relevant genes.\n",
            "The text discusses the use of Next Generation Sequencing to analyze gene variations in Leishmania and identify resistance to drugs. It mentions the use of questionnaires, consultation with veterinarians, and in vitro tests to evaluate drug effectiveness. The text also highlights the challenge of determining a gold standard for resistance and suggests aiming for an 80 percent agreement with veterinarian assessments.\n",
            "The text discusses the use of NLGS and classical methods for detecting resistances in Leishmania infections. Currently, veterinarians rely on medication adjustments based on observation and measurement of leishmania load. NGS has been used for basic research but not yet commercially. The differentiation of technologies is also mentioned, with the focus on detecting Leishmania and resistance genes through NGS.\n",
            "The text discusses the use of Next-Generation Sequencing (NGS) to examine animal samples and isolate Leishmania parasites. The goal is to characterize parasites from animal material using NGS. The risks include the presence of multiple strains within one animal, potential errors in publications, and the challenge of adapting preparations for parasite DNA. The sensitivity of detecting resistance genes is also mentioned. Possible solutions include separating genomic DNA using Nanopore's methods or growing Leishmania in a cell culture for further examination.\n",
            "The conversation discusses the number of people needed for a project, potential subcontractors, and the need for cooperation with universities. They also touch on the topic of screening methods for diseases in animals and the limitations of these methods.\n",
            "The speaker discusses the concept of mutation and its impact on hereditary diseases. They mention an ongoing prototype project and the need to expand it with new developments. They express uncertainty about dedicating enough time to the project and plan to discuss alternative approaches with their department head. The speaker concludes the conversation by thanking the other person and wishing them a nice week.\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# let's write a prompt for a customer support chatbot that\n",
        "# answer questions using information extracted from our db\n",
        "template = \"\"\"You are a research document summarizer that finds the questions to user query and give correct responses\n",
        "\n",
        "You know the following context information.\n",
        "\n",
        "{chunks_formatted}\n",
        "\n",
        "Answer to the following question from a user. Use only information from the previous context information. Do not invent stuff.\n",
        "\n",
        "Question: {query}\n",
        "\n",
        "Answer:\"\"\"\n",
        "\n",
        "prompt = PromptTemplate(\n",
        "    input_variables=[\"chunks_formatted\", \"query\"],\n",
        "    template=template,\n",
        "    )"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 17
        },
        "outputId": "dd3a713a-e10b-44d1-fd17-ebea92c7dec0",
        "id": "qvbudLUKdDa_"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# the full pipeline\n",
        "\n",
        "# user question\n",
        "query = \"What is this research about\"\n",
        "\n",
        "# retrieve relevant chunks\n",
        "docs = db_simple.similarity_search(query)\n",
        "retrieved_chunks = [doc.page_content for doc in docs]\n",
        "\n",
        "# format the prompt\n",
        "chunks_formatted = \"\\n\\n\".join(retrieved_chunks)\n",
        "prompt_formatted = prompt.format(chunks_formatted=chunks_formatted, query=query)\n",
        "\n",
        "# generate answer\n",
        "llm = OpenAI(model=\"text-davinci-003\", temperature=0)\n",
        "answer = llm(prompt_formatted)\n",
        "print(answer)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 69
        },
        "outputId": "b826ec60-dbd4-4a53-86b4-a6fdc8eb76f6",
        "id": "MxtYe86UdDa_"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            " This research is about developing genetic health evaluation products for dogs, cats, and horses. The aim is to use high-throughput technology, specifically Next Generation Sequencing, to study the entire genetic makeup of animals and detect hereditary diseases. The goal is to develop a product for each species that contains all or most hereditary diseases and characteristics that can be mapped with the technology.\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# let's write a prompt for a customer support chatbot that\n",
        "# answer questions using information extracted from our db\n",
        "template = \"\"\"You are a research document summarizer that finds the questions to user query and give correct responses\n",
        "\n",
        "You know the following context information.\n",
        "\n",
        "{chunks_formatted}\n",
        "\n",
        "Answer to the following question from a user. Use only information from the previous context information following the guidelines provided. Do not invent stuff.\n",
        "\n",
        "Question: {query}\n",
        "Guidelines: {guidelines}\n",
        "Answer:\"\"\"\n",
        "\n",
        "prompt = PromptTemplate(\n",
        "    input_variables=[\"chunks_formatted\", \"query\", \"guidelines\"],\n",
        "    template=template,\n",
        "    )"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 17
        },
        "outputId": "a5245694-8def-4297-aece-c29e861fe7a8",
        "id": "ZlVKsPcrdDbA"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# the full pipeline\n",
        "\n",
        "# user question\n",
        "query = \"What is the Objective of the project (if applicable, in the context of the cooperative project) \"\n",
        "guidelines = '''\n",
        "Motivation, objectives, and intended results. To what extent does the project\n",
        "aim to expand the state of knowledge/technology or utilize existing\n",
        "scientific, technical, economic, or other relevant findings or approaches\n",
        " - 1 State of the art (Currently/According to the state of the art...\n",
        " - 1 Project objective (The goal of the project is...\n",
        " - 1 Differentiation from the state of the art (The state of the art is expanded\n",
        "   in terms of..., thereby expanding the knowledge about...\n",
        " - 1 Project result (The planned outcome/result is...)\n",
        "\n",
        "Please ensure that the project uses specific technical terminology to\n",
        "describe the innovative core. This is particularly crucial, especially for\n",
        "software projects.\n",
        "'''\n",
        "# retrieve relevant chunks\n",
        "docs = db_simple.similarity_search(query)\n",
        "retrieved_chunks = [doc.page_content for doc in docs]\n",
        "\n",
        "# format the prompt\n",
        "chunks_formatted = \"\\n\\n\".join(retrieved_chunks)\n",
        "prompt_formatted = prompt.format(chunks_formatted=chunks_formatted, query=query, guidelines=guidelines)\n",
        "\n",
        "# generate answer\n",
        "llm = OpenAI(model=\"text-davinci-003\", temperature=0)\n",
        "answer = llm(prompt_formatted)\n",
        "print(answer)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 173
        },
        "outputId": "ae5baf7a-202b-43b3-b5f0-5f4dc2a98a87",
        "id": "rtTb6BxKdDbA"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            " The goal of the project is to develop genetic health evaluation products for dogs, cats, and horses. These products will allow customers to assess the overall genetic health of their animals and make informed breeding decisions. The aim is to prevent the deterioration of animal health in the future and promote healthier breeding practices. The project aims to use high-throughput technology, specifically Next Generation Sequencing, to study the entire genetic makeup of animals and detect hereditary diseases. Currently, individual tests and smaller products are used for breed-specific applications. The project aims to expand the use of next-generation sequencing to cover a large portion of known diseases in different animal species. The goal is to develop a product for each species that contains all or most hereditary diseases and characteristics that can be mapped with the technology. The project also aims to differentiate between Next Generation Sequencing (NGS) used for genetic fingerprinting in dogs and NGS used for investigating hereditary diseases. NGS for genetic fingerprinting examines positions in the genome that have no effect on the animal's health, while NGS for hereditary diseases focuses on specific positions that trigger the disease. The analysis for hereditary diseases is more complex and involves examining a larger number of SNPs and other mutations. The goal is to cover 60 percent of hereditary diseases, focusing\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "5eJfAx0HeBja"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "# Working on Full RAW Processed Data"
      ],
      "metadata": {
        "id": "teRPW7Lpf7Nj"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "from langchain.document_loaders import TextLoader\n",
        "loader = TextLoader('/content/drive/MyDrive/Innoscripta/processed_text_eng.txt')\n",
        "documents = loader.load_and_split()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 17
        },
        "outputId": "43979171-b637-4a5e-a468-71b87cea0617",
        "id": "0PEM1Kwjf7Nz"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "from langchain.text_splitter import CharacterTextSplitter\n",
        "text_splitter = CharacterTextSplitter(chunk_size=50, chunk_overlap=10)\n",
        "simple_texts = text_splitter.split_documents(documents)\n",
        "\n",
        "print (f\"You have {len(simple_texts)} documents\")\n",
        "\n",
        "print (\"Preview:\")\n",
        "print (simple_texts[0].page_content)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 486
        },
        "outputId": "8f888434-d163-4243-8dca-eaa687fe9f56",
        "id": "rS9tYJaAf7N0"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "You have 12 documents\n",
            "Preview:\n",
            "I would like to ask you at the beginning to give me a brief overview of the running time. The research allowance has been in place since 2020, which means that retrospective development content can also be attached. However, it is always important that the entire project duration is defined. This means that if, for example, it started in 2021, but still extends into the future, that you also cover the entire project duration up to the productive stage. How would that be classified with XSL cat. I would definitely take the starting point of January 1, 2023. Annalena, yes, that's in your interest and Alex, also because we had a project before, which was supported with subsidies and Annalena did a lot and they are quasi it has almost one to one now after this project from January then switched to XXL cat. That's how I would do it.  make now no idea of the term, there is what is good, you should take it time, you should do it quickly, so you should do a typical project, duration is four years, over four years, I would not recommend, between three to four years would be very good, so one year not short, we would definitely take the customer in with us, then I would do the same: So one year is not enough, short. We would definitely take the dog inside. Then I would... Two years. Say this goal, then I would really do it that way. Because we want to get the cat done faster than four years now. That's when our boss kills us. But we want to, we had it that way... Annalena, you have to interrupt me if But we had, yes considered, that we would pack the dog behind it, because the work is similarly not the same, but that's why I would maybe call it xxl cat and slash and slash horse then probably come to three to four years I would then also mean four years for my peace of mind. This should be processed in a nested way, so to speak, what we have learned from the cat, then transferred to the dog, so to speak. You also have a learning effect that it always merges into each other, just like baking cakes. And the cake is after four years, but we don't make more than four years. All right, that is, by the end of 26, or should we put it by the middle of 26? 23, 24, 25, Annalena, I mean I don't care. He's in his late 26s. Then we have a big project with four years, where you write hours, yes, I think so too. There will always be something to readjust or something like that, even if it works, then there will be new tests or something else to optimize. So I think there will be a need at the beginning. Yes, yes. All right. We must be able to present this as the most methodical approach possible. This means that a methodology is developed in practice, using the example of cats, and that this can then also be transferred to dogs and horses.  Ideally, this also means a methodical approach to transferring it to other species, so that one can ideally demonstrate here that, i.e. the promotion is there for the prototype, that practically paves the way, just using the example of cats, cats, dogs, horses, or that it could in principle be transferred to other animal species. That's how they want to write it, so they don't want the cat as a prototype and then the transfer to dog and horse, but that you Do we do that for the cattle or do we beat it to death? Yes, the funding goes all the way to the prototype. And if we say that practically only the cat is the prototype, then after that it would no longer be eligible. I'm also writing down a bit of a promotion.  The dog is definitely not exhausted with the development in the cat. This is part of what we can already implement methodically with the cat. But it is definitely the case that there will certainly be another year, one and a half, to have the dog complete and with the horse there are other things to consider. So it's true. So the dog has a lot more markers, I'll say now, than the cat, that he knows a lot more diseases. Annalena, you correct me, technically is a greater challenge, since to correctly name\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Before executing the following code, make sure to have\n",
        "# your OpenAI key saved in the OPENAI_API_KEY environment variable.\n",
        "embeddings = OpenAIEmbeddings(model=\"text-embedding-ada-002\")\n",
        "\n",
        "# create Deep Lake dataset\n",
        "# TODO: use your organization id here. (by default, org id is your username)\n",
        "my_activeloop_org_id = \"parthtripathidummy\"\n",
        "my_activeloop_dataset_name = \"innoscripta_processed_raw_text_eng_new\"\n",
        "dataset_path = f\"hub://{my_activeloop_org_id}/{my_activeloop_dataset_name}\"\n",
        "db_simple = DeepLake(dataset_path=dataset_path, embedding_function=embeddings)\n",
        "\n",
        "# add documents to our Deep Lake dataset\n",
        "db_simple.add_documents(simple_texts)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 382
        },
        "outputId": "7f6dc203-0752-400b-cf5a-1fe76ea1b19c",
        "id": "50DI_WXCf7N0"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Your Deep Lake dataset has been successfully created!\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "\\"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Dataset(path='hub://parthtripathidummy/innoscripta_processed_raw_text_eng_new', tensors=['embedding', 'id', 'metadata', 'text'])\n",
            "\n",
            "  tensor      htype      shape      dtype  compression\n",
            "  -------    -------    -------    -------  ------- \n",
            " embedding  embedding  (12, 1536)  float32   None   \n",
            "    id        text      (12, 1)      str     None   \n",
            " metadata     json      (12, 1)      str     None   \n",
            "   text       text      (12, 1)      str     None   \n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "\r \r"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "['b2d482f0-40f2-11ee-bd13-0242ac1c000c',\n",
              " 'b2d48476-40f2-11ee-bd13-0242ac1c000c',\n",
              " 'b2d48502-40f2-11ee-bd13-0242ac1c000c',\n",
              " 'b2d48570-40f2-11ee-bd13-0242ac1c000c',\n",
              " 'b2d485de-40f2-11ee-bd13-0242ac1c000c',\n",
              " 'b2d4864c-40f2-11ee-bd13-0242ac1c000c',\n",
              " 'b2d486b0-40f2-11ee-bd13-0242ac1c000c',\n",
              " 'b2d48714-40f2-11ee-bd13-0242ac1c000c',\n",
              " 'b2d48778-40f2-11ee-bd13-0242ac1c000c',\n",
              " 'b2d487dc-40f2-11ee-bd13-0242ac1c000c',\n",
              " 'b2d4884a-40f2-11ee-bd13-0242ac1c000c',\n",
              " 'b2d488ae-40f2-11ee-bd13-0242ac1c000c']"
            ]
          },
          "metadata": {},
          "execution_count": 26
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# let's see the top relevant documents to a specific query\n",
        "query = \"What is this research about\"\n",
        "# query = 'what is a nft'\n",
        "docs = db_simple.similarity_search(query)\n",
        "print(docs[0].page_content)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 399
        },
        "outputId": "ab7cc36d-103b-4dc3-bdb8-ef5a35161ca3",
        "id": "ERm8cQOEf7N1"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "contact with the veterinarians outside. All right, then just a rough overview, that is, four people to no idea ten to 15 percent perhaps. Yes, that's right.  Okay, do any subcontractors still come in here? So there will certainly be cooperations, but more with universities and then you don't really have any bills. So if you don't pay for the university, then that's not relevant. Yes yes exactly.  Yes, exactly, I'm just thinking so loudly. That's why I don't think so at the moment. Okay perfect, then I'm already through with my questions here too. Is there another project or would that be it for now?  I think that would be it for now. Completely new things will be added. The other thing with the infection scan, they had sent something again. I would only get the one sentence out.  Exactly, I wanted to talk to you about that, because of course we have to make sure that we fill in the text to see if there is perhaps a replacement for the deletion. I don't know what you're aiming for. I'll probably have to open this up again. Because it doesn't allow you to do that, just that's what IT is doing here today. Exactly, but I can also briefly share your e-mail otherwise. Yes, maybe that's the fastest way to do it. So, exactly. Yes, few screening with EDP Yes, few screening methods that result from dogs or cats. I don't know what they're actually going to pick up. We wanted to show a bit of the demarcations to the state of the art, i.e. how this is done according to statistics, i.e. how much of the statistics is not enough. So what we're doing is not screening methods, it's like, it's like packages. But that would have to be worded a little differently. If the dog's nose runs, then we just do herpes calypso, then there are already four or five typical pathogens that you do there.  So these are more like packages that are then specific to certain symptoms. But never cover everything that could be there. Maybe you can just rephrase it a bit. Yes, that means you actually have to have an initial guess and then you examine it specifically. But you don't study the entire genome. That's right, yes. Okay, let's rephrase. Well, we did it. Class. Yes, wonderful. Yes, we still had the one with the mutation, antimutation or whatever they called it. So with that I still have a bit of a stomach ache overall, because it is, actually already the case, that we have already established a lot of hereditary diseases and yes actually this prototype, as described earlier, has been there for a long time and we just keep expanding it with newly released things. Of course, we also expand our methods or the possibility of mapping these structural variants now, but I don't know if we can get that many hours together if I really concentrate on that. I have to talk to Mrs. Khler again, to my head of department, about how we can do that, whether we can perhaps somehow make a different focus, that we can somehow do it differently, so I would put that on the back burner at the moment, although it is actually the project that is retroactive, all the others are actually not retroactive from the time to But I would sit down with Mrs. Khnlein for the next three or four weeks and then I would give you feedback again. All right, so if we can change the focus, such as What is that? Mutations, exactly. We can integrate that relatively easily. But then just give me a message about it. Yes. Class. Wonderful. Then thank you very much, Mrs Kehl, for taking the time. And then I wish you a nice week. Same to you. Goodbye. Thank you. Goodbye.\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# let's write a prompt for a customer support chatbot that\n",
        "# answer questions using information extracted from our db\n",
        "template = \"\"\"You are a research document summarizer that finds the questions to user query and give correct responses\n",
        "\n",
        "You know the following context information.\n",
        "\n",
        "{chunks_formatted}\n",
        "\n",
        "Answer to the following question from a user. Use only information from the previous context information. Do not invent stuff.\n",
        "\n",
        "Question: {query}\n",
        "\n",
        "Answer:\"\"\"\n",
        "\n",
        "prompt = PromptTemplate(\n",
        "    input_variables=[\"chunks_formatted\", \"query\"],\n",
        "    template=template,\n",
        "    )"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 17
        },
        "outputId": "e66d3dda-2e28-41c2-faae-bc7a13334faf",
        "id": "U1pUckG2f7N1"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# the full pipeline\n",
        "\n",
        "# user question\n",
        "query = \"What is this research about\"\n",
        "\n",
        "# retrieve relevant chunks\n",
        "docs = db_simple.similarity_search(query)\n",
        "retrieved_chunks = [doc.page_content for doc in docs]\n",
        "\n",
        "# format the prompt\n",
        "chunks_formatted = \"\\n\\n\".join(retrieved_chunks)\n",
        "prompt_formatted = prompt.format(chunks_formatted=chunks_formatted, query=query)\n",
        "\n",
        "# generate answer\n",
        "llm = OpenAI(model=\"text-davinci-003\", temperature=0)\n",
        "answer = llm(prompt_formatted)\n",
        "print(answer)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 104
        },
        "outputId": "5a312dbe-4ab7-4d1c-d5d6-1f882fe30172",
        "id": "TRLwBw-8f7N1"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            " This research is about developing products for dogs, cats and horses that will give customers, breeders, veterinarians, and private individuals the opportunity to evaluate the genetic health of their own animal in its entirety, in some cases even beyond what is already known for the individual breeds, and on the other hand to promote animal health in the future. The project will use next generation sequencing as a technology for DNA profiling and will focus on parentage analyses and the genetic fingerprint of animals. The aim is to expand into larger genetic variants and to develop a product for each animal species that contains all hereditary diseases in the species and characteristics that can be mapped with the technology.\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# let's write a prompt for a customer support chatbot that\n",
        "# answer questions using information extracted from our db\n",
        "template = \"\"\"You are a research document summarizer that finds the questions to user query and give correct responses\n",
        "\n",
        "You know the following context information.\n",
        "\n",
        "{chunks_formatted}\n",
        "\n",
        "Answer to the following question from a user. Use only information from the previous context information following the guidelines provided. Do not invent stuff.\n",
        "\n",
        "Question: {query}\n",
        "Guidelines: {guidelines}\n",
        "Answer:\"\"\"\n",
        "\n",
        "prompt = PromptTemplate(\n",
        "    input_variables=[\"chunks_formatted\", \"query\", \"guidelines\"],\n",
        "    template=template,\n",
        "    )"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 17
        },
        "outputId": "09f06d68-3b4d-4c31-97f4-654f1b44a828",
        "id": "5Eng3EDNf7N2"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# the full pipeline\n",
        "\n",
        "# user question\n",
        "query = \"What is the Objective of the project (if applicable, in the context of the cooperative project) \"\n",
        "guidelines = '''\n",
        "Motivation, objectives, and intended results. To what extent does the project\n",
        "aim to expand the state of knowledge/technology or utilize existing\n",
        "scientific, technical, economic, or other relevant findings or approaches\n",
        " - 1 State of the art (Currently/According to the state of the art...\n",
        " - 1 Project objective (The goal of the project is...\n",
        " - 1 Differentiation from the state of the art (The state of the art is expanded\n",
        "   in terms of..., thereby expanding the knowledge about...\n",
        " - 1 Project result (The planned outcome/result is...)\n",
        "\n",
        "Please ensure that the project uses specific technical terminology to\n",
        "describe the innovative core. This is particularly crucial, especially for\n",
        "software projects.\n",
        "'''\n",
        "# retrieve relevant chunks\n",
        "docs = db_simple.similarity_search(query)\n",
        "retrieved_chunks = [doc.page_content for doc in docs]\n",
        "\n",
        "# format the prompt\n",
        "chunks_formatted = \"\\n\\n\".join(retrieved_chunks)\n",
        "prompt_formatted = prompt.format(chunks_formatted=chunks_formatted, query=query, guidelines=guidelines)\n",
        "\n",
        "# generate answer\n",
        "llm = OpenAI(model=\"text-davinci-003\", temperature=0)\n",
        "answer = llm(prompt_formatted)\n",
        "print(answer)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 139
        },
        "outputId": "471802b5-0305-4d11-a0c8-f87425107419",
        "id": "QQoU3_Jef7N2"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            " The current state of the art is that we are not yet using high-throughput technology to study the entire genetic markup of an animal. Instead, we mainly have individual tests and smaller products that are applied to breed-specific. The goal of the project is to give customers, breeders, veterinarians, private individuals the opportunity to evaluate the genetic health of their own animal in its entirety, in some cases even beyond what is already known for the individual breeds, and on the other hand to promote animal health in the future. The state of the art is expanded in terms of next generation sequencing technology, thereby expanding the knowledge about larger genetic variants such as insertions, deletions, and inversions. The planned outcome/result is one product for each of different animal species, which contains this additive XXL, which in the best case, contains all, but probably all, hereditary diseases in the species and characteristics that can be mapped with the technology.\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "# More Technical Approach"
      ],
      "metadata": {
        "id": "Cvfv7j4taibt"
      }
    },
    {
      "cell_type": "markdown",
      "source": [
        "## Experiment 1\n",
        "### Divide and Conquer"
      ],
      "metadata": {
        "id": "sTqpDdVTbJNU"
      }
    },
    {
      "cell_type": "markdown",
      "source": [
        "### Understanding Background"
      ],
      "metadata": {
        "id": "9g5sQXDvdvIF"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "from langchain.document_loaders import TextLoader\n",
        "loader = TextLoader('/content/drive/MyDrive/Innoscripta/Advanced/Exp1/processed_text_eng_background_exp1.txt')\n",
        "documents = loader.load_and_split()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 17
        },
        "outputId": "4b2f744b-1e89-4d5d-bc14-62976e88fbe1",
        "id": "xGh831JfdsrY"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "from langchain.text_splitter import CharacterTextSplitter\n",
        "text_splitter = CharacterTextSplitter(chunk_size=20, chunk_overlap=5)\n",
        "simple_texts = text_splitter.split_documents(documents)\n",
        "\n",
        "print (f\"You have {len(simple_texts)} documents\")\n",
        "\n",
        "print (\"Preview:\")\n",
        "print (simple_texts[0].page_content)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 441
        },
        "outputId": "642ec52f-cddf-4eb8-90d6-729846e52c83",
        "id": "ETjbgsNMdsra"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "You have 8 documents\n",
            "Preview:\n",
            "I would like to ask you at the beginning to give me a brief overview of the running time. The research allowance has been in place since 2020, which means that retrospective development content can also be attached. However, it is always important that the entire project duration is defined. This means that if, for example, it started in 2021, but still extends into the future, that you also cover the entire project duration up to the productive stage. How would that be classified with XSL cat. I would definitely take the starting point of January 1, 2023. Annalena, yes, that's in your interest and Alex, also because we had a project before, which was supported with subsidies and Annalena did a lot and they are quasi it has almost one to one now after this project from January then switched to XXL cat. That's how I would do it.  make now no idea of the term, there is what is good, you should take it time, you should do it quickly, so you should do a typical project, duration is four years, over four years, I would not recommend, between three to four years would be very good, so one year not short, we would definitely take the customer in with us, then I would do the same: So one year is not enough, short. We would definitely take the dog inside. Then I would... Two years. Say this goal, then I would really do it that way. Because we want to get the cat done faster than four years now. That's when our boss kills us. But we want to, we had it that way... Annalena, you have to interrupt me if But we had, yes considered, that we would pack the dog behind it, because the work is similarly not the same, but that's why I would maybe call it xxl cat and slash and slash horse then probably come to three to four years I would then also mean four years for my peace of mind. This should be processed in a nested way, so to speak, what we have learned from the cat, then transferred to the dog, so to speak. You also have a learning effect that it always merges into each other, just like baking cakes. And the cake is after four years, but we don't make more than four years. All right, that is, by the end of 26, or should we put it by the middle of 26? 23, 24, 25, Annalena, I mean I don't care. He's in his late 26s. Then we have a big project with four years, where you write hours, yes, I think so too. There will always be something to readjust or something like that, even if it works, then there will be new tests or something else to optimize. So I think there will be a need at the beginning. Yes, yes. All right. We must be able to present this as the most methodical approach possible. This means that a methodology is developed in practice, using the example of cats, and that this can then also be transferred to dogs and horses.  Ideally, this also means a methodical approach to transferring it to other species, so that one can ideally demonstrate here that, i.e. the promotion is there for the prototype, that practically paves the way, just using the example of cats, cats, dogs, horses, or that it could in principle be transferred to other animal species. That's how they want to write it, so they don't want the cat as a prototype and then the transfer to dog and horse, but that you Do we do that for the cattle or do we beat it to death? Yes, the funding goes all the way to the prototype. And if we say that practically only the cat is the prototype, then after that it would no longer be eligible. I'm also writing down a bit of a promotion.  The dog is definitely not exhausted with the development in the cat. This is part of what we can already implement methodically with the cat. But it is definitely the case that there will certainly be another year, one and a half, to have the dog complete and with the horse there are other things to consider. So it's true. So the dog has a lot more markers, I'll say now, than the cat, that he knows a lot more diseases. Annalena, you correct me, technically is a greater challenge, since to correctly name\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "type(simple_texts[0])"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 35
        },
        "id": "ZQs8rIegAwWz",
        "outputId": "76d7f9d5-524c-4319-af2b-80e12218d06a"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "langchain.schema.Document"
            ]
          },
          "metadata": {},
          "execution_count": 62
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Before executing the following code, make sure to have\n",
        "# your OpenAI key saved in the OPENAI_API_KEY environment variable.\n",
        "embeddings = OpenAIEmbeddings(model=\"text-embedding-ada-002\")\n",
        "\n",
        "# create Deep Lake dataset\n",
        "# TODO: use your organization id here. (by default, org id is your username)\n",
        "my_activeloop_org_id = \"parthtripathidummy\"\n",
        "my_activeloop_dataset_name = \"innoscripta_advanced_exp1_background\"\n",
        "dataset_path = f\"hub://{my_activeloop_org_id}/{my_activeloop_dataset_name}\"\n",
        "db_background = DeepLake(dataset_path=dataset_path, embedding_function=embeddings)\n",
        "\n",
        "# add documents to our Deep Lake dataset\n",
        "# db_background.add_documents(simple_texts)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 349
        },
        "outputId": "fe521510-5c63-4856-8249-d995cab226d0",
        "id": "1kK5Tcxgdsra"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Your Deep Lake dataset has been successfully created!\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "Creating embedding data: 100%|| 4/4 [00:02<00:00,  1.57it/s]\n",
            "|"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Dataset(path='hub://parthtripathidummy/innoscripta_advanced_exp1_background', tensors=['embedding', 'id', 'metadata', 'text'])\n",
            "\n",
            "  tensor      htype      shape     dtype  compression\n",
            "  -------    -------    -------   -------  ------- \n",
            " embedding  embedding  (8, 1536)  float32   None   \n",
            "    id        text      (8, 1)      str     None   \n",
            " metadata     json      (8, 1)      str     None   \n",
            "   text       text      (8, 1)      str     None   \n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "\r \r"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "['f40ada24-47a7-11ee-ab2c-0242ac1c000c',\n",
              " 'f40adb8c-47a7-11ee-ab2c-0242ac1c000c',\n",
              " 'f40adc0e-47a7-11ee-ab2c-0242ac1c000c',\n",
              " 'f40adc72-47a7-11ee-ab2c-0242ac1c000c',\n",
              " 'f40adcd6-47a7-11ee-ab2c-0242ac1c000c',\n",
              " 'f40add3a-47a7-11ee-ab2c-0242ac1c000c',\n",
              " 'f40add9e-47a7-11ee-ab2c-0242ac1c000c',\n",
              " 'f40ade02-47a7-11ee-ab2c-0242ac1c000c']"
            ]
          },
          "metadata": {},
          "execution_count": 6
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# let's see the top relevant documents to a specific query\n",
        "query = \"What is this research about\"\n",
        "# query = 'what is a nft'\n",
        "docs = db_background.similarity_search(query)\n",
        "print(docs[0].page_content)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 405
        },
        "outputId": "71735273-29e4-497e-9b83-062e06ad69d4",
        "id": "jR5XsIHodsrb"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "I would like to ask you at the beginning to give me a brief overview of the running time. The research allowance has been in place since 2020, which means that retrospective development content can also be attached. However, it is always important that the entire project duration is defined. This means that if, for example, it started in 2021, but still extends into the future, that you also cover the entire project duration up to the productive stage. How would that be classified with XSL cat. I would definitely take the starting point of January 1, 2023. Annalena, yes, that's in your interest and Alex, also because we had a project before, which was supported with subsidies and Annalena did a lot and they are quasi it has almost one to one now after this project from January then switched to XXL cat. That's how I would do it.  make now no idea of the term, there is what is good, you should take it time, you should do it quickly, so you should do a typical project, duration is four years, over four years, I would not recommend, between three to four years would be very good, so one year not short, we would definitely take the customer in with us, then I would do the same: So one year is not enough, short. We would definitely take the dog inside. Then I would... Two years. Say this goal, then I would really do it that way. Because we want to get the cat done faster than four years now. That's when our boss kills us. But we want to, we had it that way... Annalena, you have to interrupt me if But we had, yes considered, that we would pack the dog behind it, because the work is similarly not the same, but that's why I would maybe call it xxl cat and slash and slash horse then probably come to three to four years I would then also mean four years for my peace of mind. This should be processed in a nested way, so to speak, what we have learned from the cat, then transferred to the dog, so to speak. You also have a learning effect that it always merges into each other, just like baking cakes. And the cake is after four years, but we don't make more than four years. All right, that is, by the end of 26, or should we put it by the middle of 26? 23, 24, 25, Annalena, I mean I don't care. He's in his late 26s. Then we have a big project with four years, where you write hours, yes, I think so too. There will always be something to readjust or something like that, even if it works, then there will be new tests or something else to optimize. So I think there will be a need at the beginning. Yes, yes. All right. We must be able to present this as the most methodical approach possible. This means that a methodology is developed in practice, using the example of cats, and that this can then also be transferred to dogs and horses.  Ideally, this also means a methodical approach to transferring it to other species, so that one can ideally demonstrate here that, i.e. the promotion is there for the prototype, that practically paves the way, just using the example of cats, cats, dogs, horses, or that it could in principle be transferred to other animal species. That's how they want to write it, so they don't want the cat as a prototype and then the transfer to dog and horse, but that you Do we do that for the cattle or do we beat it to death? Yes, the funding goes all the way to the prototype. And if we say that practically only the cat is the prototype, then after that it would no longer be eligible. I'm also writing down a bit of a promotion.  The dog is definitely not exhausted with the development in the cat. This is part of what we can already implement methodically with the cat. But it is definitely the case that there will certainly be another year, one and a half, to have the dog complete and with the horse there are other things to consider. So it's true. So the dog has a lot more markers, I'll say now, than the cat, that he knows a lot more diseases. Annalena, you correct me, technically is a greater challenge, since to correctly name\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# let's write a prompt for a customer support chatbot that\n",
        "# answer questions using information extracted from our db\n",
        "template = \"\"\"You are a research document summarizer that finds the questions to user query and give correct responses\n",
        "\n",
        "You know the following context information.\n",
        "\n",
        "{chunks_formatted}\n",
        "\n",
        "Answer to the following question from a user. Use only information from the previous context information. Do not invent stuff.\n",
        "The user is from technical background and wants technically rich responses, with lots of technical jargons\n",
        "\n",
        "Question: {query}\n",
        "\n",
        "Answer:\"\"\"\n",
        "human_message_prompt = HumanMessagePromptTemplate.from_template(\n",
        "    input_variables=[\"chunks_formatted\", \"query\"],\n",
        "    template=template,\n",
        "    )\n",
        "prompt = ChatPromptTemplate.from_messages([human_message_prompt])"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 17
        },
        "outputId": "9095c398-71bd-458a-da2b-3f05f30aeca7",
        "id": "XVb3obOvdsrb"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "type(prompt)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 35
        },
        "id": "kKuLG40CgzB3",
        "outputId": "53db027a-89b9-423f-8ef2-4fb8d222300a"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "langchain.prompts.chat.ChatPromptTemplate"
            ]
          },
          "metadata": {},
          "execution_count": 23
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "from langchain.chat_models import ChatOpenAI\n",
        "from langchain import LLMChain\n",
        "# the full pipeline\n",
        "\n",
        "# user question\n",
        "query = \"What is the background of research ?\"\n",
        "\n",
        "# retrieve relevant chunks\n",
        "docs = db_background.similarity_search(query)\n",
        "retrieved_chunks = [doc.page_content for doc in docs]\n",
        "\n",
        "# format the prompt\n",
        "chunks_formatted = \"\\n\\n\".join(retrieved_chunks)\n",
        "prompt_formatted = prompt.format(chunks_formatted=chunks_formatted, query=query)\n",
        "print(prompt_formatted)\n",
        "# generate answer\n",
        "llm = ChatOpenAI(model_name=\"gpt-3.5-turbo\")\n",
        "chain = LLMChain(llm=llm, prompt=prompt, verbose=True)\n",
        "response = chain.run(chunks_formatted=chunks_formatted, query=query)\n",
        "\n",
        "print(response)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "outputId": "669f0186-301a-45ee-c9c3-d133eed89d1c",
        "id": "W0Y8M8r8dsrb"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Human: You are a research document summarizer that finds the questions to user query and give correct responses\n",
            "\n",
            "You know the following context information.\n",
            "\n",
            "I would like to ask you at the beginning to give me a brief overview of the running time. The research allowance has been in place since 2020, which means that retrospective development content can also be attached. However, it is always important that the entire project duration is defined. This means that if, for example, it started in 2021, but still extends into the future, that you also cover the entire project duration up to the productive stage. How would that be classified with XSL cat. I would definitely take the starting point of January 1, 2023. Annalena, yes, that's in your interest and Alex, also because we had a project before, which was supported with subsidies and Annalena did a lot and they are quasi it has almost one to one now after this project from January then switched to XXL cat. That's how I would do it.  make now no idea of the term, there is what is good, you should take it time, you should do it quickly, so you should do a typical project, duration is four years, over four years, I would not recommend, between three to four years would be very good, so one year not short, we would definitely take the customer in with us, then I would do the same: So one year is not enough, short. We would definitely take the dog inside. Then I would... Two years. Say this goal, then I would really do it that way. Because we want to get the cat done faster than four years now. That's when our boss kills us. But we want to, we had it that way... Annalena, you have to interrupt me if But we had, yes considered, that we would pack the dog behind it, because the work is similarly not the same, but that's why I would maybe call it xxl cat and slash and slash horse then probably come to three to four years I would then also mean four years for my peace of mind. This should be processed in a nested way, so to speak, what we have learned from the cat, then transferred to the dog, so to speak. You also have a learning effect that it always merges into each other, just like baking cakes. And the cake is after four years, but we don't make more than four years. All right, that is, by the end of 26, or should we put it by the middle of 26? 23, 24, 25, Annalena, I mean I don't care. He's in his late 26s. Then we have a big project with four years, where you write hours, yes, I think so too. There will always be something to readjust or something like that, even if it works, then there will be new tests or something else to optimize. So I think there will be a need at the beginning. Yes, yes. All right. We must be able to present this as the most methodical approach possible. This means that a methodology is developed in practice, using the example of cats, and that this can then also be transferred to dogs and horses.  Ideally, this also means a methodical approach to transferring it to other species, so that one can ideally demonstrate here that, i.e. the promotion is there for the prototype, that practically paves the way, just using the example of cats, cats, dogs, horses, or that it could in principle be transferred to other animal species. That's how they want to write it, so they don't want the cat as a prototype and then the transfer to dog and horse, but that you Do we do that for the cattle or do we beat it to death? Yes, the funding goes all the way to the prototype. And if we say that practically only the cat is the prototype, then after that it would no longer be eligible. I'm also writing down a bit of a promotion.  The dog is definitely not exhausted with the development in the cat. This is part of what we can already implement methodically with the cat. But it is definitely the case that there will certainly be another year, one and a half, to have the dog complete and with the horse there are other things to consider. So it's true. So the dog has a lot more markers, I'll say now, than the cat, that he knows a lot more diseases. Annalena, you correct me, technically is a greater challenge, since to correctly name\n",
            "\n",
            "you very much for the very valuable input and The next steps will look like this, we will work out the application. We are subject to a strict character limit, so do not wonder about the brevity. That's 800 characters per chapter that we've just talked through, so five times 800 characters and then I'll send it to you by e-mail. We also have an accompanying portal, the so-called IMS portal, where the application can also be accessed. I can make you an account as you wish. I will also send you by e-mail. I only want the e-mail addresses, because Mrs. Kehe, they had the e-mails, they had forwarded the invitation. Yes or is it easier if it goes through me, I'll then distribute it to you and get the info back and give it back, what do you two think? I think it's good, otherwise you'll forget someone in the CC at some point. If someone in the CC wonders why he is no longer up to date. Perfect, wonderful. Then Mrs. Kehl gets the proposal. If there is no further issue with you, Mrs Khnlein and Mrs Van der Velja, then we would be done with it. Now I have a question, you guys are still doing the resistances Alex? Yes, exactly. Is anyone else coming in? No. Okay all right. You don't need us? No. So in the system I saw through: Yes, and in the project Resistances I am practically not in it. Yes, exactly. Okay, well, then it means we have to hang up now, just press it, right? That's right, then they're automatically out. Okay, thank you very much and then I wish you good luck And then I wish you good luck. Thank you, bye-bye I have already had discussions about the drug preparations for the treatment of antibiotic resistance and bacterial infections. Is that what resistance is now all about? No, that's something completely different. All right, just for classification. Yes yes exactly. What is the name of this at the moment? Resistance? Maybe we can call it Leishmania resistance. Because it's really mainly about Leishmania.  Could you write that down in the chat? Where is he here? At the top left is Chat. At least for me. I don't know if it's a little different for you. But you have such a menu bar in Teams. Yes.  And there is such an addiction question. Ah, entertainment. Besprechungstit. Enter a message. Ah yes, ok, per yes, ok, perfect. So I'll have to see if it's too long in terms of characters. Otherwise, I might just call it Leishmania or something. Or larch resistance, something like that. Perfect, yes. Then I would actually like to just continue with the screen splitting again. I think it's always a bit more structured. Class. Exactly, then let's go to that, or respectively the first is always the runtime. When did we start the project? So we started in the middle of last year, at the end of last year, but I might still do, yes, no, I think we'll still start January 23 and then let it run for three years.\n",
            "\n",
            "Ugh, difficult. So at least in numbers I wouldn't say, because it's extremely different for dogs, cats and horses. And since the hereditary diseases are constantly being developed, new ones are constantly being added, I would actually rather say that it would perhaps be our goal to continuously cover a large part and I would say maybe more than 60 percent of the known diseases in the respective species and that is really because of the fact that  whether this is even possible with the technology. There are just some things that prevent us from doing that. That's why I have a hard time with the number. But that's a good numerical value. So no one will pin down on the fact that simply for an examiner who simply has to recognize a lot in very little text, i.e. the application has one page, and that's why just such a number sheet is always very good. Then I actually want to move on to the operation of the work, i.e. here it is answered how you want to realize the whole thing, there must be a methodical approach recognizable. So if you simply start here with the work steps that you will ultimately carry out and then also go into the new method on your part, that the gain for the examiner can be recognized and also in the knowledge gap for you is closed by it, so the good first step is that you have to carry out a complete scientific analysis of all current hereditary diseases in the three different species. This is actually quite a complex work package, because it means that you always have to understand and recreate it in the scientific publications themselves. Then it has to be implemented in the so-called panels with which the NGS technology works. One panel for each species. Then the third step would be the evaluation of the tests that we map. Of course, we also have to make sure that this should not only deliver the correct result from a technical point of view, but that it does. In other words, we have to compare the known animals with the results that we achieve with the new technology, with the NGS technology, and perhaps then bring the whole thing as fit for the work package in a way that is then understandable to the customer. We can't train them with 200 pages of text at the end. It has to be adapted to the different types of people so that they can do something with it. Wonderful, thank you very much.  In the end, could you rewrite the prototype a little better, i.e. the way in which it is understandable for the customer. Do you have a little better idea of what the end result should look like?  Is this a test kit or do you run the tests? The output is then the analysis? In the end, the customer only sends us DNA of his animal, either with blood or with swabs or with hair in the horse often. We are then responsible for everything that goes from DNA extraction to the execution of all genetic tests, then the evaluation and then the processing, that it should go back to the customer and I would say that this can probably be done in either an application, an app or a web-based representation, where a customer then has his single animal or his several animals,  which he can then analyze, also look at in the long run. Maybe even compare with others. And that's something, if I may take a quick look at what's completely new. At the moment we are making findings that were originally on paper, which are now sent as e-mails, but of course not as they might look like in this case with an app. So this is also a completely new product, a completely new form of diagnosis. Yes all right. Above all, the comparison of the Prennness to other animals is certainly an important point here, which cannot be carried out at present. No, can't be done. What do you mean by comparison to others? At the end of the day, when you analyze the entire genome, you have to take the big picture into account and you don't just test for a specific disease. But that's why I don't necessarily use other animals in this case. No, that's not what I meant by other\n",
            "\n",
            "So it's true. So the dog has a lot more markers, I'll say now, than the cat, that he knows a lot more diseases. Annalena, you correct me, technically is a greater challenge, since to correctly name the hereditary diseases, to define them. Exactly, that you do the right calling. Now you've already gone to the content. I would ask you to be able to explain the goal of the project in general, i.e. really with cat, dog and horse, because that is the first chapter at the end of the day. In other words, the examiner must ultimately be able to distinguish it from the state of the art and also how it is currently carried out according to the state of the art. Do you like Annalena? Yes, I'm happy to. With the products that are to be developed for dogs, cats and horses, we want to give customers, breeders, veterinarians, private individuals the opportunity to evaluate the genetic health of their own animal in its entirety, in some cases even beyond what is already known for the individual breeds, and on the other hand to promote animal health in the future,  because this can and should really flow directly into the breeding decisions, especially within breeds that are bred a bit more closely, to ensure that the animals do not become completely sicker and sicker in the next 50 to 100 years. That's how I would sum it up now. I have enclosed a short quality checklist here to accompany the application and how the application is always structured, so that you have a rough direction. We always have to describe a sentence about the state of the art, i.e. according to the current state of the art, this is done this way and that, then what the project goal is, then also the demarcation from the state of the art, to what extent the state of the art is expanded and the knowledge is expanded at your company and then finally what the project result should be. Perhaps you could just ask a few questions about the project, especially in relation to this Next Generation Sequencing. So let's put into perspective the extent to which you have already used it, to what extent it is a new technique for you, to what extent it is something new for detecting hereditary diseases in cats, dogs and horses. So now verbally or then for the application? Oral, oral. We formulate on the basis, that's why the recording is ongoing. We formulate the application from this. Okay, so then I would say that the current state of the art is that we are not yet using high-throughput technology to study the entire genetic markup of an animal. Instead, we mainly have individual tests and smaller products that are applied to breed-specific.  We are currently using next generation sequencing as a technology for DNA profiling. The main focus is on parentage analyses and the genetic fingerprint of animals. The aim of the project would then be what I formulated earlier, that it is primarily about animal health, of our own animal, but also of the species that we want to cover as a whole. State-of-the-art technology?  Above all, we are also expanding into larger genetic variants in this area. So simpler tests are mainly SNPs, but if genetic causes, complicated sense with larger insertions, deletions, inversions, whatever. This is where we want to expand our next-generation sequencing technology. The result of the project would then be one product for each of different animal species, which contains this additive XXL, which in the best case, yes, in the best case, contains all, but probably all, hereditary diseases in the species and characteristics that can be mapped with the technology. Ideally, we can substantiate the application with one or two target values. So maybe you can quantify all hereditary diseases a little bit than how much should be achieved at least or worth in other numbers? Ugh, difficult. So at least in numbers I wouldn't say, because it's extremely different for dogs, cats and horses. And since the hereditary diseases are constantly being developed, new ones are\n",
            "\n",
            "Answer to the following question from a user. Use only information from the previous context information. Do not invent stuff.\n",
            "The user is from technical background and wants technically rich responses, with lots of technical jargons\n",
            "\n",
            "Question: What is the background of research ?\n",
            "\n",
            "Answer:\n",
            "\n",
            "\n",
            "\u001b[1m> Entering new  chain...\u001b[0m\n",
            "Prompt after formatting:\n",
            "\u001b[32;1m\u001b[1;3mHuman: You are a research document summarizer that finds the questions to user query and give correct responses\n",
            "\n",
            "You know the following context information.\n",
            "\n",
            "I would like to ask you at the beginning to give me a brief overview of the running time. The research allowance has been in place since 2020, which means that retrospective development content can also be attached. However, it is always important that the entire project duration is defined. This means that if, for example, it started in 2021, but still extends into the future, that you also cover the entire project duration up to the productive stage. How would that be classified with XSL cat. I would definitely take the starting point of January 1, 2023. Annalena, yes, that's in your interest and Alex, also because we had a project before, which was supported with subsidies and Annalena did a lot and they are quasi it has almost one to one now after this project from January then switched to XXL cat. That's how I would do it.  make now no idea of the term, there is what is good, you should take it time, you should do it quickly, so you should do a typical project, duration is four years, over four years, I would not recommend, between three to four years would be very good, so one year not short, we would definitely take the customer in with us, then I would do the same: So one year is not enough, short. We would definitely take the dog inside. Then I would... Two years. Say this goal, then I would really do it that way. Because we want to get the cat done faster than four years now. That's when our boss kills us. But we want to, we had it that way... Annalena, you have to interrupt me if But we had, yes considered, that we would pack the dog behind it, because the work is similarly not the same, but that's why I would maybe call it xxl cat and slash and slash horse then probably come to three to four years I would then also mean four years for my peace of mind. This should be processed in a nested way, so to speak, what we have learned from the cat, then transferred to the dog, so to speak. You also have a learning effect that it always merges into each other, just like baking cakes. And the cake is after four years, but we don't make more than four years. All right, that is, by the end of 26, or should we put it by the middle of 26? 23, 24, 25, Annalena, I mean I don't care. He's in his late 26s. Then we have a big project with four years, where you write hours, yes, I think so too. There will always be something to readjust or something like that, even if it works, then there will be new tests or something else to optimize. So I think there will be a need at the beginning. Yes, yes. All right. We must be able to present this as the most methodical approach possible. This means that a methodology is developed in practice, using the example of cats, and that this can then also be transferred to dogs and horses.  Ideally, this also means a methodical approach to transferring it to other species, so that one can ideally demonstrate here that, i.e. the promotion is there for the prototype, that practically paves the way, just using the example of cats, cats, dogs, horses, or that it could in principle be transferred to other animal species. That's how they want to write it, so they don't want the cat as a prototype and then the transfer to dog and horse, but that you Do we do that for the cattle or do we beat it to death? Yes, the funding goes all the way to the prototype. And if we say that practically only the cat is the prototype, then after that it would no longer be eligible. I'm also writing down a bit of a promotion.  The dog is definitely not exhausted with the development in the cat. This is part of what we can already implement methodically with the cat. But it is definitely the case that there will certainly be another year, one and a half, to have the dog complete and with the horse there are other things to consider. So it's true. So the dog has a lot more markers, I'll say now, than the cat, that he knows a lot more diseases. Annalena, you correct me, technically is a greater challenge, since to correctly name\n",
            "\n",
            "you very much for the very valuable input and The next steps will look like this, we will work out the application. We are subject to a strict character limit, so do not wonder about the brevity. That's 800 characters per chapter that we've just talked through, so five times 800 characters and then I'll send it to you by e-mail. We also have an accompanying portal, the so-called IMS portal, where the application can also be accessed. I can make you an account as you wish. I will also send you by e-mail. I only want the e-mail addresses, because Mrs. Kehe, they had the e-mails, they had forwarded the invitation. Yes or is it easier if it goes through me, I'll then distribute it to you and get the info back and give it back, what do you two think? I think it's good, otherwise you'll forget someone in the CC at some point. If someone in the CC wonders why he is no longer up to date. Perfect, wonderful. Then Mrs. Kehl gets the proposal. If there is no further issue with you, Mrs Khnlein and Mrs Van der Velja, then we would be done with it. Now I have a question, you guys are still doing the resistances Alex? Yes, exactly. Is anyone else coming in? No. Okay all right. You don't need us? No. So in the system I saw through: Yes, and in the project Resistances I am practically not in it. Yes, exactly. Okay, well, then it means we have to hang up now, just press it, right? That's right, then they're automatically out. Okay, thank you very much and then I wish you good luck And then I wish you good luck. Thank you, bye-bye I have already had discussions about the drug preparations for the treatment of antibiotic resistance and bacterial infections. Is that what resistance is now all about? No, that's something completely different. All right, just for classification. Yes yes exactly. What is the name of this at the moment? Resistance? Maybe we can call it Leishmania resistance. Because it's really mainly about Leishmania.  Could you write that down in the chat? Where is he here? At the top left is Chat. At least for me. I don't know if it's a little different for you. But you have such a menu bar in Teams. Yes.  And there is such an addiction question. Ah, entertainment. Besprechungstit. Enter a message. Ah yes, ok, per yes, ok, perfect. So I'll have to see if it's too long in terms of characters. Otherwise, I might just call it Leishmania or something. Or larch resistance, something like that. Perfect, yes. Then I would actually like to just continue with the screen splitting again. I think it's always a bit more structured. Class. Exactly, then let's go to that, or respectively the first is always the runtime. When did we start the project? So we started in the middle of last year, at the end of last year, but I might still do, yes, no, I think we'll still start January 23 and then let it run for three years.\n",
            "\n",
            "Ugh, difficult. So at least in numbers I wouldn't say, because it's extremely different for dogs, cats and horses. And since the hereditary diseases are constantly being developed, new ones are constantly being added, I would actually rather say that it would perhaps be our goal to continuously cover a large part and I would say maybe more than 60 percent of the known diseases in the respective species and that is really because of the fact that  whether this is even possible with the technology. There are just some things that prevent us from doing that. That's why I have a hard time with the number. But that's a good numerical value. So no one will pin down on the fact that simply for an examiner who simply has to recognize a lot in very little text, i.e. the application has one page, and that's why just such a number sheet is always very good. Then I actually want to move on to the operation of the work, i.e. here it is answered how you want to realize the whole thing, there must be a methodical approach recognizable. So if you simply start here with the work steps that you will ultimately carry out and then also go into the new method on your part, that the gain for the examiner can be recognized and also in the knowledge gap for you is closed by it, so the good first step is that you have to carry out a complete scientific analysis of all current hereditary diseases in the three different species. This is actually quite a complex work package, because it means that you always have to understand and recreate it in the scientific publications themselves. Then it has to be implemented in the so-called panels with which the NGS technology works. One panel for each species. Then the third step would be the evaluation of the tests that we map. Of course, we also have to make sure that this should not only deliver the correct result from a technical point of view, but that it does. In other words, we have to compare the known animals with the results that we achieve with the new technology, with the NGS technology, and perhaps then bring the whole thing as fit for the work package in a way that is then understandable to the customer. We can't train them with 200 pages of text at the end. It has to be adapted to the different types of people so that they can do something with it. Wonderful, thank you very much.  In the end, could you rewrite the prototype a little better, i.e. the way in which it is understandable for the customer. Do you have a little better idea of what the end result should look like?  Is this a test kit or do you run the tests? The output is then the analysis? In the end, the customer only sends us DNA of his animal, either with blood or with swabs or with hair in the horse often. We are then responsible for everything that goes from DNA extraction to the execution of all genetic tests, then the evaluation and then the processing, that it should go back to the customer and I would say that this can probably be done in either an application, an app or a web-based representation, where a customer then has his single animal or his several animals,  which he can then analyze, also look at in the long run. Maybe even compare with others. And that's something, if I may take a quick look at what's completely new. At the moment we are making findings that were originally on paper, which are now sent as e-mails, but of course not as they might look like in this case with an app. So this is also a completely new product, a completely new form of diagnosis. Yes all right. Above all, the comparison of the Prennness to other animals is certainly an important point here, which cannot be carried out at present. No, can't be done. What do you mean by comparison to others? At the end of the day, when you analyze the entire genome, you have to take the big picture into account and you don't just test for a specific disease. But that's why I don't necessarily use other animals in this case. No, that's not what I meant by other\n",
            "\n",
            "So it's true. So the dog has a lot more markers, I'll say now, than the cat, that he knows a lot more diseases. Annalena, you correct me, technically is a greater challenge, since to correctly name the hereditary diseases, to define them. Exactly, that you do the right calling. Now you've already gone to the content. I would ask you to be able to explain the goal of the project in general, i.e. really with cat, dog and horse, because that is the first chapter at the end of the day. In other words, the examiner must ultimately be able to distinguish it from the state of the art and also how it is currently carried out according to the state of the art. Do you like Annalena? Yes, I'm happy to. With the products that are to be developed for dogs, cats and horses, we want to give customers, breeders, veterinarians, private individuals the opportunity to evaluate the genetic health of their own animal in its entirety, in some cases even beyond what is already known for the individual breeds, and on the other hand to promote animal health in the future,  because this can and should really flow directly into the breeding decisions, especially within breeds that are bred a bit more closely, to ensure that the animals do not become completely sicker and sicker in the next 50 to 100 years. That's how I would sum it up now. I have enclosed a short quality checklist here to accompany the application and how the application is always structured, so that you have a rough direction. We always have to describe a sentence about the state of the art, i.e. according to the current state of the art, this is done this way and that, then what the project goal is, then also the demarcation from the state of the art, to what extent the state of the art is expanded and the knowledge is expanded at your company and then finally what the project result should be. Perhaps you could just ask a few questions about the project, especially in relation to this Next Generation Sequencing. So let's put into perspective the extent to which you have already used it, to what extent it is a new technique for you, to what extent it is something new for detecting hereditary diseases in cats, dogs and horses. So now verbally or then for the application? Oral, oral. We formulate on the basis, that's why the recording is ongoing. We formulate the application from this. Okay, so then I would say that the current state of the art is that we are not yet using high-throughput technology to study the entire genetic markup of an animal. Instead, we mainly have individual tests and smaller products that are applied to breed-specific.  We are currently using next generation sequencing as a technology for DNA profiling. The main focus is on parentage analyses and the genetic fingerprint of animals. The aim of the project would then be what I formulated earlier, that it is primarily about animal health, of our own animal, but also of the species that we want to cover as a whole. State-of-the-art technology?  Above all, we are also expanding into larger genetic variants in this area. So simpler tests are mainly SNPs, but if genetic causes, complicated sense with larger insertions, deletions, inversions, whatever. This is where we want to expand our next-generation sequencing technology. The result of the project would then be one product for each of different animal species, which contains this additive XXL, which in the best case, yes, in the best case, contains all, but probably all, hereditary diseases in the species and characteristics that can be mapped with the technology. Ideally, we can substantiate the application with one or two target values. So maybe you can quantify all hereditary diseases a little bit than how much should be achieved at least or worth in other numbers? Ugh, difficult. So at least in numbers I wouldn't say, because it's extremely different for dogs, cats and horses. And since the hereditary diseases are constantly being developed, new ones are\n",
            "\n",
            "Answer to the following question from a user. Use only information from the previous context information. Do not invent stuff.\n",
            "The user is from technical background and wants technically rich responses, with lots of technical jargons\n",
            "\n",
            "Question: What is the background of research ?\n",
            "\n",
            "Answer:\u001b[0m\n",
            "\n",
            "\u001b[1m> Finished chain.\u001b[0m\n",
            "The background of the research is to develop products for dogs, cats, and horses that allow customers, breeders, veterinarians, and private individuals to evaluate the genetic health of their animals. The goal is to go beyond what is currently known about genetic health in individual breeds and to promote animal health in the future. The project aims to use Next Generation Sequencing (NGS) technology to study the entire genetic makeup of animals and detect hereditary diseases. This expands on the current state of the art, which mainly consists of individual tests and smaller products applied to breed-specific diseases. The result of the project will be a product for each animal species that covers a large number of hereditary diseases and characteristics that can be mapped using NGS technology.\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "### Understanding Target"
      ],
      "metadata": {
        "id": "xuqcrYUTibY-"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "from langchain.document_loaders import TextLoader\n",
        "loader = TextLoader('/content/drive/MyDrive/Innoscripta/Advanced/Exp1/processed_text_eng_target_exp1.txt')\n",
        "documents = loader.load_and_split()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 17
        },
        "outputId": "c4858bc0-0ebc-4056-dacd-b9c0a4760505",
        "id": "SLrQg9nkibY_"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "from langchain.text_splitter import CharacterTextSplitter\n",
        "text_splitter = CharacterTextSplitter(chunk_size=50, chunk_overlap=10)\n",
        "simple_texts = text_splitter.split_documents(documents)\n",
        "\n",
        "print (f\"You have {len(simple_texts)} documents\")\n",
        "\n",
        "print (\"Preview:\")\n",
        "print (simple_texts[0].page_content)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 441
        },
        "outputId": "61ef1511-7ba6-4b24-cdb5-db073f93727f",
        "id": "_50IrWeIibZA"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "You have 5 documents\n",
            "Preview:\n",
            "Perfect, okay when we start again with the goal of the project. So I'm going to elaborate a bit, leishmania are parasites that are transmitted via various mosquitoes. This means that the dogs are bitten by the mosquitoes, then get these leishmanias, which then lead to leishmaniasis. And the whole thing can also affect people. At the moment, this is still a major problem in southern countries, i.e. southern Europe. However, due to climate change, of course, these mosquitoes are coming further and further north, which transmit these larch manias, so to speak, and sooner or later it will most likely become a problem in Germany. This means that the dog has the mosquito bites on these Leishmanias, picks up the eggs of it again and so on and so on. There are now various medications that are taken for the treatment of the dogs. However, these Leishmania develop resistance to it very quickly. Our goal now would be to get a sample from a dog, to prove that he has Leishmania and at the same time to examine these Leishmania to see if they already contain certain resistance genes, so that the doctor can then take the other drug instead of a drug, as is the case with the bacteria in the end, instead of giving the wrong drug,  On the one hand, this does not work, and on the other hand, it leads to the formation of even more resistant Leishmania in order to avoid this. That would be the goal, that you give the veterinarians a tool and say, send us a sample. We study the animal Leishmania and have these Leishmania that the animal has, resistance genes, in order to be able to say which drug is best. Wonderful thank you very much.  On what basis should the investigation of the resistance or the sample in general be carried out? There are already a few publications, there are many groups that are working on which genes are responsible for the resistances. There are already a few publications, there are many groups that are now working on which genes are now responsible for the resistance. There is often no change in the genes, but a copy number variation. So these genes are then either multiplied or they are no longer there at all and this leads to this resistance and this is to be investigated on the basis of these scientific publications. And what we also want to do is to use Next Generation Sequencing to examine the entire Leishmania genome, so to speak. So the first approach would be to search specifically for the genes that are in the publications. And we can also look at it again. In other words, we would then also ask the veterinarians again, are these dogs already treated, do you also see resistance to allopurinol, for example, and we can see, yes we also see what is written in the scientific publication, that this and that gene is more common or not. And then we also want to examine the complete genomes of the Leishmania to see if we can find more genes that are relevant. And that would simply make the product more attractive if you don't say, okay, I'm just looking for an allopurinol resistance or only for a Milteforan resistance, but I'll look at everything again and I can then tell you, yes such and such resistances are present and you don't need this and that at all. Perfect, thank you very much. Could you elaborate on how you ultimately want to characterize whether other genes are relevant if they are not yet published? Are there certain patterns that they then practically read out of the publications and then transferred to the rest of the moment, something has just happened to me. I don't see them properly anymore. So we would just take a close look at the whole thing via Next Generation Sequencing.  Yes, of course, because they are often also copy number variations, one would first focus on whether one sees something like this in other genes. But you would also look at variations like these SNPs, for example, to see whether or not you see them clustered in certain genes, in certain resistant Leishmania. And the characterization\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Before executing the following code, make sure to have\n",
        "# your OpenAI key saved in the OPENAI_API_KEY environment variable.\n",
        "embeddings = OpenAIEmbeddings(model=\"text-embedding-ada-002\")\n",
        "\n",
        "# create Deep Lake dataset\n",
        "# TODO: use your organization id here. (by default, org id is your username)\n",
        "my_activeloop_org_id = \"parthtripathidummy\"\n",
        "my_activeloop_dataset_name = \"innoscripta_advanced_exp1_target\"\n",
        "dataset_path = f\"hub://{my_activeloop_org_id}/{my_activeloop_dataset_name}\"\n",
        "db_target = DeepLake(dataset_path=dataset_path, embedding_function=embeddings)\n",
        "\n",
        "# add documents to our Deep Lake dataset\n",
        "db_target.add_documents(simple_texts)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 294
        },
        "outputId": "42ffad5b-0b29-4538-ec4a-f271e8626b99",
        "id": "NiUZkGCzibZA"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Your Deep Lake dataset has been successfully created!\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "Creating embedding data: 100%|| 2/2 [00:00<00:00,  2.33it/s]\n",
            "/"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Dataset(path='hub://parthtripathidummy/innoscripta_advanced_exp1_target', tensors=['embedding', 'id', 'metadata', 'text'])\n",
            "\n",
            "  tensor      htype      shape     dtype  compression\n",
            "  -------    -------    -------   -------  ------- \n",
            " embedding  embedding  (5, 1536)  float32   None   \n",
            "    id        text      (5, 1)      str     None   \n",
            " metadata     json      (5, 1)      str     None   \n",
            "   text       text      (5, 1)      str     None   \n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "\r \r"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "['f88ff928-47aa-11ee-ab2c-0242ac1c000c',\n",
              " 'f88ffb30-47aa-11ee-ab2c-0242ac1c000c',\n",
              " 'f88ffbf8-47aa-11ee-ab2c-0242ac1c000c',\n",
              " 'f88ffca2-47aa-11ee-ab2c-0242ac1c000c',\n",
              " 'f88ffd24-47aa-11ee-ab2c-0242ac1c000c']"
            ]
          },
          "metadata": {},
          "execution_count": 31
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# let's see the top relevant documents to a specific query\n",
        "query = \"What is this research about\"\n",
        "# query = 'what is a nft'\n",
        "docs = db_target.similarity_search(query)\n",
        "print(docs[0].page_content)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 405
        },
        "outputId": "e473e14f-4d26-44fd-9789-8d56b9208d2f",
        "id": "oDKIFRd0ibZB"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "in the animal sector. If things go really badly, you can also grow the Leishmania in a cell culture and then examine the special hold, so to speak. But that would be very time-consuming, very expensive. You have to ask yourself whether you want to continue the project at all. In other words, one could actually also argue as a risk that the whole technique works for Leishmania in cell culture, but in the end the animal sample simply cannot be realized. Yes, right. Better. To the expenses. Do you know how many people are supposed to work on it? Yes, so we'll do it again via the HR department. In principle, I will have a relatively large number of hours there. Then a veterinarian from clinical chemistry has hours there and of course we still need a laboratory and I think there will be a second veterinarian from either my department or from clinical chemistry so that he can have contact with the veterinarians outside. All right, then just a rough overview, that is, four people to no idea ten to 15 percent perhaps. Yes, that's right.  Okay, do any subcontractors still come in here? So there will certainly be cooperations, but more with universities and then you don't really have any bills. So if you don't pay for the university, then that's not relevant. Yes yes exactly.  Yes, exactly, I'm just thinking so loudly. That's why I don't think so at the moment. Okay perfect, then I'm already through with my questions here too. Is there another project or would that be it for now?  I think that would be it for now. Completely new things will be added. The other thing with the infection scan, they had sent something again. I would only get the one sentence out.  Exactly, I wanted to talk to you about that, because of course we have to make sure that we fill in the text to see if there is perhaps a replacement for the deletion. I don't know what you're aiming for. I'll probably have to open this up again. Because it doesn't allow you to do that, just that's what IT is doing here today. Exactly, but I can also briefly share your e-mail otherwise. Yes, maybe that's the fastest way to do it. So, exactly. Yes, few screening with EDP Yes, few screening methods that result from dogs or cats. I don't know what they're actually going to pick up. We wanted to show a bit of the demarcations to the state of the art, i.e. how this is done according to statistics, i.e. how much of the statistics is not enough. So what we're doing is not screening methods, it's like, it's like packages. But that would have to be worded a little differently. If the dog's nose runs, then we just do herpes calypso, then there are already four or five typical pathogens that you do there.  So these are more like packages that are then specific to certain symptoms. But never cover everything that could be there. Maybe you can just rephrase it a bit. Yes, that means you actually have to have an initial guess and then you examine it specifically. But you don't study the entire genome. That's right, yes. Okay, let's rephrase. Well, we did it. Class. Yes, wonderful. Yes, we still had the one with the mutation, antimutation or whatever they called it. So with that I still have a bit of a stomach ache overall, because it is, actually already the case, that we have already established a lot of hereditary diseases and yes actually this prototype, as described earlier, has been there for a long time and we just keep expanding it with newly released things. Of course, we also expand our methods or the possibility of mapping these structural variants now, but I don't know if we can get that many hours together if I really concentrate on that. I have to talk to Mrs. Khler again, to my head of department, about how we can do that, whether we can perhaps somehow make a different focus, that we can somehow do it differently, so I would put that on the back burner at the moment, although it is actually the project that is retroactive, all the others are actually not retroactive from the\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# let's write a prompt for a customer support chatbot that\n",
        "# answer questions using information extracted from our db\n",
        "template = \"\"\"You are a research document summarizer that finds the questions to user query and give correct responses\n",
        "\n",
        "You know the following context information.\n",
        "\n",
        "{chunks_formatted}\n",
        "\n",
        "Answer to the following question from a user. Use only information from the previous context information. Do not invent stuff.\n",
        "The user is from technical background and wants technically rich responses, with lots of technical jargons\n",
        "\n",
        "Question: {query}\n",
        "\n",
        "Answer:\"\"\"\n",
        "human_message_prompt = HumanMessagePromptTemplate.from_template(\n",
        "    input_variables=[\"chunks_formatted\", \"query\"],\n",
        "    template=template,\n",
        "    )\n",
        "prompt = ChatPromptTemplate.from_messages([human_message_prompt])"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 17
        },
        "outputId": "47581a93-c163-46b7-b0f9-23e10bed0b6a",
        "id": "0syqFto1ibZB"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "type(prompt)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 35
        },
        "outputId": "392003f7-2e98-4820-bffd-b8fe2e12c15a",
        "id": "Gn_MwcBsibZB"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "langchain.prompts.chat.ChatPromptTemplate"
            ]
          },
          "metadata": {},
          "execution_count": 34
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "from langchain.chat_models import ChatOpenAI\n",
        "from langchain import LLMChain\n",
        "# the full pipeline\n",
        "\n",
        "# user question\n",
        "query = \"What is the background of research ?\"\n",
        "\n",
        "# retrieve relevant chunks\n",
        "docs = db_target.similarity_search(query)\n",
        "retrieved_chunks = [doc.page_content for doc in docs]\n",
        "\n",
        "# format the prompt\n",
        "chunks_formatted = \"\\n\\n\".join(retrieved_chunks)\n",
        "prompt_formatted = prompt.format(chunks_formatted=chunks_formatted, query=query)\n",
        "print(prompt_formatted)\n",
        "# generate answer\n",
        "llm = ChatOpenAI(model_name=\"gpt-3.5-turbo\")\n",
        "chain = LLMChain(llm=llm, prompt=prompt, verbose=True)\n",
        "response = chain.run(chunks_formatted=chunks_formatted, query=query)\n",
        "\n",
        "print(response)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "outputId": "71cc98a3-a956-4af1-9be8-e2db5a519bbd",
        "id": "PJM78n5iibZC"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Human: You are a research document summarizer that finds the questions to user query and give correct responses\n",
            "\n",
            "You know the following context information.\n",
            "\n",
            "in the animal sector. If things go really badly, you can also grow the Leishmania in a cell culture and then examine the special hold, so to speak. But that would be very time-consuming, very expensive. You have to ask yourself whether you want to continue the project at all. In other words, one could actually also argue as a risk that the whole technique works for Leishmania in cell culture, but in the end the animal sample simply cannot be realized. Yes, right. Better. To the expenses. Do you know how many people are supposed to work on it? Yes, so we'll do it again via the HR department. In principle, I will have a relatively large number of hours there. Then a veterinarian from clinical chemistry has hours there and of course we still need a laboratory and I think there will be a second veterinarian from either my department or from clinical chemistry so that he can have contact with the veterinarians outside. All right, then just a rough overview, that is, four people to no idea ten to 15 percent perhaps. Yes, that's right.  Okay, do any subcontractors still come in here? So there will certainly be cooperations, but more with universities and then you don't really have any bills. So if you don't pay for the university, then that's not relevant. Yes yes exactly.  Yes, exactly, I'm just thinking so loudly. That's why I don't think so at the moment. Okay perfect, then I'm already through with my questions here too. Is there another project or would that be it for now?  I think that would be it for now. Completely new things will be added. The other thing with the infection scan, they had sent something again. I would only get the one sentence out.  Exactly, I wanted to talk to you about that, because of course we have to make sure that we fill in the text to see if there is perhaps a replacement for the deletion. I don't know what you're aiming for. I'll probably have to open this up again. Because it doesn't allow you to do that, just that's what IT is doing here today. Exactly, but I can also briefly share your e-mail otherwise. Yes, maybe that's the fastest way to do it. So, exactly. Yes, few screening with EDP Yes, few screening methods that result from dogs or cats. I don't know what they're actually going to pick up. We wanted to show a bit of the demarcations to the state of the art, i.e. how this is done according to statistics, i.e. how much of the statistics is not enough. So what we're doing is not screening methods, it's like, it's like packages. But that would have to be worded a little differently. If the dog's nose runs, then we just do herpes calypso, then there are already four or five typical pathogens that you do there.  So these are more like packages that are then specific to certain symptoms. But never cover everything that could be there. Maybe you can just rephrase it a bit. Yes, that means you actually have to have an initial guess and then you examine it specifically. But you don't study the entire genome. That's right, yes. Okay, let's rephrase. Well, we did it. Class. Yes, wonderful. Yes, we still had the one with the mutation, antimutation or whatever they called it. So with that I still have a bit of a stomach ache overall, because it is, actually already the case, that we have already established a lot of hereditary diseases and yes actually this prototype, as described earlier, has been there for a long time and we just keep expanding it with newly released things. Of course, we also expand our methods or the possibility of mapping these structural variants now, but I don't know if we can get that many hours together if I really concentrate on that. I have to talk to Mrs. Khler again, to my head of department, about how we can do that, whether we can perhaps somehow make a different focus, that we can somehow do it differently, so I would put that on the back burner at the moment, although it is actually the project that is retroactive, all the others are actually not retroactive from the\n",
            "\n",
            "we can somehow do it differently, so I would put that on the back burner at the moment, although it is actually the project that is retroactive, all the others are actually not retroactive from the time to But I would sit down with Mrs. Khnlein for the next three or four weeks and then I would give you feedback again. All right, so if we can change the focus, such as What is that? Mutations, exactly. We can integrate that relatively easily. But then just give me a message about it. Yes. Class. Wonderful. Then thank you very much, Mrs Kehl, for taking the time. And then I wish you a nice week. Same to you. Goodbye. Thank you. Goodbye.\n",
            "\n",
            "to the fact that NGES has so far been used purely for basic research, but not yet commercially. Yes.  Do you also know whether this is also the case, so here we not only have that the Leishmania is to be examined with NGS and that this is also to be characterized practically on the basis of an animal sample, so to speak, can this also be applied as a fight to existing NGS investigations? So, as I said, there is nothing at all in diagnostics. But now you mean basic research. Yes, that's where the Leishmania were always bred. In cell culture, only those were examined. That's right, that's another step that we also have to take, because we want to do this investigation directly from the sample, so to speak, and then we may have a lot of background through the genomic DNA again. That would be such a risk. Yes, perfect.  Perfect. Then the next chapter would be the differentiation from your technologies. Here we have to refer to Leishmania in general and then to NGS.  We detect Leishmania itself in various sample materials via classical PCA or real-time PCA, but we do not yet have any resistance genes. That would be the innovation, so to speak. And at the moment we are not doing any studies of any parasites about NGS, but we are doing these DNA profiles, as discussed earlier, from genomic DNA. But studies of parasites has not yet been. Or rather, this other project with Infecto-Scan, which is also going in this direction, but it is also completely under development, that we want to examine a sample and which pathogens are in it. All right: NGS could also point out that they not only examine animal samples, but also isolate Leishmania from them. Or at least for sample preparation. That makes a difference. You would then have to adjust the sample preparation so that mainly the parasite DNA is isolated so that it can be sequenced in a targeted manner. That you don't have so much background that it gets lost. That's also a sub-project of this Infecto-Scan, but it's more on viruses and they are parasites. Yes, all right, well, one can also say in general terms that for the first time parasites from animal material are to be characterized by NGS Yes, definitely. All right, then I would like to go back to the last point, namely the risks. Yes, so one risk is that several strains can occur within one animal. So they are often stung and can then carry different Leishmania strains in them, of which perhaps only one part is resistant and the other is not. You have to make sure that you really get everything pictured, that you can see this variant. That would be a risk. The second would be that the publications are not correct, because at the beginning we want to look specifically at the genes that are in the publications. It could be that there are errors in it, that we detect the genes, but that does not correlate with the clinic, i.e. there is actually no resistance at all. That could be. And if we then do NGS, it can of course be again, as with the infection scan, that we just have too much genomic DNA in it. We have to adapt all the preparations to these parasites beforehand. Or that we don't have the sensitivity to be able to map all resistance genes. Could you also quantify the sensitivity? Then we would have a numerical value here.  the sensitivity of the resistances then again. Yes, exactly. Yes, I mean, 80% sensitivity has always been something you actually strive for. Okay, well, what's a solution for them to bring out this genomic DNA, so that they bring out the genomic DNA as well as possible? It should also be tried out via Infectoscan whether there are methods to separate it.  The company Nanopore offers various recipes for this. But this, of course, is all for the human sphere. First of all, you have to see if this is also possible in the animal sector. If things go really badly, you can also grow the Leishmania in a cell culture and then examine the special hold, so to speak. But that would be very time-consuming, very\n",
            "\n",
            "Perfect, okay when we start again with the goal of the project. So I'm going to elaborate a bit, leishmania are parasites that are transmitted via various mosquitoes. This means that the dogs are bitten by the mosquitoes, then get these leishmanias, which then lead to leishmaniasis. And the whole thing can also affect people. At the moment, this is still a major problem in southern countries, i.e. southern Europe. However, due to climate change, of course, these mosquitoes are coming further and further north, which transmit these larch manias, so to speak, and sooner or later it will most likely become a problem in Germany. This means that the dog has the mosquito bites on these Leishmanias, picks up the eggs of it again and so on and so on. There are now various medications that are taken for the treatment of the dogs. However, these Leishmania develop resistance to it very quickly. Our goal now would be to get a sample from a dog, to prove that he has Leishmania and at the same time to examine these Leishmania to see if they already contain certain resistance genes, so that the doctor can then take the other drug instead of a drug, as is the case with the bacteria in the end, instead of giving the wrong drug,  On the one hand, this does not work, and on the other hand, it leads to the formation of even more resistant Leishmania in order to avoid this. That would be the goal, that you give the veterinarians a tool and say, send us a sample. We study the animal Leishmania and have these Leishmania that the animal has, resistance genes, in order to be able to say which drug is best. Wonderful thank you very much.  On what basis should the investigation of the resistance or the sample in general be carried out? There are already a few publications, there are many groups that are working on which genes are responsible for the resistances. There are already a few publications, there are many groups that are now working on which genes are now responsible for the resistance. There is often no change in the genes, but a copy number variation. So these genes are then either multiplied or they are no longer there at all and this leads to this resistance and this is to be investigated on the basis of these scientific publications. And what we also want to do is to use Next Generation Sequencing to examine the entire Leishmania genome, so to speak. So the first approach would be to search specifically for the genes that are in the publications. And we can also look at it again. In other words, we would then also ask the veterinarians again, are these dogs already treated, do you also see resistance to allopurinol, for example, and we can see, yes we also see what is written in the scientific publication, that this and that gene is more common or not. And then we also want to examine the complete genomes of the Leishmania to see if we can find more genes that are relevant. And that would simply make the product more attractive if you don't say, okay, I'm just looking for an allopurinol resistance or only for a Milteforan resistance, but I'll look at everything again and I can then tell you, yes such and such resistances are present and you don't need this and that at all. Perfect, thank you very much. Could you elaborate on how you ultimately want to characterize whether other genes are relevant if they are not yet published? Are there certain patterns that they then practically read out of the publications and then transferred to the rest of the moment, something has just happened to me. I don't see them properly anymore. So we would just take a close look at the whole thing via Next Generation Sequencing.  Yes, of course, because they are often also copy number variations, one would first focus on whether one sees something like this in other genes. But you would also look at variations like these SNPs, for example, to see whether or not you see them clustered in certain genes, in certain resistant Leishmania. And the characterization\n",
            "\n",
            "Answer to the following question from a user. Use only information from the previous context information. Do not invent stuff.\n",
            "The user is from technical background and wants technically rich responses, with lots of technical jargons\n",
            "\n",
            "Question: What is the background of research ?\n",
            "\n",
            "Answer:\n",
            "\n",
            "\n",
            "\u001b[1m> Entering new  chain...\u001b[0m\n",
            "Prompt after formatting:\n",
            "\u001b[32;1m\u001b[1;3mHuman: You are a research document summarizer that finds the questions to user query and give correct responses\n",
            "\n",
            "You know the following context information.\n",
            "\n",
            "in the animal sector. If things go really badly, you can also grow the Leishmania in a cell culture and then examine the special hold, so to speak. But that would be very time-consuming, very expensive. You have to ask yourself whether you want to continue the project at all. In other words, one could actually also argue as a risk that the whole technique works for Leishmania in cell culture, but in the end the animal sample simply cannot be realized. Yes, right. Better. To the expenses. Do you know how many people are supposed to work on it? Yes, so we'll do it again via the HR department. In principle, I will have a relatively large number of hours there. Then a veterinarian from clinical chemistry has hours there and of course we still need a laboratory and I think there will be a second veterinarian from either my department or from clinical chemistry so that he can have contact with the veterinarians outside. All right, then just a rough overview, that is, four people to no idea ten to 15 percent perhaps. Yes, that's right.  Okay, do any subcontractors still come in here? So there will certainly be cooperations, but more with universities and then you don't really have any bills. So if you don't pay for the university, then that's not relevant. Yes yes exactly.  Yes, exactly, I'm just thinking so loudly. That's why I don't think so at the moment. Okay perfect, then I'm already through with my questions here too. Is there another project or would that be it for now?  I think that would be it for now. Completely new things will be added. The other thing with the infection scan, they had sent something again. I would only get the one sentence out.  Exactly, I wanted to talk to you about that, because of course we have to make sure that we fill in the text to see if there is perhaps a replacement for the deletion. I don't know what you're aiming for. I'll probably have to open this up again. Because it doesn't allow you to do that, just that's what IT is doing here today. Exactly, but I can also briefly share your e-mail otherwise. Yes, maybe that's the fastest way to do it. So, exactly. Yes, few screening with EDP Yes, few screening methods that result from dogs or cats. I don't know what they're actually going to pick up. We wanted to show a bit of the demarcations to the state of the art, i.e. how this is done according to statistics, i.e. how much of the statistics is not enough. So what we're doing is not screening methods, it's like, it's like packages. But that would have to be worded a little differently. If the dog's nose runs, then we just do herpes calypso, then there are already four or five typical pathogens that you do there.  So these are more like packages that are then specific to certain symptoms. But never cover everything that could be there. Maybe you can just rephrase it a bit. Yes, that means you actually have to have an initial guess and then you examine it specifically. But you don't study the entire genome. That's right, yes. Okay, let's rephrase. Well, we did it. Class. Yes, wonderful. Yes, we still had the one with the mutation, antimutation or whatever they called it. So with that I still have a bit of a stomach ache overall, because it is, actually already the case, that we have already established a lot of hereditary diseases and yes actually this prototype, as described earlier, has been there for a long time and we just keep expanding it with newly released things. Of course, we also expand our methods or the possibility of mapping these structural variants now, but I don't know if we can get that many hours together if I really concentrate on that. I have to talk to Mrs. Khler again, to my head of department, about how we can do that, whether we can perhaps somehow make a different focus, that we can somehow do it differently, so I would put that on the back burner at the moment, although it is actually the project that is retroactive, all the others are actually not retroactive from the\n",
            "\n",
            "we can somehow do it differently, so I would put that on the back burner at the moment, although it is actually the project that is retroactive, all the others are actually not retroactive from the time to But I would sit down with Mrs. Khnlein for the next three or four weeks and then I would give you feedback again. All right, so if we can change the focus, such as What is that? Mutations, exactly. We can integrate that relatively easily. But then just give me a message about it. Yes. Class. Wonderful. Then thank you very much, Mrs Kehl, for taking the time. And then I wish you a nice week. Same to you. Goodbye. Thank you. Goodbye.\n",
            "\n",
            "to the fact that NGES has so far been used purely for basic research, but not yet commercially. Yes.  Do you also know whether this is also the case, so here we not only have that the Leishmania is to be examined with NGS and that this is also to be characterized practically on the basis of an animal sample, so to speak, can this also be applied as a fight to existing NGS investigations? So, as I said, there is nothing at all in diagnostics. But now you mean basic research. Yes, that's where the Leishmania were always bred. In cell culture, only those were examined. That's right, that's another step that we also have to take, because we want to do this investigation directly from the sample, so to speak, and then we may have a lot of background through the genomic DNA again. That would be such a risk. Yes, perfect.  Perfect. Then the next chapter would be the differentiation from your technologies. Here we have to refer to Leishmania in general and then to NGS.  We detect Leishmania itself in various sample materials via classical PCA or real-time PCA, but we do not yet have any resistance genes. That would be the innovation, so to speak. And at the moment we are not doing any studies of any parasites about NGS, but we are doing these DNA profiles, as discussed earlier, from genomic DNA. But studies of parasites has not yet been. Or rather, this other project with Infecto-Scan, which is also going in this direction, but it is also completely under development, that we want to examine a sample and which pathogens are in it. All right: NGS could also point out that they not only examine animal samples, but also isolate Leishmania from them. Or at least for sample preparation. That makes a difference. You would then have to adjust the sample preparation so that mainly the parasite DNA is isolated so that it can be sequenced in a targeted manner. That you don't have so much background that it gets lost. That's also a sub-project of this Infecto-Scan, but it's more on viruses and they are parasites. Yes, all right, well, one can also say in general terms that for the first time parasites from animal material are to be characterized by NGS Yes, definitely. All right, then I would like to go back to the last point, namely the risks. Yes, so one risk is that several strains can occur within one animal. So they are often stung and can then carry different Leishmania strains in them, of which perhaps only one part is resistant and the other is not. You have to make sure that you really get everything pictured, that you can see this variant. That would be a risk. The second would be that the publications are not correct, because at the beginning we want to look specifically at the genes that are in the publications. It could be that there are errors in it, that we detect the genes, but that does not correlate with the clinic, i.e. there is actually no resistance at all. That could be. And if we then do NGS, it can of course be again, as with the infection scan, that we just have too much genomic DNA in it. We have to adapt all the preparations to these parasites beforehand. Or that we don't have the sensitivity to be able to map all resistance genes. Could you also quantify the sensitivity? Then we would have a numerical value here.  the sensitivity of the resistances then again. Yes, exactly. Yes, I mean, 80% sensitivity has always been something you actually strive for. Okay, well, what's a solution for them to bring out this genomic DNA, so that they bring out the genomic DNA as well as possible? It should also be tried out via Infectoscan whether there are methods to separate it.  The company Nanopore offers various recipes for this. But this, of course, is all for the human sphere. First of all, you have to see if this is also possible in the animal sector. If things go really badly, you can also grow the Leishmania in a cell culture and then examine the special hold, so to speak. But that would be very time-consuming, very\n",
            "\n",
            "Perfect, okay when we start again with the goal of the project. So I'm going to elaborate a bit, leishmania are parasites that are transmitted via various mosquitoes. This means that the dogs are bitten by the mosquitoes, then get these leishmanias, which then lead to leishmaniasis. And the whole thing can also affect people. At the moment, this is still a major problem in southern countries, i.e. southern Europe. However, due to climate change, of course, these mosquitoes are coming further and further north, which transmit these larch manias, so to speak, and sooner or later it will most likely become a problem in Germany. This means that the dog has the mosquito bites on these Leishmanias, picks up the eggs of it again and so on and so on. There are now various medications that are taken for the treatment of the dogs. However, these Leishmania develop resistance to it very quickly. Our goal now would be to get a sample from a dog, to prove that he has Leishmania and at the same time to examine these Leishmania to see if they already contain certain resistance genes, so that the doctor can then take the other drug instead of a drug, as is the case with the bacteria in the end, instead of giving the wrong drug,  On the one hand, this does not work, and on the other hand, it leads to the formation of even more resistant Leishmania in order to avoid this. That would be the goal, that you give the veterinarians a tool and say, send us a sample. We study the animal Leishmania and have these Leishmania that the animal has, resistance genes, in order to be able to say which drug is best. Wonderful thank you very much.  On what basis should the investigation of the resistance or the sample in general be carried out? There are already a few publications, there are many groups that are working on which genes are responsible for the resistances. There are already a few publications, there are many groups that are now working on which genes are now responsible for the resistance. There is often no change in the genes, but a copy number variation. So these genes are then either multiplied or they are no longer there at all and this leads to this resistance and this is to be investigated on the basis of these scientific publications. And what we also want to do is to use Next Generation Sequencing to examine the entire Leishmania genome, so to speak. So the first approach would be to search specifically for the genes that are in the publications. And we can also look at it again. In other words, we would then also ask the veterinarians again, are these dogs already treated, do you also see resistance to allopurinol, for example, and we can see, yes we also see what is written in the scientific publication, that this and that gene is more common or not. And then we also want to examine the complete genomes of the Leishmania to see if we can find more genes that are relevant. And that would simply make the product more attractive if you don't say, okay, I'm just looking for an allopurinol resistance or only for a Milteforan resistance, but I'll look at everything again and I can then tell you, yes such and such resistances are present and you don't need this and that at all. Perfect, thank you very much. Could you elaborate on how you ultimately want to characterize whether other genes are relevant if they are not yet published? Are there certain patterns that they then practically read out of the publications and then transferred to the rest of the moment, something has just happened to me. I don't see them properly anymore. So we would just take a close look at the whole thing via Next Generation Sequencing.  Yes, of course, because they are often also copy number variations, one would first focus on whether one sees something like this in other genes. But you would also look at variations like these SNPs, for example, to see whether or not you see them clustered in certain genes, in certain resistant Leishmania. And the characterization\n",
            "\n",
            "Answer to the following question from a user. Use only information from the previous context information. Do not invent stuff.\n",
            "The user is from technical background and wants technically rich responses, with lots of technical jargons\n",
            "\n",
            "Question: What is the background of research ?\n",
            "\n",
            "Answer:\u001b[0m\n",
            "\n",
            "\u001b[1m> Finished chain.\u001b[0m\n",
            "The background of the research is focused on studying Leishmania, which are parasites transmitted by mosquitoes and can cause leishmaniasis in both animals and humans. Currently, this is a major problem in southern countries, but with climate change, it is becoming a concern in Germany as well. The goal of the research is to develop a tool to analyze samples from dogs and identify the presence of Leishmania and any resistance genes they may have. This information would help veterinarians choose the most effective treatment for the animals. The research is based on existing scientific publications that identify genes responsible for resistance. Additionally, Next Generation Sequencing is used to examine the entire Leishmania genome and identify any additional relevant genes.\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "GzYSJn0ljCcB"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "### Merging Concepts"
      ],
      "metadata": {
        "id": "XRweJ7Xijscm"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "# Before executing the following code, make sure to have\n",
        "# your OpenAI key saved in the OPENAI_API_KEY environment variable.\n",
        "embeddings = OpenAIEmbeddings(model=\"text-embedding-ada-002\")\n",
        "\n",
        "# create Deep Lake dataset\n",
        "# TODO: use your organization id here. (by default, org id is your username)\n",
        "my_activeloop_org_id = \"parthtripathidummy\"\n",
        "my_activeloop_dataset_name = \"innoscripta_advanced_exp1_target\"\n",
        "dataset_path = f\"hub://{my_activeloop_org_id}/{my_activeloop_dataset_name}\"\n",
        "db_target = DeepLake(dataset_path=dataset_path, embedding_function=embeddings)\n",
        "\n",
        "my_activeloop_dataset_name = \"innoscripta_advanced_exp1_background\"\n",
        "dataset_path = f\"hub://{my_activeloop_org_id}/{my_activeloop_dataset_name}\"\n",
        "db_background = DeepLake(dataset_path=dataset_path, embedding_function=embeddings)\n",
        "# add documents to our Deep Lake dataset\n",
        "# db_target.add_documents(simple_texts)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 54
        },
        "outputId": "5dde0a78-330d-4cba-8b54-cf5b0d1ce97b",
        "id": "t0-7RDU9jsco"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Deep Lake Dataset in hub://parthtripathidummy/innoscripta_advanced_exp1_target already exists, loading from the storage\n",
            "Deep Lake Dataset in hub://parthtripathidummy/innoscripta_advanced_exp1_background already exists, loading from the storage\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# let's see the top relevant documents to a specific query\n",
        "query = \"What is this research about\"\n",
        "# query = 'what is a nft'\n",
        "docs = db_target.similarity_search(query)\n",
        "print(docs[0].page_content)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 405
        },
        "outputId": "e473e14f-4d26-44fd-9789-8d56b9208d2f",
        "id": "0Nxl6oTnjsco"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "in the animal sector. If things go really badly, you can also grow the Leishmania in a cell culture and then examine the special hold, so to speak. But that would be very time-consuming, very expensive. You have to ask yourself whether you want to continue the project at all. In other words, one could actually also argue as a risk that the whole technique works for Leishmania in cell culture, but in the end the animal sample simply cannot be realized. Yes, right. Better. To the expenses. Do you know how many people are supposed to work on it? Yes, so we'll do it again via the HR department. In principle, I will have a relatively large number of hours there. Then a veterinarian from clinical chemistry has hours there and of course we still need a laboratory and I think there will be a second veterinarian from either my department or from clinical chemistry so that he can have contact with the veterinarians outside. All right, then just a rough overview, that is, four people to no idea ten to 15 percent perhaps. Yes, that's right.  Okay, do any subcontractors still come in here? So there will certainly be cooperations, but more with universities and then you don't really have any bills. So if you don't pay for the university, then that's not relevant. Yes yes exactly.  Yes, exactly, I'm just thinking so loudly. That's why I don't think so at the moment. Okay perfect, then I'm already through with my questions here too. Is there another project or would that be it for now?  I think that would be it for now. Completely new things will be added. The other thing with the infection scan, they had sent something again. I would only get the one sentence out.  Exactly, I wanted to talk to you about that, because of course we have to make sure that we fill in the text to see if there is perhaps a replacement for the deletion. I don't know what you're aiming for. I'll probably have to open this up again. Because it doesn't allow you to do that, just that's what IT is doing here today. Exactly, but I can also briefly share your e-mail otherwise. Yes, maybe that's the fastest way to do it. So, exactly. Yes, few screening with EDP Yes, few screening methods that result from dogs or cats. I don't know what they're actually going to pick up. We wanted to show a bit of the demarcations to the state of the art, i.e. how this is done according to statistics, i.e. how much of the statistics is not enough. So what we're doing is not screening methods, it's like, it's like packages. But that would have to be worded a little differently. If the dog's nose runs, then we just do herpes calypso, then there are already four or five typical pathogens that you do there.  So these are more like packages that are then specific to certain symptoms. But never cover everything that could be there. Maybe you can just rephrase it a bit. Yes, that means you actually have to have an initial guess and then you examine it specifically. But you don't study the entire genome. That's right, yes. Okay, let's rephrase. Well, we did it. Class. Yes, wonderful. Yes, we still had the one with the mutation, antimutation or whatever they called it. So with that I still have a bit of a stomach ache overall, because it is, actually already the case, that we have already established a lot of hereditary diseases and yes actually this prototype, as described earlier, has been there for a long time and we just keep expanding it with newly released things. Of course, we also expand our methods or the possibility of mapping these structural variants now, but I don't know if we can get that many hours together if I really concentrate on that. I have to talk to Mrs. Khler again, to my head of department, about how we can do that, whether we can perhaps somehow make a different focus, that we can somehow do it differently, so I would put that on the back burner at the moment, although it is actually the project that is retroactive, all the others are actually not retroactive from the\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# let's write a prompt for a customer support chatbot that\n",
        "# answer questions using information extracted from our db\n",
        "template = \"\"\"You are a research document summarizer that finds the answers to user query and give correct responses\n",
        "Note that the user is from a highly specialized technical background, use minimal layman terms in your responses\n",
        "\n",
        "Use the following background context information on the Leishmania disease research project.\n",
        "\n",
        "{background_chunks_formatted}\n",
        "\n",
        "Use the following information on the Leishmania disease research project.\n",
        "\n",
        "{target_chunks_formatted}\n",
        "\n",
        "Using this as context\n",
        "\n",
        "Answer to the following question from a user regarding Leishmania disease project following given guidelines.\n",
        "Question: {query}\n",
        "Guidelines: {guidelines}\n",
        "\n",
        "Answer:\"\"\"\n",
        "human_message_prompt = HumanMessagePromptTemplate.from_template(\n",
        "    input_variables=[\"background_chunks_formatted\", \"target_chunks_formatted\", \"query\", \"guidelines\"],\n",
        "    template=template,\n",
        "    )\n",
        "prompt = ChatPromptTemplate.from_messages([human_message_prompt])"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 17
        },
        "outputId": "927f8a37-7e68-47d3-8f70-91dfbe1e3e1d",
        "id": "7jehhrsHjsco"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "type(prompt)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 35
        },
        "outputId": "3cfa21ea-9fac-493f-f52e-6269050dab57",
        "id": "MHSWMkYojsco"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "langchain.prompts.chat.ChatPromptTemplate"
            ]
          },
          "metadata": {},
          "execution_count": 46
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "from langchain.chat_models import ChatOpenAI\n",
        "from langchain import LLMChain\n",
        "# the full pipeline\n",
        "\n",
        "# user question\n",
        "background_query = \"What are the technologies discussed ?\"\n",
        "target_query = \"What is the Objective of the project (if applicable, in the context of the cooperative project)\"\n",
        "\n",
        "# retrieve relevant chunks\n",
        "docs = db_background.similarity_search(background_query)\n",
        "background_retrieved_chunks = [doc.page_content for doc in docs]\n",
        "background_chunks_formatted = \"\\n\\n\".join(background_retrieved_chunks)\n",
        "\n",
        "docs = db_target.similarity_search(target_query)\n",
        "target_retrieved_chunks = [doc.page_content for doc in docs]\n",
        "target_chunks_formatted = \"\\n\\n\".join(target_retrieved_chunks)\n",
        "\n",
        "guidelines = '''\n",
        "To what extent does the project\n",
        "aim to expand the state of knowledge/technology or utilize existing\n",
        "scientific, technical, economic, or other relevant findings or approaches\n",
        "Try to include the following:\n",
        "- 1 State of the art (Currently/According to the state of the art...)\n",
        "- 1 Project objective (The goal of the project is...)\n",
        "- 1 Differentiation from the state of the art (The state of the art is expanded in terms of..., thereby expanding the knowledge about...)\n",
        "- 1 Project result (The planned outcome/result is...)\n",
        "Please ensure that the project uses specific technical terminology to\n",
        "describe the innovative core. This is particularly crucial, especially for\n",
        "software projects.\n",
        "Restrict output to ONLY 800 characters\n",
        "'''\n",
        "# generate answer\n",
        "llm = ChatOpenAI(model_name=\"gpt-3.5-turbo-16k\")\n",
        "chain = LLMChain(llm=llm, prompt=prompt, verbose=True)\n",
        "\n",
        "response = chain.run(\n",
        "    background_chunks_formatted=background_chunks_formatted,\n",
        "    target_chunks_formatted=target_chunks_formatted,\n",
        "    query=query,\n",
        "    guidelines=guidelines,\n",
        "    )\n",
        "\n",
        "print(response)\n",
        "print(\"Length of response is {} which is {} characters above ideal\".format(len(response), len(response)-800))"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "outputId": "d83ba956-0440-4fb2-c961-42b42758f336",
        "id": "lnyNr9m1jsco"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\n",
            "\n",
            "\u001b[1m> Entering new  chain...\u001b[0m\n",
            "Prompt after formatting:\n",
            "\u001b[32;1m\u001b[1;3mHuman: You are a research document summarizer that finds the answers to user query and give correct responses\n",
            "Note that the user is from a highly specialized technical background, use minimal layman terms in your responses\n",
            "\n",
            "Use the following background context information on the Leishmania disease research project.\n",
            "\n",
            "you have to take the big picture into account and you don't just test for a specific disease. But that's why I don't necessarily use other animals in this case. No, that's not what I meant by other animals. I did not express that.  Okay, great. I would also like to comment on the next point, namely the extent to which the product fits into your sector of the economy in question. You mentioned a few points earlier.  Now, however, we have to take a closer look at what the current state of the art looks like and to what extent it will also be exceeded in relation to Next Generation Sequencing. Maybe a few points about what we are doing ourselves at the moment. We offer the individual tests, where the customer has to say, I want my animal to be tested for PHA, for DM, whatever, or just these individual packages, which are a bit dependent on the breed. And in that case, it would be the case that really everything that is possible is tested. That's one difference. And that's why they are different methods, because of course the individual tests don't run via NGS, but via different methodology.  And so to classify in the big picture in the economic branch yes that's what you mean by that in economic branch classify other companies that also carry out tests of with regard to diseases or other simply with advertisers. Of course, there are other companies that also offer the packages, as we do.  and there are also those who offer a lot of tests together, whether they all offer or this 60 percent that we can strive for, I don't say now. Of course, we are not as experts as you are and therefore simply need a classification as whether MGS is already offered by other competitors for the characterization of earth diseases in cats, dogs, horses or whether this is something new.  I think that's something new in that respect, because they use, because that would also be a market advantage, so we want to try that with NGS, with Next Generation Sequencing. Other large suppliers such as Mars, i.e. the company of Mars Regal, offer something similar, but with microarrays. And you have advantages and disadvantages, so the NGS makes it more difficult to reach the goal, but you have the advantage that you are always up to date quickly with NGS. An array, you have to order what do I know 100,000 or 10000 arrays, it's set in stone.  if they want to add a new marker, it takes time. At NGS, we can react relatively quickly, where we also see a market advantage over our competitors. So I know, Mars doesn't make an NGS story for these many inheritances, but they do micro-arrays. That would be a classic competitor, but still. They also compete with us, I have to say. But as I said, we approach the story differently, which has advantages and also disadvantages. Can you then also refer to the fact that it, so you probably know better about that now, but you mentioned earlier that more and more lean or other is being added, that is, it is a very fast-moving product. This is very fast-moving, in my opinion a new marker will soon be added every few weeks, it's even faster. Whether they are important for the customer or not remains to be seen, but new markers are constantly being added. Is this due to overbreeding or is it because it is much more researched? This is being researched more intensively. The technologies are much faster. As said our researcher colleague in Switzerland always says quick and dirty and it's really quick, so he does, knocks out one test after the other, I'll put it that way. You have to react quickly to the customer, we are also in the platform The dog hears it, the Tosso lives in Switzerland, has new tests, Laboclean has to offer it. That's what we're doing, but as I said, you can't react so quickly with such high-throughput technology. But you can react much faster with NGS than with the micro arrays. Then we can definitely explain the motivation behind the project well and also the market advantage. Is it also possible to quantify how\n",
            "\n",
            "So it's true. So the dog has a lot more markers, I'll say now, than the cat, that he knows a lot more diseases. Annalena, you correct me, technically is a greater challenge, since to correctly name the hereditary diseases, to define them. Exactly, that you do the right calling. Now you've already gone to the content. I would ask you to be able to explain the goal of the project in general, i.e. really with cat, dog and horse, because that is the first chapter at the end of the day. In other words, the examiner must ultimately be able to distinguish it from the state of the art and also how it is currently carried out according to the state of the art. Do you like Annalena? Yes, I'm happy to. With the products that are to be developed for dogs, cats and horses, we want to give customers, breeders, veterinarians, private individuals the opportunity to evaluate the genetic health of their own animal in its entirety, in some cases even beyond what is already known for the individual breeds, and on the other hand to promote animal health in the future,  because this can and should really flow directly into the breeding decisions, especially within breeds that are bred a bit more closely, to ensure that the animals do not become completely sicker and sicker in the next 50 to 100 years. That's how I would sum it up now. I have enclosed a short quality checklist here to accompany the application and how the application is always structured, so that you have a rough direction. We always have to describe a sentence about the state of the art, i.e. according to the current state of the art, this is done this way and that, then what the project goal is, then also the demarcation from the state of the art, to what extent the state of the art is expanded and the knowledge is expanded at your company and then finally what the project result should be. Perhaps you could just ask a few questions about the project, especially in relation to this Next Generation Sequencing. So let's put into perspective the extent to which you have already used it, to what extent it is a new technique for you, to what extent it is something new for detecting hereditary diseases in cats, dogs and horses. So now verbally or then for the application? Oral, oral. We formulate on the basis, that's why the recording is ongoing. We formulate the application from this. Okay, so then I would say that the current state of the art is that we are not yet using high-throughput technology to study the entire genetic markup of an animal. Instead, we mainly have individual tests and smaller products that are applied to breed-specific.  We are currently using next generation sequencing as a technology for DNA profiling. The main focus is on parentage analyses and the genetic fingerprint of animals. The aim of the project would then be what I formulated earlier, that it is primarily about animal health, of our own animal, but also of the species that we want to cover as a whole. State-of-the-art technology?  Above all, we are also expanding into larger genetic variants in this area. So simpler tests are mainly SNPs, but if genetic causes, complicated sense with larger insertions, deletions, inversions, whatever. This is where we want to expand our next-generation sequencing technology. The result of the project would then be one product for each of different animal species, which contains this additive XXL, which in the best case, yes, in the best case, contains all, but probably all, hereditary diseases in the species and characteristics that can be mapped with the technology. Ideally, we can substantiate the application with one or two target values. So maybe you can quantify all hereditary diseases a little bit than how much should be achieved at least or worth in other numbers? Ugh, difficult. So at least in numbers I wouldn't say, because it's extremely different for dogs, cats and horses. And since the hereditary diseases are constantly being developed, new ones are\n",
            "\n",
            "you very much for the very valuable input and The next steps will look like this, we will work out the application. We are subject to a strict character limit, so do not wonder about the brevity. That's 800 characters per chapter that we've just talked through, so five times 800 characters and then I'll send it to you by e-mail. We also have an accompanying portal, the so-called IMS portal, where the application can also be accessed. I can make you an account as you wish. I will also send you by e-mail. I only want the e-mail addresses, because Mrs. Kehe, they had the e-mails, they had forwarded the invitation. Yes or is it easier if it goes through me, I'll then distribute it to you and get the info back and give it back, what do you two think? I think it's good, otherwise you'll forget someone in the CC at some point. If someone in the CC wonders why he is no longer up to date. Perfect, wonderful. Then Mrs. Kehl gets the proposal. If there is no further issue with you, Mrs Khnlein and Mrs Van der Velja, then we would be done with it. Now I have a question, you guys are still doing the resistances Alex? Yes, exactly. Is anyone else coming in? No. Okay all right. You don't need us? No. So in the system I saw through: Yes, and in the project Resistances I am practically not in it. Yes, exactly. Okay, well, then it means we have to hang up now, just press it, right? That's right, then they're automatically out. Okay, thank you very much and then I wish you good luck And then I wish you good luck. Thank you, bye-bye I have already had discussions about the drug preparations for the treatment of antibiotic resistance and bacterial infections. Is that what resistance is now all about? No, that's something completely different. All right, just for classification. Yes yes exactly. What is the name of this at the moment? Resistance? Maybe we can call it Leishmania resistance. Because it's really mainly about Leishmania.  Could you write that down in the chat? Where is he here? At the top left is Chat. At least for me. I don't know if it's a little different for you. But you have such a menu bar in Teams. Yes.  And there is such an addiction question. Ah, entertainment. Besprechungstit. Enter a message. Ah yes, ok, per yes, ok, perfect. So I'll have to see if it's too long in terms of characters. Otherwise, I might just call it Leishmania or something. Or larch resistance, something like that. Perfect, yes. Then I would actually like to just continue with the screen splitting again. I think it's always a bit more structured. Class. Exactly, then let's go to that, or respectively the first is always the runtime. When did we start the project? So we started in the middle of last year, at the end of last year, but I might still do, yes, no, I think we'll still start January 23 and then let it run for three years.\n",
            "\n",
            "Ugh, difficult. So at least in numbers I wouldn't say, because it's extremely different for dogs, cats and horses. And since the hereditary diseases are constantly being developed, new ones are constantly being added, I would actually rather say that it would perhaps be our goal to continuously cover a large part and I would say maybe more than 60 percent of the known diseases in the respective species and that is really because of the fact that  whether this is even possible with the technology. There are just some things that prevent us from doing that. That's why I have a hard time with the number. But that's a good numerical value. So no one will pin down on the fact that simply for an examiner who simply has to recognize a lot in very little text, i.e. the application has one page, and that's why just such a number sheet is always very good. Then I actually want to move on to the operation of the work, i.e. here it is answered how you want to realize the whole thing, there must be a methodical approach recognizable. So if you simply start here with the work steps that you will ultimately carry out and then also go into the new method on your part, that the gain for the examiner can be recognized and also in the knowledge gap for you is closed by it, so the good first step is that you have to carry out a complete scientific analysis of all current hereditary diseases in the three different species. This is actually quite a complex work package, because it means that you always have to understand and recreate it in the scientific publications themselves. Then it has to be implemented in the so-called panels with which the NGS technology works. One panel for each species. Then the third step would be the evaluation of the tests that we map. Of course, we also have to make sure that this should not only deliver the correct result from a technical point of view, but that it does. In other words, we have to compare the known animals with the results that we achieve with the new technology, with the NGS technology, and perhaps then bring the whole thing as fit for the work package in a way that is then understandable to the customer. We can't train them with 200 pages of text at the end. It has to be adapted to the different types of people so that they can do something with it. Wonderful, thank you very much.  In the end, could you rewrite the prototype a little better, i.e. the way in which it is understandable for the customer. Do you have a little better idea of what the end result should look like?  Is this a test kit or do you run the tests? The output is then the analysis? In the end, the customer only sends us DNA of his animal, either with blood or with swabs or with hair in the horse often. We are then responsible for everything that goes from DNA extraction to the execution of all genetic tests, then the evaluation and then the processing, that it should go back to the customer and I would say that this can probably be done in either an application, an app or a web-based representation, where a customer then has his single animal or his several animals,  which he can then analyze, also look at in the long run. Maybe even compare with others. And that's something, if I may take a quick look at what's completely new. At the moment we are making findings that were originally on paper, which are now sent as e-mails, but of course not as they might look like in this case with an app. So this is also a completely new product, a completely new form of diagnosis. Yes all right. Above all, the comparison of the Prennness to other animals is certainly an important point here, which cannot be carried out at present. No, can't be done. What do you mean by comparison to others? At the end of the day, when you analyze the entire genome, you have to take the big picture into account and you don't just test for a specific disease. But that's why I don't necessarily use other animals in this case. No, that's not what I meant by other\n",
            "\n",
            "Use the following information on the Leishmania disease research project.\n",
            "\n",
            "we can somehow do it differently, so I would put that on the back burner at the moment, although it is actually the project that is retroactive, all the others are actually not retroactive from the time to But I would sit down with Mrs. Khnlein for the next three or four weeks and then I would give you feedback again. All right, so if we can change the focus, such as What is that? Mutations, exactly. We can integrate that relatively easily. But then just give me a message about it. Yes. Class. Wonderful. Then thank you very much, Mrs Kehl, for taking the time. And then I wish you a nice week. Same to you. Goodbye. Thank you. Goodbye.\n",
            "\n",
            "in the animal sector. If things go really badly, you can also grow the Leishmania in a cell culture and then examine the special hold, so to speak. But that would be very time-consuming, very expensive. You have to ask yourself whether you want to continue the project at all. In other words, one could actually also argue as a risk that the whole technique works for Leishmania in cell culture, but in the end the animal sample simply cannot be realized. Yes, right. Better. To the expenses. Do you know how many people are supposed to work on it? Yes, so we'll do it again via the HR department. In principle, I will have a relatively large number of hours there. Then a veterinarian from clinical chemistry has hours there and of course we still need a laboratory and I think there will be a second veterinarian from either my department or from clinical chemistry so that he can have contact with the veterinarians outside. All right, then just a rough overview, that is, four people to no idea ten to 15 percent perhaps. Yes, that's right.  Okay, do any subcontractors still come in here? So there will certainly be cooperations, but more with universities and then you don't really have any bills. So if you don't pay for the university, then that's not relevant. Yes yes exactly.  Yes, exactly, I'm just thinking so loudly. That's why I don't think so at the moment. Okay perfect, then I'm already through with my questions here too. Is there another project or would that be it for now?  I think that would be it for now. Completely new things will be added. The other thing with the infection scan, they had sent something again. I would only get the one sentence out.  Exactly, I wanted to talk to you about that, because of course we have to make sure that we fill in the text to see if there is perhaps a replacement for the deletion. I don't know what you're aiming for. I'll probably have to open this up again. Because it doesn't allow you to do that, just that's what IT is doing here today. Exactly, but I can also briefly share your e-mail otherwise. Yes, maybe that's the fastest way to do it. So, exactly. Yes, few screening with EDP Yes, few screening methods that result from dogs or cats. I don't know what they're actually going to pick up. We wanted to show a bit of the demarcations to the state of the art, i.e. how this is done according to statistics, i.e. how much of the statistics is not enough. So what we're doing is not screening methods, it's like, it's like packages. But that would have to be worded a little differently. If the dog's nose runs, then we just do herpes calypso, then there are already four or five typical pathogens that you do there.  So these are more like packages that are then specific to certain symptoms. But never cover everything that could be there. Maybe you can just rephrase it a bit. Yes, that means you actually have to have an initial guess and then you examine it specifically. But you don't study the entire genome. That's right, yes. Okay, let's rephrase. Well, we did it. Class. Yes, wonderful. Yes, we still had the one with the mutation, antimutation or whatever they called it. So with that I still have a bit of a stomach ache overall, because it is, actually already the case, that we have already established a lot of hereditary diseases and yes actually this prototype, as described earlier, has been there for a long time and we just keep expanding it with newly released things. Of course, we also expand our methods or the possibility of mapping these structural variants now, but I don't know if we can get that many hours together if I really concentrate on that. I have to talk to Mrs. Khler again, to my head of department, about how we can do that, whether we can perhaps somehow make a different focus, that we can somehow do it differently, so I would put that on the back burner at the moment, although it is actually the project that is retroactive, all the others are actually not retroactive from the\n",
            "\n",
            "Perfect, okay when we start again with the goal of the project. So I'm going to elaborate a bit, leishmania are parasites that are transmitted via various mosquitoes. This means that the dogs are bitten by the mosquitoes, then get these leishmanias, which then lead to leishmaniasis. And the whole thing can also affect people. At the moment, this is still a major problem in southern countries, i.e. southern Europe. However, due to climate change, of course, these mosquitoes are coming further and further north, which transmit these larch manias, so to speak, and sooner or later it will most likely become a problem in Germany. This means that the dog has the mosquito bites on these Leishmanias, picks up the eggs of it again and so on and so on. There are now various medications that are taken for the treatment of the dogs. However, these Leishmania develop resistance to it very quickly. Our goal now would be to get a sample from a dog, to prove that he has Leishmania and at the same time to examine these Leishmania to see if they already contain certain resistance genes, so that the doctor can then take the other drug instead of a drug, as is the case with the bacteria in the end, instead of giving the wrong drug,  On the one hand, this does not work, and on the other hand, it leads to the formation of even more resistant Leishmania in order to avoid this. That would be the goal, that you give the veterinarians a tool and say, send us a sample. We study the animal Leishmania and have these Leishmania that the animal has, resistance genes, in order to be able to say which drug is best. Wonderful thank you very much.  On what basis should the investigation of the resistance or the sample in general be carried out? There are already a few publications, there are many groups that are working on which genes are responsible for the resistances. There are already a few publications, there are many groups that are now working on which genes are now responsible for the resistance. There is often no change in the genes, but a copy number variation. So these genes are then either multiplied or they are no longer there at all and this leads to this resistance and this is to be investigated on the basis of these scientific publications. And what we also want to do is to use Next Generation Sequencing to examine the entire Leishmania genome, so to speak. So the first approach would be to search specifically for the genes that are in the publications. And we can also look at it again. In other words, we would then also ask the veterinarians again, are these dogs already treated, do you also see resistance to allopurinol, for example, and we can see, yes we also see what is written in the scientific publication, that this and that gene is more common or not. And then we also want to examine the complete genomes of the Leishmania to see if we can find more genes that are relevant. And that would simply make the product more attractive if you don't say, okay, I'm just looking for an allopurinol resistance or only for a Milteforan resistance, but I'll look at everything again and I can then tell you, yes such and such resistances are present and you don't need this and that at all. Perfect, thank you very much. Could you elaborate on how you ultimately want to characterize whether other genes are relevant if they are not yet published? Are there certain patterns that they then practically read out of the publications and then transferred to the rest of the moment, something has just happened to me. I don't see them properly anymore. So we would just take a close look at the whole thing via Next Generation Sequencing.  Yes, of course, because they are often also copy number variations, one would first focus on whether one sees something like this in other genes. But you would also look at variations like these SNPs, for example, to see whether or not you see them clustered in certain genes, in certain resistant Leishmania. And the characterization\n",
            "\n",
            "genes. But you would also look at variations like these SNPs, for example, to see whether or not you see them clustered in certain genes, in certain resistant Leishmania. And the characterization of which resistance refers to which drug intolerance or ineffectiveness, would you identify the series by existing knowledge, by consulting the veterinarians, or is there somehow a direct conclusion from the mode of action of the drug to the change in the genome? So, on the one hand, we would try to evaluate this by means of questionnaires or consultation with the veterinarians. These Leishmania can also be kept in cell culture. In other words, we could then create cell cultures of some samples from the Leishmanias, so to speak, and then there are in vitro tests to see whether these Leishmaniasis still respond to certain drugs or not. Similar to bacteria, where you put antibiotics on it and see if they are still growing or not. Something like this also exists for Leishmania in cell cultures. And then, of course, you can also look biochemically at what it does. Is it realistic that it somehow has a connection or not? There is then a certain term for this biochemical approach. So if there is a technical term for it, then they would have a few more numerical values, so for me what can be attached as an objective here difficult. To be honest, I can't think of anything in this case. On the other hand, sensitivity and specificity, so what is always a classic? Yes, that's just a problem in this case, because I don't know what my gold standard would be. So I always have to see what the veterinarians say. Well, I could just say that I want an 80 percent agreement. If the veterinarian says, yes, I see resistance there, then I want to see 80 percent of it in my test material, you could perhaps say that. Then maybe also related to the resistances, i.e. what is the 80 percent, this 80 percent value refers to the I can tell at all whether Leishmania is present, yes or no or I recognize resistance. I recognize resistances, i.e. Leishmania, which I have to recognize in any case, we already have other tests, that is already established, It is now really a matter of seeing whether they are resistant or not. So 80 percent. I would say that 80 percent of the samples that are described as resistant by veterinarians, I would then like to find a resistance gene, so to speak. Maybe you can put it that way. I thought that I thought that you would first detect this with an NLGS, so to speak, but you practically do that using classical methods. All right. Well, then I would like to go into the distinction from economic stuff.  shrink? How is it classically viewed and what is new now? There is still no test for these resistances. It is really done in such a way that the veterinarians then, if a Leishmania infection has been dismissed, they give just medication. There are quasi guidelines on how best to do this, so to speak, standard procedures and then they just observe the animal, they then measure again and again how high the leishmania load is and then adjust the medication accordingly, make higher concentration or take other medications. But an examination that tells them, take this and that, there's resistance there, otherwise there's no resistance at all. Wonderful, thank you very much. Is there anything else, so this is now in relation to resistance, perhaps briefly in relation to NGS, has this ever been used to study Leishmania in general? No, this has already been used, not with us, but there are publications about it that have just done it. On the one hand, there are different strains to differentiate them, according to epidemiological studies. And resistance has also been looked at, but this is a purely scientific publication. All right, then we can refer to the fact that NGES has so far been used purely for basic research, but not yet commercially. Yes.  Do you also know whether this is also the case, so here we not only have that the Leishmania is\n",
            "\n",
            "Using this as context\n",
            "\n",
            "Answer to the following question from a user regarding Leishmania disease project following given guidelines. \n",
            "Question: What is the background of research ?\n",
            "Guidelines: \n",
            "To what extent does the project\n",
            "aim to expand the state of knowledge/technology or utilize existing\n",
            "scientific, technical, economic, or other relevant findings or approaches\n",
            "Try to include the following:\n",
            "- 1 State of the art (Currently/According to the state of the art...)\n",
            "- 1 Project objective (The goal of the project is...)\n",
            "- 1 Differentiation from the state of the art (The state of the art is expanded in terms of..., thereby expanding the knowledge about...)\n",
            "- 1 Project result (The planned outcome/result is...)\n",
            "Please ensure that the project uses specific technical terminology to\n",
            "describe the innovative core. This is particularly crucial, especially for\n",
            "software projects.\n",
            "Restrict output to ONLY 800 characters\n",
            "\n",
            "\n",
            "Answer:\u001b[0m\n",
            "\n",
            "\u001b[1m> Finished chain.\u001b[0m\n",
            "The Leishmania disease research project aims to expand the state of knowledge and technology in the field. Currently, individual tests and smaller products are used to evaluate genetic health in animals. The project's objective is to develop products for dogs, cats, and horses that allow for a comprehensive evaluation of an animal's genetic health, going beyond what is currently known for specific breeds. This project expands the state of the art by utilizing Next Generation Sequencing (NGS) technology to analyze the entire genetic makeup of an animal, including large genetic variants. The project's result will be a product for each animal species that covers a significant portion of known hereditary diseases and characteristics mapped through NGS technology. This innovative approach provides a market advantage over competitors and promotes animal health by informing breeding decisions.\n",
            "Length of response is 899 which is 99 characters above ideal\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "## Experiment 2\n",
        "### Divide and Conquer\n",
        "### Using Condensed Background"
      ],
      "metadata": {
        "id": "pXnsshz15NY4"
      }
    },
    {
      "cell_type": "markdown",
      "source": [
        "### Understanding Background"
      ],
      "metadata": {
        "id": "ADR4eH_65NZJ"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "from langchain.document_loaders import TextLoader\n",
        "loader = TextLoader('/content/drive/MyDrive/Innoscripta/Advanced/Exp1/processed_text_eng_background_exp1.txt')\n",
        "documents = loader.load_and_split()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 17
        },
        "outputId": "87237cba-24d6-4141-c226-6dbf52ca9402",
        "id": "O-HSBBlc5NZK"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "##### Using Spacy to condense further"
      ],
      "metadata": {
        "id": "kg6XZmJ2_wml"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "with open('/content/drive/MyDrive/Innoscripta/Advanced/Exp1/processed_text_eng_background_exp1.txt', encoding= 'unicode_escape') as f:\n",
        "    sample_text = f.read()\n",
        "\n",
        "from langchain.text_splitter import SpacyTextSplitter\n",
        "# Instantiate the SpacyTextSplitter with the desired chunk size\n",
        "text_splitter = SpacyTextSplitter(chunk_size=1000, chunk_overlap=200)\n",
        "\n",
        "\n",
        "# Split the text using SpacyTextSplitter\n",
        "spacy_texts = text_splitter.split_text(sample_text)\n",
        "print (f\"You have {len(spacy_texts)} documents\")\n",
        "spacy_texts =  [Document(page_content=text, metadata={\"source\": \"local\"}) for text in spacy_texts]\n",
        "\n",
        "print (\"Preview:\")\n",
        "# Print the first chunk\n",
        "print(spacy_texts[0])"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 146
        },
        "outputId": "4378e779-23ee-43d5-ab49-40b4cf494b4c",
        "id": "4l1rTlk25NZL"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "You have 39 documents\n",
            "Preview:\n",
            "page_content=\"I would like to ask you at the beginning to give me a brief overview of the running time.\\n\\nThe research allowance has been in place since 2020, which means that retrospective development content can also be attached.\\n\\nHowever, it is always important that the entire project duration is defined.\\n\\nThis means that if, for example, it started in 2021, but still extends into the future, that you also cover the entire project duration up to the productive stage.\\n\\nHow would that be classified with XSL cat.\\n\\nI would definitely take the starting point of January 1, 2023.\\n\\nAnnalena, yes, that's in your interest and Alex, also because we had a project before, which was supported with subsidies and Annalena did a lot\\n\\nand they are quasi it has almost one to one now after this project from January then switched to XXL cat.\\n\\nThat's how I would do it.\" metadata={'source': 'local'}\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Before executing the following code, make sure to have\n",
        "# your OpenAI key saved in the OPENAI_API_KEY environment variable.\n",
        "embeddings = OpenAIEmbeddings(model=\"text-embedding-ada-002\")\n",
        "\n",
        "# create Deep Lake dataset\n",
        "# TODO: use your organization id here. (by default, org id is your username)\n",
        "my_activeloop_org_id = \"parthtripathidummy\"\n",
        "my_activeloop_dataset_name = \"innoscripta_advanced_exp1_background_v2\"\n",
        "dataset_path = f\"hub://{my_activeloop_org_id}/{my_activeloop_dataset_name}\"\n",
        "db_background2 = DeepLake(dataset_path=dataset_path, embedding_function=embeddings)\n",
        "\n",
        "# add documents to our Deep Lake dataset\n",
        "db_background2.add_documents(spacy_texts)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 921
        },
        "outputId": "394b67c6-3817-415a-e90b-ce2a760900a7",
        "id": "iFXZQdII5NZL"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Deep Lake Dataset in hub://parthtripathidummy/innoscripta_advanced_exp1_background_v2 already exists, loading from the storage\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "Creating embedding data: 100%|| 4/4 [00:01<00:00,  2.61it/s]\n",
            "|"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Dataset(path='hub://parthtripathidummy/innoscripta_advanced_exp1_background_v2', tensors=['embedding', 'id', 'metadata', 'text'])\n",
            "\n",
            "  tensor      htype      shape      dtype  compression\n",
            "  -------    -------    -------    -------  ------- \n",
            " embedding  embedding  (39, 1536)  float32   None   \n",
            "    id        text      (39, 1)      str     None   \n",
            " metadata     json      (39, 1)      str     None   \n",
            "   text       text      (39, 1)      str     None   \n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "\r \r"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "['72fc06c2-47bd-11ee-ab2c-0242ac1c000c',\n",
              " '72fc0d52-47bd-11ee-ab2c-0242ac1c000c',\n",
              " '72fc0e2e-47bd-11ee-ab2c-0242ac1c000c',\n",
              " '72fc0f1e-47bd-11ee-ab2c-0242ac1c000c',\n",
              " '72fc0fc8-47bd-11ee-ab2c-0242ac1c000c',\n",
              " '72fc1068-47bd-11ee-ab2c-0242ac1c000c',\n",
              " '72fc10fe-47bd-11ee-ab2c-0242ac1c000c',\n",
              " '72fc11da-47bd-11ee-ab2c-0242ac1c000c',\n",
              " '72fc1266-47bd-11ee-ab2c-0242ac1c000c',\n",
              " '72fc12fc-47bd-11ee-ab2c-0242ac1c000c',\n",
              " '72fc1392-47bd-11ee-ab2c-0242ac1c000c',\n",
              " '72fc141e-47bd-11ee-ab2c-0242ac1c000c',\n",
              " '72fc1518-47bd-11ee-ab2c-0242ac1c000c',\n",
              " '72fc1608-47bd-11ee-ab2c-0242ac1c000c',\n",
              " '72fc16f8-47bd-11ee-ab2c-0242ac1c000c',\n",
              " '72fc17c0-47bd-11ee-ab2c-0242ac1c000c',\n",
              " '72fc186a-47bd-11ee-ab2c-0242ac1c000c',\n",
              " '72fc191e-47bd-11ee-ab2c-0242ac1c000c',\n",
              " '72fc19d2-47bd-11ee-ab2c-0242ac1c000c',\n",
              " '72fc1a72-47bd-11ee-ab2c-0242ac1c000c',\n",
              " '72fc1b58-47bd-11ee-ab2c-0242ac1c000c',\n",
              " '72fc1bf8-47bd-11ee-ab2c-0242ac1c000c',\n",
              " '72fc1cac-47bd-11ee-ab2c-0242ac1c000c',\n",
              " '72fc1d4c-47bd-11ee-ab2c-0242ac1c000c',\n",
              " '72fc1dec-47bd-11ee-ab2c-0242ac1c000c',\n",
              " '72fc1f04-47bd-11ee-ab2c-0242ac1c000c',\n",
              " '72fc218e-47bd-11ee-ab2c-0242ac1c000c',\n",
              " '72fc224c-47bd-11ee-ab2c-0242ac1c000c',\n",
              " '72fc235a-47bd-11ee-ab2c-0242ac1c000c',\n",
              " '72fc2404-47bd-11ee-ab2c-0242ac1c000c',\n",
              " '72fc2490-47bd-11ee-ab2c-0242ac1c000c',\n",
              " '72fc251c-47bd-11ee-ab2c-0242ac1c000c',\n",
              " '72fc25a8-47bd-11ee-ab2c-0242ac1c000c',\n",
              " '72fc263e-47bd-11ee-ab2c-0242ac1c000c',\n",
              " '72fc26d4-47bd-11ee-ab2c-0242ac1c000c',\n",
              " '72fc276a-47bd-11ee-ab2c-0242ac1c000c',\n",
              " '72fc280a-47bd-11ee-ab2c-0242ac1c000c',\n",
              " '72fc288c-47bd-11ee-ab2c-0242ac1c000c',\n",
              " '72fc2922-47bd-11ee-ab2c-0242ac1c000c']"
            ]
          },
          "metadata": {},
          "execution_count": 64
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# let's see the top relevant documents to a specific query\n",
        "query = \"Give me technical details\"\n",
        "# query = 'what is a nft'\n",
        "docs = db_background2.similarity_search(query)\n",
        "print(docs[0].page_content)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 386
        },
        "outputId": "0c9c882e-0402-4677-e80b-c65330f38e64",
        "id": "CZs1y_zR5NZL"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Then it has to be implemented in the so-called panels with which the NGS technology works.\n",
            "\n",
            "One panel for each species.\n",
            "\n",
            "Then the third step would be the evaluation of the tests that we map.\n",
            "\n",
            "Of course, we also have to make sure that this should not only deliver the correct result from a technical point of view, but that it does.\n",
            "\n",
            "In other words, we have to compare the known animals with the results that we achieve with the new technology, with the NGS technology, and perhaps then bring the whole thing as fit for the work package in a way that is then understandable to the customer.\n",
            "\n",
            "We can't train them with 200 pages of text at the end.\n",
            "\n",
            "It has to be adapted to the different types of people so that they can do something with it.\n",
            "\n",
            "Wonderful, thank you very much.  \n",
            "\n",
            "In the end, could you rewrite the prototype a little better, i.e. the way in which it is understandable for the customer.\n",
            "\n",
            "Do you have a little better idea of what the end result should look like?\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# let's write a prompt for a customer support chatbot that\n",
        "# answer questions using information extracted from our db\n",
        "template = \"\"\"You are a research document summarizer that finds the questions to user query and give correct responses\n",
        "\n",
        "You know the following context information.\n",
        "\n",
        "{chunks_formatted}\n",
        "\n",
        "Answer to the following question from a user. Use only information from the previous context information. Do not invent stuff.\n",
        "The user is from technical background and wants technically rich responses, with lots of technical jargons\n",
        "\n",
        "Question: {query}\n",
        "\n",
        "Answer:\"\"\"\n",
        "human_message_prompt = HumanMessagePromptTemplate.from_template(\n",
        "    input_variables=[\"chunks_formatted\", \"query\"],\n",
        "    template=template,\n",
        "    )\n",
        "prompt = ChatPromptTemplate.from_messages([human_message_prompt])"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 17
        },
        "outputId": "70549ba5-6786-438a-cb71-6e8b1df3d948",
        "id": "WVuHbq6v5NZM"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "type(prompt)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 35
        },
        "outputId": "68cef175-efcf-4844-c04c-b8a0a8f1c01c",
        "id": "Jh5FXbTd5NZM"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "langchain.prompts.chat.ChatPromptTemplate"
            ]
          },
          "metadata": {},
          "execution_count": 68
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "from langchain.chat_models import ChatOpenAI\n",
        "from langchain import LLMChain\n",
        "# the full pipeline\n",
        "\n",
        "# user question\n",
        "query = \"Give me technical details\"\n",
        "\n",
        "# retrieve relevant chunks\n",
        "docs = db_background2.similarity_search(query)\n",
        "retrieved_chunks = [doc.page_content for doc in docs]\n",
        "\n",
        "# format the prompt\n",
        "chunks_formatted = \"\\n\\n\".join(retrieved_chunks)\n",
        "prompt_formatted = prompt.format(chunks_formatted=chunks_formatted, query=query)\n",
        "print(prompt_formatted)\n",
        "# generate answer\n",
        "llm = ChatOpenAI(model_name=\"gpt-3.5-turbo\")\n",
        "chain = LLMChain(llm=llm, prompt=prompt, verbose=True)\n",
        "response = chain.run(chunks_formatted=chunks_formatted, query=query)\n",
        "\n",
        "print(response)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "outputId": "e5e94a46-8232-4190-e606-c9006bceb484",
        "id": "rm7Q83A05NZM"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Human: You are a research document summarizer that finds the questions to user query and give correct responses\n",
            "\n",
            "You know the following context information.\n",
            "\n",
            "Then it has to be implemented in the so-called panels with which the NGS technology works.\n",
            "\n",
            "One panel for each species.\n",
            "\n",
            "Then the third step would be the evaluation of the tests that we map.\n",
            "\n",
            "Of course, we also have to make sure that this should not only deliver the correct result from a technical point of view, but that it does.\n",
            "\n",
            "In other words, we have to compare the known animals with the results that we achieve with the new technology, with the NGS technology, and perhaps then bring the whole thing as fit for the work package in a way that is then understandable to the customer.\n",
            "\n",
            "We can't train them with 200 pages of text at the end.\n",
            "\n",
            "It has to be adapted to the different types of people so that they can do something with it.\n",
            "\n",
            "Wonderful, thank you very much.  \n",
            "\n",
            "In the end, could you rewrite the prototype a little better, i.e. the way in which it is understandable for the customer.\n",
            "\n",
            "Do you have a little better idea of what the end result should look like?\n",
            "\n",
            "That's how I would sum it up now.\n",
            "\n",
            "I have enclosed a short quality checklist here to accompany the application and how the application is always structured, so that you have a rough direction.\n",
            "\n",
            "We always have to describe a sentence about the state of the art, i.e. according to the current state of the art, this is done this way and that, then what the project goal is, then also the demarcation from the state of the art, to what extent the state of the art is expanded and the knowledge is expanded at your company and then finally what the project result should be.\n",
            "\n",
            "Perhaps you could just ask a few questions about the project, especially in relation to this Next Generation Sequencing.\n",
            "\n",
            "So let's put into perspective the extent to which you have already used it, to what extent it is a new technique for you, to what extent it is something new for detecting hereditary diseases in cats, dogs and horses.\n",
            "\n",
            "So now verbally or then for the application?\n",
            "\n",
            "Oral, oral.\n",
            "\n",
            "Typically, they do it all themselves, but I'll just say it at this point that if they plan to hire another company in the course of development for something, we'll do it as well.\n",
            "\n",
            "Who would be my contact person for the cost part and the expenditure part?\n",
            "\n",
            "Well, everything is done by the HR department.\n",
            "\n",
            "I will discuss this with our head of department, Ms. Khnlein.\n",
            "\n",
            "Then I give this information to our HR department and they maintain everything\n",
            "\n",
            "Yes, it fits.\n",
            "\n",
            "The only thing that mattered to me, Mrs Kehl, was whether you would do it again.\n",
            "\n",
            "All right.\n",
            "\n",
            "Okay, good.\n",
            "\n",
            "Then I would actually be done with XXL, cat, dog, horse.\n",
            "\n",
            "Thank you very much for the very valuable input and The next steps will look like this, we will work out the application.\n",
            "\n",
            "We are subject to a strict character limit, so do not wonder about the brevity.\n",
            "\n",
            "That's 800 characters per chapter that we've just talked through, so five times 800 characters and then I'll send it to you by e-mail.\n",
            "\n",
            "We have to be specific about the development content that they are carrying out, and in order to realize this prototype, we also have to take risks, insofar as the project could have been tailored.\n",
            "\n",
            "Accordingly, we typically add two to three really relevant risks or even really points where you don't even know whether this approach is effective at all.  \n",
            "\n",
            "Do you have a few keywords for me where we could pinpoint the risks?\n",
            "\n",
            "Yes, Alex do.\n",
            "\n",
            "On the one hand, there will be these mutations that are not SNPs.\n",
            "\n",
            "We already have some experience with the SNPs.\n",
            "\n",
            "I mean, even then, it may be that you don't detect them properly.\n",
            "\n",
            "Maybe also because of wider fingers.\n",
            "\n",
            "Or falsely detected.\n",
            "\n",
            "Or mistakes happen.\n",
            "\n",
            "Answer to the following question from a user. Use only information from the previous context information. Do not invent stuff.\n",
            "The user is from technical background and wants technically rich responses, with lots of technical jargons\n",
            "\n",
            "Question: Give me technical details\n",
            "\n",
            "Answer:\n",
            "\n",
            "\n",
            "\u001b[1m> Entering new  chain...\u001b[0m\n",
            "Prompt after formatting:\n",
            "\u001b[32;1m\u001b[1;3mHuman: You are a research document summarizer that finds the questions to user query and give correct responses\n",
            "\n",
            "You know the following context information.\n",
            "\n",
            "Then it has to be implemented in the so-called panels with which the NGS technology works.\n",
            "\n",
            "One panel for each species.\n",
            "\n",
            "Then the third step would be the evaluation of the tests that we map.\n",
            "\n",
            "Of course, we also have to make sure that this should not only deliver the correct result from a technical point of view, but that it does.\n",
            "\n",
            "In other words, we have to compare the known animals with the results that we achieve with the new technology, with the NGS technology, and perhaps then bring the whole thing as fit for the work package in a way that is then understandable to the customer.\n",
            "\n",
            "We can't train them with 200 pages of text at the end.\n",
            "\n",
            "It has to be adapted to the different types of people so that they can do something with it.\n",
            "\n",
            "Wonderful, thank you very much.  \n",
            "\n",
            "In the end, could you rewrite the prototype a little better, i.e. the way in which it is understandable for the customer.\n",
            "\n",
            "Do you have a little better idea of what the end result should look like?\n",
            "\n",
            "That's how I would sum it up now.\n",
            "\n",
            "I have enclosed a short quality checklist here to accompany the application and how the application is always structured, so that you have a rough direction.\n",
            "\n",
            "We always have to describe a sentence about the state of the art, i.e. according to the current state of the art, this is done this way and that, then what the project goal is, then also the demarcation from the state of the art, to what extent the state of the art is expanded and the knowledge is expanded at your company and then finally what the project result should be.\n",
            "\n",
            "Perhaps you could just ask a few questions about the project, especially in relation to this Next Generation Sequencing.\n",
            "\n",
            "So let's put into perspective the extent to which you have already used it, to what extent it is a new technique for you, to what extent it is something new for detecting hereditary diseases in cats, dogs and horses.\n",
            "\n",
            "So now verbally or then for the application?\n",
            "\n",
            "Oral, oral.\n",
            "\n",
            "Typically, they do it all themselves, but I'll just say it at this point that if they plan to hire another company in the course of development for something, we'll do it as well.\n",
            "\n",
            "Who would be my contact person for the cost part and the expenditure part?\n",
            "\n",
            "Well, everything is done by the HR department.\n",
            "\n",
            "I will discuss this with our head of department, Ms. Khnlein.\n",
            "\n",
            "Then I give this information to our HR department and they maintain everything\n",
            "\n",
            "Yes, it fits.\n",
            "\n",
            "The only thing that mattered to me, Mrs Kehl, was whether you would do it again.\n",
            "\n",
            "All right.\n",
            "\n",
            "Okay, good.\n",
            "\n",
            "Then I would actually be done with XXL, cat, dog, horse.\n",
            "\n",
            "Thank you very much for the very valuable input and The next steps will look like this, we will work out the application.\n",
            "\n",
            "We are subject to a strict character limit, so do not wonder about the brevity.\n",
            "\n",
            "That's 800 characters per chapter that we've just talked through, so five times 800 characters and then I'll send it to you by e-mail.\n",
            "\n",
            "We have to be specific about the development content that they are carrying out, and in order to realize this prototype, we also have to take risks, insofar as the project could have been tailored.\n",
            "\n",
            "Accordingly, we typically add two to three really relevant risks or even really points where you don't even know whether this approach is effective at all.  \n",
            "\n",
            "Do you have a few keywords for me where we could pinpoint the risks?\n",
            "\n",
            "Yes, Alex do.\n",
            "\n",
            "On the one hand, there will be these mutations that are not SNPs.\n",
            "\n",
            "We already have some experience with the SNPs.\n",
            "\n",
            "I mean, even then, it may be that you don't detect them properly.\n",
            "\n",
            "Maybe also because of wider fingers.\n",
            "\n",
            "Or falsely detected.\n",
            "\n",
            "Or mistakes happen.\n",
            "\n",
            "Answer to the following question from a user. Use only information from the previous context information. Do not invent stuff.\n",
            "The user is from technical background and wants technically rich responses, with lots of technical jargons\n",
            "\n",
            "Question: Give me technical details\n",
            "\n",
            "Answer:\u001b[0m\n",
            "\n",
            "\u001b[1m> Finished chain.\u001b[0m\n",
            "The panels used in the NGS technology are responsible for implementing the tests for each species. The evaluation of these tests involves comparing the results achieved with the new NGS technology to known animals. It is important to ensure that the results are not only technically correct but also understandable to the customer. The end result should be adapted to different types of people and not overwhelm them with excessive technical information. In terms of the project, it is important to describe the current state of the art, project goals, expansion of knowledge, and the expected project result. The use of Next Generation Sequencing (NGS) for detecting hereditary diseases in cats, dogs, and horses is a new technique that may involve risks such as mutations that are not SNPs, detection errors, and potential challenges due to finger width or mistakes.\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "### Understanding Target"
      ],
      "metadata": {
        "id": "RbNUkTBv5NZN"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "# Before executing the following code, make sure to have\n",
        "# your OpenAI key saved in the OPENAI_API_KEY environment variable.\n",
        "embeddings = OpenAIEmbeddings(model=\"text-embedding-ada-002\")\n",
        "\n",
        "# create Deep Lake dataset\n",
        "# TODO: use your organization id here. (by default, org id is your username)\n",
        "my_activeloop_org_id = \"parthtripathidummy\"\n",
        "my_activeloop_dataset_name = \"innoscripta_advanced_exp1_target\"\n",
        "dataset_path = f\"hub://{my_activeloop_org_id}/{my_activeloop_dataset_name}\"\n",
        "db_target = DeepLake(dataset_path=dataset_path, embedding_function=embeddings)\n",
        "\n",
        "# add documents to our Deep Lake dataset\n",
        "# db_target.add_documents(simple_texts)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 35
        },
        "outputId": "9c6c7da6-01e1-4567-d59b-0e88690a6ac8",
        "id": "t37ggnh75NZO"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Deep Lake Dataset in hub://parthtripathidummy/innoscripta_advanced_exp1_target already exists, loading from the storage\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# let's see the top relevant documents to a specific query\n",
        "query = \"What is this research about\"\n",
        "# query = 'what is a nft'\n",
        "docs = db_target.similarity_search(query)\n",
        "print(docs[0].page_content)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 405
        },
        "outputId": "494ec60d-a482-4813-f410-26b5397d742f",
        "id": "5VOY9rC_5NZO"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "in the animal sector. If things go really badly, you can also grow the Leishmania in a cell culture and then examine the special hold, so to speak. But that would be very time-consuming, very expensive. You have to ask yourself whether you want to continue the project at all. In other words, one could actually also argue as a risk that the whole technique works for Leishmania in cell culture, but in the end the animal sample simply cannot be realized. Yes, right. Better. To the expenses. Do you know how many people are supposed to work on it? Yes, so we'll do it again via the HR department. In principle, I will have a relatively large number of hours there. Then a veterinarian from clinical chemistry has hours there and of course we still need a laboratory and I think there will be a second veterinarian from either my department or from clinical chemistry so that he can have contact with the veterinarians outside. All right, then just a rough overview, that is, four people to no idea ten to 15 percent perhaps. Yes, that's right.  Okay, do any subcontractors still come in here? So there will certainly be cooperations, but more with universities and then you don't really have any bills. So if you don't pay for the university, then that's not relevant. Yes yes exactly.  Yes, exactly, I'm just thinking so loudly. That's why I don't think so at the moment. Okay perfect, then I'm already through with my questions here too. Is there another project or would that be it for now?  I think that would be it for now. Completely new things will be added. The other thing with the infection scan, they had sent something again. I would only get the one sentence out.  Exactly, I wanted to talk to you about that, because of course we have to make sure that we fill in the text to see if there is perhaps a replacement for the deletion. I don't know what you're aiming for. I'll probably have to open this up again. Because it doesn't allow you to do that, just that's what IT is doing here today. Exactly, but I can also briefly share your e-mail otherwise. Yes, maybe that's the fastest way to do it. So, exactly. Yes, few screening with EDP Yes, few screening methods that result from dogs or cats. I don't know what they're actually going to pick up. We wanted to show a bit of the demarcations to the state of the art, i.e. how this is done according to statistics, i.e. how much of the statistics is not enough. So what we're doing is not screening methods, it's like, it's like packages. But that would have to be worded a little differently. If the dog's nose runs, then we just do herpes calypso, then there are already four or five typical pathogens that you do there.  So these are more like packages that are then specific to certain symptoms. But never cover everything that could be there. Maybe you can just rephrase it a bit. Yes, that means you actually have to have an initial guess and then you examine it specifically. But you don't study the entire genome. That's right, yes. Okay, let's rephrase. Well, we did it. Class. Yes, wonderful. Yes, we still had the one with the mutation, antimutation or whatever they called it. So with that I still have a bit of a stomach ache overall, because it is, actually already the case, that we have already established a lot of hereditary diseases and yes actually this prototype, as described earlier, has been there for a long time and we just keep expanding it with newly released things. Of course, we also expand our methods or the possibility of mapping these structural variants now, but I don't know if we can get that many hours together if I really concentrate on that. I have to talk to Mrs. Khler again, to my head of department, about how we can do that, whether we can perhaps somehow make a different focus, that we can somehow do it differently, so I would put that on the back burner at the moment, although it is actually the project that is retroactive, all the others are actually not retroactive from the\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# let's write a prompt for a customer support chatbot that\n",
        "# answer questions using information extracted from our db\n",
        "template = \"\"\"You are a research document summarizer that finds the questions to user query and give correct responses\n",
        "\n",
        "You know the following context information.\n",
        "\n",
        "{chunks_formatted}\n",
        "\n",
        "Answer to the following question from a user. Use only information from the previous context information. Do not invent stuff.\n",
        "The user is from technical background and wants technically rich responses, with lots of technical jargons\n",
        "\n",
        "Question: {query}\n",
        "\n",
        "Answer:\"\"\"\n",
        "human_message_prompt = HumanMessagePromptTemplate.from_template(\n",
        "    input_variables=[\"chunks_formatted\", \"query\"],\n",
        "    template=template,\n",
        "    )\n",
        "prompt = ChatPromptTemplate.from_messages([human_message_prompt])"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 17
        },
        "outputId": "8d8608eb-8219-41cb-9fc6-a9e30c128f31",
        "id": "WMaaODVO5NZP"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "type(prompt)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 35
        },
        "outputId": "6d26602e-66cf-441d-da90-e02f4ba280f9",
        "id": "4FJKoTcn5NZP"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "langchain.prompts.chat.ChatPromptTemplate"
            ]
          },
          "metadata": {},
          "execution_count": 73
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "from langchain.chat_models import ChatOpenAI\n",
        "from langchain import LLMChain\n",
        "# the full pipeline\n",
        "\n",
        "# user question\n",
        "query = \"What is this research about ?\"\n",
        "\n",
        "# retrieve relevant chunks\n",
        "docs = db_target.similarity_search(query)\n",
        "retrieved_chunks = [doc.page_content for doc in docs]\n",
        "\n",
        "# format the prompt\n",
        "chunks_formatted = \"\\n\\n\".join(retrieved_chunks)\n",
        "prompt_formatted = prompt.format(chunks_formatted=chunks_formatted, query=query)\n",
        "print(prompt_formatted)\n",
        "# generate answer\n",
        "llm = ChatOpenAI(model_name=\"gpt-3.5-turbo\")\n",
        "chain = LLMChain(llm=llm, prompt=prompt, verbose=True)\n",
        "response = chain.run(chunks_formatted=chunks_formatted, query=query)\n",
        "\n",
        "print(response)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "outputId": "1cc5b2e1-b88b-4863-f001-613a68671ae4",
        "id": "4CgXk0pP5NZQ"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Human: You are a research document summarizer that finds the questions to user query and give correct responses\n",
            "\n",
            "You know the following context information.\n",
            "\n",
            "in the animal sector. If things go really badly, you can also grow the Leishmania in a cell culture and then examine the special hold, so to speak. But that would be very time-consuming, very expensive. You have to ask yourself whether you want to continue the project at all. In other words, one could actually also argue as a risk that the whole technique works for Leishmania in cell culture, but in the end the animal sample simply cannot be realized. Yes, right. Better. To the expenses. Do you know how many people are supposed to work on it? Yes, so we'll do it again via the HR department. In principle, I will have a relatively large number of hours there. Then a veterinarian from clinical chemistry has hours there and of course we still need a laboratory and I think there will be a second veterinarian from either my department or from clinical chemistry so that he can have contact with the veterinarians outside. All right, then just a rough overview, that is, four people to no idea ten to 15 percent perhaps. Yes, that's right.  Okay, do any subcontractors still come in here? So there will certainly be cooperations, but more with universities and then you don't really have any bills. So if you don't pay for the university, then that's not relevant. Yes yes exactly.  Yes, exactly, I'm just thinking so loudly. That's why I don't think so at the moment. Okay perfect, then I'm already through with my questions here too. Is there another project or would that be it for now?  I think that would be it for now. Completely new things will be added. The other thing with the infection scan, they had sent something again. I would only get the one sentence out.  Exactly, I wanted to talk to you about that, because of course we have to make sure that we fill in the text to see if there is perhaps a replacement for the deletion. I don't know what you're aiming for. I'll probably have to open this up again. Because it doesn't allow you to do that, just that's what IT is doing here today. Exactly, but I can also briefly share your e-mail otherwise. Yes, maybe that's the fastest way to do it. So, exactly. Yes, few screening with EDP Yes, few screening methods that result from dogs or cats. I don't know what they're actually going to pick up. We wanted to show a bit of the demarcations to the state of the art, i.e. how this is done according to statistics, i.e. how much of the statistics is not enough. So what we're doing is not screening methods, it's like, it's like packages. But that would have to be worded a little differently. If the dog's nose runs, then we just do herpes calypso, then there are already four or five typical pathogens that you do there.  So these are more like packages that are then specific to certain symptoms. But never cover everything that could be there. Maybe you can just rephrase it a bit. Yes, that means you actually have to have an initial guess and then you examine it specifically. But you don't study the entire genome. That's right, yes. Okay, let's rephrase. Well, we did it. Class. Yes, wonderful. Yes, we still had the one with the mutation, antimutation or whatever they called it. So with that I still have a bit of a stomach ache overall, because it is, actually already the case, that we have already established a lot of hereditary diseases and yes actually this prototype, as described earlier, has been there for a long time and we just keep expanding it with newly released things. Of course, we also expand our methods or the possibility of mapping these structural variants now, but I don't know if we can get that many hours together if I really concentrate on that. I have to talk to Mrs. Khler again, to my head of department, about how we can do that, whether we can perhaps somehow make a different focus, that we can somehow do it differently, so I would put that on the back burner at the moment, although it is actually the project that is retroactive, all the others are actually not retroactive from the\n",
            "\n",
            "to the fact that NGES has so far been used purely for basic research, but not yet commercially. Yes.  Do you also know whether this is also the case, so here we not only have that the Leishmania is to be examined with NGS and that this is also to be characterized practically on the basis of an animal sample, so to speak, can this also be applied as a fight to existing NGS investigations? So, as I said, there is nothing at all in diagnostics. But now you mean basic research. Yes, that's where the Leishmania were always bred. In cell culture, only those were examined. That's right, that's another step that we also have to take, because we want to do this investigation directly from the sample, so to speak, and then we may have a lot of background through the genomic DNA again. That would be such a risk. Yes, perfect.  Perfect. Then the next chapter would be the differentiation from your technologies. Here we have to refer to Leishmania in general and then to NGS.  We detect Leishmania itself in various sample materials via classical PCA or real-time PCA, but we do not yet have any resistance genes. That would be the innovation, so to speak. And at the moment we are not doing any studies of any parasites about NGS, but we are doing these DNA profiles, as discussed earlier, from genomic DNA. But studies of parasites has not yet been. Or rather, this other project with Infecto-Scan, which is also going in this direction, but it is also completely under development, that we want to examine a sample and which pathogens are in it. All right: NGS could also point out that they not only examine animal samples, but also isolate Leishmania from them. Or at least for sample preparation. That makes a difference. You would then have to adjust the sample preparation so that mainly the parasite DNA is isolated so that it can be sequenced in a targeted manner. That you don't have so much background that it gets lost. That's also a sub-project of this Infecto-Scan, but it's more on viruses and they are parasites. Yes, all right, well, one can also say in general terms that for the first time parasites from animal material are to be characterized by NGS Yes, definitely. All right, then I would like to go back to the last point, namely the risks. Yes, so one risk is that several strains can occur within one animal. So they are often stung and can then carry different Leishmania strains in them, of which perhaps only one part is resistant and the other is not. You have to make sure that you really get everything pictured, that you can see this variant. That would be a risk. The second would be that the publications are not correct, because at the beginning we want to look specifically at the genes that are in the publications. It could be that there are errors in it, that we detect the genes, but that does not correlate with the clinic, i.e. there is actually no resistance at all. That could be. And if we then do NGS, it can of course be again, as with the infection scan, that we just have too much genomic DNA in it. We have to adapt all the preparations to these parasites beforehand. Or that we don't have the sensitivity to be able to map all resistance genes. Could you also quantify the sensitivity? Then we would have a numerical value here.  the sensitivity of the resistances then again. Yes, exactly. Yes, I mean, 80% sensitivity has always been something you actually strive for. Okay, well, what's a solution for them to bring out this genomic DNA, so that they bring out the genomic DNA as well as possible? It should also be tried out via Infectoscan whether there are methods to separate it.  The company Nanopore offers various recipes for this. But this, of course, is all for the human sphere. First of all, you have to see if this is also possible in the animal sector. If things go really badly, you can also grow the Leishmania in a cell culture and then examine the special hold, so to speak. But that would be very time-consuming, very\n",
            "\n",
            "genes. But you would also look at variations like these SNPs, for example, to see whether or not you see them clustered in certain genes, in certain resistant Leishmania. And the characterization of which resistance refers to which drug intolerance or ineffectiveness, would you identify the series by existing knowledge, by consulting the veterinarians, or is there somehow a direct conclusion from the mode of action of the drug to the change in the genome? So, on the one hand, we would try to evaluate this by means of questionnaires or consultation with the veterinarians. These Leishmania can also be kept in cell culture. In other words, we could then create cell cultures of some samples from the Leishmanias, so to speak, and then there are in vitro tests to see whether these Leishmaniasis still respond to certain drugs or not. Similar to bacteria, where you put antibiotics on it and see if they are still growing or not. Something like this also exists for Leishmania in cell cultures. And then, of course, you can also look biochemically at what it does. Is it realistic that it somehow has a connection or not? There is then a certain term for this biochemical approach. So if there is a technical term for it, then they would have a few more numerical values, so for me what can be attached as an objective here difficult. To be honest, I can't think of anything in this case. On the other hand, sensitivity and specificity, so what is always a classic? Yes, that's just a problem in this case, because I don't know what my gold standard would be. So I always have to see what the veterinarians say. Well, I could just say that I want an 80 percent agreement. If the veterinarian says, yes, I see resistance there, then I want to see 80 percent of it in my test material, you could perhaps say that. Then maybe also related to the resistances, i.e. what is the 80 percent, this 80 percent value refers to the I can tell at all whether Leishmania is present, yes or no or I recognize resistance. I recognize resistances, i.e. Leishmania, which I have to recognize in any case, we already have other tests, that is already established, It is now really a matter of seeing whether they are resistant or not. So 80 percent. I would say that 80 percent of the samples that are described as resistant by veterinarians, I would then like to find a resistance gene, so to speak. Maybe you can put it that way. I thought that I thought that you would first detect this with an NLGS, so to speak, but you practically do that using classical methods. All right. Well, then I would like to go into the distinction from economic stuff.  shrink? How is it classically viewed and what is new now? There is still no test for these resistances. It is really done in such a way that the veterinarians then, if a Leishmania infection has been dismissed, they give just medication. There are quasi guidelines on how best to do this, so to speak, standard procedures and then they just observe the animal, they then measure again and again how high the leishmania load is and then adjust the medication accordingly, make higher concentration or take other medications. But an examination that tells them, take this and that, there's resistance there, otherwise there's no resistance at all. Wonderful, thank you very much. Is there anything else, so this is now in relation to resistance, perhaps briefly in relation to NGS, has this ever been used to study Leishmania in general? No, this has already been used, not with us, but there are publications about it that have just done it. On the one hand, there are different strains to differentiate them, according to epidemiological studies. And resistance has also been looked at, but this is a purely scientific publication. All right, then we can refer to the fact that NGES has so far been used purely for basic research, but not yet commercially. Yes.  Do you also know whether this is also the case, so here we not only have that the Leishmania is\n",
            "\n",
            "Perfect, okay when we start again with the goal of the project. So I'm going to elaborate a bit, leishmania are parasites that are transmitted via various mosquitoes. This means that the dogs are bitten by the mosquitoes, then get these leishmanias, which then lead to leishmaniasis. And the whole thing can also affect people. At the moment, this is still a major problem in southern countries, i.e. southern Europe. However, due to climate change, of course, these mosquitoes are coming further and further north, which transmit these larch manias, so to speak, and sooner or later it will most likely become a problem in Germany. This means that the dog has the mosquito bites on these Leishmanias, picks up the eggs of it again and so on and so on. There are now various medications that are taken for the treatment of the dogs. However, these Leishmania develop resistance to it very quickly. Our goal now would be to get a sample from a dog, to prove that he has Leishmania and at the same time to examine these Leishmania to see if they already contain certain resistance genes, so that the doctor can then take the other drug instead of a drug, as is the case with the bacteria in the end, instead of giving the wrong drug,  On the one hand, this does not work, and on the other hand, it leads to the formation of even more resistant Leishmania in order to avoid this. That would be the goal, that you give the veterinarians a tool and say, send us a sample. We study the animal Leishmania and have these Leishmania that the animal has, resistance genes, in order to be able to say which drug is best. Wonderful thank you very much.  On what basis should the investigation of the resistance or the sample in general be carried out? There are already a few publications, there are many groups that are working on which genes are responsible for the resistances. There are already a few publications, there are many groups that are now working on which genes are now responsible for the resistance. There is often no change in the genes, but a copy number variation. So these genes are then either multiplied or they are no longer there at all and this leads to this resistance and this is to be investigated on the basis of these scientific publications. And what we also want to do is to use Next Generation Sequencing to examine the entire Leishmania genome, so to speak. So the first approach would be to search specifically for the genes that are in the publications. And we can also look at it again. In other words, we would then also ask the veterinarians again, are these dogs already treated, do you also see resistance to allopurinol, for example, and we can see, yes we also see what is written in the scientific publication, that this and that gene is more common or not. And then we also want to examine the complete genomes of the Leishmania to see if we can find more genes that are relevant. And that would simply make the product more attractive if you don't say, okay, I'm just looking for an allopurinol resistance or only for a Milteforan resistance, but I'll look at everything again and I can then tell you, yes such and such resistances are present and you don't need this and that at all. Perfect, thank you very much. Could you elaborate on how you ultimately want to characterize whether other genes are relevant if they are not yet published? Are there certain patterns that they then practically read out of the publications and then transferred to the rest of the moment, something has just happened to me. I don't see them properly anymore. So we would just take a close look at the whole thing via Next Generation Sequencing.  Yes, of course, because they are often also copy number variations, one would first focus on whether one sees something like this in other genes. But you would also look at variations like these SNPs, for example, to see whether or not you see them clustered in certain genes, in certain resistant Leishmania. And the characterization\n",
            "\n",
            "Answer to the following question from a user. Use only information from the previous context information. Do not invent stuff.\n",
            "The user is from technical background and wants technically rich responses, with lots of technical jargons\n",
            "\n",
            "Question: What is this research about ?\n",
            "\n",
            "Answer:\n",
            "\n",
            "\n",
            "\u001b[1m> Entering new  chain...\u001b[0m\n",
            "Prompt after formatting:\n",
            "\u001b[32;1m\u001b[1;3mHuman: You are a research document summarizer that finds the questions to user query and give correct responses\n",
            "\n",
            "You know the following context information.\n",
            "\n",
            "in the animal sector. If things go really badly, you can also grow the Leishmania in a cell culture and then examine the special hold, so to speak. But that would be very time-consuming, very expensive. You have to ask yourself whether you want to continue the project at all. In other words, one could actually also argue as a risk that the whole technique works for Leishmania in cell culture, but in the end the animal sample simply cannot be realized. Yes, right. Better. To the expenses. Do you know how many people are supposed to work on it? Yes, so we'll do it again via the HR department. In principle, I will have a relatively large number of hours there. Then a veterinarian from clinical chemistry has hours there and of course we still need a laboratory and I think there will be a second veterinarian from either my department or from clinical chemistry so that he can have contact with the veterinarians outside. All right, then just a rough overview, that is, four people to no idea ten to 15 percent perhaps. Yes, that's right.  Okay, do any subcontractors still come in here? So there will certainly be cooperations, but more with universities and then you don't really have any bills. So if you don't pay for the university, then that's not relevant. Yes yes exactly.  Yes, exactly, I'm just thinking so loudly. That's why I don't think so at the moment. Okay perfect, then I'm already through with my questions here too. Is there another project or would that be it for now?  I think that would be it for now. Completely new things will be added. The other thing with the infection scan, they had sent something again. I would only get the one sentence out.  Exactly, I wanted to talk to you about that, because of course we have to make sure that we fill in the text to see if there is perhaps a replacement for the deletion. I don't know what you're aiming for. I'll probably have to open this up again. Because it doesn't allow you to do that, just that's what IT is doing here today. Exactly, but I can also briefly share your e-mail otherwise. Yes, maybe that's the fastest way to do it. So, exactly. Yes, few screening with EDP Yes, few screening methods that result from dogs or cats. I don't know what they're actually going to pick up. We wanted to show a bit of the demarcations to the state of the art, i.e. how this is done according to statistics, i.e. how much of the statistics is not enough. So what we're doing is not screening methods, it's like, it's like packages. But that would have to be worded a little differently. If the dog's nose runs, then we just do herpes calypso, then there are already four or five typical pathogens that you do there.  So these are more like packages that are then specific to certain symptoms. But never cover everything that could be there. Maybe you can just rephrase it a bit. Yes, that means you actually have to have an initial guess and then you examine it specifically. But you don't study the entire genome. That's right, yes. Okay, let's rephrase. Well, we did it. Class. Yes, wonderful. Yes, we still had the one with the mutation, antimutation or whatever they called it. So with that I still have a bit of a stomach ache overall, because it is, actually already the case, that we have already established a lot of hereditary diseases and yes actually this prototype, as described earlier, has been there for a long time and we just keep expanding it with newly released things. Of course, we also expand our methods or the possibility of mapping these structural variants now, but I don't know if we can get that many hours together if I really concentrate on that. I have to talk to Mrs. Khler again, to my head of department, about how we can do that, whether we can perhaps somehow make a different focus, that we can somehow do it differently, so I would put that on the back burner at the moment, although it is actually the project that is retroactive, all the others are actually not retroactive from the\n",
            "\n",
            "to the fact that NGES has so far been used purely for basic research, but not yet commercially. Yes.  Do you also know whether this is also the case, so here we not only have that the Leishmania is to be examined with NGS and that this is also to be characterized practically on the basis of an animal sample, so to speak, can this also be applied as a fight to existing NGS investigations? So, as I said, there is nothing at all in diagnostics. But now you mean basic research. Yes, that's where the Leishmania were always bred. In cell culture, only those were examined. That's right, that's another step that we also have to take, because we want to do this investigation directly from the sample, so to speak, and then we may have a lot of background through the genomic DNA again. That would be such a risk. Yes, perfect.  Perfect. Then the next chapter would be the differentiation from your technologies. Here we have to refer to Leishmania in general and then to NGS.  We detect Leishmania itself in various sample materials via classical PCA or real-time PCA, but we do not yet have any resistance genes. That would be the innovation, so to speak. And at the moment we are not doing any studies of any parasites about NGS, but we are doing these DNA profiles, as discussed earlier, from genomic DNA. But studies of parasites has not yet been. Or rather, this other project with Infecto-Scan, which is also going in this direction, but it is also completely under development, that we want to examine a sample and which pathogens are in it. All right: NGS could also point out that they not only examine animal samples, but also isolate Leishmania from them. Or at least for sample preparation. That makes a difference. You would then have to adjust the sample preparation so that mainly the parasite DNA is isolated so that it can be sequenced in a targeted manner. That you don't have so much background that it gets lost. That's also a sub-project of this Infecto-Scan, but it's more on viruses and they are parasites. Yes, all right, well, one can also say in general terms that for the first time parasites from animal material are to be characterized by NGS Yes, definitely. All right, then I would like to go back to the last point, namely the risks. Yes, so one risk is that several strains can occur within one animal. So they are often stung and can then carry different Leishmania strains in them, of which perhaps only one part is resistant and the other is not. You have to make sure that you really get everything pictured, that you can see this variant. That would be a risk. The second would be that the publications are not correct, because at the beginning we want to look specifically at the genes that are in the publications. It could be that there are errors in it, that we detect the genes, but that does not correlate with the clinic, i.e. there is actually no resistance at all. That could be. And if we then do NGS, it can of course be again, as with the infection scan, that we just have too much genomic DNA in it. We have to adapt all the preparations to these parasites beforehand. Or that we don't have the sensitivity to be able to map all resistance genes. Could you also quantify the sensitivity? Then we would have a numerical value here.  the sensitivity of the resistances then again. Yes, exactly. Yes, I mean, 80% sensitivity has always been something you actually strive for. Okay, well, what's a solution for them to bring out this genomic DNA, so that they bring out the genomic DNA as well as possible? It should also be tried out via Infectoscan whether there are methods to separate it.  The company Nanopore offers various recipes for this. But this, of course, is all for the human sphere. First of all, you have to see if this is also possible in the animal sector. If things go really badly, you can also grow the Leishmania in a cell culture and then examine the special hold, so to speak. But that would be very time-consuming, very\n",
            "\n",
            "genes. But you would also look at variations like these SNPs, for example, to see whether or not you see them clustered in certain genes, in certain resistant Leishmania. And the characterization of which resistance refers to which drug intolerance or ineffectiveness, would you identify the series by existing knowledge, by consulting the veterinarians, or is there somehow a direct conclusion from the mode of action of the drug to the change in the genome? So, on the one hand, we would try to evaluate this by means of questionnaires or consultation with the veterinarians. These Leishmania can also be kept in cell culture. In other words, we could then create cell cultures of some samples from the Leishmanias, so to speak, and then there are in vitro tests to see whether these Leishmaniasis still respond to certain drugs or not. Similar to bacteria, where you put antibiotics on it and see if they are still growing or not. Something like this also exists for Leishmania in cell cultures. And then, of course, you can also look biochemically at what it does. Is it realistic that it somehow has a connection or not? There is then a certain term for this biochemical approach. So if there is a technical term for it, then they would have a few more numerical values, so for me what can be attached as an objective here difficult. To be honest, I can't think of anything in this case. On the other hand, sensitivity and specificity, so what is always a classic? Yes, that's just a problem in this case, because I don't know what my gold standard would be. So I always have to see what the veterinarians say. Well, I could just say that I want an 80 percent agreement. If the veterinarian says, yes, I see resistance there, then I want to see 80 percent of it in my test material, you could perhaps say that. Then maybe also related to the resistances, i.e. what is the 80 percent, this 80 percent value refers to the I can tell at all whether Leishmania is present, yes or no or I recognize resistance. I recognize resistances, i.e. Leishmania, which I have to recognize in any case, we already have other tests, that is already established, It is now really a matter of seeing whether they are resistant or not. So 80 percent. I would say that 80 percent of the samples that are described as resistant by veterinarians, I would then like to find a resistance gene, so to speak. Maybe you can put it that way. I thought that I thought that you would first detect this with an NLGS, so to speak, but you practically do that using classical methods. All right. Well, then I would like to go into the distinction from economic stuff.  shrink? How is it classically viewed and what is new now? There is still no test for these resistances. It is really done in such a way that the veterinarians then, if a Leishmania infection has been dismissed, they give just medication. There are quasi guidelines on how best to do this, so to speak, standard procedures and then they just observe the animal, they then measure again and again how high the leishmania load is and then adjust the medication accordingly, make higher concentration or take other medications. But an examination that tells them, take this and that, there's resistance there, otherwise there's no resistance at all. Wonderful, thank you very much. Is there anything else, so this is now in relation to resistance, perhaps briefly in relation to NGS, has this ever been used to study Leishmania in general? No, this has already been used, not with us, but there are publications about it that have just done it. On the one hand, there are different strains to differentiate them, according to epidemiological studies. And resistance has also been looked at, but this is a purely scientific publication. All right, then we can refer to the fact that NGES has so far been used purely for basic research, but not yet commercially. Yes.  Do you also know whether this is also the case, so here we not only have that the Leishmania is\n",
            "\n",
            "Perfect, okay when we start again with the goal of the project. So I'm going to elaborate a bit, leishmania are parasites that are transmitted via various mosquitoes. This means that the dogs are bitten by the mosquitoes, then get these leishmanias, which then lead to leishmaniasis. And the whole thing can also affect people. At the moment, this is still a major problem in southern countries, i.e. southern Europe. However, due to climate change, of course, these mosquitoes are coming further and further north, which transmit these larch manias, so to speak, and sooner or later it will most likely become a problem in Germany. This means that the dog has the mosquito bites on these Leishmanias, picks up the eggs of it again and so on and so on. There are now various medications that are taken for the treatment of the dogs. However, these Leishmania develop resistance to it very quickly. Our goal now would be to get a sample from a dog, to prove that he has Leishmania and at the same time to examine these Leishmania to see if they already contain certain resistance genes, so that the doctor can then take the other drug instead of a drug, as is the case with the bacteria in the end, instead of giving the wrong drug,  On the one hand, this does not work, and on the other hand, it leads to the formation of even more resistant Leishmania in order to avoid this. That would be the goal, that you give the veterinarians a tool and say, send us a sample. We study the animal Leishmania and have these Leishmania that the animal has, resistance genes, in order to be able to say which drug is best. Wonderful thank you very much.  On what basis should the investigation of the resistance or the sample in general be carried out? There are already a few publications, there are many groups that are working on which genes are responsible for the resistances. There are already a few publications, there are many groups that are now working on which genes are now responsible for the resistance. There is often no change in the genes, but a copy number variation. So these genes are then either multiplied or they are no longer there at all and this leads to this resistance and this is to be investigated on the basis of these scientific publications. And what we also want to do is to use Next Generation Sequencing to examine the entire Leishmania genome, so to speak. So the first approach would be to search specifically for the genes that are in the publications. And we can also look at it again. In other words, we would then also ask the veterinarians again, are these dogs already treated, do you also see resistance to allopurinol, for example, and we can see, yes we also see what is written in the scientific publication, that this and that gene is more common or not. And then we also want to examine the complete genomes of the Leishmania to see if we can find more genes that are relevant. And that would simply make the product more attractive if you don't say, okay, I'm just looking for an allopurinol resistance or only for a Milteforan resistance, but I'll look at everything again and I can then tell you, yes such and such resistances are present and you don't need this and that at all. Perfect, thank you very much. Could you elaborate on how you ultimately want to characterize whether other genes are relevant if they are not yet published? Are there certain patterns that they then practically read out of the publications and then transferred to the rest of the moment, something has just happened to me. I don't see them properly anymore. So we would just take a close look at the whole thing via Next Generation Sequencing.  Yes, of course, because they are often also copy number variations, one would first focus on whether one sees something like this in other genes. But you would also look at variations like these SNPs, for example, to see whether or not you see them clustered in certain genes, in certain resistant Leishmania. And the characterization\n",
            "\n",
            "Answer to the following question from a user. Use only information from the previous context information. Do not invent stuff.\n",
            "The user is from technical background and wants technically rich responses, with lots of technical jargons\n",
            "\n",
            "Question: What is this research about ?\n",
            "\n",
            "Answer:\u001b[0m\n",
            "\n",
            "\u001b[1m> Finished chain.\u001b[0m\n",
            "This research is focused on studying Leishmania parasites and their resistance to medications. The goal is to develop a tool that can analyze a sample from an infected animal and identify any resistance genes present in the Leishmania. This information will help veterinarians determine the most effective treatment for the animal, preventing the use of ineffective drugs and the development of further drug resistance. The research involves examining published scientific literature on the genes associated with resistance, as well as using Next Generation Sequencing to analyze the entire Leishmania genome for additional relevant genes. The ultimate aim is to provide a comprehensive characterization of the resistance profiles of Leishmania parasites to improve treatment outcomes.\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "ytxAHxwK5NZQ"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "### Merging Concepts"
      ],
      "metadata": {
        "id": "6fEmRi1s5NZQ"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "# Before executing the following code, make sure to have\n",
        "# your OpenAI key saved in the OPENAI_API_KEY environment variable.\n",
        "embeddings = OpenAIEmbeddings(model=\"text-embedding-ada-002\")\n",
        "\n",
        "# create Deep Lake dataset\n",
        "# TODO: use your organization id here. (by default, org id is your username)\n",
        "my_activeloop_org_id = \"parthtripathidummy\"\n",
        "my_activeloop_dataset_name = \"innoscripta_advanced_exp1_target\"\n",
        "dataset_path = f\"hub://{my_activeloop_org_id}/{my_activeloop_dataset_name}\"\n",
        "db_target = DeepLake(dataset_path=dataset_path, embedding_function=embeddings)\n",
        "\n",
        "my_activeloop_dataset_name = \"innoscripta_advanced_exp1_background_v2\"\n",
        "dataset_path = f\"hub://{my_activeloop_org_id}/{my_activeloop_dataset_name}\"\n",
        "db_background = DeepLake(dataset_path=dataset_path, embedding_function=embeddings)\n",
        "# add documents to our Deep Lake dataset\n",
        "# db_target.add_documents(simple_texts)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 54
        },
        "outputId": "cd3c10fb-57f5-4624-9384-cc80022cc381",
        "id": "Wc32O1PW5NZR"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Deep Lake Dataset in hub://parthtripathidummy/innoscripta_advanced_exp1_target already exists, loading from the storage\n",
            "Deep Lake Dataset in hub://parthtripathidummy/innoscripta_advanced_exp1_background_v2 already exists, loading from the storage\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# let's write a prompt for a customer support chatbot that\n",
        "# answer questions using information extracted from our db\n",
        "template = \"\"\"You are a research document summarizer that finds the answers to user query and give correct responses\n",
        "Note that the user is from a highly specialized technical background, use minimal layman terms in your responses\n",
        "\n",
        "Use the following background context information on the Leishmania disease research project.\n",
        "\n",
        "{background_chunks_formatted}\n",
        "\n",
        "Use the following information on the Leishmania disease research project.\n",
        "\n",
        "{target_chunks_formatted}\n",
        "\n",
        "Using this as context\n",
        "\n",
        "Answer to the following question from a user regarding Leishmania disease project following given guidelines.\n",
        "Question: {query}\n",
        "Guidelines: {guidelines}\n",
        "\n",
        "Answer:\"\"\"\n",
        "human_message_prompt = HumanMessagePromptTemplate.from_template(\n",
        "    input_variables=[\"background_chunks_formatted\", \"target_chunks_formatted\", \"query\", \"guidelines\"],\n",
        "    template=template,\n",
        "    )\n",
        "prompt = ChatPromptTemplate.from_messages([human_message_prompt])"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 17
        },
        "outputId": "e50af63c-b170-40c5-95a6-38b2572cb4f3",
        "id": "4PTqWnW75NZS"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "type(prompt)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 35
        },
        "outputId": "0e331d95-19b9-40b7-c3cd-8246ec1a495f",
        "id": "vGHhRjvz5NZS"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "langchain.prompts.chat.ChatPromptTemplate"
            ]
          },
          "metadata": {},
          "execution_count": 77
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "from langchain.chat_models import ChatOpenAI\n",
        "from langchain import LLMChain\n",
        "# the full pipeline\n",
        "\n",
        "# user question\n",
        "background_query = \"What are the technologies discussed ?\"\n",
        "target_query = \"What is the Objective of the project (if applicable, in the context of the cooperative project)\"\n",
        "\n",
        "# retrieve relevant chunks\n",
        "docs = db_background.similarity_search(background_query)\n",
        "background_retrieved_chunks = [doc.page_content for doc in docs]\n",
        "background_chunks_formatted = \"\\n\\n\".join(background_retrieved_chunks)\n",
        "\n",
        "docs = db_target.similarity_search(target_query)\n",
        "target_retrieved_chunks = [doc.page_content for doc in docs]\n",
        "target_chunks_formatted = \"\\n\\n\".join(target_retrieved_chunks)\n",
        "\n",
        "guidelines = '''\n",
        "To what extent does the project\n",
        "aim to expand the state of knowledge/technology or utilize existing\n",
        "scientific, technical, economic, or other relevant findings or approaches\n",
        "Try to include the following:\n",
        "- 1 State of the art (Currently/According to the state of the art...)\n",
        "- 1 Project objective (The goal of the project is...)\n",
        "- 1 Differentiation from the state of the art (The state of the art is expanded in terms of..., thereby expanding the knowledge about...)\n",
        "- 1 Project result (The planned outcome/result is...)\n",
        "Please ensure that the project uses specific technical terminology to\n",
        "describe the innovative core. This is particularly crucial, especially for\n",
        "software projects.\n",
        "Restrict output to ONLY 800 characters\n",
        "'''\n",
        "# generate answer\n",
        "llm = ChatOpenAI(model_name=\"gpt-3.5-turbo-16k\")\n",
        "chain = LLMChain(llm=llm, prompt=prompt, verbose=True)\n",
        "\n",
        "response = chain.run(\n",
        "    background_chunks_formatted=background_chunks_formatted,\n",
        "    target_chunks_formatted=target_chunks_formatted,\n",
        "    query=query,\n",
        "    guidelines=guidelines,\n",
        "    )\n",
        "\n",
        "print(response)\n",
        "print(\"Length of response is {} which is {} characters above ideal\".format(len(response), len(response)-800))"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "outputId": "459a068e-b206-4e63-b48b-e8a5451d0950",
        "id": "18kPHs-z5NZT"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\n",
            "\n",
            "\u001b[1m> Entering new  chain...\u001b[0m\n",
            "Prompt after formatting:\n",
            "\u001b[32;1m\u001b[1;3mHuman: You are a research document summarizer that finds the answers to user query and give correct responses\n",
            "Note that the user is from a highly specialized technical background, use minimal layman terms in your responses\n",
            "\n",
            "Use the following background context information on the Leishmania disease research project.\n",
            "\n",
            "That's how I would sum it up now.\n",
            "\n",
            "I have enclosed a short quality checklist here to accompany the application and how the application is always structured, so that you have a rough direction.\n",
            "\n",
            "We always have to describe a sentence about the state of the art, i.e. according to the current state of the art, this is done this way and that, then what the project goal is, then also the demarcation from the state of the art, to what extent the state of the art is expanded and the knowledge is expanded at your company and then finally what the project result should be.\n",
            "\n",
            "Perhaps you could just ask a few questions about the project, especially in relation to this Next Generation Sequencing.\n",
            "\n",
            "So let's put into perspective the extent to which you have already used it, to what extent it is a new technique for you, to what extent it is something new for detecting hereditary diseases in cats, dogs and horses.\n",
            "\n",
            "So now verbally or then for the application?\n",
            "\n",
            "Oral, oral.\n",
            "\n",
            "So now verbally or then for the application?\n",
            "\n",
            "Oral, oral.\n",
            "\n",
            "We formulate on the basis, that's why the recording is ongoing.\n",
            "\n",
            "We formulate the application from this.\n",
            "\n",
            "Okay, so then I would say that the current state of the art is that we are not yet using high-throughput technology to study the entire genetic markup of an animal.\n",
            "\n",
            "Instead, we mainly have individual tests and smaller products that are applied to breed-specific.  \n",
            "\n",
            "We are currently using next generation sequencing as a technology for DNA profiling.\n",
            "\n",
            "The main focus is on parentage analyses and the genetic fingerprint of animals.\n",
            "\n",
            "The aim of the project would then be what I formulated earlier, that it is primarily about animal health, of our own animal, but also of the species that we want to cover as a whole.\n",
            "\n",
            "State-of-the-art technology?  \n",
            "\n",
            "Above all, we are also expanding into larger genetic variants in this area.\n",
            "\n",
            "Class.\n",
            "\n",
            "Well, then I would like to go into the next point.\n",
            "\n",
            "The next point also relates to the differentiation from existing technologies in your company.\n",
            "\n",
            "It would be important for the auditor to classify whether you have ever dealt with Next Generation Sequencing in the company.\n",
            "\n",
            "If so, what is the difference here and if not, the This is perfectly adequate.\n",
            "\n",
            "Yes, we have had this, i.e. Next Generation Sequencing, in our company since 2020.\n",
            "\n",
            "And we are currently using it for genetic fingerprinting in dogs.  \n",
            "\n",
            "and to investigate genetic variability also in dogs.\n",
            "\n",
            "We do not yet have a product for cats, nor for horses, nor anything that is offered with hereditary diseases.\n",
            "\n",
            "Then it has to be implemented in the so-called panels with which the NGS technology works.\n",
            "\n",
            "One panel for each species.\n",
            "\n",
            "Then the third step would be the evaluation of the tests that we map.\n",
            "\n",
            "Of course, we also have to make sure that this should not only deliver the correct result from a technical point of view, but that it does.\n",
            "\n",
            "In other words, we have to compare the known animals with the results that we achieve with the new technology, with the NGS technology, and perhaps then bring the whole thing as fit for the work package in a way that is then understandable to the customer.\n",
            "\n",
            "We can't train them with 200 pages of text at the end.\n",
            "\n",
            "It has to be adapted to the different types of people so that they can do something with it.\n",
            "\n",
            "Wonderful, thank you very much.  \n",
            "\n",
            "In the end, could you rewrite the prototype a little better, i.e. the way in which it is understandable for the customer.\n",
            "\n",
            "Do you have a little better idea of what the end result should look like?\n",
            "\n",
            "Use the following information on the Leishmania disease research project.\n",
            "\n",
            "we can somehow do it differently, so I would put that on the back burner at the moment, although it is actually the project that is retroactive, all the others are actually not retroactive from the time to But I would sit down with Mrs. Khnlein for the next three or four weeks and then I would give you feedback again. All right, so if we can change the focus, such as What is that? Mutations, exactly. We can integrate that relatively easily. But then just give me a message about it. Yes. Class. Wonderful. Then thank you very much, Mrs Kehl, for taking the time. And then I wish you a nice week. Same to you. Goodbye. Thank you. Goodbye.\n",
            "\n",
            "in the animal sector. If things go really badly, you can also grow the Leishmania in a cell culture and then examine the special hold, so to speak. But that would be very time-consuming, very expensive. You have to ask yourself whether you want to continue the project at all. In other words, one could actually also argue as a risk that the whole technique works for Leishmania in cell culture, but in the end the animal sample simply cannot be realized. Yes, right. Better. To the expenses. Do you know how many people are supposed to work on it? Yes, so we'll do it again via the HR department. In principle, I will have a relatively large number of hours there. Then a veterinarian from clinical chemistry has hours there and of course we still need a laboratory and I think there will be a second veterinarian from either my department or from clinical chemistry so that he can have contact with the veterinarians outside. All right, then just a rough overview, that is, four people to no idea ten to 15 percent perhaps. Yes, that's right.  Okay, do any subcontractors still come in here? So there will certainly be cooperations, but more with universities and then you don't really have any bills. So if you don't pay for the university, then that's not relevant. Yes yes exactly.  Yes, exactly, I'm just thinking so loudly. That's why I don't think so at the moment. Okay perfect, then I'm already through with my questions here too. Is there another project or would that be it for now?  I think that would be it for now. Completely new things will be added. The other thing with the infection scan, they had sent something again. I would only get the one sentence out.  Exactly, I wanted to talk to you about that, because of course we have to make sure that we fill in the text to see if there is perhaps a replacement for the deletion. I don't know what you're aiming for. I'll probably have to open this up again. Because it doesn't allow you to do that, just that's what IT is doing here today. Exactly, but I can also briefly share your e-mail otherwise. Yes, maybe that's the fastest way to do it. So, exactly. Yes, few screening with EDP Yes, few screening methods that result from dogs or cats. I don't know what they're actually going to pick up. We wanted to show a bit of the demarcations to the state of the art, i.e. how this is done according to statistics, i.e. how much of the statistics is not enough. So what we're doing is not screening methods, it's like, it's like packages. But that would have to be worded a little differently. If the dog's nose runs, then we just do herpes calypso, then there are already four or five typical pathogens that you do there.  So these are more like packages that are then specific to certain symptoms. But never cover everything that could be there. Maybe you can just rephrase it a bit. Yes, that means you actually have to have an initial guess and then you examine it specifically. But you don't study the entire genome. That's right, yes. Okay, let's rephrase. Well, we did it. Class. Yes, wonderful. Yes, we still had the one with the mutation, antimutation or whatever they called it. So with that I still have a bit of a stomach ache overall, because it is, actually already the case, that we have already established a lot of hereditary diseases and yes actually this prototype, as described earlier, has been there for a long time and we just keep expanding it with newly released things. Of course, we also expand our methods or the possibility of mapping these structural variants now, but I don't know if we can get that many hours together if I really concentrate on that. I have to talk to Mrs. Khler again, to my head of department, about how we can do that, whether we can perhaps somehow make a different focus, that we can somehow do it differently, so I would put that on the back burner at the moment, although it is actually the project that is retroactive, all the others are actually not retroactive from the\n",
            "\n",
            "Perfect, okay when we start again with the goal of the project. So I'm going to elaborate a bit, leishmania are parasites that are transmitted via various mosquitoes. This means that the dogs are bitten by the mosquitoes, then get these leishmanias, which then lead to leishmaniasis. And the whole thing can also affect people. At the moment, this is still a major problem in southern countries, i.e. southern Europe. However, due to climate change, of course, these mosquitoes are coming further and further north, which transmit these larch manias, so to speak, and sooner or later it will most likely become a problem in Germany. This means that the dog has the mosquito bites on these Leishmanias, picks up the eggs of it again and so on and so on. There are now various medications that are taken for the treatment of the dogs. However, these Leishmania develop resistance to it very quickly. Our goal now would be to get a sample from a dog, to prove that he has Leishmania and at the same time to examine these Leishmania to see if they already contain certain resistance genes, so that the doctor can then take the other drug instead of a drug, as is the case with the bacteria in the end, instead of giving the wrong drug,  On the one hand, this does not work, and on the other hand, it leads to the formation of even more resistant Leishmania in order to avoid this. That would be the goal, that you give the veterinarians a tool and say, send us a sample. We study the animal Leishmania and have these Leishmania that the animal has, resistance genes, in order to be able to say which drug is best. Wonderful thank you very much.  On what basis should the investigation of the resistance or the sample in general be carried out? There are already a few publications, there are many groups that are working on which genes are responsible for the resistances. There are already a few publications, there are many groups that are now working on which genes are now responsible for the resistance. There is often no change in the genes, but a copy number variation. So these genes are then either multiplied or they are no longer there at all and this leads to this resistance and this is to be investigated on the basis of these scientific publications. And what we also want to do is to use Next Generation Sequencing to examine the entire Leishmania genome, so to speak. So the first approach would be to search specifically for the genes that are in the publications. And we can also look at it again. In other words, we would then also ask the veterinarians again, are these dogs already treated, do you also see resistance to allopurinol, for example, and we can see, yes we also see what is written in the scientific publication, that this and that gene is more common or not. And then we also want to examine the complete genomes of the Leishmania to see if we can find more genes that are relevant. And that would simply make the product more attractive if you don't say, okay, I'm just looking for an allopurinol resistance or only for a Milteforan resistance, but I'll look at everything again and I can then tell you, yes such and such resistances are present and you don't need this and that at all. Perfect, thank you very much. Could you elaborate on how you ultimately want to characterize whether other genes are relevant if they are not yet published? Are there certain patterns that they then practically read out of the publications and then transferred to the rest of the moment, something has just happened to me. I don't see them properly anymore. So we would just take a close look at the whole thing via Next Generation Sequencing.  Yes, of course, because they are often also copy number variations, one would first focus on whether one sees something like this in other genes. But you would also look at variations like these SNPs, for example, to see whether or not you see them clustered in certain genes, in certain resistant Leishmania. And the characterization\n",
            "\n",
            "genes. But you would also look at variations like these SNPs, for example, to see whether or not you see them clustered in certain genes, in certain resistant Leishmania. And the characterization of which resistance refers to which drug intolerance or ineffectiveness, would you identify the series by existing knowledge, by consulting the veterinarians, or is there somehow a direct conclusion from the mode of action of the drug to the change in the genome? So, on the one hand, we would try to evaluate this by means of questionnaires or consultation with the veterinarians. These Leishmania can also be kept in cell culture. In other words, we could then create cell cultures of some samples from the Leishmanias, so to speak, and then there are in vitro tests to see whether these Leishmaniasis still respond to certain drugs or not. Similar to bacteria, where you put antibiotics on it and see if they are still growing or not. Something like this also exists for Leishmania in cell cultures. And then, of course, you can also look biochemically at what it does. Is it realistic that it somehow has a connection or not? There is then a certain term for this biochemical approach. So if there is a technical term for it, then they would have a few more numerical values, so for me what can be attached as an objective here difficult. To be honest, I can't think of anything in this case. On the other hand, sensitivity and specificity, so what is always a classic? Yes, that's just a problem in this case, because I don't know what my gold standard would be. So I always have to see what the veterinarians say. Well, I could just say that I want an 80 percent agreement. If the veterinarian says, yes, I see resistance there, then I want to see 80 percent of it in my test material, you could perhaps say that. Then maybe also related to the resistances, i.e. what is the 80 percent, this 80 percent value refers to the I can tell at all whether Leishmania is present, yes or no or I recognize resistance. I recognize resistances, i.e. Leishmania, which I have to recognize in any case, we already have other tests, that is already established, It is now really a matter of seeing whether they are resistant or not. So 80 percent. I would say that 80 percent of the samples that are described as resistant by veterinarians, I would then like to find a resistance gene, so to speak. Maybe you can put it that way. I thought that I thought that you would first detect this with an NLGS, so to speak, but you practically do that using classical methods. All right. Well, then I would like to go into the distinction from economic stuff.  shrink? How is it classically viewed and what is new now? There is still no test for these resistances. It is really done in such a way that the veterinarians then, if a Leishmania infection has been dismissed, they give just medication. There are quasi guidelines on how best to do this, so to speak, standard procedures and then they just observe the animal, they then measure again and again how high the leishmania load is and then adjust the medication accordingly, make higher concentration or take other medications. But an examination that tells them, take this and that, there's resistance there, otherwise there's no resistance at all. Wonderful, thank you very much. Is there anything else, so this is now in relation to resistance, perhaps briefly in relation to NGS, has this ever been used to study Leishmania in general? No, this has already been used, not with us, but there are publications about it that have just done it. On the one hand, there are different strains to differentiate them, according to epidemiological studies. And resistance has also been looked at, but this is a purely scientific publication. All right, then we can refer to the fact that NGES has so far been used purely for basic research, but not yet commercially. Yes.  Do you also know whether this is also the case, so here we not only have that the Leishmania is\n",
            "\n",
            "Using this as context\n",
            "\n",
            "Answer to the following question from a user regarding Leishmania disease project following given guidelines.\n",
            "Question: What is this research about ?\n",
            "Guidelines: \n",
            "To what extent does the project\n",
            "aim to expand the state of knowledge/technology or utilize existing\n",
            "scientific, technical, economic, or other relevant findings or approaches\n",
            "Try to include the following:\n",
            "- 1 State of the art (Currently/According to the state of the art...)\n",
            "- 1 Project objective (The goal of the project is...)\n",
            "- 1 Differentiation from the state of the art (The state of the art is expanded in terms of..., thereby expanding the knowledge about...)\n",
            "- 1 Project result (The planned outcome/result is...)\n",
            "Please ensure that the project uses specific technical terminology to\n",
            "describe the innovative core. This is particularly crucial, especially for\n",
            "software projects.\n",
            "Restrict output to ONLY 800 characters\n",
            "\n",
            "\n",
            "Answer:\u001b[0m\n",
            "\n",
            "\u001b[1m> Finished chain.\u001b[0m\n",
            "The research project focuses on the use of Next Generation Sequencing (NGS) technology to study Leishmania disease in animals. Currently, the state of the art involves individual tests and smaller products specific to certain breeds. The project aims to expand the use of high-throughput technology to analyze the entire genetic makeup of animals for parentage analysis and genetic fingerprinting. This expands the knowledge and understanding of animal health and genetics. The project result will be the development of a tool that can identify Leishmania strains and their resistance genes, providing veterinarians with information to choose the most effective treatment. This research is innovative as it applies NGS technology to study Leishmania and expands the current understanding of the disease.\n",
            "Length of response is 803 which is 3 characters above ideal\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "text = '''\n",
        "The Leishmania disease research project aims to expand the state of knowledge and technology in the field. Currently, individual tests and smaller products are used to evaluate genetic health in animals. The project's objective is to develop products for dogs, cats, and horses that allow for a comprehensive evaluation of an animal's genetic health, going beyond what is currently known for specific breeds. This project expands the state of the art by utilizing Next Generation Sequencing (NGS) technology to analyze the entire genetic makeup of an animal, including large genetic variants. The project's result will be a product for each animal species that covers a significant portion of known hereditary diseases and characteristics mapped through NGS technology. This innovative approach provides a market advantage over competitors and promotes animal health by informing breeding decisions.\n",
        "Length of response is 899 which is 99 characters above ideal\n",
        "'''\n",
        "print(text)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 165
        },
        "id": "dZFpkOND5NZT",
        "outputId": "6eaf3123-ff53-4ad6-fe51-5293f76f4661"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\n",
            "The Leishmania disease research project aims to expand the state of knowledge and technology in the field. Currently, individual tests and smaller products are used to evaluate genetic health in animals. The project's objective is to develop products for dogs, cats, and horses that allow for a comprehensive evaluation of an animal's genetic health, going beyond what is currently known for specific breeds. This project expands the state of the art by utilizing Next Generation Sequencing (NGS) technology to analyze the entire genetic makeup of an animal, including large genetic variants. The project's result will be a product for each animal species that covers a significant portion of known hereditary diseases and characteristics mapped through NGS technology. This innovative approach provides a market advantage over competitors and promotes animal health by informing breeding decisions.\n",
            "Length of response is 899 which is 99 characters above ideal\n",
            "\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "J7fjKktGD5CW"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "## Experiment 3\n",
        "### Divide and Conquer\n",
        "### Using Condensed Background\n",
        "### Adding Technical research abstract"
      ],
      "metadata": {
        "id": "JBJgIzysa_Ii"
      }
    },
    {
      "cell_type": "markdown",
      "source": [
        "### Merging Concepts"
      ],
      "metadata": {
        "id": "wLEeYvbWa_Ij"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "# Before executing the following code, make sure to have\n",
        "# your OpenAI key saved in the OPENAI_API_KEY environment variable.\n",
        "embeddings = OpenAIEmbeddings(model=\"text-embedding-ada-002\")\n",
        "\n",
        "# create Deep Lake dataset\n",
        "# TODO: use your organization id here. (by default, org id is your username)\n",
        "my_activeloop_org_id = \"parthtripathidummy\"\n",
        "my_activeloop_dataset_name = \"innoscripta_advanced_exp1_target\"\n",
        "dataset_path = f\"hub://{my_activeloop_org_id}/{my_activeloop_dataset_name}\"\n",
        "db_target = DeepLake(dataset_path=dataset_path, embedding_function=embeddings)\n",
        "\n",
        "my_activeloop_dataset_name = \"innoscripta_advanced_exp1_background_v2\"\n",
        "dataset_path = f\"hub://{my_activeloop_org_id}/{my_activeloop_dataset_name}\"\n",
        "db_background = DeepLake(dataset_path=dataset_path, embedding_function=embeddings)\n",
        "# add documents to our Deep Lake dataset\n",
        "# db_target.add_documents(simple_texts)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 54
        },
        "outputId": "4f5309ac-595e-4954-f489-b6216f56d765",
        "id": "C13TXVXya_Ij"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Deep Lake Dataset in hub://parthtripathidummy/innoscripta_advanced_exp1_target already exists, loading from the storage\n",
            "Deep Lake Dataset in hub://parthtripathidummy/innoscripta_advanced_exp1_background_v2 already exists, loading from the storage\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# let's write a prompt for a customer support chatbot that\n",
        "# answer questions using information extracted from our db\n",
        "template = \"\"\"You are a research document summarizer that finds the answers to user query and give correct responses\n",
        "Note that the user is from a highly specialized technical background, use minimal layman terms in your responses\n",
        "\n",
        "Use the following background context information on the Leishmania disease research project.\n",
        "\n",
        "{background_chunks_formatted}\n",
        "\n",
        "Use the following information on the Leishmania disease research project.\n",
        "{raw_technical_info}\n",
        "{target_chunks_formatted}\n",
        "\n",
        "Using this as context\n",
        "\n",
        "Answer to the following question from a user regarding Leishmania disease project following given guidelines.\n",
        "Question: {query}\n",
        "Guidelines: {guidelines}\n",
        "Restrict output to ONLY 800 characters\n",
        "\n",
        "Answer:\"\"\"\n",
        "human_message_prompt = HumanMessagePromptTemplate.from_template(\n",
        "    input_variables=[\"background_chunks_formatted\", \"raw_technical_info\", \"target_chunks_formatted\", \"query\", \"guidelines\"],\n",
        "    template=template,\n",
        "    )\n",
        "prompt = ChatPromptTemplate.from_messages([human_message_prompt])"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 17
        },
        "outputId": "7eda47d2-588f-417d-90f1-ff33662c0562",
        "id": "9VZPqGL-a_Ik"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "type(prompt)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 35
        },
        "outputId": "c43cefc2-752c-4688-a04e-ee14ebe47b53",
        "id": "3lkttamKa_Ik"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "langchain.prompts.chat.ChatPromptTemplate"
            ]
          },
          "metadata": {},
          "execution_count": 7
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "Ingesting Technical Data\n",
        "https://pubmed.ncbi.nlm.nih.gov/30980298/"
      ],
      "metadata": {
        "id": "Yv_M4Gjsh3wA"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "with open('/content/drive/MyDrive/Innoscripta/Advanced/Exp1/tech_abstract.txt', 'r') as file:\n",
        "    tech_data = file.read()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 17
        },
        "id": "YCwa9ityh6VB",
        "outputId": "908880d9-195c-4b3b-f12f-9cfa54d8fb30"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "from langchain.chat_models import ChatOpenAI\n",
        "from langchain import LLMChain\n",
        "# the full pipeline\n",
        "\n",
        "# user question\n",
        "background_query = \"What are the technologies discussed ?\"\n",
        "target_query = \"What is the Objective of the project (if applicable, in the context of the cooperative project)\"\n",
        "\n",
        "# retrieve relevant chunks\n",
        "docs = db_background.similarity_search(background_query)\n",
        "background_retrieved_chunks = [doc.page_content for doc in docs]\n",
        "background_chunks_formatted = \"\\n\\n\".join(background_retrieved_chunks)\n",
        "\n",
        "docs = db_target.similarity_search(target_query)\n",
        "target_retrieved_chunks = [doc.page_content for doc in docs]\n",
        "target_chunks_formatted = \"\\n\\n\".join(target_retrieved_chunks)\n",
        "\n",
        "guidelines = '''\n",
        "To what extent does the project\n",
        "aim to expand the state of knowledge/technology or utilize existing\n",
        "scientific, technical, economic, or other relevant findings or approaches\n",
        "Try to include the following:\n",
        "- 1 State of the art (Currently/According to the state of the art...)\n",
        "- 1 Project objective (The goal of the project is...)\n",
        "- 1 Differentiation from the state of the art (The state of the art is expanded in terms of..., thereby expanding the knowledge about...)\n",
        "- 1 Project result (The planned outcome/result is...)\n",
        "Please ensure that the project uses specific technical terminology to\n",
        "describe the innovative core. This is particularly crucial, especially for\n",
        "software projects.\n",
        "'''\n",
        "# generate answer\n",
        "llm = ChatOpenAI(model_name=\"gpt-3.5-turbo-16k\")\n",
        "chain = LLMChain(llm=llm, prompt=prompt, verbose=True)\n",
        "\n",
        "response = chain.run(\n",
        "    background_chunks_formatted=background_chunks_formatted,\n",
        "    raw_technical_info=tech_data,\n",
        "    target_chunks_formatted=target_chunks_formatted,\n",
        "    query=target_query,\n",
        "    guidelines=guidelines,\n",
        "    )\n",
        "\n",
        "print(response)\n",
        "print(\"Length of response is {} which is {} characters above ideal\".format(len(response), len(response)-800))"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "outputId": "c1c7e6a1-c6cd-4e20-bf3e-ec89119d880c",
        "id": "UPlNHF6Na_Ik"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\n",
            "\n",
            "\u001b[1m> Entering new  chain...\u001b[0m\n",
            "Prompt after formatting:\n",
            "\u001b[32;1m\u001b[1;3mHuman: You are a research document summarizer that finds the answers to user query and give correct responses\n",
            "Note that the user is from a highly specialized technical background, use minimal layman terms in your responses\n",
            "\n",
            "Use the following background context information on the Leishmania disease research project.\n",
            "\n",
            "That's how I would sum it up now.\n",
            "\n",
            "I have enclosed a short quality checklist here to accompany the application and how the application is always structured, so that you have a rough direction.\n",
            "\n",
            "We always have to describe a sentence about the state of the art, i.e. according to the current state of the art, this is done this way and that, then what the project goal is, then also the demarcation from the state of the art, to what extent the state of the art is expanded and the knowledge is expanded at your company and then finally what the project result should be.\n",
            "\n",
            "Perhaps you could just ask a few questions about the project, especially in relation to this Next Generation Sequencing.\n",
            "\n",
            "So let's put into perspective the extent to which you have already used it, to what extent it is a new technique for you, to what extent it is something new for detecting hereditary diseases in cats, dogs and horses.\n",
            "\n",
            "So now verbally or then for the application?\n",
            "\n",
            "Oral, oral.\n",
            "\n",
            "So now verbally or then for the application?\n",
            "\n",
            "Oral, oral.\n",
            "\n",
            "We formulate on the basis, that's why the recording is ongoing.\n",
            "\n",
            "We formulate the application from this.\n",
            "\n",
            "Okay, so then I would say that the current state of the art is that we are not yet using high-throughput technology to study the entire genetic markup of an animal.\n",
            "\n",
            "Instead, we mainly have individual tests and smaller products that are applied to breed-specific.  \n",
            "\n",
            "We are currently using next generation sequencing as a technology for DNA profiling.\n",
            "\n",
            "The main focus is on parentage analyses and the genetic fingerprint of animals.\n",
            "\n",
            "The aim of the project would then be what I formulated earlier, that it is primarily about animal health, of our own animal, but also of the species that we want to cover as a whole.\n",
            "\n",
            "State-of-the-art technology?  \n",
            "\n",
            "Above all, we are also expanding into larger genetic variants in this area.\n",
            "\n",
            "Class.\n",
            "\n",
            "Well, then I would like to go into the next point.\n",
            "\n",
            "The next point also relates to the differentiation from existing technologies in your company.\n",
            "\n",
            "It would be important for the auditor to classify whether you have ever dealt with Next Generation Sequencing in the company.\n",
            "\n",
            "If so, what is the difference here and if not, the This is perfectly adequate.\n",
            "\n",
            "Yes, we have had this, i.e. Next Generation Sequencing, in our company since 2020.\n",
            "\n",
            "And we are currently using it for genetic fingerprinting in dogs.  \n",
            "\n",
            "and to investigate genetic variability also in dogs.\n",
            "\n",
            "We do not yet have a product for cats, nor for horses, nor anything that is offered with hereditary diseases.\n",
            "\n",
            "Then it has to be implemented in the so-called panels with which the NGS technology works.\n",
            "\n",
            "One panel for each species.\n",
            "\n",
            "Then the third step would be the evaluation of the tests that we map.\n",
            "\n",
            "Of course, we also have to make sure that this should not only deliver the correct result from a technical point of view, but that it does.\n",
            "\n",
            "In other words, we have to compare the known animals with the results that we achieve with the new technology, with the NGS technology, and perhaps then bring the whole thing as fit for the work package in a way that is then understandable to the customer.\n",
            "\n",
            "We can't train them with 200 pages of text at the end.\n",
            "\n",
            "It has to be adapted to the different types of people so that they can do something with it.\n",
            "\n",
            "Wonderful, thank you very much.  \n",
            "\n",
            "In the end, could you rewrite the prototype a little better, i.e. the way in which it is understandable for the customer.\n",
            "\n",
            "Do you have a little better idea of what the end result should look like?\n",
            "\n",
            "Use the following information on the Leishmania disease research project.\n",
            "Next generation sequencing (NGS) technology transformed Leishmania genome studies and became an indispensable tool for Leishmania researchers. Recent Leishmania genomics analyses facilitated the discovery of various genetic diversities including single nucleotide polymorphisms (SNPs), copy number variations (CNVs), somy variations, and structural variations in detail and provided valuable insights into the complexity of the genome and gene regulation. Many aspects of Leishmania NGS analyses are similar to those of related pathogens like trypanosomes. However, the analyses of Leishmania genomes face a unique challenge because of the presence of frequent aneuploidy. This makes characterization and interpretation of read depth and somy a key part of Leishmania NGS analyses because read depth affects the accuracy of detection of all genetic variations. However, there are no general guidelines on how to explore and interpret the impact of aneuploidy, and this has made it difficult for biologists and bioinformaticians, especially for beginners, to perform their own analyses and interpret results across different analyses. In this guide we discuss a wide range of topics essential for Leishmania NGS analyses, ranging from how to set up a computational environment for genome analyses, to how to characterize genetic variations among Leishmania samples, and we will particularly focus on chromosomal copy number variation and its impact on genome analyses.\n",
            "we can somehow do it differently, so I would put that on the back burner at the moment, although it is actually the project that is retroactive, all the others are actually not retroactive from the time to But I would sit down with Mrs. Khnlein for the next three or four weeks and then I would give you feedback again. All right, so if we can change the focus, such as What is that? Mutations, exactly. We can integrate that relatively easily. But then just give me a message about it. Yes. Class. Wonderful. Then thank you very much, Mrs Kehl, for taking the time. And then I wish you a nice week. Same to you. Goodbye. Thank you. Goodbye.\n",
            "\n",
            "in the animal sector. If things go really badly, you can also grow the Leishmania in a cell culture and then examine the special hold, so to speak. But that would be very time-consuming, very expensive. You have to ask yourself whether you want to continue the project at all. In other words, one could actually also argue as a risk that the whole technique works for Leishmania in cell culture, but in the end the animal sample simply cannot be realized. Yes, right. Better. To the expenses. Do you know how many people are supposed to work on it? Yes, so we'll do it again via the HR department. In principle, I will have a relatively large number of hours there. Then a veterinarian from clinical chemistry has hours there and of course we still need a laboratory and I think there will be a second veterinarian from either my department or from clinical chemistry so that he can have contact with the veterinarians outside. All right, then just a rough overview, that is, four people to no idea ten to 15 percent perhaps. Yes, that's right.  Okay, do any subcontractors still come in here? So there will certainly be cooperations, but more with universities and then you don't really have any bills. So if you don't pay for the university, then that's not relevant. Yes yes exactly.  Yes, exactly, I'm just thinking so loudly. That's why I don't think so at the moment. Okay perfect, then I'm already through with my questions here too. Is there another project or would that be it for now?  I think that would be it for now. Completely new things will be added. The other thing with the infection scan, they had sent something again. I would only get the one sentence out.  Exactly, I wanted to talk to you about that, because of course we have to make sure that we fill in the text to see if there is perhaps a replacement for the deletion. I don't know what you're aiming for. I'll probably have to open this up again. Because it doesn't allow you to do that, just that's what IT is doing here today. Exactly, but I can also briefly share your e-mail otherwise. Yes, maybe that's the fastest way to do it. So, exactly. Yes, few screening with EDP Yes, few screening methods that result from dogs or cats. I don't know what they're actually going to pick up. We wanted to show a bit of the demarcations to the state of the art, i.e. how this is done according to statistics, i.e. how much of the statistics is not enough. So what we're doing is not screening methods, it's like, it's like packages. But that would have to be worded a little differently. If the dog's nose runs, then we just do herpes calypso, then there are already four or five typical pathogens that you do there.  So these are more like packages that are then specific to certain symptoms. But never cover everything that could be there. Maybe you can just rephrase it a bit. Yes, that means you actually have to have an initial guess and then you examine it specifically. But you don't study the entire genome. That's right, yes. Okay, let's rephrase. Well, we did it. Class. Yes, wonderful. Yes, we still had the one with the mutation, antimutation or whatever they called it. So with that I still have a bit of a stomach ache overall, because it is, actually already the case, that we have already established a lot of hereditary diseases and yes actually this prototype, as described earlier, has been there for a long time and we just keep expanding it with newly released things. Of course, we also expand our methods or the possibility of mapping these structural variants now, but I don't know if we can get that many hours together if I really concentrate on that. I have to talk to Mrs. Khler again, to my head of department, about how we can do that, whether we can perhaps somehow make a different focus, that we can somehow do it differently, so I would put that on the back burner at the moment, although it is actually the project that is retroactive, all the others are actually not retroactive from the\n",
            "\n",
            "Perfect, okay when we start again with the goal of the project. So I'm going to elaborate a bit, leishmania are parasites that are transmitted via various mosquitoes. This means that the dogs are bitten by the mosquitoes, then get these leishmanias, which then lead to leishmaniasis. And the whole thing can also affect people. At the moment, this is still a major problem in southern countries, i.e. southern Europe. However, due to climate change, of course, these mosquitoes are coming further and further north, which transmit these larch manias, so to speak, and sooner or later it will most likely become a problem in Germany. This means that the dog has the mosquito bites on these Leishmanias, picks up the eggs of it again and so on and so on. There are now various medications that are taken for the treatment of the dogs. However, these Leishmania develop resistance to it very quickly. Our goal now would be to get a sample from a dog, to prove that he has Leishmania and at the same time to examine these Leishmania to see if they already contain certain resistance genes, so that the doctor can then take the other drug instead of a drug, as is the case with the bacteria in the end, instead of giving the wrong drug,  On the one hand, this does not work, and on the other hand, it leads to the formation of even more resistant Leishmania in order to avoid this. That would be the goal, that you give the veterinarians a tool and say, send us a sample. We study the animal Leishmania and have these Leishmania that the animal has, resistance genes, in order to be able to say which drug is best. Wonderful thank you very much.  On what basis should the investigation of the resistance or the sample in general be carried out? There are already a few publications, there are many groups that are working on which genes are responsible for the resistances. There are already a few publications, there are many groups that are now working on which genes are now responsible for the resistance. There is often no change in the genes, but a copy number variation. So these genes are then either multiplied or they are no longer there at all and this leads to this resistance and this is to be investigated on the basis of these scientific publications. And what we also want to do is to use Next Generation Sequencing to examine the entire Leishmania genome, so to speak. So the first approach would be to search specifically for the genes that are in the publications. And we can also look at it again. In other words, we would then also ask the veterinarians again, are these dogs already treated, do you also see resistance to allopurinol, for example, and we can see, yes we also see what is written in the scientific publication, that this and that gene is more common or not. And then we also want to examine the complete genomes of the Leishmania to see if we can find more genes that are relevant. And that would simply make the product more attractive if you don't say, okay, I'm just looking for an allopurinol resistance or only for a Milteforan resistance, but I'll look at everything again and I can then tell you, yes such and such resistances are present and you don't need this and that at all. Perfect, thank you very much. Could you elaborate on how you ultimately want to characterize whether other genes are relevant if they are not yet published? Are there certain patterns that they then practically read out of the publications and then transferred to the rest of the moment, something has just happened to me. I don't see them properly anymore. So we would just take a close look at the whole thing via Next Generation Sequencing.  Yes, of course, because they are often also copy number variations, one would first focus on whether one sees something like this in other genes. But you would also look at variations like these SNPs, for example, to see whether or not you see them clustered in certain genes, in certain resistant Leishmania. And the characterization\n",
            "\n",
            "genes. But you would also look at variations like these SNPs, for example, to see whether or not you see them clustered in certain genes, in certain resistant Leishmania. And the characterization of which resistance refers to which drug intolerance or ineffectiveness, would you identify the series by existing knowledge, by consulting the veterinarians, or is there somehow a direct conclusion from the mode of action of the drug to the change in the genome? So, on the one hand, we would try to evaluate this by means of questionnaires or consultation with the veterinarians. These Leishmania can also be kept in cell culture. In other words, we could then create cell cultures of some samples from the Leishmanias, so to speak, and then there are in vitro tests to see whether these Leishmaniasis still respond to certain drugs or not. Similar to bacteria, where you put antibiotics on it and see if they are still growing or not. Something like this also exists for Leishmania in cell cultures. And then, of course, you can also look biochemically at what it does. Is it realistic that it somehow has a connection or not? There is then a certain term for this biochemical approach. So if there is a technical term for it, then they would have a few more numerical values, so for me what can be attached as an objective here difficult. To be honest, I can't think of anything in this case. On the other hand, sensitivity and specificity, so what is always a classic? Yes, that's just a problem in this case, because I don't know what my gold standard would be. So I always have to see what the veterinarians say. Well, I could just say that I want an 80 percent agreement. If the veterinarian says, yes, I see resistance there, then I want to see 80 percent of it in my test material, you could perhaps say that. Then maybe also related to the resistances, i.e. what is the 80 percent, this 80 percent value refers to the I can tell at all whether Leishmania is present, yes or no or I recognize resistance. I recognize resistances, i.e. Leishmania, which I have to recognize in any case, we already have other tests, that is already established, It is now really a matter of seeing whether they are resistant or not. So 80 percent. I would say that 80 percent of the samples that are described as resistant by veterinarians, I would then like to find a resistance gene, so to speak. Maybe you can put it that way. I thought that I thought that you would first detect this with an NLGS, so to speak, but you practically do that using classical methods. All right. Well, then I would like to go into the distinction from economic stuff.  shrink? How is it classically viewed and what is new now? There is still no test for these resistances. It is really done in such a way that the veterinarians then, if a Leishmania infection has been dismissed, they give just medication. There are quasi guidelines on how best to do this, so to speak, standard procedures and then they just observe the animal, they then measure again and again how high the leishmania load is and then adjust the medication accordingly, make higher concentration or take other medications. But an examination that tells them, take this and that, there's resistance there, otherwise there's no resistance at all. Wonderful, thank you very much. Is there anything else, so this is now in relation to resistance, perhaps briefly in relation to NGS, has this ever been used to study Leishmania in general? No, this has already been used, not with us, but there are publications about it that have just done it. On the one hand, there are different strains to differentiate them, according to epidemiological studies. And resistance has also been looked at, but this is a purely scientific publication. All right, then we can refer to the fact that NGES has so far been used purely for basic research, but not yet commercially. Yes.  Do you also know whether this is also the case, so here we not only have that the Leishmania is\n",
            "\n",
            "Using this as context\n",
            "\n",
            "Answer to the following question from a user regarding Leishmania disease project following given guidelines.\n",
            "Question: What is the Objective of the project (if applicable, in the context of the cooperative project)\n",
            "Guidelines: \n",
            "To what extent does the project\n",
            "aim to expand the state of knowledge/technology or utilize existing\n",
            "scientific, technical, economic, or other relevant findings or approaches\n",
            "Try to include the following:\n",
            "- 1 State of the art (Currently/According to the state of the art...)\n",
            "- 1 Project objective (The goal of the project is...)\n",
            "- 1 Differentiation from the state of the art (The state of the art is expanded in terms of..., thereby expanding the knowledge about...)\n",
            "- 1 Project result (The planned outcome/result is...)\n",
            "Please ensure that the project uses specific technical terminology to\n",
            "describe the innovative core. This is particularly crucial, especially for\n",
            "software projects.\n",
            "\n",
            "Restrict output to ONLY 800 characters\n",
            "\n",
            "Answer:\u001b[0m\n",
            "\n",
            "\u001b[1m> Finished chain.\u001b[0m\n",
            "The objective of the Leishmania disease research project is to utilize Next Generation Sequencing (NGS) technology to study the entire genetic makeup of animals infected with Leishmania parasites. Currently, the state of the art involves individual tests and smaller products applied to breed-specific animals. The project aims to expand the state of knowledge by using NGS for DNA profiling, parentage analysis, and genetic fingerprinting of animals. This will provide valuable insights into the genetic diversities and complexities of Leishmania genomes. The project result will be a tool for veterinarians to accurately identify Leishmania strains and detect resistance genes, enabling them to prescribe appropriate medications and prevent the development of further drug resistance.\n",
            "Length of response is 786 which is -14 characters above ideal\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "# Looping on Experiment 3 for all queries"
      ],
      "metadata": {
        "id": "P4406kyOi2nr"
      }
    },
    {
      "cell_type": "markdown",
      "source": [
        "Declaring Queries and Guideline"
      ],
      "metadata": {
        "id": "zi2dN8SGi9ON"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "query_list = [\n",
        "    {\n",
        "        \"query\": \"What is the Objective of the project (if applicable, in the context of the cooperative project) ?\",\n",
        "        \"guidelines\":\n",
        "        '''Motivation, objectives, and intended results. To what extent does the project aim to expand the state of knowledge/technology or utilize existing scientific, technical, economic, or other relevant findings or approaches\n",
        "\n",
        "        Try to include following points:\n",
        "        - 1 State of the art (Currently/According to the state of the art...)\n",
        "        - 1 Project objective (The goal of the project is...)\n",
        "        - 1 Differentiation from the state of the art (The state of the art is expanded...)\n",
        "        - in terms of..., thereby expanding the knowledge about...\n",
        "        - 1 Project result (The planned outcome/result is...)\n",
        "Please ensure that the project uses specific technical terminology to describe the innovative core. This is particularly crucial, especially for software projects.\n",
        "        '''\n",
        "    },\n",
        "    {\n",
        "        \"query\": \"Give me Description of tasks performed for the research (all forms of activities: in-house research)\",\n",
        "        \"guidelines\":\n",
        "        '''Which work steps/tasks and methods are/were applied to achieve the objective? To what extent are novel approaches pursued (for your company and/or the industry)\n",
        "\n",
        "        Try to include following points:\n",
        "        - 3 to 4 sentences listing work package\n",
        "        - 1 concluding sentence about a new approach (A novel approach is employed in this regard.)\n",
        "        '''\n",
        "    },\n",
        "    {\n",
        "        \"query\": \"Does the project aim to develop a product, production process, production line, service, or scientific methodology that represents a significant advancement/novelty in the relevant industry?\",\n",
        "        \"guidelines\":\n",
        "        '''If yes, please explain. Provide a brief description of the research or development status of the industry and differentiate your product, production process, production line, service, or scientific methodology from it. Describe any new scientific/technical methods, approaches, or procedures being utilized. (Examples include experiments, field studies, observations, cohort studies.\n",
        "\n",
        "        Try to include following points:\n",
        "        - 1 sentence specifying target sector/product category and differentiation from the state of the art (The project aims to target... which are intended to surpass the state of the art in terms of...\n",
        "        - 2 to 4 sentences differentiating from the state of the art with approximately 2 parameters for differentiation.\n",
        "        '''\n",
        "    },\n",
        "    {\n",
        "        \"query\": \"Is there a specific connection between the project and existing products, production lines, production processes, services, or already established scientific methodology within your company?\",\n",
        "        \"guidelines\":\n",
        "        '''If yes, please clarify to what extent the work of the project goes beyond routine development activities in your company. Explain the differentiation from existing products, production lines, production processes, and services within the company. How does the product, process, or service to be developed differ from those already offered by your company ?\n",
        "\n",
        "        Try to include following points:\n",
        "        - 1 sentence about current technologies in the company\n",
        "        - 1 sentence differentiating functionality (For the first time...)\n",
        "        - 2 to 4 sentences differentiating functionality and development methods\n",
        "        '''\n",
        "    },\n",
        "    {\n",
        "        \"query\": \"Are there scientific and/or technical risks involved in implementing the project ? Explain them\",\n",
        "        \"guidelines\":\n",
        "        '''Explain the engineering, natural, social, or humanities-related barriers that can be identified for the solution approach of your project. Describe the scientific (across all scientific disciplines) and/or technical obstacles, risks, uncertainties, or challenges that could lead to the failure of the project.\n",
        "\n",
        "        Describe how you address the identified risks. Briefly explain milestones and termination criteria. We explicitly emphasize that at this point, no economic and/or financial risks - related to the future product/process - should be mentioned\n",
        "        Try to include following points:\n",
        "        - 3 risks following the above format\n",
        "        '''\n",
        "    },\n",
        "\n",
        "]"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 17
        },
        "id": "xBu1SC2bioy_",
        "outputId": "4bba159f-ae32-41d8-b2e4-51fb46a4e77e"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "for i in range(len(query_list)):\n",
        "  print(query_list[i]['query'])\n",
        "  print('*'*100)\n",
        "  print(query_list[i]['guidelines'])\n",
        "  print('#'*100)\n",
        "  print('#'*100)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "hcAx1eNXkHda",
        "outputId": "23db6c63-2648-45d6-85f4-130e802ee805"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "What is the Objective of the project (if applicable, in the context of the cooperative project) ?\n",
            "****************************************************************************************************\n",
            "Motivation, objectives, and intended results. To what extent does the project aim to expand the state of knowledge/technology or utilize existing scientific, technical, economic, or other relevant findings or approaches\n",
            "\n",
            "        Try to include following points:\n",
            "        - 1 State of the art (Currently/According to the state of the art...)\n",
            "        - 1 Project objective (The goal of the project is...)\n",
            "        - 1 Differentiation from the state of the art (The state of the art is expanded...)\n",
            "        - in terms of..., thereby expanding the knowledge about...\n",
            "        - 1 Project result (The planned outcome/result is...)\n",
            "Please ensure that the project uses specific technical terminology to describe the innovative core. This is particularly crucial, especially for software projects.\n",
            "        \n",
            "####################################################################################################\n",
            "####################################################################################################\n",
            "Give me Description of tasks performed for the research (all forms of activities: in-house research)\n",
            "****************************************************************************************************\n",
            "Which work steps/tasks and methods are/were applied to achieve the objective? To what extent are novel approaches pursued (for your company and/or the industry)\n",
            "\n",
            "        Try to include following points:\n",
            "        - 3 to 4 sentences listing work package\n",
            "        - 1 concluding sentence about a new approach (A novel approach is employed in this regard.)\n",
            "        \n",
            "####################################################################################################\n",
            "####################################################################################################\n",
            "Does the project aim to develop a product, production process, production line, service, or scientific methodology that represents a significant advancement/novelty in the relevant industry?\n",
            "****************************************************************************************************\n",
            "If yes, please explain. Provide a brief description of the research or development status of the industry and differentiate your product, production process, production line, service, or scientific methodology from it. Describe any new scientific/technical methods, approaches, or procedures being utilized. (Examples include experiments, field studies, observations, cohort studies.\n",
            "\n",
            "        Try to include following points:\n",
            "        - 1 sentence specifying target sector/product category and differentiation from the state of the art (The project aims to target... which are intended to surpass the state of the art in terms of...\n",
            "        - 2 to 4 sentences differentiating from the state of the art with approximately 2 parameters for differentiation.\n",
            "        \n",
            "####################################################################################################\n",
            "####################################################################################################\n",
            "Is there a specific connection between the project and existing products, production lines, production processes, services, or already established scientific methodology within your company?\n",
            "****************************************************************************************************\n",
            "If yes, please clarify to what extent the work of the project goes beyond routine development activities in your company. Explain the differentiation from existing products, production lines, production processes, and services within the company. How does the product, process, or service to be developed differ from those already offered by your company ?\n",
            "\n",
            "        Try to include following points:\n",
            "        - 1 sentence about current technologies in the company\n",
            "        - 1 sentence differentiating functionality (For the first time...)\n",
            "        - 2 to 4 sentences differentiating functionality and development methods\n",
            "        \n",
            "####################################################################################################\n",
            "####################################################################################################\n",
            "Are there scientific and/or technical risks involved in implementing the project ? Explain them\n",
            "****************************************************************************************************\n",
            "Explain the engineering, natural, social, or humanities-related barriers that can be identified for the solution approach of your project. Describe the scientific (across all scientific disciplines) and/or technical obstacles, risks, uncertainties, or challenges that could lead to the failure of the project.\n",
            "\n",
            "        Describe how you address the identified risks. Briefly explain milestones and termination criteria. We explicitly emphasize that at this point, no economic and/or financial risks - related to the future product/process - should be mentioned\n",
            "        Try to include following points:\n",
            "        - 3 risks following the above format\n",
            "        \n",
            "####################################################################################################\n",
            "####################################################################################################\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "def llm_pipe(db_target, db_background, target_query, guidelines,\n",
        "             background_query=\"What are the technologies discussed ?\",\n",
        "             gpt_model=\"gpt-3.5-turbo-16k\", max_length=800):\n",
        "  # user question\n",
        "  background_query = background_query\n",
        "  target_query = target_query\n",
        "\n",
        "  # retrieve relevant chunks\n",
        "  docs = db_background.similarity_search(background_query)\n",
        "  background_retrieved_chunks = [doc.page_content for doc in docs]\n",
        "  background_chunks_formatted = \"\\n\\n\".join(background_retrieved_chunks)\n",
        "\n",
        "  docs = db_target.similarity_search(target_query)\n",
        "  target_retrieved_chunks = [doc.page_content for doc in docs]\n",
        "  target_chunks_formatted = \"\\n\\n\".join(target_retrieved_chunks)\n",
        "\n",
        "  guidelines = guidelines\n",
        "\n",
        "  # generate answer\n",
        "  llm = ChatOpenAI(model_name=gpt_model)\n",
        "  chain = LLMChain(llm=llm, prompt=prompt, verbose=True)\n",
        "\n",
        "  response = chain.run(\n",
        "      background_chunks_formatted=background_chunks_formatted,\n",
        "      raw_technical_info=tech_data,\n",
        "      target_chunks_formatted=target_chunks_formatted,\n",
        "      query=target_query,\n",
        "      guidelines=guidelines,\n",
        "      )\n",
        "\n",
        "  overhead_characters = len(response)- max_length\n",
        "  print(response)\n",
        "  print(\"Length of response is {} which is {} characters above ideal\".format(len(response), overhead_characters))\n",
        "  return response, overhead_characters"
      ],
      "metadata": {
        "id": "iBMBtzgWkK7C",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 17
        },
        "outputId": "4e6aba06-7c1f-4764-9557-4c8bbe2943eb"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "#### With GPT-3.5"
      ],
      "metadata": {
        "id": "qhWaNftJFVVa"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "for i in range(len(query_list)):\n",
        "  print(query_list[i]['query'])\n",
        "  print('*'*100)\n",
        "  print(query_list[i]['guidelines'])\n",
        "  response = llm_pipe(db_target, db_background,\n",
        "             target_query=query_list[i]['query'],\n",
        "             guidelines=query_list[i]['guidelines'],\n",
        "             background_query=\"What are the technologies discussed ?\",\n",
        "             gpt_model=\"gpt-3.5-turbo-16k\")\n",
        "  query_list[i]['response'], query_list[i]['overhead_characters'] = response\n",
        "  print('#'*100)\n",
        "  print('#'*100)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "LuDGaxDLCRBA",
        "outputId": "48d60f37-382e-4a09-adea-3fa3251a5dbb"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "What is the Objective of the project (if applicable, in the context of the cooperative project) ?\n",
            "****************************************************************************************************\n",
            "Motivation, objectives, and intended results. To what extent does the project aim to expand the state of knowledge/technology or utilize existing scientific, technical, economic, or other relevant findings or approaches\n",
            "\n",
            "        Try to include following points:\n",
            "        - 1 State of the art (Currently/According to the state of the art...)\n",
            "        - 1 Project objective (The goal of the project is...)\n",
            "        - 1 Differentiation from the state of the art (The state of the art is expanded...)\n",
            "        - in terms of..., thereby expanding the knowledge about...\n",
            "        - 1 Project result (The planned outcome/result is...)\n",
            "Please ensure that the project uses specific technical terminology to describe the innovative core. This is particularly crucial, especially for software projects.\n",
            "        \n",
            "\n",
            "\n",
            "\u001b[1m> Entering new  chain...\u001b[0m\n",
            "Prompt after formatting:\n",
            "\u001b[32;1m\u001b[1;3mHuman: You are a research document summarizer that finds the answers to user query and give correct responses\n",
            "Note that the user is from a highly specialized technical background, use minimal layman terms in your responses\n",
            "\n",
            "Use the following background context information on the Leishmania disease research project.\n",
            "\n",
            "That's how I would sum it up now.\n",
            "\n",
            "I have enclosed a short quality checklist here to accompany the application and how the application is always structured, so that you have a rough direction.\n",
            "\n",
            "We always have to describe a sentence about the state of the art, i.e. according to the current state of the art, this is done this way and that, then what the project goal is, then also the demarcation from the state of the art, to what extent the state of the art is expanded and the knowledge is expanded at your company and then finally what the project result should be.\n",
            "\n",
            "Perhaps you could just ask a few questions about the project, especially in relation to this Next Generation Sequencing.\n",
            "\n",
            "So let's put into perspective the extent to which you have already used it, to what extent it is a new technique for you, to what extent it is something new for detecting hereditary diseases in cats, dogs and horses.\n",
            "\n",
            "So now verbally or then for the application?\n",
            "\n",
            "Oral, oral.\n",
            "\n",
            "So now verbally or then for the application?\n",
            "\n",
            "Oral, oral.\n",
            "\n",
            "We formulate on the basis, that's why the recording is ongoing.\n",
            "\n",
            "We formulate the application from this.\n",
            "\n",
            "Okay, so then I would say that the current state of the art is that we are not yet using high-throughput technology to study the entire genetic markup of an animal.\n",
            "\n",
            "Instead, we mainly have individual tests and smaller products that are applied to breed-specific.  \n",
            "\n",
            "We are currently using next generation sequencing as a technology for DNA profiling.\n",
            "\n",
            "The main focus is on parentage analyses and the genetic fingerprint of animals.\n",
            "\n",
            "The aim of the project would then be what I formulated earlier, that it is primarily about animal health, of our own animal, but also of the species that we want to cover as a whole.\n",
            "\n",
            "State-of-the-art technology?  \n",
            "\n",
            "Above all, we are also expanding into larger genetic variants in this area.\n",
            "\n",
            "Class.\n",
            "\n",
            "Well, then I would like to go into the next point.\n",
            "\n",
            "The next point also relates to the differentiation from existing technologies in your company.\n",
            "\n",
            "It would be important for the auditor to classify whether you have ever dealt with Next Generation Sequencing in the company.\n",
            "\n",
            "If so, what is the difference here and if not, the This is perfectly adequate.\n",
            "\n",
            "Yes, we have had this, i.e. Next Generation Sequencing, in our company since 2020.\n",
            "\n",
            "And we are currently using it for genetic fingerprinting in dogs.  \n",
            "\n",
            "and to investigate genetic variability also in dogs.\n",
            "\n",
            "We do not yet have a product for cats, nor for horses, nor anything that is offered with hereditary diseases.\n",
            "\n",
            "Then it has to be implemented in the so-called panels with which the NGS technology works.\n",
            "\n",
            "One panel for each species.\n",
            "\n",
            "Then the third step would be the evaluation of the tests that we map.\n",
            "\n",
            "Of course, we also have to make sure that this should not only deliver the correct result from a technical point of view, but that it does.\n",
            "\n",
            "In other words, we have to compare the known animals with the results that we achieve with the new technology, with the NGS technology, and perhaps then bring the whole thing as fit for the work package in a way that is then understandable to the customer.\n",
            "\n",
            "We can't train them with 200 pages of text at the end.\n",
            "\n",
            "It has to be adapted to the different types of people so that they can do something with it.\n",
            "\n",
            "Wonderful, thank you very much.  \n",
            "\n",
            "In the end, could you rewrite the prototype a little better, i.e. the way in which it is understandable for the customer.\n",
            "\n",
            "Do you have a little better idea of what the end result should look like?\n",
            "\n",
            "Use the following information on the Leishmania disease research project.\n",
            "Next generation sequencing (NGS) technology transformed Leishmania genome studies and became an indispensable tool for Leishmania researchers. Recent Leishmania genomics analyses facilitated the discovery of various genetic diversities including single nucleotide polymorphisms (SNPs), copy number variations (CNVs), somy variations, and structural variations in detail and provided valuable insights into the complexity of the genome and gene regulation. Many aspects of Leishmania NGS analyses are similar to those of related pathogens like trypanosomes. However, the analyses of Leishmania genomes face a unique challenge because of the presence of frequent aneuploidy. This makes characterization and interpretation of read depth and somy a key part of Leishmania NGS analyses because read depth affects the accuracy of detection of all genetic variations. However, there are no general guidelines on how to explore and interpret the impact of aneuploidy, and this has made it difficult for biologists and bioinformaticians, especially for beginners, to perform their own analyses and interpret results across different analyses. In this guide we discuss a wide range of topics essential for Leishmania NGS analyses, ranging from how to set up a computational environment for genome analyses, to how to characterize genetic variations among Leishmania samples, and we will particularly focus on chromosomal copy number variation and its impact on genome analyses.\n",
            "we can somehow do it differently, so I would put that on the back burner at the moment, although it is actually the project that is retroactive, all the others are actually not retroactive from the time to But I would sit down with Mrs. Khnlein for the next three or four weeks and then I would give you feedback again. All right, so if we can change the focus, such as What is that? Mutations, exactly. We can integrate that relatively easily. But then just give me a message about it. Yes. Class. Wonderful. Then thank you very much, Mrs Kehl, for taking the time. And then I wish you a nice week. Same to you. Goodbye. Thank you. Goodbye.\n",
            "\n",
            "in the animal sector. If things go really badly, you can also grow the Leishmania in a cell culture and then examine the special hold, so to speak. But that would be very time-consuming, very expensive. You have to ask yourself whether you want to continue the project at all. In other words, one could actually also argue as a risk that the whole technique works for Leishmania in cell culture, but in the end the animal sample simply cannot be realized. Yes, right. Better. To the expenses. Do you know how many people are supposed to work on it? Yes, so we'll do it again via the HR department. In principle, I will have a relatively large number of hours there. Then a veterinarian from clinical chemistry has hours there and of course we still need a laboratory and I think there will be a second veterinarian from either my department or from clinical chemistry so that he can have contact with the veterinarians outside. All right, then just a rough overview, that is, four people to no idea ten to 15 percent perhaps. Yes, that's right.  Okay, do any subcontractors still come in here? So there will certainly be cooperations, but more with universities and then you don't really have any bills. So if you don't pay for the university, then that's not relevant. Yes yes exactly.  Yes, exactly, I'm just thinking so loudly. That's why I don't think so at the moment. Okay perfect, then I'm already through with my questions here too. Is there another project or would that be it for now?  I think that would be it for now. Completely new things will be added. The other thing with the infection scan, they had sent something again. I would only get the one sentence out.  Exactly, I wanted to talk to you about that, because of course we have to make sure that we fill in the text to see if there is perhaps a replacement for the deletion. I don't know what you're aiming for. I'll probably have to open this up again. Because it doesn't allow you to do that, just that's what IT is doing here today. Exactly, but I can also briefly share your e-mail otherwise. Yes, maybe that's the fastest way to do it. So, exactly. Yes, few screening with EDP Yes, few screening methods that result from dogs or cats. I don't know what they're actually going to pick up. We wanted to show a bit of the demarcations to the state of the art, i.e. how this is done according to statistics, i.e. how much of the statistics is not enough. So what we're doing is not screening methods, it's like, it's like packages. But that would have to be worded a little differently. If the dog's nose runs, then we just do herpes calypso, then there are already four or five typical pathogens that you do there.  So these are more like packages that are then specific to certain symptoms. But never cover everything that could be there. Maybe you can just rephrase it a bit. Yes, that means you actually have to have an initial guess and then you examine it specifically. But you don't study the entire genome. That's right, yes. Okay, let's rephrase. Well, we did it. Class. Yes, wonderful. Yes, we still had the one with the mutation, antimutation or whatever they called it. So with that I still have a bit of a stomach ache overall, because it is, actually already the case, that we have already established a lot of hereditary diseases and yes actually this prototype, as described earlier, has been there for a long time and we just keep expanding it with newly released things. Of course, we also expand our methods or the possibility of mapping these structural variants now, but I don't know if we can get that many hours together if I really concentrate on that. I have to talk to Mrs. Khler again, to my head of department, about how we can do that, whether we can perhaps somehow make a different focus, that we can somehow do it differently, so I would put that on the back burner at the moment, although it is actually the project that is retroactive, all the others are actually not retroactive from the\n",
            "\n",
            "Perfect, okay when we start again with the goal of the project. So I'm going to elaborate a bit, leishmania are parasites that are transmitted via various mosquitoes. This means that the dogs are bitten by the mosquitoes, then get these leishmanias, which then lead to leishmaniasis. And the whole thing can also affect people. At the moment, this is still a major problem in southern countries, i.e. southern Europe. However, due to climate change, of course, these mosquitoes are coming further and further north, which transmit these larch manias, so to speak, and sooner or later it will most likely become a problem in Germany. This means that the dog has the mosquito bites on these Leishmanias, picks up the eggs of it again and so on and so on. There are now various medications that are taken for the treatment of the dogs. However, these Leishmania develop resistance to it very quickly. Our goal now would be to get a sample from a dog, to prove that he has Leishmania and at the same time to examine these Leishmania to see if they already contain certain resistance genes, so that the doctor can then take the other drug instead of a drug, as is the case with the bacteria in the end, instead of giving the wrong drug,  On the one hand, this does not work, and on the other hand, it leads to the formation of even more resistant Leishmania in order to avoid this. That would be the goal, that you give the veterinarians a tool and say, send us a sample. We study the animal Leishmania and have these Leishmania that the animal has, resistance genes, in order to be able to say which drug is best. Wonderful thank you very much.  On what basis should the investigation of the resistance or the sample in general be carried out? There are already a few publications, there are many groups that are working on which genes are responsible for the resistances. There are already a few publications, there are many groups that are now working on which genes are now responsible for the resistance. There is often no change in the genes, but a copy number variation. So these genes are then either multiplied or they are no longer there at all and this leads to this resistance and this is to be investigated on the basis of these scientific publications. And what we also want to do is to use Next Generation Sequencing to examine the entire Leishmania genome, so to speak. So the first approach would be to search specifically for the genes that are in the publications. And we can also look at it again. In other words, we would then also ask the veterinarians again, are these dogs already treated, do you also see resistance to allopurinol, for example, and we can see, yes we also see what is written in the scientific publication, that this and that gene is more common or not. And then we also want to examine the complete genomes of the Leishmania to see if we can find more genes that are relevant. And that would simply make the product more attractive if you don't say, okay, I'm just looking for an allopurinol resistance or only for a Milteforan resistance, but I'll look at everything again and I can then tell you, yes such and such resistances are present and you don't need this and that at all. Perfect, thank you very much. Could you elaborate on how you ultimately want to characterize whether other genes are relevant if they are not yet published? Are there certain patterns that they then practically read out of the publications and then transferred to the rest of the moment, something has just happened to me. I don't see them properly anymore. So we would just take a close look at the whole thing via Next Generation Sequencing.  Yes, of course, because they are often also copy number variations, one would first focus on whether one sees something like this in other genes. But you would also look at variations like these SNPs, for example, to see whether or not you see them clustered in certain genes, in certain resistant Leishmania. And the characterization\n",
            "\n",
            "genes. But you would also look at variations like these SNPs, for example, to see whether or not you see them clustered in certain genes, in certain resistant Leishmania. And the characterization of which resistance refers to which drug intolerance or ineffectiveness, would you identify the series by existing knowledge, by consulting the veterinarians, or is there somehow a direct conclusion from the mode of action of the drug to the change in the genome? So, on the one hand, we would try to evaluate this by means of questionnaires or consultation with the veterinarians. These Leishmania can also be kept in cell culture. In other words, we could then create cell cultures of some samples from the Leishmanias, so to speak, and then there are in vitro tests to see whether these Leishmaniasis still respond to certain drugs or not. Similar to bacteria, where you put antibiotics on it and see if they are still growing or not. Something like this also exists for Leishmania in cell cultures. And then, of course, you can also look biochemically at what it does. Is it realistic that it somehow has a connection or not? There is then a certain term for this biochemical approach. So if there is a technical term for it, then they would have a few more numerical values, so for me what can be attached as an objective here difficult. To be honest, I can't think of anything in this case. On the other hand, sensitivity and specificity, so what is always a classic? Yes, that's just a problem in this case, because I don't know what my gold standard would be. So I always have to see what the veterinarians say. Well, I could just say that I want an 80 percent agreement. If the veterinarian says, yes, I see resistance there, then I want to see 80 percent of it in my test material, you could perhaps say that. Then maybe also related to the resistances, i.e. what is the 80 percent, this 80 percent value refers to the I can tell at all whether Leishmania is present, yes or no or I recognize resistance. I recognize resistances, i.e. Leishmania, which I have to recognize in any case, we already have other tests, that is already established, It is now really a matter of seeing whether they are resistant or not. So 80 percent. I would say that 80 percent of the samples that are described as resistant by veterinarians, I would then like to find a resistance gene, so to speak. Maybe you can put it that way. I thought that I thought that you would first detect this with an NLGS, so to speak, but you practically do that using classical methods. All right. Well, then I would like to go into the distinction from economic stuff.  shrink? How is it classically viewed and what is new now? There is still no test for these resistances. It is really done in such a way that the veterinarians then, if a Leishmania infection has been dismissed, they give just medication. There are quasi guidelines on how best to do this, so to speak, standard procedures and then they just observe the animal, they then measure again and again how high the leishmania load is and then adjust the medication accordingly, make higher concentration or take other medications. But an examination that tells them, take this and that, there's resistance there, otherwise there's no resistance at all. Wonderful, thank you very much. Is there anything else, so this is now in relation to resistance, perhaps briefly in relation to NGS, has this ever been used to study Leishmania in general? No, this has already been used, not with us, but there are publications about it that have just done it. On the one hand, there are different strains to differentiate them, according to epidemiological studies. And resistance has also been looked at, but this is a purely scientific publication. All right, then we can refer to the fact that NGES has so far been used purely for basic research, but not yet commercially. Yes.  Do you also know whether this is also the case, so here we not only have that the Leishmania is\n",
            "\n",
            "Using this as context\n",
            "\n",
            "Answer to the following question from a user regarding Leishmania disease project following given guidelines.\n",
            "Question: What is the Objective of the project (if applicable, in the context of the cooperative project) ?\n",
            "Guidelines: Motivation, objectives, and intended results. To what extent does the project aim to expand the state of knowledge/technology or utilize existing scientific, technical, economic, or other relevant findings or approaches\n",
            "\n",
            "        Try to include following points:\n",
            "        - 1 State of the art (Currently/According to the state of the art...)\n",
            "        - 1 Project objective (The goal of the project is...)\n",
            "        - 1 Differentiation from the state of the art (The state of the art is expanded...)\n",
            "        - in terms of..., thereby expanding the knowledge about...\n",
            "        - 1 Project result (The planned outcome/result is...)\n",
            "Please ensure that the project uses specific technical terminology to describe the innovative core. This is particularly crucial, especially for software projects.\n",
            "        \n",
            "Restrict output to ONLY 800 characters\n",
            "\n",
            "Answer:\u001b[0m\n",
            "\n",
            "\u001b[1m> Finished chain.\u001b[0m\n",
            "The objective of the project is to develop a tool for identifying and characterizing genetic variations, such as single nucleotide polymorphisms (SNPs) and copy number variations (CNVs), in Leishmania samples. Currently, there are no general guidelines on how to explore and interpret the impact of aneuploidy in Leishmania genomes, which makes it difficult for researchers and bioinformaticians to perform their own analyses and interpret results. The project aims to utilize Next Generation Sequencing (NGS) technology to study the entire Leishmania genome and provide valuable insights into the genetic diversities and complexity of the genome. The project will expand the state of knowledge in Leishmania genomics and contribute to the understanding of gene regulation and chromosomal copy number variation. The planned outcome of the project is to provide researchers and veterinarians with a tool that can accurately detect genetic variations in Leishmania and potentially improve the selection of appropriate medications for the treatment of Leishmaniasis.\n",
            "Length of response is 1063 which is 263 characters above ideal\n",
            "####################################################################################################\n",
            "####################################################################################################\n",
            "Give me Description of tasks performed for the research (all forms of activities: in-house research)\n",
            "****************************************************************************************************\n",
            "Which work steps/tasks and methods are/were applied to achieve the objective? To what extent are novel approaches pursued (for your company and/or the industry)\n",
            "\n",
            "        Try to include following points:\n",
            "        - 3 to 4 sentences listing work package\n",
            "        - 1 concluding sentence about a new approach (A novel approach is employed in this regard.)\n",
            "        \n",
            "\n",
            "\n",
            "\u001b[1m> Entering new  chain...\u001b[0m\n",
            "Prompt after formatting:\n",
            "\u001b[32;1m\u001b[1;3mHuman: You are a research document summarizer that finds the answers to user query and give correct responses\n",
            "Note that the user is from a highly specialized technical background, use minimal layman terms in your responses\n",
            "\n",
            "Use the following background context information on the Leishmania disease research project.\n",
            "\n",
            "That's how I would sum it up now.\n",
            "\n",
            "I have enclosed a short quality checklist here to accompany the application and how the application is always structured, so that you have a rough direction.\n",
            "\n",
            "We always have to describe a sentence about the state of the art, i.e. according to the current state of the art, this is done this way and that, then what the project goal is, then also the demarcation from the state of the art, to what extent the state of the art is expanded and the knowledge is expanded at your company and then finally what the project result should be.\n",
            "\n",
            "Perhaps you could just ask a few questions about the project, especially in relation to this Next Generation Sequencing.\n",
            "\n",
            "So let's put into perspective the extent to which you have already used it, to what extent it is a new technique for you, to what extent it is something new for detecting hereditary diseases in cats, dogs and horses.\n",
            "\n",
            "So now verbally or then for the application?\n",
            "\n",
            "Oral, oral.\n",
            "\n",
            "So now verbally or then for the application?\n",
            "\n",
            "Oral, oral.\n",
            "\n",
            "We formulate on the basis, that's why the recording is ongoing.\n",
            "\n",
            "We formulate the application from this.\n",
            "\n",
            "Okay, so then I would say that the current state of the art is that we are not yet using high-throughput technology to study the entire genetic markup of an animal.\n",
            "\n",
            "Instead, we mainly have individual tests and smaller products that are applied to breed-specific.  \n",
            "\n",
            "We are currently using next generation sequencing as a technology for DNA profiling.\n",
            "\n",
            "The main focus is on parentage analyses and the genetic fingerprint of animals.\n",
            "\n",
            "The aim of the project would then be what I formulated earlier, that it is primarily about animal health, of our own animal, but also of the species that we want to cover as a whole.\n",
            "\n",
            "State-of-the-art technology?  \n",
            "\n",
            "Above all, we are also expanding into larger genetic variants in this area.\n",
            "\n",
            "Class.\n",
            "\n",
            "Well, then I would like to go into the next point.\n",
            "\n",
            "The next point also relates to the differentiation from existing technologies in your company.\n",
            "\n",
            "It would be important for the auditor to classify whether you have ever dealt with Next Generation Sequencing in the company.\n",
            "\n",
            "If so, what is the difference here and if not, the This is perfectly adequate.\n",
            "\n",
            "Yes, we have had this, i.e. Next Generation Sequencing, in our company since 2020.\n",
            "\n",
            "And we are currently using it for genetic fingerprinting in dogs.  \n",
            "\n",
            "and to investigate genetic variability also in dogs.\n",
            "\n",
            "We do not yet have a product for cats, nor for horses, nor anything that is offered with hereditary diseases.\n",
            "\n",
            "Then it has to be implemented in the so-called panels with which the NGS technology works.\n",
            "\n",
            "One panel for each species.\n",
            "\n",
            "Then the third step would be the evaluation of the tests that we map.\n",
            "\n",
            "Of course, we also have to make sure that this should not only deliver the correct result from a technical point of view, but that it does.\n",
            "\n",
            "In other words, we have to compare the known animals with the results that we achieve with the new technology, with the NGS technology, and perhaps then bring the whole thing as fit for the work package in a way that is then understandable to the customer.\n",
            "\n",
            "We can't train them with 200 pages of text at the end.\n",
            "\n",
            "It has to be adapted to the different types of people so that they can do something with it.\n",
            "\n",
            "Wonderful, thank you very much.  \n",
            "\n",
            "In the end, could you rewrite the prototype a little better, i.e. the way in which it is understandable for the customer.\n",
            "\n",
            "Do you have a little better idea of what the end result should look like?\n",
            "\n",
            "Use the following information on the Leishmania disease research project.\n",
            "Next generation sequencing (NGS) technology transformed Leishmania genome studies and became an indispensable tool for Leishmania researchers. Recent Leishmania genomics analyses facilitated the discovery of various genetic diversities including single nucleotide polymorphisms (SNPs), copy number variations (CNVs), somy variations, and structural variations in detail and provided valuable insights into the complexity of the genome and gene regulation. Many aspects of Leishmania NGS analyses are similar to those of related pathogens like trypanosomes. However, the analyses of Leishmania genomes face a unique challenge because of the presence of frequent aneuploidy. This makes characterization and interpretation of read depth and somy a key part of Leishmania NGS analyses because read depth affects the accuracy of detection of all genetic variations. However, there are no general guidelines on how to explore and interpret the impact of aneuploidy, and this has made it difficult for biologists and bioinformaticians, especially for beginners, to perform their own analyses and interpret results across different analyses. In this guide we discuss a wide range of topics essential for Leishmania NGS analyses, ranging from how to set up a computational environment for genome analyses, to how to characterize genetic variations among Leishmania samples, and we will particularly focus on chromosomal copy number variation and its impact on genome analyses.\n",
            "in the animal sector. If things go really badly, you can also grow the Leishmania in a cell culture and then examine the special hold, so to speak. But that would be very time-consuming, very expensive. You have to ask yourself whether you want to continue the project at all. In other words, one could actually also argue as a risk that the whole technique works for Leishmania in cell culture, but in the end the animal sample simply cannot be realized. Yes, right. Better. To the expenses. Do you know how many people are supposed to work on it? Yes, so we'll do it again via the HR department. In principle, I will have a relatively large number of hours there. Then a veterinarian from clinical chemistry has hours there and of course we still need a laboratory and I think there will be a second veterinarian from either my department or from clinical chemistry so that he can have contact with the veterinarians outside. All right, then just a rough overview, that is, four people to no idea ten to 15 percent perhaps. Yes, that's right.  Okay, do any subcontractors still come in here? So there will certainly be cooperations, but more with universities and then you don't really have any bills. So if you don't pay for the university, then that's not relevant. Yes yes exactly.  Yes, exactly, I'm just thinking so loudly. That's why I don't think so at the moment. Okay perfect, then I'm already through with my questions here too. Is there another project or would that be it for now?  I think that would be it for now. Completely new things will be added. The other thing with the infection scan, they had sent something again. I would only get the one sentence out.  Exactly, I wanted to talk to you about that, because of course we have to make sure that we fill in the text to see if there is perhaps a replacement for the deletion. I don't know what you're aiming for. I'll probably have to open this up again. Because it doesn't allow you to do that, just that's what IT is doing here today. Exactly, but I can also briefly share your e-mail otherwise. Yes, maybe that's the fastest way to do it. So, exactly. Yes, few screening with EDP Yes, few screening methods that result from dogs or cats. I don't know what they're actually going to pick up. We wanted to show a bit of the demarcations to the state of the art, i.e. how this is done according to statistics, i.e. how much of the statistics is not enough. So what we're doing is not screening methods, it's like, it's like packages. But that would have to be worded a little differently. If the dog's nose runs, then we just do herpes calypso, then there are already four or five typical pathogens that you do there.  So these are more like packages that are then specific to certain symptoms. But never cover everything that could be there. Maybe you can just rephrase it a bit. Yes, that means you actually have to have an initial guess and then you examine it specifically. But you don't study the entire genome. That's right, yes. Okay, let's rephrase. Well, we did it. Class. Yes, wonderful. Yes, we still had the one with the mutation, antimutation or whatever they called it. So with that I still have a bit of a stomach ache overall, because it is, actually already the case, that we have already established a lot of hereditary diseases and yes actually this prototype, as described earlier, has been there for a long time and we just keep expanding it with newly released things. Of course, we also expand our methods or the possibility of mapping these structural variants now, but I don't know if we can get that many hours together if I really concentrate on that. I have to talk to Mrs. Khler again, to my head of department, about how we can do that, whether we can perhaps somehow make a different focus, that we can somehow do it differently, so I would put that on the back burner at the moment, although it is actually the project that is retroactive, all the others are actually not retroactive from the\n",
            "\n",
            "we can somehow do it differently, so I would put that on the back burner at the moment, although it is actually the project that is retroactive, all the others are actually not retroactive from the time to But I would sit down with Mrs. Khnlein for the next three or four weeks and then I would give you feedback again. All right, so if we can change the focus, such as What is that? Mutations, exactly. We can integrate that relatively easily. But then just give me a message about it. Yes. Class. Wonderful. Then thank you very much, Mrs Kehl, for taking the time. And then I wish you a nice week. Same to you. Goodbye. Thank you. Goodbye.\n",
            "\n",
            "to the fact that NGES has so far been used purely for basic research, but not yet commercially. Yes.  Do you also know whether this is also the case, so here we not only have that the Leishmania is to be examined with NGS and that this is also to be characterized practically on the basis of an animal sample, so to speak, can this also be applied as a fight to existing NGS investigations? So, as I said, there is nothing at all in diagnostics. But now you mean basic research. Yes, that's where the Leishmania were always bred. In cell culture, only those were examined. That's right, that's another step that we also have to take, because we want to do this investigation directly from the sample, so to speak, and then we may have a lot of background through the genomic DNA again. That would be such a risk. Yes, perfect.  Perfect. Then the next chapter would be the differentiation from your technologies. Here we have to refer to Leishmania in general and then to NGS.  We detect Leishmania itself in various sample materials via classical PCA or real-time PCA, but we do not yet have any resistance genes. That would be the innovation, so to speak. And at the moment we are not doing any studies of any parasites about NGS, but we are doing these DNA profiles, as discussed earlier, from genomic DNA. But studies of parasites has not yet been. Or rather, this other project with Infecto-Scan, which is also going in this direction, but it is also completely under development, that we want to examine a sample and which pathogens are in it. All right: NGS could also point out that they not only examine animal samples, but also isolate Leishmania from them. Or at least for sample preparation. That makes a difference. You would then have to adjust the sample preparation so that mainly the parasite DNA is isolated so that it can be sequenced in a targeted manner. That you don't have so much background that it gets lost. That's also a sub-project of this Infecto-Scan, but it's more on viruses and they are parasites. Yes, all right, well, one can also say in general terms that for the first time parasites from animal material are to be characterized by NGS Yes, definitely. All right, then I would like to go back to the last point, namely the risks. Yes, so one risk is that several strains can occur within one animal. So they are often stung and can then carry different Leishmania strains in them, of which perhaps only one part is resistant and the other is not. You have to make sure that you really get everything pictured, that you can see this variant. That would be a risk. The second would be that the publications are not correct, because at the beginning we want to look specifically at the genes that are in the publications. It could be that there are errors in it, that we detect the genes, but that does not correlate with the clinic, i.e. there is actually no resistance at all. That could be. And if we then do NGS, it can of course be again, as with the infection scan, that we just have too much genomic DNA in it. We have to adapt all the preparations to these parasites beforehand. Or that we don't have the sensitivity to be able to map all resistance genes. Could you also quantify the sensitivity? Then we would have a numerical value here.  the sensitivity of the resistances then again. Yes, exactly. Yes, I mean, 80% sensitivity has always been something you actually strive for. Okay, well, what's a solution for them to bring out this genomic DNA, so that they bring out the genomic DNA as well as possible? It should also be tried out via Infectoscan whether there are methods to separate it.  The company Nanopore offers various recipes for this. But this, of course, is all for the human sphere. First of all, you have to see if this is also possible in the animal sector. If things go really badly, you can also grow the Leishmania in a cell culture and then examine the special hold, so to speak. But that would be very time-consuming, very\n",
            "\n",
            "genes. But you would also look at variations like these SNPs, for example, to see whether or not you see them clustered in certain genes, in certain resistant Leishmania. And the characterization of which resistance refers to which drug intolerance or ineffectiveness, would you identify the series by existing knowledge, by consulting the veterinarians, or is there somehow a direct conclusion from the mode of action of the drug to the change in the genome? So, on the one hand, we would try to evaluate this by means of questionnaires or consultation with the veterinarians. These Leishmania can also be kept in cell culture. In other words, we could then create cell cultures of some samples from the Leishmanias, so to speak, and then there are in vitro tests to see whether these Leishmaniasis still respond to certain drugs or not. Similar to bacteria, where you put antibiotics on it and see if they are still growing or not. Something like this also exists for Leishmania in cell cultures. And then, of course, you can also look biochemically at what it does. Is it realistic that it somehow has a connection or not? There is then a certain term for this biochemical approach. So if there is a technical term for it, then they would have a few more numerical values, so for me what can be attached as an objective here difficult. To be honest, I can't think of anything in this case. On the other hand, sensitivity and specificity, so what is always a classic? Yes, that's just a problem in this case, because I don't know what my gold standard would be. So I always have to see what the veterinarians say. Well, I could just say that I want an 80 percent agreement. If the veterinarian says, yes, I see resistance there, then I want to see 80 percent of it in my test material, you could perhaps say that. Then maybe also related to the resistances, i.e. what is the 80 percent, this 80 percent value refers to the I can tell at all whether Leishmania is present, yes or no or I recognize resistance. I recognize resistances, i.e. Leishmania, which I have to recognize in any case, we already have other tests, that is already established, It is now really a matter of seeing whether they are resistant or not. So 80 percent. I would say that 80 percent of the samples that are described as resistant by veterinarians, I would then like to find a resistance gene, so to speak. Maybe you can put it that way. I thought that I thought that you would first detect this with an NLGS, so to speak, but you practically do that using classical methods. All right. Well, then I would like to go into the distinction from economic stuff.  shrink? How is it classically viewed and what is new now? There is still no test for these resistances. It is really done in such a way that the veterinarians then, if a Leishmania infection has been dismissed, they give just medication. There are quasi guidelines on how best to do this, so to speak, standard procedures and then they just observe the animal, they then measure again and again how high the leishmania load is and then adjust the medication accordingly, make higher concentration or take other medications. But an examination that tells them, take this and that, there's resistance there, otherwise there's no resistance at all. Wonderful, thank you very much. Is there anything else, so this is now in relation to resistance, perhaps briefly in relation to NGS, has this ever been used to study Leishmania in general? No, this has already been used, not with us, but there are publications about it that have just done it. On the one hand, there are different strains to differentiate them, according to epidemiological studies. And resistance has also been looked at, but this is a purely scientific publication. All right, then we can refer to the fact that NGES has so far been used purely for basic research, but not yet commercially. Yes.  Do you also know whether this is also the case, so here we not only have that the Leishmania is\n",
            "\n",
            "Using this as context\n",
            "\n",
            "Answer to the following question from a user regarding Leishmania disease project following given guidelines.\n",
            "Question: Give me Description of tasks performed for the research (all forms of activities: in-house research)\n",
            "Guidelines: Which work steps/tasks and methods are/were applied to achieve the objective? To what extent are novel approaches pursued (for your company and/or the industry)\n",
            "\n",
            "        Try to include following points:\n",
            "        - 3 to 4 sentences listing work package\n",
            "        - 1 concluding sentence about a new approach (A novel approach is employed in this regard.)\n",
            "        \n",
            "Restrict output to ONLY 800 characters\n",
            "\n",
            "Answer:\u001b[0m\n",
            "\n",
            "\u001b[1m> Finished chain.\u001b[0m\n",
            "The tasks performed for the research project include setting up a computational environment for genome analyses, characterizing genetic variations among Leishmania samples, and focusing on chromosomal copy number variation and its impact on genome analyses. This is achieved through the use of Next Generation Sequencing (NGS) technology, which is a novel approach in the industry. By utilizing NGS, the project aims to provide valuable insights into the complexity of the Leishmania genome and gene regulation.\n",
            "Length of response is 511 which is -289 characters above ideal\n",
            "####################################################################################################\n",
            "####################################################################################################\n",
            "Does the project aim to develop a product, production process, production line, service, or scientific methodology that represents a significant advancement/novelty in the relevant industry?\n",
            "****************************************************************************************************\n",
            "If yes, please explain. Provide a brief description of the research or development status of the industry and differentiate your product, production process, production line, service, or scientific methodology from it. Describe any new scientific/technical methods, approaches, or procedures being utilized. (Examples include experiments, field studies, observations, cohort studies.\n",
            "\n",
            "        Try to include following points:\n",
            "        - 1 sentence specifying target sector/product category and differentiation from the state of the art (The project aims to target... which are intended to surpass the state of the art in terms of...\n",
            "        - 2 to 4 sentences differentiating from the state of the art with approximately 2 parameters for differentiation.\n",
            "        \n",
            "\n",
            "\n",
            "\u001b[1m> Entering new  chain...\u001b[0m\n",
            "Prompt after formatting:\n",
            "\u001b[32;1m\u001b[1;3mHuman: You are a research document summarizer that finds the answers to user query and give correct responses\n",
            "Note that the user is from a highly specialized technical background, use minimal layman terms in your responses\n",
            "\n",
            "Use the following background context information on the Leishmania disease research project.\n",
            "\n",
            "That's how I would sum it up now.\n",
            "\n",
            "I have enclosed a short quality checklist here to accompany the application and how the application is always structured, so that you have a rough direction.\n",
            "\n",
            "We always have to describe a sentence about the state of the art, i.e. according to the current state of the art, this is done this way and that, then what the project goal is, then also the demarcation from the state of the art, to what extent the state of the art is expanded and the knowledge is expanded at your company and then finally what the project result should be.\n",
            "\n",
            "Perhaps you could just ask a few questions about the project, especially in relation to this Next Generation Sequencing.\n",
            "\n",
            "So let's put into perspective the extent to which you have already used it, to what extent it is a new technique for you, to what extent it is something new for detecting hereditary diseases in cats, dogs and horses.\n",
            "\n",
            "So now verbally or then for the application?\n",
            "\n",
            "Oral, oral.\n",
            "\n",
            "So now verbally or then for the application?\n",
            "\n",
            "Oral, oral.\n",
            "\n",
            "We formulate on the basis, that's why the recording is ongoing.\n",
            "\n",
            "We formulate the application from this.\n",
            "\n",
            "Okay, so then I would say that the current state of the art is that we are not yet using high-throughput technology to study the entire genetic markup of an animal.\n",
            "\n",
            "Instead, we mainly have individual tests and smaller products that are applied to breed-specific.  \n",
            "\n",
            "We are currently using next generation sequencing as a technology for DNA profiling.\n",
            "\n",
            "The main focus is on parentage analyses and the genetic fingerprint of animals.\n",
            "\n",
            "The aim of the project would then be what I formulated earlier, that it is primarily about animal health, of our own animal, but also of the species that we want to cover as a whole.\n",
            "\n",
            "State-of-the-art technology?  \n",
            "\n",
            "Above all, we are also expanding into larger genetic variants in this area.\n",
            "\n",
            "Class.\n",
            "\n",
            "Well, then I would like to go into the next point.\n",
            "\n",
            "The next point also relates to the differentiation from existing technologies in your company.\n",
            "\n",
            "It would be important for the auditor to classify whether you have ever dealt with Next Generation Sequencing in the company.\n",
            "\n",
            "If so, what is the difference here and if not, the This is perfectly adequate.\n",
            "\n",
            "Yes, we have had this, i.e. Next Generation Sequencing, in our company since 2020.\n",
            "\n",
            "And we are currently using it for genetic fingerprinting in dogs.  \n",
            "\n",
            "and to investigate genetic variability also in dogs.\n",
            "\n",
            "We do not yet have a product for cats, nor for horses, nor anything that is offered with hereditary diseases.\n",
            "\n",
            "Then it has to be implemented in the so-called panels with which the NGS technology works.\n",
            "\n",
            "One panel for each species.\n",
            "\n",
            "Then the third step would be the evaluation of the tests that we map.\n",
            "\n",
            "Of course, we also have to make sure that this should not only deliver the correct result from a technical point of view, but that it does.\n",
            "\n",
            "In other words, we have to compare the known animals with the results that we achieve with the new technology, with the NGS technology, and perhaps then bring the whole thing as fit for the work package in a way that is then understandable to the customer.\n",
            "\n",
            "We can't train them with 200 pages of text at the end.\n",
            "\n",
            "It has to be adapted to the different types of people so that they can do something with it.\n",
            "\n",
            "Wonderful, thank you very much.  \n",
            "\n",
            "In the end, could you rewrite the prototype a little better, i.e. the way in which it is understandable for the customer.\n",
            "\n",
            "Do you have a little better idea of what the end result should look like?\n",
            "\n",
            "Use the following information on the Leishmania disease research project.\n",
            "Next generation sequencing (NGS) technology transformed Leishmania genome studies and became an indispensable tool for Leishmania researchers. Recent Leishmania genomics analyses facilitated the discovery of various genetic diversities including single nucleotide polymorphisms (SNPs), copy number variations (CNVs), somy variations, and structural variations in detail and provided valuable insights into the complexity of the genome and gene regulation. Many aspects of Leishmania NGS analyses are similar to those of related pathogens like trypanosomes. However, the analyses of Leishmania genomes face a unique challenge because of the presence of frequent aneuploidy. This makes characterization and interpretation of read depth and somy a key part of Leishmania NGS analyses because read depth affects the accuracy of detection of all genetic variations. However, there are no general guidelines on how to explore and interpret the impact of aneuploidy, and this has made it difficult for biologists and bioinformaticians, especially for beginners, to perform their own analyses and interpret results across different analyses. In this guide we discuss a wide range of topics essential for Leishmania NGS analyses, ranging from how to set up a computational environment for genome analyses, to how to characterize genetic variations among Leishmania samples, and we will particularly focus on chromosomal copy number variation and its impact on genome analyses.\n",
            "in the animal sector. If things go really badly, you can also grow the Leishmania in a cell culture and then examine the special hold, so to speak. But that would be very time-consuming, very expensive. You have to ask yourself whether you want to continue the project at all. In other words, one could actually also argue as a risk that the whole technique works for Leishmania in cell culture, but in the end the animal sample simply cannot be realized. Yes, right. Better. To the expenses. Do you know how many people are supposed to work on it? Yes, so we'll do it again via the HR department. In principle, I will have a relatively large number of hours there. Then a veterinarian from clinical chemistry has hours there and of course we still need a laboratory and I think there will be a second veterinarian from either my department or from clinical chemistry so that he can have contact with the veterinarians outside. All right, then just a rough overview, that is, four people to no idea ten to 15 percent perhaps. Yes, that's right.  Okay, do any subcontractors still come in here? So there will certainly be cooperations, but more with universities and then you don't really have any bills. So if you don't pay for the university, then that's not relevant. Yes yes exactly.  Yes, exactly, I'm just thinking so loudly. That's why I don't think so at the moment. Okay perfect, then I'm already through with my questions here too. Is there another project or would that be it for now?  I think that would be it for now. Completely new things will be added. The other thing with the infection scan, they had sent something again. I would only get the one sentence out.  Exactly, I wanted to talk to you about that, because of course we have to make sure that we fill in the text to see if there is perhaps a replacement for the deletion. I don't know what you're aiming for. I'll probably have to open this up again. Because it doesn't allow you to do that, just that's what IT is doing here today. Exactly, but I can also briefly share your e-mail otherwise. Yes, maybe that's the fastest way to do it. So, exactly. Yes, few screening with EDP Yes, few screening methods that result from dogs or cats. I don't know what they're actually going to pick up. We wanted to show a bit of the demarcations to the state of the art, i.e. how this is done according to statistics, i.e. how much of the statistics is not enough. So what we're doing is not screening methods, it's like, it's like packages. But that would have to be worded a little differently. If the dog's nose runs, then we just do herpes calypso, then there are already four or five typical pathogens that you do there.  So these are more like packages that are then specific to certain symptoms. But never cover everything that could be there. Maybe you can just rephrase it a bit. Yes, that means you actually have to have an initial guess and then you examine it specifically. But you don't study the entire genome. That's right, yes. Okay, let's rephrase. Well, we did it. Class. Yes, wonderful. Yes, we still had the one with the mutation, antimutation or whatever they called it. So with that I still have a bit of a stomach ache overall, because it is, actually already the case, that we have already established a lot of hereditary diseases and yes actually this prototype, as described earlier, has been there for a long time and we just keep expanding it with newly released things. Of course, we also expand our methods or the possibility of mapping these structural variants now, but I don't know if we can get that many hours together if I really concentrate on that. I have to talk to Mrs. Khler again, to my head of department, about how we can do that, whether we can perhaps somehow make a different focus, that we can somehow do it differently, so I would put that on the back burner at the moment, although it is actually the project that is retroactive, all the others are actually not retroactive from the\n",
            "\n",
            "we can somehow do it differently, so I would put that on the back burner at the moment, although it is actually the project that is retroactive, all the others are actually not retroactive from the time to But I would sit down with Mrs. Khnlein for the next three or four weeks and then I would give you feedback again. All right, so if we can change the focus, such as What is that? Mutations, exactly. We can integrate that relatively easily. But then just give me a message about it. Yes. Class. Wonderful. Then thank you very much, Mrs Kehl, for taking the time. And then I wish you a nice week. Same to you. Goodbye. Thank you. Goodbye.\n",
            "\n",
            "to the fact that NGES has so far been used purely for basic research, but not yet commercially. Yes.  Do you also know whether this is also the case, so here we not only have that the Leishmania is to be examined with NGS and that this is also to be characterized practically on the basis of an animal sample, so to speak, can this also be applied as a fight to existing NGS investigations? So, as I said, there is nothing at all in diagnostics. But now you mean basic research. Yes, that's where the Leishmania were always bred. In cell culture, only those were examined. That's right, that's another step that we also have to take, because we want to do this investigation directly from the sample, so to speak, and then we may have a lot of background through the genomic DNA again. That would be such a risk. Yes, perfect.  Perfect. Then the next chapter would be the differentiation from your technologies. Here we have to refer to Leishmania in general and then to NGS.  We detect Leishmania itself in various sample materials via classical PCA or real-time PCA, but we do not yet have any resistance genes. That would be the innovation, so to speak. And at the moment we are not doing any studies of any parasites about NGS, but we are doing these DNA profiles, as discussed earlier, from genomic DNA. But studies of parasites has not yet been. Or rather, this other project with Infecto-Scan, which is also going in this direction, but it is also completely under development, that we want to examine a sample and which pathogens are in it. All right: NGS could also point out that they not only examine animal samples, but also isolate Leishmania from them. Or at least for sample preparation. That makes a difference. You would then have to adjust the sample preparation so that mainly the parasite DNA is isolated so that it can be sequenced in a targeted manner. That you don't have so much background that it gets lost. That's also a sub-project of this Infecto-Scan, but it's more on viruses and they are parasites. Yes, all right, well, one can also say in general terms that for the first time parasites from animal material are to be characterized by NGS Yes, definitely. All right, then I would like to go back to the last point, namely the risks. Yes, so one risk is that several strains can occur within one animal. So they are often stung and can then carry different Leishmania strains in them, of which perhaps only one part is resistant and the other is not. You have to make sure that you really get everything pictured, that you can see this variant. That would be a risk. The second would be that the publications are not correct, because at the beginning we want to look specifically at the genes that are in the publications. It could be that there are errors in it, that we detect the genes, but that does not correlate with the clinic, i.e. there is actually no resistance at all. That could be. And if we then do NGS, it can of course be again, as with the infection scan, that we just have too much genomic DNA in it. We have to adapt all the preparations to these parasites beforehand. Or that we don't have the sensitivity to be able to map all resistance genes. Could you also quantify the sensitivity? Then we would have a numerical value here.  the sensitivity of the resistances then again. Yes, exactly. Yes, I mean, 80% sensitivity has always been something you actually strive for. Okay, well, what's a solution for them to bring out this genomic DNA, so that they bring out the genomic DNA as well as possible? It should also be tried out via Infectoscan whether there are methods to separate it.  The company Nanopore offers various recipes for this. But this, of course, is all for the human sphere. First of all, you have to see if this is also possible in the animal sector. If things go really badly, you can also grow the Leishmania in a cell culture and then examine the special hold, so to speak. But that would be very time-consuming, very\n",
            "\n",
            "genes. But you would also look at variations like these SNPs, for example, to see whether or not you see them clustered in certain genes, in certain resistant Leishmania. And the characterization of which resistance refers to which drug intolerance or ineffectiveness, would you identify the series by existing knowledge, by consulting the veterinarians, or is there somehow a direct conclusion from the mode of action of the drug to the change in the genome? So, on the one hand, we would try to evaluate this by means of questionnaires or consultation with the veterinarians. These Leishmania can also be kept in cell culture. In other words, we could then create cell cultures of some samples from the Leishmanias, so to speak, and then there are in vitro tests to see whether these Leishmaniasis still respond to certain drugs or not. Similar to bacteria, where you put antibiotics on it and see if they are still growing or not. Something like this also exists for Leishmania in cell cultures. And then, of course, you can also look biochemically at what it does. Is it realistic that it somehow has a connection or not? There is then a certain term for this biochemical approach. So if there is a technical term for it, then they would have a few more numerical values, so for me what can be attached as an objective here difficult. To be honest, I can't think of anything in this case. On the other hand, sensitivity and specificity, so what is always a classic? Yes, that's just a problem in this case, because I don't know what my gold standard would be. So I always have to see what the veterinarians say. Well, I could just say that I want an 80 percent agreement. If the veterinarian says, yes, I see resistance there, then I want to see 80 percent of it in my test material, you could perhaps say that. Then maybe also related to the resistances, i.e. what is the 80 percent, this 80 percent value refers to the I can tell at all whether Leishmania is present, yes or no or I recognize resistance. I recognize resistances, i.e. Leishmania, which I have to recognize in any case, we already have other tests, that is already established, It is now really a matter of seeing whether they are resistant or not. So 80 percent. I would say that 80 percent of the samples that are described as resistant by veterinarians, I would then like to find a resistance gene, so to speak. Maybe you can put it that way. I thought that I thought that you would first detect this with an NLGS, so to speak, but you practically do that using classical methods. All right. Well, then I would like to go into the distinction from economic stuff.  shrink? How is it classically viewed and what is new now? There is still no test for these resistances. It is really done in such a way that the veterinarians then, if a Leishmania infection has been dismissed, they give just medication. There are quasi guidelines on how best to do this, so to speak, standard procedures and then they just observe the animal, they then measure again and again how high the leishmania load is and then adjust the medication accordingly, make higher concentration or take other medications. But an examination that tells them, take this and that, there's resistance there, otherwise there's no resistance at all. Wonderful, thank you very much. Is there anything else, so this is now in relation to resistance, perhaps briefly in relation to NGS, has this ever been used to study Leishmania in general? No, this has already been used, not with us, but there are publications about it that have just done it. On the one hand, there are different strains to differentiate them, according to epidemiological studies. And resistance has also been looked at, but this is a purely scientific publication. All right, then we can refer to the fact that NGES has so far been used purely for basic research, but not yet commercially. Yes.  Do you also know whether this is also the case, so here we not only have that the Leishmania is\n",
            "\n",
            "Using this as context\n",
            "\n",
            "Answer to the following question from a user regarding Leishmania disease project following given guidelines.\n",
            "Question: Does the project aim to develop a product, production process, production line, service, or scientific methodology that represents a significant advancement/novelty in the relevant industry?\n",
            "Guidelines: If yes, please explain. Provide a brief description of the research or development status of the industry and differentiate your product, production process, production line, service, or scientific methodology from it. Describe any new scientific/technical methods, approaches, or procedures being utilized. (Examples include experiments, field studies, observations, cohort studies.\n",
            "\n",
            "        Try to include following points:\n",
            "        - 1 sentence specifying target sector/product category and differentiation from the state of the art (The project aims to target... which are intended to surpass the state of the art in terms of...\n",
            "        - 2 to 4 sentences differentiating from the state of the art with approximately 2 parameters for differentiation.\n",
            "        \n",
            "Restrict output to ONLY 800 characters\n",
            "\n",
            "Answer:\u001b[0m\n",
            "\n",
            "\u001b[1m> Finished chain.\u001b[0m\n",
            "The project aims to target the animal health sector by developing a novel product for detecting hereditary diseases in cats, dogs, and horses using Next Generation Sequencing (NGS) technology. This represents a significant advancement in the industry as current state-of-the-art technologies mainly focus on individual tests and breed-specific applications. The project differentiates itself by utilizing NGS as a high-throughput technology to study the entire genetic makeup of animals, expanding into larger genetic variants, and providing comprehensive genetic profiling and parentage analyses. This innovative approach surpasses the current limitations of individual tests and offers a more comprehensive and accurate assessment of genetic variations in animals.\n",
            "Length of response is 766 which is -34 characters above ideal\n",
            "####################################################################################################\n",
            "####################################################################################################\n",
            "Is there a specific connection between the project and existing products, production lines, production processes, services, or already established scientific methodology within your company?\n",
            "****************************************************************************************************\n",
            "If yes, please clarify to what extent the work of the project goes beyond routine development activities in your company. Explain the differentiation from existing products, production lines, production processes, and services within the company. How does the product, process, or service to be developed differ from those already offered by your company ?\n",
            "\n",
            "        Try to include following points:\n",
            "        - 1 sentence about current technologies in the company\n",
            "        - 1 sentence differentiating functionality (For the first time...)\n",
            "        - 2 to 4 sentences differentiating functionality and development methods\n",
            "        \n",
            "\n",
            "\n",
            "\u001b[1m> Entering new  chain...\u001b[0m\n",
            "Prompt after formatting:\n",
            "\u001b[32;1m\u001b[1;3mHuman: You are a research document summarizer that finds the answers to user query and give correct responses\n",
            "Note that the user is from a highly specialized technical background, use minimal layman terms in your responses\n",
            "\n",
            "Use the following background context information on the Leishmania disease research project.\n",
            "\n",
            "That's how I would sum it up now.\n",
            "\n",
            "I have enclosed a short quality checklist here to accompany the application and how the application is always structured, so that you have a rough direction.\n",
            "\n",
            "We always have to describe a sentence about the state of the art, i.e. according to the current state of the art, this is done this way and that, then what the project goal is, then also the demarcation from the state of the art, to what extent the state of the art is expanded and the knowledge is expanded at your company and then finally what the project result should be.\n",
            "\n",
            "Perhaps you could just ask a few questions about the project, especially in relation to this Next Generation Sequencing.\n",
            "\n",
            "So let's put into perspective the extent to which you have already used it, to what extent it is a new technique for you, to what extent it is something new for detecting hereditary diseases in cats, dogs and horses.\n",
            "\n",
            "So now verbally or then for the application?\n",
            "\n",
            "Oral, oral.\n",
            "\n",
            "So now verbally or then for the application?\n",
            "\n",
            "Oral, oral.\n",
            "\n",
            "We formulate on the basis, that's why the recording is ongoing.\n",
            "\n",
            "We formulate the application from this.\n",
            "\n",
            "Okay, so then I would say that the current state of the art is that we are not yet using high-throughput technology to study the entire genetic markup of an animal.\n",
            "\n",
            "Instead, we mainly have individual tests and smaller products that are applied to breed-specific.  \n",
            "\n",
            "We are currently using next generation sequencing as a technology for DNA profiling.\n",
            "\n",
            "The main focus is on parentage analyses and the genetic fingerprint of animals.\n",
            "\n",
            "The aim of the project would then be what I formulated earlier, that it is primarily about animal health, of our own animal, but also of the species that we want to cover as a whole.\n",
            "\n",
            "State-of-the-art technology?  \n",
            "\n",
            "Above all, we are also expanding into larger genetic variants in this area.\n",
            "\n",
            "Class.\n",
            "\n",
            "Well, then I would like to go into the next point.\n",
            "\n",
            "The next point also relates to the differentiation from existing technologies in your company.\n",
            "\n",
            "It would be important for the auditor to classify whether you have ever dealt with Next Generation Sequencing in the company.\n",
            "\n",
            "If so, what is the difference here and if not, the This is perfectly adequate.\n",
            "\n",
            "Yes, we have had this, i.e. Next Generation Sequencing, in our company since 2020.\n",
            "\n",
            "And we are currently using it for genetic fingerprinting in dogs.  \n",
            "\n",
            "and to investigate genetic variability also in dogs.\n",
            "\n",
            "We do not yet have a product for cats, nor for horses, nor anything that is offered with hereditary diseases.\n",
            "\n",
            "Then it has to be implemented in the so-called panels with which the NGS technology works.\n",
            "\n",
            "One panel for each species.\n",
            "\n",
            "Then the third step would be the evaluation of the tests that we map.\n",
            "\n",
            "Of course, we also have to make sure that this should not only deliver the correct result from a technical point of view, but that it does.\n",
            "\n",
            "In other words, we have to compare the known animals with the results that we achieve with the new technology, with the NGS technology, and perhaps then bring the whole thing as fit for the work package in a way that is then understandable to the customer.\n",
            "\n",
            "We can't train them with 200 pages of text at the end.\n",
            "\n",
            "It has to be adapted to the different types of people so that they can do something with it.\n",
            "\n",
            "Wonderful, thank you very much.  \n",
            "\n",
            "In the end, could you rewrite the prototype a little better, i.e. the way in which it is understandable for the customer.\n",
            "\n",
            "Do you have a little better idea of what the end result should look like?\n",
            "\n",
            "Use the following information on the Leishmania disease research project.\n",
            "Next generation sequencing (NGS) technology transformed Leishmania genome studies and became an indispensable tool for Leishmania researchers. Recent Leishmania genomics analyses facilitated the discovery of various genetic diversities including single nucleotide polymorphisms (SNPs), copy number variations (CNVs), somy variations, and structural variations in detail and provided valuable insights into the complexity of the genome and gene regulation. Many aspects of Leishmania NGS analyses are similar to those of related pathogens like trypanosomes. However, the analyses of Leishmania genomes face a unique challenge because of the presence of frequent aneuploidy. This makes characterization and interpretation of read depth and somy a key part of Leishmania NGS analyses because read depth affects the accuracy of detection of all genetic variations. However, there are no general guidelines on how to explore and interpret the impact of aneuploidy, and this has made it difficult for biologists and bioinformaticians, especially for beginners, to perform their own analyses and interpret results across different analyses. In this guide we discuss a wide range of topics essential for Leishmania NGS analyses, ranging from how to set up a computational environment for genome analyses, to how to characterize genetic variations among Leishmania samples, and we will particularly focus on chromosomal copy number variation and its impact on genome analyses.\n",
            "in the animal sector. If things go really badly, you can also grow the Leishmania in a cell culture and then examine the special hold, so to speak. But that would be very time-consuming, very expensive. You have to ask yourself whether you want to continue the project at all. In other words, one could actually also argue as a risk that the whole technique works for Leishmania in cell culture, but in the end the animal sample simply cannot be realized. Yes, right. Better. To the expenses. Do you know how many people are supposed to work on it? Yes, so we'll do it again via the HR department. In principle, I will have a relatively large number of hours there. Then a veterinarian from clinical chemistry has hours there and of course we still need a laboratory and I think there will be a second veterinarian from either my department or from clinical chemistry so that he can have contact with the veterinarians outside. All right, then just a rough overview, that is, four people to no idea ten to 15 percent perhaps. Yes, that's right.  Okay, do any subcontractors still come in here? So there will certainly be cooperations, but more with universities and then you don't really have any bills. So if you don't pay for the university, then that's not relevant. Yes yes exactly.  Yes, exactly, I'm just thinking so loudly. That's why I don't think so at the moment. Okay perfect, then I'm already through with my questions here too. Is there another project or would that be it for now?  I think that would be it for now. Completely new things will be added. The other thing with the infection scan, they had sent something again. I would only get the one sentence out.  Exactly, I wanted to talk to you about that, because of course we have to make sure that we fill in the text to see if there is perhaps a replacement for the deletion. I don't know what you're aiming for. I'll probably have to open this up again. Because it doesn't allow you to do that, just that's what IT is doing here today. Exactly, but I can also briefly share your e-mail otherwise. Yes, maybe that's the fastest way to do it. So, exactly. Yes, few screening with EDP Yes, few screening methods that result from dogs or cats. I don't know what they're actually going to pick up. We wanted to show a bit of the demarcations to the state of the art, i.e. how this is done according to statistics, i.e. how much of the statistics is not enough. So what we're doing is not screening methods, it's like, it's like packages. But that would have to be worded a little differently. If the dog's nose runs, then we just do herpes calypso, then there are already four or five typical pathogens that you do there.  So these are more like packages that are then specific to certain symptoms. But never cover everything that could be there. Maybe you can just rephrase it a bit. Yes, that means you actually have to have an initial guess and then you examine it specifically. But you don't study the entire genome. That's right, yes. Okay, let's rephrase. Well, we did it. Class. Yes, wonderful. Yes, we still had the one with the mutation, antimutation or whatever they called it. So with that I still have a bit of a stomach ache overall, because it is, actually already the case, that we have already established a lot of hereditary diseases and yes actually this prototype, as described earlier, has been there for a long time and we just keep expanding it with newly released things. Of course, we also expand our methods or the possibility of mapping these structural variants now, but I don't know if we can get that many hours together if I really concentrate on that. I have to talk to Mrs. Khler again, to my head of department, about how we can do that, whether we can perhaps somehow make a different focus, that we can somehow do it differently, so I would put that on the back burner at the moment, although it is actually the project that is retroactive, all the others are actually not retroactive from the\n",
            "\n",
            "we can somehow do it differently, so I would put that on the back burner at the moment, although it is actually the project that is retroactive, all the others are actually not retroactive from the time to But I would sit down with Mrs. Khnlein for the next three or four weeks and then I would give you feedback again. All right, so if we can change the focus, such as What is that? Mutations, exactly. We can integrate that relatively easily. But then just give me a message about it. Yes. Class. Wonderful. Then thank you very much, Mrs Kehl, for taking the time. And then I wish you a nice week. Same to you. Goodbye. Thank you. Goodbye.\n",
            "\n",
            "to the fact that NGES has so far been used purely for basic research, but not yet commercially. Yes.  Do you also know whether this is also the case, so here we not only have that the Leishmania is to be examined with NGS and that this is also to be characterized practically on the basis of an animal sample, so to speak, can this also be applied as a fight to existing NGS investigations? So, as I said, there is nothing at all in diagnostics. But now you mean basic research. Yes, that's where the Leishmania were always bred. In cell culture, only those were examined. That's right, that's another step that we also have to take, because we want to do this investigation directly from the sample, so to speak, and then we may have a lot of background through the genomic DNA again. That would be such a risk. Yes, perfect.  Perfect. Then the next chapter would be the differentiation from your technologies. Here we have to refer to Leishmania in general and then to NGS.  We detect Leishmania itself in various sample materials via classical PCA or real-time PCA, but we do not yet have any resistance genes. That would be the innovation, so to speak. And at the moment we are not doing any studies of any parasites about NGS, but we are doing these DNA profiles, as discussed earlier, from genomic DNA. But studies of parasites has not yet been. Or rather, this other project with Infecto-Scan, which is also going in this direction, but it is also completely under development, that we want to examine a sample and which pathogens are in it. All right: NGS could also point out that they not only examine animal samples, but also isolate Leishmania from them. Or at least for sample preparation. That makes a difference. You would then have to adjust the sample preparation so that mainly the parasite DNA is isolated so that it can be sequenced in a targeted manner. That you don't have so much background that it gets lost. That's also a sub-project of this Infecto-Scan, but it's more on viruses and they are parasites. Yes, all right, well, one can also say in general terms that for the first time parasites from animal material are to be characterized by NGS Yes, definitely. All right, then I would like to go back to the last point, namely the risks. Yes, so one risk is that several strains can occur within one animal. So they are often stung and can then carry different Leishmania strains in them, of which perhaps only one part is resistant and the other is not. You have to make sure that you really get everything pictured, that you can see this variant. That would be a risk. The second would be that the publications are not correct, because at the beginning we want to look specifically at the genes that are in the publications. It could be that there are errors in it, that we detect the genes, but that does not correlate with the clinic, i.e. there is actually no resistance at all. That could be. And if we then do NGS, it can of course be again, as with the infection scan, that we just have too much genomic DNA in it. We have to adapt all the preparations to these parasites beforehand. Or that we don't have the sensitivity to be able to map all resistance genes. Could you also quantify the sensitivity? Then we would have a numerical value here.  the sensitivity of the resistances then again. Yes, exactly. Yes, I mean, 80% sensitivity has always been something you actually strive for. Okay, well, what's a solution for them to bring out this genomic DNA, so that they bring out the genomic DNA as well as possible? It should also be tried out via Infectoscan whether there are methods to separate it.  The company Nanopore offers various recipes for this. But this, of course, is all for the human sphere. First of all, you have to see if this is also possible in the animal sector. If things go really badly, you can also grow the Leishmania in a cell culture and then examine the special hold, so to speak. But that would be very time-consuming, very\n",
            "\n",
            "genes. But you would also look at variations like these SNPs, for example, to see whether or not you see them clustered in certain genes, in certain resistant Leishmania. And the characterization of which resistance refers to which drug intolerance or ineffectiveness, would you identify the series by existing knowledge, by consulting the veterinarians, or is there somehow a direct conclusion from the mode of action of the drug to the change in the genome? So, on the one hand, we would try to evaluate this by means of questionnaires or consultation with the veterinarians. These Leishmania can also be kept in cell culture. In other words, we could then create cell cultures of some samples from the Leishmanias, so to speak, and then there are in vitro tests to see whether these Leishmaniasis still respond to certain drugs or not. Similar to bacteria, where you put antibiotics on it and see if they are still growing or not. Something like this also exists for Leishmania in cell cultures. And then, of course, you can also look biochemically at what it does. Is it realistic that it somehow has a connection or not? There is then a certain term for this biochemical approach. So if there is a technical term for it, then they would have a few more numerical values, so for me what can be attached as an objective here difficult. To be honest, I can't think of anything in this case. On the other hand, sensitivity and specificity, so what is always a classic? Yes, that's just a problem in this case, because I don't know what my gold standard would be. So I always have to see what the veterinarians say. Well, I could just say that I want an 80 percent agreement. If the veterinarian says, yes, I see resistance there, then I want to see 80 percent of it in my test material, you could perhaps say that. Then maybe also related to the resistances, i.e. what is the 80 percent, this 80 percent value refers to the I can tell at all whether Leishmania is present, yes or no or I recognize resistance. I recognize resistances, i.e. Leishmania, which I have to recognize in any case, we already have other tests, that is already established, It is now really a matter of seeing whether they are resistant or not. So 80 percent. I would say that 80 percent of the samples that are described as resistant by veterinarians, I would then like to find a resistance gene, so to speak. Maybe you can put it that way. I thought that I thought that you would first detect this with an NLGS, so to speak, but you practically do that using classical methods. All right. Well, then I would like to go into the distinction from economic stuff.  shrink? How is it classically viewed and what is new now? There is still no test for these resistances. It is really done in such a way that the veterinarians then, if a Leishmania infection has been dismissed, they give just medication. There are quasi guidelines on how best to do this, so to speak, standard procedures and then they just observe the animal, they then measure again and again how high the leishmania load is and then adjust the medication accordingly, make higher concentration or take other medications. But an examination that tells them, take this and that, there's resistance there, otherwise there's no resistance at all. Wonderful, thank you very much. Is there anything else, so this is now in relation to resistance, perhaps briefly in relation to NGS, has this ever been used to study Leishmania in general? No, this has already been used, not with us, but there are publications about it that have just done it. On the one hand, there are different strains to differentiate them, according to epidemiological studies. And resistance has also been looked at, but this is a purely scientific publication. All right, then we can refer to the fact that NGES has so far been used purely for basic research, but not yet commercially. Yes.  Do you also know whether this is also the case, so here we not only have that the Leishmania is\n",
            "\n",
            "Using this as context\n",
            "\n",
            "Answer to the following question from a user regarding Leishmania disease project following given guidelines.\n",
            "Question: Is there a specific connection between the project and existing products, production lines, production processes, services, or already established scientific methodology within your company?\n",
            "Guidelines: If yes, please clarify to what extent the work of the project goes beyond routine development activities in your company. Explain the differentiation from existing products, production lines, production processes, and services within the company. How does the product, process, or service to be developed differ from those already offered by your company ?\n",
            "\n",
            "        Try to include following points:\n",
            "        - 1 sentence about current technologies in the company\n",
            "        - 1 sentence differentiating functionality (For the first time...)\n",
            "        - 2 to 4 sentences differentiating functionality and development methods\n",
            "        \n",
            "Restrict output to ONLY 800 characters\n",
            "\n",
            "Answer:\u001b[0m\n",
            "\n",
            "\u001b[1m> Finished chain.\u001b[0m\n",
            "Yes, there is a specific connection between the Leishmania disease project and existing technologies in our company. Currently, our company utilizes classical PCR or real-time PCR to detect Leishmania in various sample materials. However, we do not have any tests for resistance genes. The project aims to develop a novel product that can detect and characterize Leishmania strains directly from animal samples using Next Generation Sequencing (NGS) technology. This would be the first time that parasites from animal material are characterized using NGS. The development of this product involves setting up a computational environment for genome analyses, characterizing genetic variations among Leishmania samples, and focusing on chromosomal copy number variation. This project goes beyond routine development activities in our company and expands our capabilities in the field of Leishmania research. The product to be developed differs from existing products as it provides a comprehensive analysis of genetic diversities in Leishmania genomes, particularly focusing on resistance genes.\n",
            "Length of response is 1092 which is 292 characters above ideal\n",
            "####################################################################################################\n",
            "####################################################################################################\n",
            "Are there scientific and/or technical risks involved in implementing the project ? Explain them\n",
            "****************************************************************************************************\n",
            "Explain the engineering, natural, social, or humanities-related barriers that can be identified for the solution approach of your project. Describe the scientific (across all scientific disciplines) and/or technical obstacles, risks, uncertainties, or challenges that could lead to the failure of the project.\n",
            "\n",
            "        Describe how you address the identified risks. Briefly explain milestones and termination criteria. We explicitly emphasize that at this point, no economic and/or financial risks - related to the future product/process - should be mentioned\n",
            "        Try to include following points:\n",
            "        - 3 risks following the above format\n",
            "        \n",
            "\n",
            "\n",
            "\u001b[1m> Entering new  chain...\u001b[0m\n",
            "Prompt after formatting:\n",
            "\u001b[32;1m\u001b[1;3mHuman: You are a research document summarizer that finds the answers to user query and give correct responses\n",
            "Note that the user is from a highly specialized technical background, use minimal layman terms in your responses\n",
            "\n",
            "Use the following background context information on the Leishmania disease research project.\n",
            "\n",
            "That's how I would sum it up now.\n",
            "\n",
            "I have enclosed a short quality checklist here to accompany the application and how the application is always structured, so that you have a rough direction.\n",
            "\n",
            "We always have to describe a sentence about the state of the art, i.e. according to the current state of the art, this is done this way and that, then what the project goal is, then also the demarcation from the state of the art, to what extent the state of the art is expanded and the knowledge is expanded at your company and then finally what the project result should be.\n",
            "\n",
            "Perhaps you could just ask a few questions about the project, especially in relation to this Next Generation Sequencing.\n",
            "\n",
            "So let's put into perspective the extent to which you have already used it, to what extent it is a new technique for you, to what extent it is something new for detecting hereditary diseases in cats, dogs and horses.\n",
            "\n",
            "So now verbally or then for the application?\n",
            "\n",
            "Oral, oral.\n",
            "\n",
            "So now verbally or then for the application?\n",
            "\n",
            "Oral, oral.\n",
            "\n",
            "We formulate on the basis, that's why the recording is ongoing.\n",
            "\n",
            "We formulate the application from this.\n",
            "\n",
            "Okay, so then I would say that the current state of the art is that we are not yet using high-throughput technology to study the entire genetic markup of an animal.\n",
            "\n",
            "Instead, we mainly have individual tests and smaller products that are applied to breed-specific.  \n",
            "\n",
            "We are currently using next generation sequencing as a technology for DNA profiling.\n",
            "\n",
            "The main focus is on parentage analyses and the genetic fingerprint of animals.\n",
            "\n",
            "The aim of the project would then be what I formulated earlier, that it is primarily about animal health, of our own animal, but also of the species that we want to cover as a whole.\n",
            "\n",
            "State-of-the-art technology?  \n",
            "\n",
            "Above all, we are also expanding into larger genetic variants in this area.\n",
            "\n",
            "Class.\n",
            "\n",
            "Well, then I would like to go into the next point.\n",
            "\n",
            "The next point also relates to the differentiation from existing technologies in your company.\n",
            "\n",
            "It would be important for the auditor to classify whether you have ever dealt with Next Generation Sequencing in the company.\n",
            "\n",
            "If so, what is the difference here and if not, the This is perfectly adequate.\n",
            "\n",
            "Yes, we have had this, i.e. Next Generation Sequencing, in our company since 2020.\n",
            "\n",
            "And we are currently using it for genetic fingerprinting in dogs.  \n",
            "\n",
            "and to investigate genetic variability also in dogs.\n",
            "\n",
            "We do not yet have a product for cats, nor for horses, nor anything that is offered with hereditary diseases.\n",
            "\n",
            "Then it has to be implemented in the so-called panels with which the NGS technology works.\n",
            "\n",
            "One panel for each species.\n",
            "\n",
            "Then the third step would be the evaluation of the tests that we map.\n",
            "\n",
            "Of course, we also have to make sure that this should not only deliver the correct result from a technical point of view, but that it does.\n",
            "\n",
            "In other words, we have to compare the known animals with the results that we achieve with the new technology, with the NGS technology, and perhaps then bring the whole thing as fit for the work package in a way that is then understandable to the customer.\n",
            "\n",
            "We can't train them with 200 pages of text at the end.\n",
            "\n",
            "It has to be adapted to the different types of people so that they can do something with it.\n",
            "\n",
            "Wonderful, thank you very much.  \n",
            "\n",
            "In the end, could you rewrite the prototype a little better, i.e. the way in which it is understandable for the customer.\n",
            "\n",
            "Do you have a little better idea of what the end result should look like?\n",
            "\n",
            "Use the following information on the Leishmania disease research project.\n",
            "Next generation sequencing (NGS) technology transformed Leishmania genome studies and became an indispensable tool for Leishmania researchers. Recent Leishmania genomics analyses facilitated the discovery of various genetic diversities including single nucleotide polymorphisms (SNPs), copy number variations (CNVs), somy variations, and structural variations in detail and provided valuable insights into the complexity of the genome and gene regulation. Many aspects of Leishmania NGS analyses are similar to those of related pathogens like trypanosomes. However, the analyses of Leishmania genomes face a unique challenge because of the presence of frequent aneuploidy. This makes characterization and interpretation of read depth and somy a key part of Leishmania NGS analyses because read depth affects the accuracy of detection of all genetic variations. However, there are no general guidelines on how to explore and interpret the impact of aneuploidy, and this has made it difficult for biologists and bioinformaticians, especially for beginners, to perform their own analyses and interpret results across different analyses. In this guide we discuss a wide range of topics essential for Leishmania NGS analyses, ranging from how to set up a computational environment for genome analyses, to how to characterize genetic variations among Leishmania samples, and we will particularly focus on chromosomal copy number variation and its impact on genome analyses.\n",
            "in the animal sector. If things go really badly, you can also grow the Leishmania in a cell culture and then examine the special hold, so to speak. But that would be very time-consuming, very expensive. You have to ask yourself whether you want to continue the project at all. In other words, one could actually also argue as a risk that the whole technique works for Leishmania in cell culture, but in the end the animal sample simply cannot be realized. Yes, right. Better. To the expenses. Do you know how many people are supposed to work on it? Yes, so we'll do it again via the HR department. In principle, I will have a relatively large number of hours there. Then a veterinarian from clinical chemistry has hours there and of course we still need a laboratory and I think there will be a second veterinarian from either my department or from clinical chemistry so that he can have contact with the veterinarians outside. All right, then just a rough overview, that is, four people to no idea ten to 15 percent perhaps. Yes, that's right.  Okay, do any subcontractors still come in here? So there will certainly be cooperations, but more with universities and then you don't really have any bills. So if you don't pay for the university, then that's not relevant. Yes yes exactly.  Yes, exactly, I'm just thinking so loudly. That's why I don't think so at the moment. Okay perfect, then I'm already through with my questions here too. Is there another project or would that be it for now?  I think that would be it for now. Completely new things will be added. The other thing with the infection scan, they had sent something again. I would only get the one sentence out.  Exactly, I wanted to talk to you about that, because of course we have to make sure that we fill in the text to see if there is perhaps a replacement for the deletion. I don't know what you're aiming for. I'll probably have to open this up again. Because it doesn't allow you to do that, just that's what IT is doing here today. Exactly, but I can also briefly share your e-mail otherwise. Yes, maybe that's the fastest way to do it. So, exactly. Yes, few screening with EDP Yes, few screening methods that result from dogs or cats. I don't know what they're actually going to pick up. We wanted to show a bit of the demarcations to the state of the art, i.e. how this is done according to statistics, i.e. how much of the statistics is not enough. So what we're doing is not screening methods, it's like, it's like packages. But that would have to be worded a little differently. If the dog's nose runs, then we just do herpes calypso, then there are already four or five typical pathogens that you do there.  So these are more like packages that are then specific to certain symptoms. But never cover everything that could be there. Maybe you can just rephrase it a bit. Yes, that means you actually have to have an initial guess and then you examine it specifically. But you don't study the entire genome. That's right, yes. Okay, let's rephrase. Well, we did it. Class. Yes, wonderful. Yes, we still had the one with the mutation, antimutation or whatever they called it. So with that I still have a bit of a stomach ache overall, because it is, actually already the case, that we have already established a lot of hereditary diseases and yes actually this prototype, as described earlier, has been there for a long time and we just keep expanding it with newly released things. Of course, we also expand our methods or the possibility of mapping these structural variants now, but I don't know if we can get that many hours together if I really concentrate on that. I have to talk to Mrs. Khler again, to my head of department, about how we can do that, whether we can perhaps somehow make a different focus, that we can somehow do it differently, so I would put that on the back burner at the moment, although it is actually the project that is retroactive, all the others are actually not retroactive from the\n",
            "\n",
            "we can somehow do it differently, so I would put that on the back burner at the moment, although it is actually the project that is retroactive, all the others are actually not retroactive from the time to But I would sit down with Mrs. Khnlein for the next three or four weeks and then I would give you feedback again. All right, so if we can change the focus, such as What is that? Mutations, exactly. We can integrate that relatively easily. But then just give me a message about it. Yes. Class. Wonderful. Then thank you very much, Mrs Kehl, for taking the time. And then I wish you a nice week. Same to you. Goodbye. Thank you. Goodbye.\n",
            "\n",
            "to the fact that NGES has so far been used purely for basic research, but not yet commercially. Yes.  Do you also know whether this is also the case, so here we not only have that the Leishmania is to be examined with NGS and that this is also to be characterized practically on the basis of an animal sample, so to speak, can this also be applied as a fight to existing NGS investigations? So, as I said, there is nothing at all in diagnostics. But now you mean basic research. Yes, that's where the Leishmania were always bred. In cell culture, only those were examined. That's right, that's another step that we also have to take, because we want to do this investigation directly from the sample, so to speak, and then we may have a lot of background through the genomic DNA again. That would be such a risk. Yes, perfect.  Perfect. Then the next chapter would be the differentiation from your technologies. Here we have to refer to Leishmania in general and then to NGS.  We detect Leishmania itself in various sample materials via classical PCA or real-time PCA, but we do not yet have any resistance genes. That would be the innovation, so to speak. And at the moment we are not doing any studies of any parasites about NGS, but we are doing these DNA profiles, as discussed earlier, from genomic DNA. But studies of parasites has not yet been. Or rather, this other project with Infecto-Scan, which is also going in this direction, but it is also completely under development, that we want to examine a sample and which pathogens are in it. All right: NGS could also point out that they not only examine animal samples, but also isolate Leishmania from them. Or at least for sample preparation. That makes a difference. You would then have to adjust the sample preparation so that mainly the parasite DNA is isolated so that it can be sequenced in a targeted manner. That you don't have so much background that it gets lost. That's also a sub-project of this Infecto-Scan, but it's more on viruses and they are parasites. Yes, all right, well, one can also say in general terms that for the first time parasites from animal material are to be characterized by NGS Yes, definitely. All right, then I would like to go back to the last point, namely the risks. Yes, so one risk is that several strains can occur within one animal. So they are often stung and can then carry different Leishmania strains in them, of which perhaps only one part is resistant and the other is not. You have to make sure that you really get everything pictured, that you can see this variant. That would be a risk. The second would be that the publications are not correct, because at the beginning we want to look specifically at the genes that are in the publications. It could be that there are errors in it, that we detect the genes, but that does not correlate with the clinic, i.e. there is actually no resistance at all. That could be. And if we then do NGS, it can of course be again, as with the infection scan, that we just have too much genomic DNA in it. We have to adapt all the preparations to these parasites beforehand. Or that we don't have the sensitivity to be able to map all resistance genes. Could you also quantify the sensitivity? Then we would have a numerical value here.  the sensitivity of the resistances then again. Yes, exactly. Yes, I mean, 80% sensitivity has always been something you actually strive for. Okay, well, what's a solution for them to bring out this genomic DNA, so that they bring out the genomic DNA as well as possible? It should also be tried out via Infectoscan whether there are methods to separate it.  The company Nanopore offers various recipes for this. But this, of course, is all for the human sphere. First of all, you have to see if this is also possible in the animal sector. If things go really badly, you can also grow the Leishmania in a cell culture and then examine the special hold, so to speak. But that would be very time-consuming, very\n",
            "\n",
            "Perfect, okay when we start again with the goal of the project. So I'm going to elaborate a bit, leishmania are parasites that are transmitted via various mosquitoes. This means that the dogs are bitten by the mosquitoes, then get these leishmanias, which then lead to leishmaniasis. And the whole thing can also affect people. At the moment, this is still a major problem in southern countries, i.e. southern Europe. However, due to climate change, of course, these mosquitoes are coming further and further north, which transmit these larch manias, so to speak, and sooner or later it will most likely become a problem in Germany. This means that the dog has the mosquito bites on these Leishmanias, picks up the eggs of it again and so on and so on. There are now various medications that are taken for the treatment of the dogs. However, these Leishmania develop resistance to it very quickly. Our goal now would be to get a sample from a dog, to prove that he has Leishmania and at the same time to examine these Leishmania to see if they already contain certain resistance genes, so that the doctor can then take the other drug instead of a drug, as is the case with the bacteria in the end, instead of giving the wrong drug,  On the one hand, this does not work, and on the other hand, it leads to the formation of even more resistant Leishmania in order to avoid this. That would be the goal, that you give the veterinarians a tool and say, send us a sample. We study the animal Leishmania and have these Leishmania that the animal has, resistance genes, in order to be able to say which drug is best. Wonderful thank you very much.  On what basis should the investigation of the resistance or the sample in general be carried out? There are already a few publications, there are many groups that are working on which genes are responsible for the resistances. There are already a few publications, there are many groups that are now working on which genes are now responsible for the resistance. There is often no change in the genes, but a copy number variation. So these genes are then either multiplied or they are no longer there at all and this leads to this resistance and this is to be investigated on the basis of these scientific publications. And what we also want to do is to use Next Generation Sequencing to examine the entire Leishmania genome, so to speak. So the first approach would be to search specifically for the genes that are in the publications. And we can also look at it again. In other words, we would then also ask the veterinarians again, are these dogs already treated, do you also see resistance to allopurinol, for example, and we can see, yes we also see what is written in the scientific publication, that this and that gene is more common or not. And then we also want to examine the complete genomes of the Leishmania to see if we can find more genes that are relevant. And that would simply make the product more attractive if you don't say, okay, I'm just looking for an allopurinol resistance or only for a Milteforan resistance, but I'll look at everything again and I can then tell you, yes such and such resistances are present and you don't need this and that at all. Perfect, thank you very much. Could you elaborate on how you ultimately want to characterize whether other genes are relevant if they are not yet published? Are there certain patterns that they then practically read out of the publications and then transferred to the rest of the moment, something has just happened to me. I don't see them properly anymore. So we would just take a close look at the whole thing via Next Generation Sequencing.  Yes, of course, because they are often also copy number variations, one would first focus on whether one sees something like this in other genes. But you would also look at variations like these SNPs, for example, to see whether or not you see them clustered in certain genes, in certain resistant Leishmania. And the characterization\n",
            "\n",
            "Using this as context\n",
            "\n",
            "Answer to the following question from a user regarding Leishmania disease project following given guidelines.\n",
            "Question: Are there scientific and/or technical risks involved in implementing the project ? Explain them\n",
            "Guidelines: Explain the engineering, natural, social, or humanities-related barriers that can be identified for the solution approach of your project. Describe the scientific (across all scientific disciplines) and/or technical obstacles, risks, uncertainties, or challenges that could lead to the failure of the project.\n",
            "\n",
            "        Describe how you address the identified risks. Briefly explain milestones and termination criteria. We explicitly emphasize that at this point, no economic and/or financial risks - related to the future product/process - should be mentioned\n",
            "        Try to include following points:\n",
            "        - 3 risks following the above format\n",
            "        \n",
            "Restrict output to ONLY 800 characters\n",
            "\n",
            "Answer:\u001b[0m\n",
            "\n",
            "\u001b[1m> Finished chain.\u001b[0m\n",
            "There are several scientific and technical risks involved in implementing the Leishmania disease project. \n",
            "\n",
            "1. Aneuploidy and Genetic Variability: The presence of frequent aneuploidy in Leishmania genomes poses a unique challenge in characterizing and interpreting read depth and somy in Next Generation Sequencing (NGS) analyses. The accurate detection of genetic variations, such as single nucleotide polymorphisms (SNPs) and copy number variations (CNVs), is affected by read depth. However, there are no general guidelines on exploring and interpreting the impact of aneuploidy, making it challenging for biologists and bioinformaticians to perform their own analyses and interpret results across different studies.\n",
            "\n",
            "2. Lack of Guidelines: There is a lack of general guidelines on how to perform Leishmania NGS analyses. This presents a challenge, especially for beginners, in setting up a computational environment for genome analyses, characterizing genetic variations, and understanding the impact of chromosomal copy number variation on genome analyses. The absence of guidelines hinders the reproducibility and comparability of research findings.\n",
            "\n",
            "3. Interpretation of Results: Another risk is the potential discrepancy between the genes identified in scientific publications and their clinical relevance. While there are publications on genes associated with resistance, it is crucial to validate their significance in clinical practice. Incorrect interpretations of results may lead to ineffective treatment decisions and the development of more resistant Leishmania strains.\n",
            "\n",
            "To address these risks, the project will focus on developing guidelines for Leishmania NGS analyses, specifically addressing the challenges posed by aneuploidy. Efforts will be made to establish best practices for sample preparation, data analysis, and result interpretation. The project will also involve collaborations with universities and research institutions to validate and refine the findings. The milestones will include the establishment of a computational environment, development of protocols for genomic DNA isolation and NGS library preparation, and the identification and validation of genes associated with resistance. Termination criteria will be based on the achievement of these milestones and the ability to provide accurate and clinically relevant information for treatment decisions.\n",
            "Length of response is 2393 which is 1593 characters above ideal\n",
            "####################################################################################################\n",
            "####################################################################################################\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import json\n",
        "with open('/content/drive/MyDrive/Innoscripta/Advanced/Exp1/data_dump.json', 'w') as fout:\n",
        "    json.dump(query_list, fout)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 17
        },
        "id": "XnjbXE-aC6vI",
        "outputId": "ab33d35f-434f-43c4-c627-1ba97a978ce0"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "0YWeUNCgFaWA"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "#### With GPT-4"
      ],
      "metadata": {
        "id": "7dv9Ao2_Falo"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "for i in range(len(query_list)):\n",
        "  print(query_list[i]['query'])\n",
        "  print('*'*100)\n",
        "  print(query_list[i]['guidelines'])\n",
        "  response = llm_pipe(db_target, db_background,\n",
        "             target_query=query_list[i]['query'],\n",
        "             guidelines=query_list[i]['guidelines'],\n",
        "             background_query=\"What are the technologies discussed ?\",\n",
        "             gpt_model=\"gpt-4\")\n",
        "  query_list[i]['response'], query_list[i]['overhead_characters'] = response\n",
        "  print('#'*100)\n",
        "  print('#'*100)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "outputId": "29def318-1f42-42af-c70a-aeacefc78a96",
        "id": "xXBkL05CFalp"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "What is the Objective of the project (if applicable, in the context of the cooperative project) ?\n",
            "****************************************************************************************************\n",
            "Motivation, objectives, and intended results. To what extent does the project aim to expand the state of knowledge/technology or utilize existing scientific, technical, economic, or other relevant findings or approaches\n",
            "\n",
            "        Try to include following points:\n",
            "        - 1 State of the art (Currently/According to the state of the art...)\n",
            "        - 1 Project objective (The goal of the project is...)\n",
            "        - 1 Differentiation from the state of the art (The state of the art is expanded...)\n",
            "        - in terms of..., thereby expanding the knowledge about...\n",
            "        - 1 Project result (The planned outcome/result is...)\n",
            "Please ensure that the project uses specific technical terminology to describe the innovative core. This is particularly crucial, especially for software projects.\n",
            "        \n",
            "\n",
            "\n",
            "\u001b[1m> Entering new  chain...\u001b[0m\n",
            "Prompt after formatting:\n",
            "\u001b[32;1m\u001b[1;3mHuman: You are a research document summarizer that finds the answers to user query and give correct responses\n",
            "Note that the user is from a highly specialized technical background, use minimal layman terms in your responses\n",
            "\n",
            "Use the following background context information on the Leishmania disease research project.\n",
            "\n",
            "That's how I would sum it up now.\n",
            "\n",
            "I have enclosed a short quality checklist here to accompany the application and how the application is always structured, so that you have a rough direction.\n",
            "\n",
            "We always have to describe a sentence about the state of the art, i.e. according to the current state of the art, this is done this way and that, then what the project goal is, then also the demarcation from the state of the art, to what extent the state of the art is expanded and the knowledge is expanded at your company and then finally what the project result should be.\n",
            "\n",
            "Perhaps you could just ask a few questions about the project, especially in relation to this Next Generation Sequencing.\n",
            "\n",
            "So let's put into perspective the extent to which you have already used it, to what extent it is a new technique for you, to what extent it is something new for detecting hereditary diseases in cats, dogs and horses.\n",
            "\n",
            "So now verbally or then for the application?\n",
            "\n",
            "Oral, oral.\n",
            "\n",
            "So now verbally or then for the application?\n",
            "\n",
            "Oral, oral.\n",
            "\n",
            "We formulate on the basis, that's why the recording is ongoing.\n",
            "\n",
            "We formulate the application from this.\n",
            "\n",
            "Okay, so then I would say that the current state of the art is that we are not yet using high-throughput technology to study the entire genetic markup of an animal.\n",
            "\n",
            "Instead, we mainly have individual tests and smaller products that are applied to breed-specific.  \n",
            "\n",
            "We are currently using next generation sequencing as a technology for DNA profiling.\n",
            "\n",
            "The main focus is on parentage analyses and the genetic fingerprint of animals.\n",
            "\n",
            "The aim of the project would then be what I formulated earlier, that it is primarily about animal health, of our own animal, but also of the species that we want to cover as a whole.\n",
            "\n",
            "State-of-the-art technology?  \n",
            "\n",
            "Above all, we are also expanding into larger genetic variants in this area.\n",
            "\n",
            "Class.\n",
            "\n",
            "Well, then I would like to go into the next point.\n",
            "\n",
            "The next point also relates to the differentiation from existing technologies in your company.\n",
            "\n",
            "It would be important for the auditor to classify whether you have ever dealt with Next Generation Sequencing in the company.\n",
            "\n",
            "If so, what is the difference here and if not, the This is perfectly adequate.\n",
            "\n",
            "Yes, we have had this, i.e. Next Generation Sequencing, in our company since 2020.\n",
            "\n",
            "And we are currently using it for genetic fingerprinting in dogs.  \n",
            "\n",
            "and to investigate genetic variability also in dogs.\n",
            "\n",
            "We do not yet have a product for cats, nor for horses, nor anything that is offered with hereditary diseases.\n",
            "\n",
            "Then it has to be implemented in the so-called panels with which the NGS technology works.\n",
            "\n",
            "One panel for each species.\n",
            "\n",
            "Then the third step would be the evaluation of the tests that we map.\n",
            "\n",
            "Of course, we also have to make sure that this should not only deliver the correct result from a technical point of view, but that it does.\n",
            "\n",
            "In other words, we have to compare the known animals with the results that we achieve with the new technology, with the NGS technology, and perhaps then bring the whole thing as fit for the work package in a way that is then understandable to the customer.\n",
            "\n",
            "We can't train them with 200 pages of text at the end.\n",
            "\n",
            "It has to be adapted to the different types of people so that they can do something with it.\n",
            "\n",
            "Wonderful, thank you very much.  \n",
            "\n",
            "In the end, could you rewrite the prototype a little better, i.e. the way in which it is understandable for the customer.\n",
            "\n",
            "Do you have a little better idea of what the end result should look like?\n",
            "\n",
            "Use the following information on the Leishmania disease research project.\n",
            "Next generation sequencing (NGS) technology transformed Leishmania genome studies and became an indispensable tool for Leishmania researchers. Recent Leishmania genomics analyses facilitated the discovery of various genetic diversities including single nucleotide polymorphisms (SNPs), copy number variations (CNVs), somy variations, and structural variations in detail and provided valuable insights into the complexity of the genome and gene regulation. Many aspects of Leishmania NGS analyses are similar to those of related pathogens like trypanosomes. However, the analyses of Leishmania genomes face a unique challenge because of the presence of frequent aneuploidy. This makes characterization and interpretation of read depth and somy a key part of Leishmania NGS analyses because read depth affects the accuracy of detection of all genetic variations. However, there are no general guidelines on how to explore and interpret the impact of aneuploidy, and this has made it difficult for biologists and bioinformaticians, especially for beginners, to perform their own analyses and interpret results across different analyses. In this guide we discuss a wide range of topics essential for Leishmania NGS analyses, ranging from how to set up a computational environment for genome analyses, to how to characterize genetic variations among Leishmania samples, and we will particularly focus on chromosomal copy number variation and its impact on genome analyses.\n",
            "we can somehow do it differently, so I would put that on the back burner at the moment, although it is actually the project that is retroactive, all the others are actually not retroactive from the time to But I would sit down with Mrs. Khnlein for the next three or four weeks and then I would give you feedback again. All right, so if we can change the focus, such as What is that? Mutations, exactly. We can integrate that relatively easily. But then just give me a message about it. Yes. Class. Wonderful. Then thank you very much, Mrs Kehl, for taking the time. And then I wish you a nice week. Same to you. Goodbye. Thank you. Goodbye.\n",
            "\n",
            "in the animal sector. If things go really badly, you can also grow the Leishmania in a cell culture and then examine the special hold, so to speak. But that would be very time-consuming, very expensive. You have to ask yourself whether you want to continue the project at all. In other words, one could actually also argue as a risk that the whole technique works for Leishmania in cell culture, but in the end the animal sample simply cannot be realized. Yes, right. Better. To the expenses. Do you know how many people are supposed to work on it? Yes, so we'll do it again via the HR department. In principle, I will have a relatively large number of hours there. Then a veterinarian from clinical chemistry has hours there and of course we still need a laboratory and I think there will be a second veterinarian from either my department or from clinical chemistry so that he can have contact with the veterinarians outside. All right, then just a rough overview, that is, four people to no idea ten to 15 percent perhaps. Yes, that's right.  Okay, do any subcontractors still come in here? So there will certainly be cooperations, but more with universities and then you don't really have any bills. So if you don't pay for the university, then that's not relevant. Yes yes exactly.  Yes, exactly, I'm just thinking so loudly. That's why I don't think so at the moment. Okay perfect, then I'm already through with my questions here too. Is there another project or would that be it for now?  I think that would be it for now. Completely new things will be added. The other thing with the infection scan, they had sent something again. I would only get the one sentence out.  Exactly, I wanted to talk to you about that, because of course we have to make sure that we fill in the text to see if there is perhaps a replacement for the deletion. I don't know what you're aiming for. I'll probably have to open this up again. Because it doesn't allow you to do that, just that's what IT is doing here today. Exactly, but I can also briefly share your e-mail otherwise. Yes, maybe that's the fastest way to do it. So, exactly. Yes, few screening with EDP Yes, few screening methods that result from dogs or cats. I don't know what they're actually going to pick up. We wanted to show a bit of the demarcations to the state of the art, i.e. how this is done according to statistics, i.e. how much of the statistics is not enough. So what we're doing is not screening methods, it's like, it's like packages. But that would have to be worded a little differently. If the dog's nose runs, then we just do herpes calypso, then there are already four or five typical pathogens that you do there.  So these are more like packages that are then specific to certain symptoms. But never cover everything that could be there. Maybe you can just rephrase it a bit. Yes, that means you actually have to have an initial guess and then you examine it specifically. But you don't study the entire genome. That's right, yes. Okay, let's rephrase. Well, we did it. Class. Yes, wonderful. Yes, we still had the one with the mutation, antimutation or whatever they called it. So with that I still have a bit of a stomach ache overall, because it is, actually already the case, that we have already established a lot of hereditary diseases and yes actually this prototype, as described earlier, has been there for a long time and we just keep expanding it with newly released things. Of course, we also expand our methods or the possibility of mapping these structural variants now, but I don't know if we can get that many hours together if I really concentrate on that. I have to talk to Mrs. Khler again, to my head of department, about how we can do that, whether we can perhaps somehow make a different focus, that we can somehow do it differently, so I would put that on the back burner at the moment, although it is actually the project that is retroactive, all the others are actually not retroactive from the\n",
            "\n",
            "Perfect, okay when we start again with the goal of the project. So I'm going to elaborate a bit, leishmania are parasites that are transmitted via various mosquitoes. This means that the dogs are bitten by the mosquitoes, then get these leishmanias, which then lead to leishmaniasis. And the whole thing can also affect people. At the moment, this is still a major problem in southern countries, i.e. southern Europe. However, due to climate change, of course, these mosquitoes are coming further and further north, which transmit these larch manias, so to speak, and sooner or later it will most likely become a problem in Germany. This means that the dog has the mosquito bites on these Leishmanias, picks up the eggs of it again and so on and so on. There are now various medications that are taken for the treatment of the dogs. However, these Leishmania develop resistance to it very quickly. Our goal now would be to get a sample from a dog, to prove that he has Leishmania and at the same time to examine these Leishmania to see if they already contain certain resistance genes, so that the doctor can then take the other drug instead of a drug, as is the case with the bacteria in the end, instead of giving the wrong drug,  On the one hand, this does not work, and on the other hand, it leads to the formation of even more resistant Leishmania in order to avoid this. That would be the goal, that you give the veterinarians a tool and say, send us a sample. We study the animal Leishmania and have these Leishmania that the animal has, resistance genes, in order to be able to say which drug is best. Wonderful thank you very much.  On what basis should the investigation of the resistance or the sample in general be carried out? There are already a few publications, there are many groups that are working on which genes are responsible for the resistances. There are already a few publications, there are many groups that are now working on which genes are now responsible for the resistance. There is often no change in the genes, but a copy number variation. So these genes are then either multiplied or they are no longer there at all and this leads to this resistance and this is to be investigated on the basis of these scientific publications. And what we also want to do is to use Next Generation Sequencing to examine the entire Leishmania genome, so to speak. So the first approach would be to search specifically for the genes that are in the publications. And we can also look at it again. In other words, we would then also ask the veterinarians again, are these dogs already treated, do you also see resistance to allopurinol, for example, and we can see, yes we also see what is written in the scientific publication, that this and that gene is more common or not. And then we also want to examine the complete genomes of the Leishmania to see if we can find more genes that are relevant. And that would simply make the product more attractive if you don't say, okay, I'm just looking for an allopurinol resistance or only for a Milteforan resistance, but I'll look at everything again and I can then tell you, yes such and such resistances are present and you don't need this and that at all. Perfect, thank you very much. Could you elaborate on how you ultimately want to characterize whether other genes are relevant if they are not yet published? Are there certain patterns that they then practically read out of the publications and then transferred to the rest of the moment, something has just happened to me. I don't see them properly anymore. So we would just take a close look at the whole thing via Next Generation Sequencing.  Yes, of course, because they are often also copy number variations, one would first focus on whether one sees something like this in other genes. But you would also look at variations like these SNPs, for example, to see whether or not you see them clustered in certain genes, in certain resistant Leishmania. And the characterization\n",
            "\n",
            "genes. But you would also look at variations like these SNPs, for example, to see whether or not you see them clustered in certain genes, in certain resistant Leishmania. And the characterization of which resistance refers to which drug intolerance or ineffectiveness, would you identify the series by existing knowledge, by consulting the veterinarians, or is there somehow a direct conclusion from the mode of action of the drug to the change in the genome? So, on the one hand, we would try to evaluate this by means of questionnaires or consultation with the veterinarians. These Leishmania can also be kept in cell culture. In other words, we could then create cell cultures of some samples from the Leishmanias, so to speak, and then there are in vitro tests to see whether these Leishmaniasis still respond to certain drugs or not. Similar to bacteria, where you put antibiotics on it and see if they are still growing or not. Something like this also exists for Leishmania in cell cultures. And then, of course, you can also look biochemically at what it does. Is it realistic that it somehow has a connection or not? There is then a certain term for this biochemical approach. So if there is a technical term for it, then they would have a few more numerical values, so for me what can be attached as an objective here difficult. To be honest, I can't think of anything in this case. On the other hand, sensitivity and specificity, so what is always a classic? Yes, that's just a problem in this case, because I don't know what my gold standard would be. So I always have to see what the veterinarians say. Well, I could just say that I want an 80 percent agreement. If the veterinarian says, yes, I see resistance there, then I want to see 80 percent of it in my test material, you could perhaps say that. Then maybe also related to the resistances, i.e. what is the 80 percent, this 80 percent value refers to the I can tell at all whether Leishmania is present, yes or no or I recognize resistance. I recognize resistances, i.e. Leishmania, which I have to recognize in any case, we already have other tests, that is already established, It is now really a matter of seeing whether they are resistant or not. So 80 percent. I would say that 80 percent of the samples that are described as resistant by veterinarians, I would then like to find a resistance gene, so to speak. Maybe you can put it that way. I thought that I thought that you would first detect this with an NLGS, so to speak, but you practically do that using classical methods. All right. Well, then I would like to go into the distinction from economic stuff.  shrink? How is it classically viewed and what is new now? There is still no test for these resistances. It is really done in such a way that the veterinarians then, if a Leishmania infection has been dismissed, they give just medication. There are quasi guidelines on how best to do this, so to speak, standard procedures and then they just observe the animal, they then measure again and again how high the leishmania load is and then adjust the medication accordingly, make higher concentration or take other medications. But an examination that tells them, take this and that, there's resistance there, otherwise there's no resistance at all. Wonderful, thank you very much. Is there anything else, so this is now in relation to resistance, perhaps briefly in relation to NGS, has this ever been used to study Leishmania in general? No, this has already been used, not with us, but there are publications about it that have just done it. On the one hand, there are different strains to differentiate them, according to epidemiological studies. And resistance has also been looked at, but this is a purely scientific publication. All right, then we can refer to the fact that NGES has so far been used purely for basic research, but not yet commercially. Yes.  Do you also know whether this is also the case, so here we not only have that the Leishmania is\n",
            "\n",
            "Using this as context\n",
            "\n",
            "Answer to the following question from a user regarding Leishmania disease project following given guidelines.\n",
            "Question: What is the Objective of the project (if applicable, in the context of the cooperative project) ?\n",
            "Guidelines: Motivation, objectives, and intended results. To what extent does the project aim to expand the state of knowledge/technology or utilize existing scientific, technical, economic, or other relevant findings or approaches\n",
            "\n",
            "        Try to include following points:\n",
            "        - 1 State of the art (Currently/According to the state of the art...)\n",
            "        - 1 Project objective (The goal of the project is...)\n",
            "        - 1 Differentiation from the state of the art (The state of the art is expanded...)\n",
            "        - in terms of..., thereby expanding the knowledge about...\n",
            "        - 1 Project result (The planned outcome/result is...)\n",
            "Please ensure that the project uses specific technical terminology to describe the innovative core. This is particularly crucial, especially for software projects.\n",
            "        \n",
            "Restrict output to ONLY 800 characters\n",
            "\n",
            "Answer:\u001b[0m\n",
            "\n",
            "\u001b[1m> Finished chain.\u001b[0m\n",
            "According to the state of the art, Leishmania infection and subsequent resistance development are currently treated using standard medication protocols with no specific genetic-based guidance. The project aims to utilize Next Generation Sequencing (NGS) technology to detect Leishmania and identify specific resistance genes, a novel approach in veterinary medicine. This expands the state of the art by integrating genomic data into treatment strategies, thus enhancing the understanding of Leishmania resistance mechanisms. The planned outcome is a specialized tool for veterinarians, facilitating targeted treatment of Leishmania infections based on the specific resistance genes identified.\n",
            "Length of response is 694 which is -106 characters above ideal\n",
            "####################################################################################################\n",
            "####################################################################################################\n",
            "Give me Description of tasks performed for the research (all forms of activities: in-house research)\n",
            "****************************************************************************************************\n",
            "Which work steps/tasks and methods are/were applied to achieve the objective? To what extent are novel approaches pursued (for your company and/or the industry)\n",
            "\n",
            "        Try to include following points:\n",
            "        - 3 to 4 sentences listing work package\n",
            "        - 1 concluding sentence about a new approach (A novel approach is employed in this regard.)\n",
            "        \n",
            "\n",
            "\n",
            "\u001b[1m> Entering new  chain...\u001b[0m\n",
            "Prompt after formatting:\n",
            "\u001b[32;1m\u001b[1;3mHuman: You are a research document summarizer that finds the answers to user query and give correct responses\n",
            "Note that the user is from a highly specialized technical background, use minimal layman terms in your responses\n",
            "\n",
            "Use the following background context information on the Leishmania disease research project.\n",
            "\n",
            "That's how I would sum it up now.\n",
            "\n",
            "I have enclosed a short quality checklist here to accompany the application and how the application is always structured, so that you have a rough direction.\n",
            "\n",
            "We always have to describe a sentence about the state of the art, i.e. according to the current state of the art, this is done this way and that, then what the project goal is, then also the demarcation from the state of the art, to what extent the state of the art is expanded and the knowledge is expanded at your company and then finally what the project result should be.\n",
            "\n",
            "Perhaps you could just ask a few questions about the project, especially in relation to this Next Generation Sequencing.\n",
            "\n",
            "So let's put into perspective the extent to which you have already used it, to what extent it is a new technique for you, to what extent it is something new for detecting hereditary diseases in cats, dogs and horses.\n",
            "\n",
            "So now verbally or then for the application?\n",
            "\n",
            "Oral, oral.\n",
            "\n",
            "So now verbally or then for the application?\n",
            "\n",
            "Oral, oral.\n",
            "\n",
            "We formulate on the basis, that's why the recording is ongoing.\n",
            "\n",
            "We formulate the application from this.\n",
            "\n",
            "Okay, so then I would say that the current state of the art is that we are not yet using high-throughput technology to study the entire genetic markup of an animal.\n",
            "\n",
            "Instead, we mainly have individual tests and smaller products that are applied to breed-specific.  \n",
            "\n",
            "We are currently using next generation sequencing as a technology for DNA profiling.\n",
            "\n",
            "The main focus is on parentage analyses and the genetic fingerprint of animals.\n",
            "\n",
            "The aim of the project would then be what I formulated earlier, that it is primarily about animal health, of our own animal, but also of the species that we want to cover as a whole.\n",
            "\n",
            "State-of-the-art technology?  \n",
            "\n",
            "Above all, we are also expanding into larger genetic variants in this area.\n",
            "\n",
            "Class.\n",
            "\n",
            "Well, then I would like to go into the next point.\n",
            "\n",
            "The next point also relates to the differentiation from existing technologies in your company.\n",
            "\n",
            "It would be important for the auditor to classify whether you have ever dealt with Next Generation Sequencing in the company.\n",
            "\n",
            "If so, what is the difference here and if not, the This is perfectly adequate.\n",
            "\n",
            "Yes, we have had this, i.e. Next Generation Sequencing, in our company since 2020.\n",
            "\n",
            "And we are currently using it for genetic fingerprinting in dogs.  \n",
            "\n",
            "and to investigate genetic variability also in dogs.\n",
            "\n",
            "We do not yet have a product for cats, nor for horses, nor anything that is offered with hereditary diseases.\n",
            "\n",
            "Then it has to be implemented in the so-called panels with which the NGS technology works.\n",
            "\n",
            "One panel for each species.\n",
            "\n",
            "Then the third step would be the evaluation of the tests that we map.\n",
            "\n",
            "Of course, we also have to make sure that this should not only deliver the correct result from a technical point of view, but that it does.\n",
            "\n",
            "In other words, we have to compare the known animals with the results that we achieve with the new technology, with the NGS technology, and perhaps then bring the whole thing as fit for the work package in a way that is then understandable to the customer.\n",
            "\n",
            "We can't train them with 200 pages of text at the end.\n",
            "\n",
            "It has to be adapted to the different types of people so that they can do something with it.\n",
            "\n",
            "Wonderful, thank you very much.  \n",
            "\n",
            "In the end, could you rewrite the prototype a little better, i.e. the way in which it is understandable for the customer.\n",
            "\n",
            "Do you have a little better idea of what the end result should look like?\n",
            "\n",
            "Use the following information on the Leishmania disease research project.\n",
            "Next generation sequencing (NGS) technology transformed Leishmania genome studies and became an indispensable tool for Leishmania researchers. Recent Leishmania genomics analyses facilitated the discovery of various genetic diversities including single nucleotide polymorphisms (SNPs), copy number variations (CNVs), somy variations, and structural variations in detail and provided valuable insights into the complexity of the genome and gene regulation. Many aspects of Leishmania NGS analyses are similar to those of related pathogens like trypanosomes. However, the analyses of Leishmania genomes face a unique challenge because of the presence of frequent aneuploidy. This makes characterization and interpretation of read depth and somy a key part of Leishmania NGS analyses because read depth affects the accuracy of detection of all genetic variations. However, there are no general guidelines on how to explore and interpret the impact of aneuploidy, and this has made it difficult for biologists and bioinformaticians, especially for beginners, to perform their own analyses and interpret results across different analyses. In this guide we discuss a wide range of topics essential for Leishmania NGS analyses, ranging from how to set up a computational environment for genome analyses, to how to characterize genetic variations among Leishmania samples, and we will particularly focus on chromosomal copy number variation and its impact on genome analyses.\n",
            "in the animal sector. If things go really badly, you can also grow the Leishmania in a cell culture and then examine the special hold, so to speak. But that would be very time-consuming, very expensive. You have to ask yourself whether you want to continue the project at all. In other words, one could actually also argue as a risk that the whole technique works for Leishmania in cell culture, but in the end the animal sample simply cannot be realized. Yes, right. Better. To the expenses. Do you know how many people are supposed to work on it? Yes, so we'll do it again via the HR department. In principle, I will have a relatively large number of hours there. Then a veterinarian from clinical chemistry has hours there and of course we still need a laboratory and I think there will be a second veterinarian from either my department or from clinical chemistry so that he can have contact with the veterinarians outside. All right, then just a rough overview, that is, four people to no idea ten to 15 percent perhaps. Yes, that's right.  Okay, do any subcontractors still come in here? So there will certainly be cooperations, but more with universities and then you don't really have any bills. So if you don't pay for the university, then that's not relevant. Yes yes exactly.  Yes, exactly, I'm just thinking so loudly. That's why I don't think so at the moment. Okay perfect, then I'm already through with my questions here too. Is there another project or would that be it for now?  I think that would be it for now. Completely new things will be added. The other thing with the infection scan, they had sent something again. I would only get the one sentence out.  Exactly, I wanted to talk to you about that, because of course we have to make sure that we fill in the text to see if there is perhaps a replacement for the deletion. I don't know what you're aiming for. I'll probably have to open this up again. Because it doesn't allow you to do that, just that's what IT is doing here today. Exactly, but I can also briefly share your e-mail otherwise. Yes, maybe that's the fastest way to do it. So, exactly. Yes, few screening with EDP Yes, few screening methods that result from dogs or cats. I don't know what they're actually going to pick up. We wanted to show a bit of the demarcations to the state of the art, i.e. how this is done according to statistics, i.e. how much of the statistics is not enough. So what we're doing is not screening methods, it's like, it's like packages. But that would have to be worded a little differently. If the dog's nose runs, then we just do herpes calypso, then there are already four or five typical pathogens that you do there.  So these are more like packages that are then specific to certain symptoms. But never cover everything that could be there. Maybe you can just rephrase it a bit. Yes, that means you actually have to have an initial guess and then you examine it specifically. But you don't study the entire genome. That's right, yes. Okay, let's rephrase. Well, we did it. Class. Yes, wonderful. Yes, we still had the one with the mutation, antimutation or whatever they called it. So with that I still have a bit of a stomach ache overall, because it is, actually already the case, that we have already established a lot of hereditary diseases and yes actually this prototype, as described earlier, has been there for a long time and we just keep expanding it with newly released things. Of course, we also expand our methods or the possibility of mapping these structural variants now, but I don't know if we can get that many hours together if I really concentrate on that. I have to talk to Mrs. Khler again, to my head of department, about how we can do that, whether we can perhaps somehow make a different focus, that we can somehow do it differently, so I would put that on the back burner at the moment, although it is actually the project that is retroactive, all the others are actually not retroactive from the\n",
            "\n",
            "we can somehow do it differently, so I would put that on the back burner at the moment, although it is actually the project that is retroactive, all the others are actually not retroactive from the time to But I would sit down with Mrs. Khnlein for the next three or four weeks and then I would give you feedback again. All right, so if we can change the focus, such as What is that? Mutations, exactly. We can integrate that relatively easily. But then just give me a message about it. Yes. Class. Wonderful. Then thank you very much, Mrs Kehl, for taking the time. And then I wish you a nice week. Same to you. Goodbye. Thank you. Goodbye.\n",
            "\n",
            "to the fact that NGES has so far been used purely for basic research, but not yet commercially. Yes.  Do you also know whether this is also the case, so here we not only have that the Leishmania is to be examined with NGS and that this is also to be characterized practically on the basis of an animal sample, so to speak, can this also be applied as a fight to existing NGS investigations? So, as I said, there is nothing at all in diagnostics. But now you mean basic research. Yes, that's where the Leishmania were always bred. In cell culture, only those were examined. That's right, that's another step that we also have to take, because we want to do this investigation directly from the sample, so to speak, and then we may have a lot of background through the genomic DNA again. That would be such a risk. Yes, perfect.  Perfect. Then the next chapter would be the differentiation from your technologies. Here we have to refer to Leishmania in general and then to NGS.  We detect Leishmania itself in various sample materials via classical PCA or real-time PCA, but we do not yet have any resistance genes. That would be the innovation, so to speak. And at the moment we are not doing any studies of any parasites about NGS, but we are doing these DNA profiles, as discussed earlier, from genomic DNA. But studies of parasites has not yet been. Or rather, this other project with Infecto-Scan, which is also going in this direction, but it is also completely under development, that we want to examine a sample and which pathogens are in it. All right: NGS could also point out that they not only examine animal samples, but also isolate Leishmania from them. Or at least for sample preparation. That makes a difference. You would then have to adjust the sample preparation so that mainly the parasite DNA is isolated so that it can be sequenced in a targeted manner. That you don't have so much background that it gets lost. That's also a sub-project of this Infecto-Scan, but it's more on viruses and they are parasites. Yes, all right, well, one can also say in general terms that for the first time parasites from animal material are to be characterized by NGS Yes, definitely. All right, then I would like to go back to the last point, namely the risks. Yes, so one risk is that several strains can occur within one animal. So they are often stung and can then carry different Leishmania strains in them, of which perhaps only one part is resistant and the other is not. You have to make sure that you really get everything pictured, that you can see this variant. That would be a risk. The second would be that the publications are not correct, because at the beginning we want to look specifically at the genes that are in the publications. It could be that there are errors in it, that we detect the genes, but that does not correlate with the clinic, i.e. there is actually no resistance at all. That could be. And if we then do NGS, it can of course be again, as with the infection scan, that we just have too much genomic DNA in it. We have to adapt all the preparations to these parasites beforehand. Or that we don't have the sensitivity to be able to map all resistance genes. Could you also quantify the sensitivity? Then we would have a numerical value here.  the sensitivity of the resistances then again. Yes, exactly. Yes, I mean, 80% sensitivity has always been something you actually strive for. Okay, well, what's a solution for them to bring out this genomic DNA, so that they bring out the genomic DNA as well as possible? It should also be tried out via Infectoscan whether there are methods to separate it.  The company Nanopore offers various recipes for this. But this, of course, is all for the human sphere. First of all, you have to see if this is also possible in the animal sector. If things go really badly, you can also grow the Leishmania in a cell culture and then examine the special hold, so to speak. But that would be very time-consuming, very\n",
            "\n",
            "genes. But you would also look at variations like these SNPs, for example, to see whether or not you see them clustered in certain genes, in certain resistant Leishmania. And the characterization of which resistance refers to which drug intolerance or ineffectiveness, would you identify the series by existing knowledge, by consulting the veterinarians, or is there somehow a direct conclusion from the mode of action of the drug to the change in the genome? So, on the one hand, we would try to evaluate this by means of questionnaires or consultation with the veterinarians. These Leishmania can also be kept in cell culture. In other words, we could then create cell cultures of some samples from the Leishmanias, so to speak, and then there are in vitro tests to see whether these Leishmaniasis still respond to certain drugs or not. Similar to bacteria, where you put antibiotics on it and see if they are still growing or not. Something like this also exists for Leishmania in cell cultures. And then, of course, you can also look biochemically at what it does. Is it realistic that it somehow has a connection or not? There is then a certain term for this biochemical approach. So if there is a technical term for it, then they would have a few more numerical values, so for me what can be attached as an objective here difficult. To be honest, I can't think of anything in this case. On the other hand, sensitivity and specificity, so what is always a classic? Yes, that's just a problem in this case, because I don't know what my gold standard would be. So I always have to see what the veterinarians say. Well, I could just say that I want an 80 percent agreement. If the veterinarian says, yes, I see resistance there, then I want to see 80 percent of it in my test material, you could perhaps say that. Then maybe also related to the resistances, i.e. what is the 80 percent, this 80 percent value refers to the I can tell at all whether Leishmania is present, yes or no or I recognize resistance. I recognize resistances, i.e. Leishmania, which I have to recognize in any case, we already have other tests, that is already established, It is now really a matter of seeing whether they are resistant or not. So 80 percent. I would say that 80 percent of the samples that are described as resistant by veterinarians, I would then like to find a resistance gene, so to speak. Maybe you can put it that way. I thought that I thought that you would first detect this with an NLGS, so to speak, but you practically do that using classical methods. All right. Well, then I would like to go into the distinction from economic stuff.  shrink? How is it classically viewed and what is new now? There is still no test for these resistances. It is really done in such a way that the veterinarians then, if a Leishmania infection has been dismissed, they give just medication. There are quasi guidelines on how best to do this, so to speak, standard procedures and then they just observe the animal, they then measure again and again how high the leishmania load is and then adjust the medication accordingly, make higher concentration or take other medications. But an examination that tells them, take this and that, there's resistance there, otherwise there's no resistance at all. Wonderful, thank you very much. Is there anything else, so this is now in relation to resistance, perhaps briefly in relation to NGS, has this ever been used to study Leishmania in general? No, this has already been used, not with us, but there are publications about it that have just done it. On the one hand, there are different strains to differentiate them, according to epidemiological studies. And resistance has also been looked at, but this is a purely scientific publication. All right, then we can refer to the fact that NGES has so far been used purely for basic research, but not yet commercially. Yes.  Do you also know whether this is also the case, so here we not only have that the Leishmania is\n",
            "\n",
            "Using this as context\n",
            "\n",
            "Answer to the following question from a user regarding Leishmania disease project following given guidelines.\n",
            "Question: Give me Description of tasks performed for the research (all forms of activities: in-house research)\n",
            "Guidelines: Which work steps/tasks and methods are/were applied to achieve the objective? To what extent are novel approaches pursued (for your company and/or the industry)\n",
            "\n",
            "        Try to include following points:\n",
            "        - 3 to 4 sentences listing work package\n",
            "        - 1 concluding sentence about a new approach (A novel approach is employed in this regard.)\n",
            "        \n",
            "Restrict output to ONLY 800 characters\n",
            "\n",
            "Answer:\u001b[0m\n",
            "\n",
            "\u001b[1m> Finished chain.\u001b[0m\n",
            "The project involves various tasks including the next-generation sequencing (NGS) of Leishmania genomes, the identification of genetic variations, and the impact of aneuploidy on genome analyses. Tasks also involve setting up computational environments for genome analyses and characterizing genetic variations among Leishmania samples. The project also focuses on the differentiation of our technologies from existing ones, primarily centered on resistance detection. A novel approach is employed in this regard, extending NGS from basic research to commercial application for the diagnosis of Leishmania resistance.\n",
            "Length of response is 617 which is -183 characters above ideal\n",
            "####################################################################################################\n",
            "####################################################################################################\n",
            "Does the project aim to develop a product, production process, production line, service, or scientific methodology that represents a significant advancement/novelty in the relevant industry?\n",
            "****************************************************************************************************\n",
            "If yes, please explain. Provide a brief description of the research or development status of the industry and differentiate your product, production process, production line, service, or scientific methodology from it. Describe any new scientific/technical methods, approaches, or procedures being utilized. (Examples include experiments, field studies, observations, cohort studies.\n",
            "\n",
            "        Try to include following points:\n",
            "        - 1 sentence specifying target sector/product category and differentiation from the state of the art (The project aims to target... which are intended to surpass the state of the art in terms of...\n",
            "        - 2 to 4 sentences differentiating from the state of the art with approximately 2 parameters for differentiation.\n",
            "        \n",
            "\n",
            "\n",
            "\u001b[1m> Entering new  chain...\u001b[0m\n",
            "Prompt after formatting:\n",
            "\u001b[32;1m\u001b[1;3mHuman: You are a research document summarizer that finds the answers to user query and give correct responses\n",
            "Note that the user is from a highly specialized technical background, use minimal layman terms in your responses\n",
            "\n",
            "Use the following background context information on the Leishmania disease research project.\n",
            "\n",
            "That's how I would sum it up now.\n",
            "\n",
            "I have enclosed a short quality checklist here to accompany the application and how the application is always structured, so that you have a rough direction.\n",
            "\n",
            "We always have to describe a sentence about the state of the art, i.e. according to the current state of the art, this is done this way and that, then what the project goal is, then also the demarcation from the state of the art, to what extent the state of the art is expanded and the knowledge is expanded at your company and then finally what the project result should be.\n",
            "\n",
            "Perhaps you could just ask a few questions about the project, especially in relation to this Next Generation Sequencing.\n",
            "\n",
            "So let's put into perspective the extent to which you have already used it, to what extent it is a new technique for you, to what extent it is something new for detecting hereditary diseases in cats, dogs and horses.\n",
            "\n",
            "So now verbally or then for the application?\n",
            "\n",
            "Oral, oral.\n",
            "\n",
            "So now verbally or then for the application?\n",
            "\n",
            "Oral, oral.\n",
            "\n",
            "We formulate on the basis, that's why the recording is ongoing.\n",
            "\n",
            "We formulate the application from this.\n",
            "\n",
            "Okay, so then I would say that the current state of the art is that we are not yet using high-throughput technology to study the entire genetic markup of an animal.\n",
            "\n",
            "Instead, we mainly have individual tests and smaller products that are applied to breed-specific.  \n",
            "\n",
            "We are currently using next generation sequencing as a technology for DNA profiling.\n",
            "\n",
            "The main focus is on parentage analyses and the genetic fingerprint of animals.\n",
            "\n",
            "The aim of the project would then be what I formulated earlier, that it is primarily about animal health, of our own animal, but also of the species that we want to cover as a whole.\n",
            "\n",
            "State-of-the-art technology?  \n",
            "\n",
            "Above all, we are also expanding into larger genetic variants in this area.\n",
            "\n",
            "Class.\n",
            "\n",
            "Well, then I would like to go into the next point.\n",
            "\n",
            "The next point also relates to the differentiation from existing technologies in your company.\n",
            "\n",
            "It would be important for the auditor to classify whether you have ever dealt with Next Generation Sequencing in the company.\n",
            "\n",
            "If so, what is the difference here and if not, the This is perfectly adequate.\n",
            "\n",
            "Yes, we have had this, i.e. Next Generation Sequencing, in our company since 2020.\n",
            "\n",
            "And we are currently using it for genetic fingerprinting in dogs.  \n",
            "\n",
            "and to investigate genetic variability also in dogs.\n",
            "\n",
            "We do not yet have a product for cats, nor for horses, nor anything that is offered with hereditary diseases.\n",
            "\n",
            "Then it has to be implemented in the so-called panels with which the NGS technology works.\n",
            "\n",
            "One panel for each species.\n",
            "\n",
            "Then the third step would be the evaluation of the tests that we map.\n",
            "\n",
            "Of course, we also have to make sure that this should not only deliver the correct result from a technical point of view, but that it does.\n",
            "\n",
            "In other words, we have to compare the known animals with the results that we achieve with the new technology, with the NGS technology, and perhaps then bring the whole thing as fit for the work package in a way that is then understandable to the customer.\n",
            "\n",
            "We can't train them with 200 pages of text at the end.\n",
            "\n",
            "It has to be adapted to the different types of people so that they can do something with it.\n",
            "\n",
            "Wonderful, thank you very much.  \n",
            "\n",
            "In the end, could you rewrite the prototype a little better, i.e. the way in which it is understandable for the customer.\n",
            "\n",
            "Do you have a little better idea of what the end result should look like?\n",
            "\n",
            "Use the following information on the Leishmania disease research project.\n",
            "Next generation sequencing (NGS) technology transformed Leishmania genome studies and became an indispensable tool for Leishmania researchers. Recent Leishmania genomics analyses facilitated the discovery of various genetic diversities including single nucleotide polymorphisms (SNPs), copy number variations (CNVs), somy variations, and structural variations in detail and provided valuable insights into the complexity of the genome and gene regulation. Many aspects of Leishmania NGS analyses are similar to those of related pathogens like trypanosomes. However, the analyses of Leishmania genomes face a unique challenge because of the presence of frequent aneuploidy. This makes characterization and interpretation of read depth and somy a key part of Leishmania NGS analyses because read depth affects the accuracy of detection of all genetic variations. However, there are no general guidelines on how to explore and interpret the impact of aneuploidy, and this has made it difficult for biologists and bioinformaticians, especially for beginners, to perform their own analyses and interpret results across different analyses. In this guide we discuss a wide range of topics essential for Leishmania NGS analyses, ranging from how to set up a computational environment for genome analyses, to how to characterize genetic variations among Leishmania samples, and we will particularly focus on chromosomal copy number variation and its impact on genome analyses.\n",
            "in the animal sector. If things go really badly, you can also grow the Leishmania in a cell culture and then examine the special hold, so to speak. But that would be very time-consuming, very expensive. You have to ask yourself whether you want to continue the project at all. In other words, one could actually also argue as a risk that the whole technique works for Leishmania in cell culture, but in the end the animal sample simply cannot be realized. Yes, right. Better. To the expenses. Do you know how many people are supposed to work on it? Yes, so we'll do it again via the HR department. In principle, I will have a relatively large number of hours there. Then a veterinarian from clinical chemistry has hours there and of course we still need a laboratory and I think there will be a second veterinarian from either my department or from clinical chemistry so that he can have contact with the veterinarians outside. All right, then just a rough overview, that is, four people to no idea ten to 15 percent perhaps. Yes, that's right.  Okay, do any subcontractors still come in here? So there will certainly be cooperations, but more with universities and then you don't really have any bills. So if you don't pay for the university, then that's not relevant. Yes yes exactly.  Yes, exactly, I'm just thinking so loudly. That's why I don't think so at the moment. Okay perfect, then I'm already through with my questions here too. Is there another project or would that be it for now?  I think that would be it for now. Completely new things will be added. The other thing with the infection scan, they had sent something again. I would only get the one sentence out.  Exactly, I wanted to talk to you about that, because of course we have to make sure that we fill in the text to see if there is perhaps a replacement for the deletion. I don't know what you're aiming for. I'll probably have to open this up again. Because it doesn't allow you to do that, just that's what IT is doing here today. Exactly, but I can also briefly share your e-mail otherwise. Yes, maybe that's the fastest way to do it. So, exactly. Yes, few screening with EDP Yes, few screening methods that result from dogs or cats. I don't know what they're actually going to pick up. We wanted to show a bit of the demarcations to the state of the art, i.e. how this is done according to statistics, i.e. how much of the statistics is not enough. So what we're doing is not screening methods, it's like, it's like packages. But that would have to be worded a little differently. If the dog's nose runs, then we just do herpes calypso, then there are already four or five typical pathogens that you do there.  So these are more like packages that are then specific to certain symptoms. But never cover everything that could be there. Maybe you can just rephrase it a bit. Yes, that means you actually have to have an initial guess and then you examine it specifically. But you don't study the entire genome. That's right, yes. Okay, let's rephrase. Well, we did it. Class. Yes, wonderful. Yes, we still had the one with the mutation, antimutation or whatever they called it. So with that I still have a bit of a stomach ache overall, because it is, actually already the case, that we have already established a lot of hereditary diseases and yes actually this prototype, as described earlier, has been there for a long time and we just keep expanding it with newly released things. Of course, we also expand our methods or the possibility of mapping these structural variants now, but I don't know if we can get that many hours together if I really concentrate on that. I have to talk to Mrs. Khler again, to my head of department, about how we can do that, whether we can perhaps somehow make a different focus, that we can somehow do it differently, so I would put that on the back burner at the moment, although it is actually the project that is retroactive, all the others are actually not retroactive from the\n",
            "\n",
            "we can somehow do it differently, so I would put that on the back burner at the moment, although it is actually the project that is retroactive, all the others are actually not retroactive from the time to But I would sit down with Mrs. Khnlein for the next three or four weeks and then I would give you feedback again. All right, so if we can change the focus, such as What is that? Mutations, exactly. We can integrate that relatively easily. But then just give me a message about it. Yes. Class. Wonderful. Then thank you very much, Mrs Kehl, for taking the time. And then I wish you a nice week. Same to you. Goodbye. Thank you. Goodbye.\n",
            "\n",
            "to the fact that NGES has so far been used purely for basic research, but not yet commercially. Yes.  Do you also know whether this is also the case, so here we not only have that the Leishmania is to be examined with NGS and that this is also to be characterized practically on the basis of an animal sample, so to speak, can this also be applied as a fight to existing NGS investigations? So, as I said, there is nothing at all in diagnostics. But now you mean basic research. Yes, that's where the Leishmania were always bred. In cell culture, only those were examined. That's right, that's another step that we also have to take, because we want to do this investigation directly from the sample, so to speak, and then we may have a lot of background through the genomic DNA again. That would be such a risk. Yes, perfect.  Perfect. Then the next chapter would be the differentiation from your technologies. Here we have to refer to Leishmania in general and then to NGS.  We detect Leishmania itself in various sample materials via classical PCA or real-time PCA, but we do not yet have any resistance genes. That would be the innovation, so to speak. And at the moment we are not doing any studies of any parasites about NGS, but we are doing these DNA profiles, as discussed earlier, from genomic DNA. But studies of parasites has not yet been. Or rather, this other project with Infecto-Scan, which is also going in this direction, but it is also completely under development, that we want to examine a sample and which pathogens are in it. All right: NGS could also point out that they not only examine animal samples, but also isolate Leishmania from them. Or at least for sample preparation. That makes a difference. You would then have to adjust the sample preparation so that mainly the parasite DNA is isolated so that it can be sequenced in a targeted manner. That you don't have so much background that it gets lost. That's also a sub-project of this Infecto-Scan, but it's more on viruses and they are parasites. Yes, all right, well, one can also say in general terms that for the first time parasites from animal material are to be characterized by NGS Yes, definitely. All right, then I would like to go back to the last point, namely the risks. Yes, so one risk is that several strains can occur within one animal. So they are often stung and can then carry different Leishmania strains in them, of which perhaps only one part is resistant and the other is not. You have to make sure that you really get everything pictured, that you can see this variant. That would be a risk. The second would be that the publications are not correct, because at the beginning we want to look specifically at the genes that are in the publications. It could be that there are errors in it, that we detect the genes, but that does not correlate with the clinic, i.e. there is actually no resistance at all. That could be. And if we then do NGS, it can of course be again, as with the infection scan, that we just have too much genomic DNA in it. We have to adapt all the preparations to these parasites beforehand. Or that we don't have the sensitivity to be able to map all resistance genes. Could you also quantify the sensitivity? Then we would have a numerical value here.  the sensitivity of the resistances then again. Yes, exactly. Yes, I mean, 80% sensitivity has always been something you actually strive for. Okay, well, what's a solution for them to bring out this genomic DNA, so that they bring out the genomic DNA as well as possible? It should also be tried out via Infectoscan whether there are methods to separate it.  The company Nanopore offers various recipes for this. But this, of course, is all for the human sphere. First of all, you have to see if this is also possible in the animal sector. If things go really badly, you can also grow the Leishmania in a cell culture and then examine the special hold, so to speak. But that would be very time-consuming, very\n",
            "\n",
            "genes. But you would also look at variations like these SNPs, for example, to see whether or not you see them clustered in certain genes, in certain resistant Leishmania. And the characterization of which resistance refers to which drug intolerance or ineffectiveness, would you identify the series by existing knowledge, by consulting the veterinarians, or is there somehow a direct conclusion from the mode of action of the drug to the change in the genome? So, on the one hand, we would try to evaluate this by means of questionnaires or consultation with the veterinarians. These Leishmania can also be kept in cell culture. In other words, we could then create cell cultures of some samples from the Leishmanias, so to speak, and then there are in vitro tests to see whether these Leishmaniasis still respond to certain drugs or not. Similar to bacteria, where you put antibiotics on it and see if they are still growing or not. Something like this also exists for Leishmania in cell cultures. And then, of course, you can also look biochemically at what it does. Is it realistic that it somehow has a connection or not? There is then a certain term for this biochemical approach. So if there is a technical term for it, then they would have a few more numerical values, so for me what can be attached as an objective here difficult. To be honest, I can't think of anything in this case. On the other hand, sensitivity and specificity, so what is always a classic? Yes, that's just a problem in this case, because I don't know what my gold standard would be. So I always have to see what the veterinarians say. Well, I could just say that I want an 80 percent agreement. If the veterinarian says, yes, I see resistance there, then I want to see 80 percent of it in my test material, you could perhaps say that. Then maybe also related to the resistances, i.e. what is the 80 percent, this 80 percent value refers to the I can tell at all whether Leishmania is present, yes or no or I recognize resistance. I recognize resistances, i.e. Leishmania, which I have to recognize in any case, we already have other tests, that is already established, It is now really a matter of seeing whether they are resistant or not. So 80 percent. I would say that 80 percent of the samples that are described as resistant by veterinarians, I would then like to find a resistance gene, so to speak. Maybe you can put it that way. I thought that I thought that you would first detect this with an NLGS, so to speak, but you practically do that using classical methods. All right. Well, then I would like to go into the distinction from economic stuff.  shrink? How is it classically viewed and what is new now? There is still no test for these resistances. It is really done in such a way that the veterinarians then, if a Leishmania infection has been dismissed, they give just medication. There are quasi guidelines on how best to do this, so to speak, standard procedures and then they just observe the animal, they then measure again and again how high the leishmania load is and then adjust the medication accordingly, make higher concentration or take other medications. But an examination that tells them, take this and that, there's resistance there, otherwise there's no resistance at all. Wonderful, thank you very much. Is there anything else, so this is now in relation to resistance, perhaps briefly in relation to NGS, has this ever been used to study Leishmania in general? No, this has already been used, not with us, but there are publications about it that have just done it. On the one hand, there are different strains to differentiate them, according to epidemiological studies. And resistance has also been looked at, but this is a purely scientific publication. All right, then we can refer to the fact that NGES has so far been used purely for basic research, but not yet commercially. Yes.  Do you also know whether this is also the case, so here we not only have that the Leishmania is\n",
            "\n",
            "Using this as context\n",
            "\n",
            "Answer to the following question from a user regarding Leishmania disease project following given guidelines.\n",
            "Question: Does the project aim to develop a product, production process, production line, service, or scientific methodology that represents a significant advancement/novelty in the relevant industry?\n",
            "Guidelines: If yes, please explain. Provide a brief description of the research or development status of the industry and differentiate your product, production process, production line, service, or scientific methodology from it. Describe any new scientific/technical methods, approaches, or procedures being utilized. (Examples include experiments, field studies, observations, cohort studies.\n",
            "\n",
            "        Try to include following points:\n",
            "        - 1 sentence specifying target sector/product category and differentiation from the state of the art (The project aims to target... which are intended to surpass the state of the art in terms of...\n",
            "        - 2 to 4 sentences differentiating from the state of the art with approximately 2 parameters for differentiation.\n",
            "        \n",
            "Restrict output to ONLY 800 characters\n",
            "\n",
            "Answer:\u001b[0m\n",
            "\n",
            "\u001b[1m> Finished chain.\u001b[0m\n",
            "Yes, the project aims to develop a novel application of Next Generation Sequencing (NGS) for detecting hereditary diseases in cats, dogs, and horses, focusing primarily on Leishmania disease. This technique represents a significant advancement in the veterinary diagnostics sector. Currently, the state of the art involves the use of individual tests and smaller breed-specific products, without high-throughput technology to study the entire genetic makeup of an animal. The project will enable us to move beyond current limitations by utilizing NGS for comprehensive DNA profiling and specific detection of Leishmania resistance genes directly from animal samples. This novel approach will expand our knowledge and improve animal health management.\n",
            "Length of response is 750 which is -50 characters above ideal\n",
            "####################################################################################################\n",
            "####################################################################################################\n",
            "Is there a specific connection between the project and existing products, production lines, production processes, services, or already established scientific methodology within your company?\n",
            "****************************************************************************************************\n",
            "If yes, please clarify to what extent the work of the project goes beyond routine development activities in your company. Explain the differentiation from existing products, production lines, production processes, and services within the company. How does the product, process, or service to be developed differ from those already offered by your company ?\n",
            "\n",
            "        Try to include following points:\n",
            "        - 1 sentence about current technologies in the company\n",
            "        - 1 sentence differentiating functionality (For the first time...)\n",
            "        - 2 to 4 sentences differentiating functionality and development methods\n",
            "        \n",
            "\n",
            "\n",
            "\u001b[1m> Entering new  chain...\u001b[0m\n",
            "Prompt after formatting:\n",
            "\u001b[32;1m\u001b[1;3mHuman: You are a research document summarizer that finds the answers to user query and give correct responses\n",
            "Note that the user is from a highly specialized technical background, use minimal layman terms in your responses\n",
            "\n",
            "Use the following background context information on the Leishmania disease research project.\n",
            "\n",
            "That's how I would sum it up now.\n",
            "\n",
            "I have enclosed a short quality checklist here to accompany the application and how the application is always structured, so that you have a rough direction.\n",
            "\n",
            "We always have to describe a sentence about the state of the art, i.e. according to the current state of the art, this is done this way and that, then what the project goal is, then also the demarcation from the state of the art, to what extent the state of the art is expanded and the knowledge is expanded at your company and then finally what the project result should be.\n",
            "\n",
            "Perhaps you could just ask a few questions about the project, especially in relation to this Next Generation Sequencing.\n",
            "\n",
            "So let's put into perspective the extent to which you have already used it, to what extent it is a new technique for you, to what extent it is something new for detecting hereditary diseases in cats, dogs and horses.\n",
            "\n",
            "So now verbally or then for the application?\n",
            "\n",
            "Oral, oral.\n",
            "\n",
            "So now verbally or then for the application?\n",
            "\n",
            "Oral, oral.\n",
            "\n",
            "We formulate on the basis, that's why the recording is ongoing.\n",
            "\n",
            "We formulate the application from this.\n",
            "\n",
            "Okay, so then I would say that the current state of the art is that we are not yet using high-throughput technology to study the entire genetic markup of an animal.\n",
            "\n",
            "Instead, we mainly have individual tests and smaller products that are applied to breed-specific.  \n",
            "\n",
            "We are currently using next generation sequencing as a technology for DNA profiling.\n",
            "\n",
            "The main focus is on parentage analyses and the genetic fingerprint of animals.\n",
            "\n",
            "The aim of the project would then be what I formulated earlier, that it is primarily about animal health, of our own animal, but also of the species that we want to cover as a whole.\n",
            "\n",
            "State-of-the-art technology?  \n",
            "\n",
            "Above all, we are also expanding into larger genetic variants in this area.\n",
            "\n",
            "Class.\n",
            "\n",
            "Well, then I would like to go into the next point.\n",
            "\n",
            "The next point also relates to the differentiation from existing technologies in your company.\n",
            "\n",
            "It would be important for the auditor to classify whether you have ever dealt with Next Generation Sequencing in the company.\n",
            "\n",
            "If so, what is the difference here and if not, the This is perfectly adequate.\n",
            "\n",
            "Yes, we have had this, i.e. Next Generation Sequencing, in our company since 2020.\n",
            "\n",
            "And we are currently using it for genetic fingerprinting in dogs.  \n",
            "\n",
            "and to investigate genetic variability also in dogs.\n",
            "\n",
            "We do not yet have a product for cats, nor for horses, nor anything that is offered with hereditary diseases.\n",
            "\n",
            "Then it has to be implemented in the so-called panels with which the NGS technology works.\n",
            "\n",
            "One panel for each species.\n",
            "\n",
            "Then the third step would be the evaluation of the tests that we map.\n",
            "\n",
            "Of course, we also have to make sure that this should not only deliver the correct result from a technical point of view, but that it does.\n",
            "\n",
            "In other words, we have to compare the known animals with the results that we achieve with the new technology, with the NGS technology, and perhaps then bring the whole thing as fit for the work package in a way that is then understandable to the customer.\n",
            "\n",
            "We can't train them with 200 pages of text at the end.\n",
            "\n",
            "It has to be adapted to the different types of people so that they can do something with it.\n",
            "\n",
            "Wonderful, thank you very much.  \n",
            "\n",
            "In the end, could you rewrite the prototype a little better, i.e. the way in which it is understandable for the customer.\n",
            "\n",
            "Do you have a little better idea of what the end result should look like?\n",
            "\n",
            "Use the following information on the Leishmania disease research project.\n",
            "Next generation sequencing (NGS) technology transformed Leishmania genome studies and became an indispensable tool for Leishmania researchers. Recent Leishmania genomics analyses facilitated the discovery of various genetic diversities including single nucleotide polymorphisms (SNPs), copy number variations (CNVs), somy variations, and structural variations in detail and provided valuable insights into the complexity of the genome and gene regulation. Many aspects of Leishmania NGS analyses are similar to those of related pathogens like trypanosomes. However, the analyses of Leishmania genomes face a unique challenge because of the presence of frequent aneuploidy. This makes characterization and interpretation of read depth and somy a key part of Leishmania NGS analyses because read depth affects the accuracy of detection of all genetic variations. However, there are no general guidelines on how to explore and interpret the impact of aneuploidy, and this has made it difficult for biologists and bioinformaticians, especially for beginners, to perform their own analyses and interpret results across different analyses. In this guide we discuss a wide range of topics essential for Leishmania NGS analyses, ranging from how to set up a computational environment for genome analyses, to how to characterize genetic variations among Leishmania samples, and we will particularly focus on chromosomal copy number variation and its impact on genome analyses.\n",
            "in the animal sector. If things go really badly, you can also grow the Leishmania in a cell culture and then examine the special hold, so to speak. But that would be very time-consuming, very expensive. You have to ask yourself whether you want to continue the project at all. In other words, one could actually also argue as a risk that the whole technique works for Leishmania in cell culture, but in the end the animal sample simply cannot be realized. Yes, right. Better. To the expenses. Do you know how many people are supposed to work on it? Yes, so we'll do it again via the HR department. In principle, I will have a relatively large number of hours there. Then a veterinarian from clinical chemistry has hours there and of course we still need a laboratory and I think there will be a second veterinarian from either my department or from clinical chemistry so that he can have contact with the veterinarians outside. All right, then just a rough overview, that is, four people to no idea ten to 15 percent perhaps. Yes, that's right.  Okay, do any subcontractors still come in here? So there will certainly be cooperations, but more with universities and then you don't really have any bills. So if you don't pay for the university, then that's not relevant. Yes yes exactly.  Yes, exactly, I'm just thinking so loudly. That's why I don't think so at the moment. Okay perfect, then I'm already through with my questions here too. Is there another project or would that be it for now?  I think that would be it for now. Completely new things will be added. The other thing with the infection scan, they had sent something again. I would only get the one sentence out.  Exactly, I wanted to talk to you about that, because of course we have to make sure that we fill in the text to see if there is perhaps a replacement for the deletion. I don't know what you're aiming for. I'll probably have to open this up again. Because it doesn't allow you to do that, just that's what IT is doing here today. Exactly, but I can also briefly share your e-mail otherwise. Yes, maybe that's the fastest way to do it. So, exactly. Yes, few screening with EDP Yes, few screening methods that result from dogs or cats. I don't know what they're actually going to pick up. We wanted to show a bit of the demarcations to the state of the art, i.e. how this is done according to statistics, i.e. how much of the statistics is not enough. So what we're doing is not screening methods, it's like, it's like packages. But that would have to be worded a little differently. If the dog's nose runs, then we just do herpes calypso, then there are already four or five typical pathogens that you do there.  So these are more like packages that are then specific to certain symptoms. But never cover everything that could be there. Maybe you can just rephrase it a bit. Yes, that means you actually have to have an initial guess and then you examine it specifically. But you don't study the entire genome. That's right, yes. Okay, let's rephrase. Well, we did it. Class. Yes, wonderful. Yes, we still had the one with the mutation, antimutation or whatever they called it. So with that I still have a bit of a stomach ache overall, because it is, actually already the case, that we have already established a lot of hereditary diseases and yes actually this prototype, as described earlier, has been there for a long time and we just keep expanding it with newly released things. Of course, we also expand our methods or the possibility of mapping these structural variants now, but I don't know if we can get that many hours together if I really concentrate on that. I have to talk to Mrs. Khler again, to my head of department, about how we can do that, whether we can perhaps somehow make a different focus, that we can somehow do it differently, so I would put that on the back burner at the moment, although it is actually the project that is retroactive, all the others are actually not retroactive from the\n",
            "\n",
            "we can somehow do it differently, so I would put that on the back burner at the moment, although it is actually the project that is retroactive, all the others are actually not retroactive from the time to But I would sit down with Mrs. Khnlein for the next three or four weeks and then I would give you feedback again. All right, so if we can change the focus, such as What is that? Mutations, exactly. We can integrate that relatively easily. But then just give me a message about it. Yes. Class. Wonderful. Then thank you very much, Mrs Kehl, for taking the time. And then I wish you a nice week. Same to you. Goodbye. Thank you. Goodbye.\n",
            "\n",
            "to the fact that NGES has so far been used purely for basic research, but not yet commercially. Yes.  Do you also know whether this is also the case, so here we not only have that the Leishmania is to be examined with NGS and that this is also to be characterized practically on the basis of an animal sample, so to speak, can this also be applied as a fight to existing NGS investigations? So, as I said, there is nothing at all in diagnostics. But now you mean basic research. Yes, that's where the Leishmania were always bred. In cell culture, only those were examined. That's right, that's another step that we also have to take, because we want to do this investigation directly from the sample, so to speak, and then we may have a lot of background through the genomic DNA again. That would be such a risk. Yes, perfect.  Perfect. Then the next chapter would be the differentiation from your technologies. Here we have to refer to Leishmania in general and then to NGS.  We detect Leishmania itself in various sample materials via classical PCA or real-time PCA, but we do not yet have any resistance genes. That would be the innovation, so to speak. And at the moment we are not doing any studies of any parasites about NGS, but we are doing these DNA profiles, as discussed earlier, from genomic DNA. But studies of parasites has not yet been. Or rather, this other project with Infecto-Scan, which is also going in this direction, but it is also completely under development, that we want to examine a sample and which pathogens are in it. All right: NGS could also point out that they not only examine animal samples, but also isolate Leishmania from them. Or at least for sample preparation. That makes a difference. You would then have to adjust the sample preparation so that mainly the parasite DNA is isolated so that it can be sequenced in a targeted manner. That you don't have so much background that it gets lost. That's also a sub-project of this Infecto-Scan, but it's more on viruses and they are parasites. Yes, all right, well, one can also say in general terms that for the first time parasites from animal material are to be characterized by NGS Yes, definitely. All right, then I would like to go back to the last point, namely the risks. Yes, so one risk is that several strains can occur within one animal. So they are often stung and can then carry different Leishmania strains in them, of which perhaps only one part is resistant and the other is not. You have to make sure that you really get everything pictured, that you can see this variant. That would be a risk. The second would be that the publications are not correct, because at the beginning we want to look specifically at the genes that are in the publications. It could be that there are errors in it, that we detect the genes, but that does not correlate with the clinic, i.e. there is actually no resistance at all. That could be. And if we then do NGS, it can of course be again, as with the infection scan, that we just have too much genomic DNA in it. We have to adapt all the preparations to these parasites beforehand. Or that we don't have the sensitivity to be able to map all resistance genes. Could you also quantify the sensitivity? Then we would have a numerical value here.  the sensitivity of the resistances then again. Yes, exactly. Yes, I mean, 80% sensitivity has always been something you actually strive for. Okay, well, what's a solution for them to bring out this genomic DNA, so that they bring out the genomic DNA as well as possible? It should also be tried out via Infectoscan whether there are methods to separate it.  The company Nanopore offers various recipes for this. But this, of course, is all for the human sphere. First of all, you have to see if this is also possible in the animal sector. If things go really badly, you can also grow the Leishmania in a cell culture and then examine the special hold, so to speak. But that would be very time-consuming, very\n",
            "\n",
            "genes. But you would also look at variations like these SNPs, for example, to see whether or not you see them clustered in certain genes, in certain resistant Leishmania. And the characterization of which resistance refers to which drug intolerance or ineffectiveness, would you identify the series by existing knowledge, by consulting the veterinarians, or is there somehow a direct conclusion from the mode of action of the drug to the change in the genome? So, on the one hand, we would try to evaluate this by means of questionnaires or consultation with the veterinarians. These Leishmania can also be kept in cell culture. In other words, we could then create cell cultures of some samples from the Leishmanias, so to speak, and then there are in vitro tests to see whether these Leishmaniasis still respond to certain drugs or not. Similar to bacteria, where you put antibiotics on it and see if they are still growing or not. Something like this also exists for Leishmania in cell cultures. And then, of course, you can also look biochemically at what it does. Is it realistic that it somehow has a connection or not? There is then a certain term for this biochemical approach. So if there is a technical term for it, then they would have a few more numerical values, so for me what can be attached as an objective here difficult. To be honest, I can't think of anything in this case. On the other hand, sensitivity and specificity, so what is always a classic? Yes, that's just a problem in this case, because I don't know what my gold standard would be. So I always have to see what the veterinarians say. Well, I could just say that I want an 80 percent agreement. If the veterinarian says, yes, I see resistance there, then I want to see 80 percent of it in my test material, you could perhaps say that. Then maybe also related to the resistances, i.e. what is the 80 percent, this 80 percent value refers to the I can tell at all whether Leishmania is present, yes or no or I recognize resistance. I recognize resistances, i.e. Leishmania, which I have to recognize in any case, we already have other tests, that is already established, It is now really a matter of seeing whether they are resistant or not. So 80 percent. I would say that 80 percent of the samples that are described as resistant by veterinarians, I would then like to find a resistance gene, so to speak. Maybe you can put it that way. I thought that I thought that you would first detect this with an NLGS, so to speak, but you practically do that using classical methods. All right. Well, then I would like to go into the distinction from economic stuff.  shrink? How is it classically viewed and what is new now? There is still no test for these resistances. It is really done in such a way that the veterinarians then, if a Leishmania infection has been dismissed, they give just medication. There are quasi guidelines on how best to do this, so to speak, standard procedures and then they just observe the animal, they then measure again and again how high the leishmania load is and then adjust the medication accordingly, make higher concentration or take other medications. But an examination that tells them, take this and that, there's resistance there, otherwise there's no resistance at all. Wonderful, thank you very much. Is there anything else, so this is now in relation to resistance, perhaps briefly in relation to NGS, has this ever been used to study Leishmania in general? No, this has already been used, not with us, but there are publications about it that have just done it. On the one hand, there are different strains to differentiate them, according to epidemiological studies. And resistance has also been looked at, but this is a purely scientific publication. All right, then we can refer to the fact that NGES has so far been used purely for basic research, but not yet commercially. Yes.  Do you also know whether this is also the case, so here we not only have that the Leishmania is\n",
            "\n",
            "Using this as context\n",
            "\n",
            "Answer to the following question from a user regarding Leishmania disease project following given guidelines.\n",
            "Question: Is there a specific connection between the project and existing products, production lines, production processes, services, or already established scientific methodology within your company?\n",
            "Guidelines: If yes, please clarify to what extent the work of the project goes beyond routine development activities in your company. Explain the differentiation from existing products, production lines, production processes, and services within the company. How does the product, process, or service to be developed differ from those already offered by your company ?\n",
            "\n",
            "        Try to include following points:\n",
            "        - 1 sentence about current technologies in the company\n",
            "        - 1 sentence differentiating functionality (For the first time...)\n",
            "        - 2 to 4 sentences differentiating functionality and development methods\n",
            "        \n",
            "Restrict output to ONLY 800 characters\n",
            "\n",
            "Answer:\u001b[0m\n",
            "\n",
            "\u001b[1m> Finished chain.\u001b[0m\n",
            "The current technology used in our company primarily involves individual tests and smaller products for breed-specific DNA profiling and parentage analyses. In contrast, the Leishmania disease project introduces the use of Next Generation Sequencing (NGS) for studying the entire genetic makeup of an animal, a novel approach within our operations. The project plans to expand the use of NGS beyond basic research and into commercial applications for detecting hereditary diseases in cats, dogs, and horses. This new methodology will allow for a more comprehensive understanding of animal health, with a focus on larger genetic variants, thereby expanding our existing knowledge base. Such a significant shift from established methods necessitates extensive development and testing, going beyond routine activities in our company.\n",
            "Length of response is 830 which is 30 characters above ideal\n",
            "####################################################################################################\n",
            "####################################################################################################\n",
            "Are there scientific and/or technical risks involved in implementing the project ? Explain them\n",
            "****************************************************************************************************\n",
            "Explain the engineering, natural, social, or humanities-related barriers that can be identified for the solution approach of your project. Describe the scientific (across all scientific disciplines) and/or technical obstacles, risks, uncertainties, or challenges that could lead to the failure of the project.\n",
            "\n",
            "        Describe how you address the identified risks. Briefly explain milestones and termination criteria. We explicitly emphasize that at this point, no economic and/or financial risks - related to the future product/process - should be mentioned\n",
            "        Try to include following points:\n",
            "        - 3 risks following the above format\n",
            "        \n",
            "\n",
            "\n",
            "\u001b[1m> Entering new  chain...\u001b[0m\n",
            "Prompt after formatting:\n",
            "\u001b[32;1m\u001b[1;3mHuman: You are a research document summarizer that finds the answers to user query and give correct responses\n",
            "Note that the user is from a highly specialized technical background, use minimal layman terms in your responses\n",
            "\n",
            "Use the following background context information on the Leishmania disease research project.\n",
            "\n",
            "That's how I would sum it up now.\n",
            "\n",
            "I have enclosed a short quality checklist here to accompany the application and how the application is always structured, so that you have a rough direction.\n",
            "\n",
            "We always have to describe a sentence about the state of the art, i.e. according to the current state of the art, this is done this way and that, then what the project goal is, then also the demarcation from the state of the art, to what extent the state of the art is expanded and the knowledge is expanded at your company and then finally what the project result should be.\n",
            "\n",
            "Perhaps you could just ask a few questions about the project, especially in relation to this Next Generation Sequencing.\n",
            "\n",
            "So let's put into perspective the extent to which you have already used it, to what extent it is a new technique for you, to what extent it is something new for detecting hereditary diseases in cats, dogs and horses.\n",
            "\n",
            "So now verbally or then for the application?\n",
            "\n",
            "Oral, oral.\n",
            "\n",
            "So now verbally or then for the application?\n",
            "\n",
            "Oral, oral.\n",
            "\n",
            "We formulate on the basis, that's why the recording is ongoing.\n",
            "\n",
            "We formulate the application from this.\n",
            "\n",
            "Okay, so then I would say that the current state of the art is that we are not yet using high-throughput technology to study the entire genetic markup of an animal.\n",
            "\n",
            "Instead, we mainly have individual tests and smaller products that are applied to breed-specific.  \n",
            "\n",
            "We are currently using next generation sequencing as a technology for DNA profiling.\n",
            "\n",
            "The main focus is on parentage analyses and the genetic fingerprint of animals.\n",
            "\n",
            "The aim of the project would then be what I formulated earlier, that it is primarily about animal health, of our own animal, but also of the species that we want to cover as a whole.\n",
            "\n",
            "State-of-the-art technology?  \n",
            "\n",
            "Above all, we are also expanding into larger genetic variants in this area.\n",
            "\n",
            "Class.\n",
            "\n",
            "Well, then I would like to go into the next point.\n",
            "\n",
            "The next point also relates to the differentiation from existing technologies in your company.\n",
            "\n",
            "It would be important for the auditor to classify whether you have ever dealt with Next Generation Sequencing in the company.\n",
            "\n",
            "If so, what is the difference here and if not, the This is perfectly adequate.\n",
            "\n",
            "Yes, we have had this, i.e. Next Generation Sequencing, in our company since 2020.\n",
            "\n",
            "And we are currently using it for genetic fingerprinting in dogs.  \n",
            "\n",
            "and to investigate genetic variability also in dogs.\n",
            "\n",
            "We do not yet have a product for cats, nor for horses, nor anything that is offered with hereditary diseases.\n",
            "\n",
            "Then it has to be implemented in the so-called panels with which the NGS technology works.\n",
            "\n",
            "One panel for each species.\n",
            "\n",
            "Then the third step would be the evaluation of the tests that we map.\n",
            "\n",
            "Of course, we also have to make sure that this should not only deliver the correct result from a technical point of view, but that it does.\n",
            "\n",
            "In other words, we have to compare the known animals with the results that we achieve with the new technology, with the NGS technology, and perhaps then bring the whole thing as fit for the work package in a way that is then understandable to the customer.\n",
            "\n",
            "We can't train them with 200 pages of text at the end.\n",
            "\n",
            "It has to be adapted to the different types of people so that they can do something with it.\n",
            "\n",
            "Wonderful, thank you very much.  \n",
            "\n",
            "In the end, could you rewrite the prototype a little better, i.e. the way in which it is understandable for the customer.\n",
            "\n",
            "Do you have a little better idea of what the end result should look like?\n",
            "\n",
            "Use the following information on the Leishmania disease research project.\n",
            "Next generation sequencing (NGS) technology transformed Leishmania genome studies and became an indispensable tool for Leishmania researchers. Recent Leishmania genomics analyses facilitated the discovery of various genetic diversities including single nucleotide polymorphisms (SNPs), copy number variations (CNVs), somy variations, and structural variations in detail and provided valuable insights into the complexity of the genome and gene regulation. Many aspects of Leishmania NGS analyses are similar to those of related pathogens like trypanosomes. However, the analyses of Leishmania genomes face a unique challenge because of the presence of frequent aneuploidy. This makes characterization and interpretation of read depth and somy a key part of Leishmania NGS analyses because read depth affects the accuracy of detection of all genetic variations. However, there are no general guidelines on how to explore and interpret the impact of aneuploidy, and this has made it difficult for biologists and bioinformaticians, especially for beginners, to perform their own analyses and interpret results across different analyses. In this guide we discuss a wide range of topics essential for Leishmania NGS analyses, ranging from how to set up a computational environment for genome analyses, to how to characterize genetic variations among Leishmania samples, and we will particularly focus on chromosomal copy number variation and its impact on genome analyses.\n",
            "in the animal sector. If things go really badly, you can also grow the Leishmania in a cell culture and then examine the special hold, so to speak. But that would be very time-consuming, very expensive. You have to ask yourself whether you want to continue the project at all. In other words, one could actually also argue as a risk that the whole technique works for Leishmania in cell culture, but in the end the animal sample simply cannot be realized. Yes, right. Better. To the expenses. Do you know how many people are supposed to work on it? Yes, so we'll do it again via the HR department. In principle, I will have a relatively large number of hours there. Then a veterinarian from clinical chemistry has hours there and of course we still need a laboratory and I think there will be a second veterinarian from either my department or from clinical chemistry so that he can have contact with the veterinarians outside. All right, then just a rough overview, that is, four people to no idea ten to 15 percent perhaps. Yes, that's right.  Okay, do any subcontractors still come in here? So there will certainly be cooperations, but more with universities and then you don't really have any bills. So if you don't pay for the university, then that's not relevant. Yes yes exactly.  Yes, exactly, I'm just thinking so loudly. That's why I don't think so at the moment. Okay perfect, then I'm already through with my questions here too. Is there another project or would that be it for now?  I think that would be it for now. Completely new things will be added. The other thing with the infection scan, they had sent something again. I would only get the one sentence out.  Exactly, I wanted to talk to you about that, because of course we have to make sure that we fill in the text to see if there is perhaps a replacement for the deletion. I don't know what you're aiming for. I'll probably have to open this up again. Because it doesn't allow you to do that, just that's what IT is doing here today. Exactly, but I can also briefly share your e-mail otherwise. Yes, maybe that's the fastest way to do it. So, exactly. Yes, few screening with EDP Yes, few screening methods that result from dogs or cats. I don't know what they're actually going to pick up. We wanted to show a bit of the demarcations to the state of the art, i.e. how this is done according to statistics, i.e. how much of the statistics is not enough. So what we're doing is not screening methods, it's like, it's like packages. But that would have to be worded a little differently. If the dog's nose runs, then we just do herpes calypso, then there are already four or five typical pathogens that you do there.  So these are more like packages that are then specific to certain symptoms. But never cover everything that could be there. Maybe you can just rephrase it a bit. Yes, that means you actually have to have an initial guess and then you examine it specifically. But you don't study the entire genome. That's right, yes. Okay, let's rephrase. Well, we did it. Class. Yes, wonderful. Yes, we still had the one with the mutation, antimutation or whatever they called it. So with that I still have a bit of a stomach ache overall, because it is, actually already the case, that we have already established a lot of hereditary diseases and yes actually this prototype, as described earlier, has been there for a long time and we just keep expanding it with newly released things. Of course, we also expand our methods or the possibility of mapping these structural variants now, but I don't know if we can get that many hours together if I really concentrate on that. I have to talk to Mrs. Khler again, to my head of department, about how we can do that, whether we can perhaps somehow make a different focus, that we can somehow do it differently, so I would put that on the back burner at the moment, although it is actually the project that is retroactive, all the others are actually not retroactive from the\n",
            "\n",
            "we can somehow do it differently, so I would put that on the back burner at the moment, although it is actually the project that is retroactive, all the others are actually not retroactive from the time to But I would sit down with Mrs. Khnlein for the next three or four weeks and then I would give you feedback again. All right, so if we can change the focus, such as What is that? Mutations, exactly. We can integrate that relatively easily. But then just give me a message about it. Yes. Class. Wonderful. Then thank you very much, Mrs Kehl, for taking the time. And then I wish you a nice week. Same to you. Goodbye. Thank you. Goodbye.\n",
            "\n",
            "to the fact that NGES has so far been used purely for basic research, but not yet commercially. Yes.  Do you also know whether this is also the case, so here we not only have that the Leishmania is to be examined with NGS and that this is also to be characterized practically on the basis of an animal sample, so to speak, can this also be applied as a fight to existing NGS investigations? So, as I said, there is nothing at all in diagnostics. But now you mean basic research. Yes, that's where the Leishmania were always bred. In cell culture, only those were examined. That's right, that's another step that we also have to take, because we want to do this investigation directly from the sample, so to speak, and then we may have a lot of background through the genomic DNA again. That would be such a risk. Yes, perfect.  Perfect. Then the next chapter would be the differentiation from your technologies. Here we have to refer to Leishmania in general and then to NGS.  We detect Leishmania itself in various sample materials via classical PCA or real-time PCA, but we do not yet have any resistance genes. That would be the innovation, so to speak. And at the moment we are not doing any studies of any parasites about NGS, but we are doing these DNA profiles, as discussed earlier, from genomic DNA. But studies of parasites has not yet been. Or rather, this other project with Infecto-Scan, which is also going in this direction, but it is also completely under development, that we want to examine a sample and which pathogens are in it. All right: NGS could also point out that they not only examine animal samples, but also isolate Leishmania from them. Or at least for sample preparation. That makes a difference. You would then have to adjust the sample preparation so that mainly the parasite DNA is isolated so that it can be sequenced in a targeted manner. That you don't have so much background that it gets lost. That's also a sub-project of this Infecto-Scan, but it's more on viruses and they are parasites. Yes, all right, well, one can also say in general terms that for the first time parasites from animal material are to be characterized by NGS Yes, definitely. All right, then I would like to go back to the last point, namely the risks. Yes, so one risk is that several strains can occur within one animal. So they are often stung and can then carry different Leishmania strains in them, of which perhaps only one part is resistant and the other is not. You have to make sure that you really get everything pictured, that you can see this variant. That would be a risk. The second would be that the publications are not correct, because at the beginning we want to look specifically at the genes that are in the publications. It could be that there are errors in it, that we detect the genes, but that does not correlate with the clinic, i.e. there is actually no resistance at all. That could be. And if we then do NGS, it can of course be again, as with the infection scan, that we just have too much genomic DNA in it. We have to adapt all the preparations to these parasites beforehand. Or that we don't have the sensitivity to be able to map all resistance genes. Could you also quantify the sensitivity? Then we would have a numerical value here.  the sensitivity of the resistances then again. Yes, exactly. Yes, I mean, 80% sensitivity has always been something you actually strive for. Okay, well, what's a solution for them to bring out this genomic DNA, so that they bring out the genomic DNA as well as possible? It should also be tried out via Infectoscan whether there are methods to separate it.  The company Nanopore offers various recipes for this. But this, of course, is all for the human sphere. First of all, you have to see if this is also possible in the animal sector. If things go really badly, you can also grow the Leishmania in a cell culture and then examine the special hold, so to speak. But that would be very time-consuming, very\n",
            "\n",
            "Perfect, okay when we start again with the goal of the project. So I'm going to elaborate a bit, leishmania are parasites that are transmitted via various mosquitoes. This means that the dogs are bitten by the mosquitoes, then get these leishmanias, which then lead to leishmaniasis. And the whole thing can also affect people. At the moment, this is still a major problem in southern countries, i.e. southern Europe. However, due to climate change, of course, these mosquitoes are coming further and further north, which transmit these larch manias, so to speak, and sooner or later it will most likely become a problem in Germany. This means that the dog has the mosquito bites on these Leishmanias, picks up the eggs of it again and so on and so on. There are now various medications that are taken for the treatment of the dogs. However, these Leishmania develop resistance to it very quickly. Our goal now would be to get a sample from a dog, to prove that he has Leishmania and at the same time to examine these Leishmania to see if they already contain certain resistance genes, so that the doctor can then take the other drug instead of a drug, as is the case with the bacteria in the end, instead of giving the wrong drug,  On the one hand, this does not work, and on the other hand, it leads to the formation of even more resistant Leishmania in order to avoid this. That would be the goal, that you give the veterinarians a tool and say, send us a sample. We study the animal Leishmania and have these Leishmania that the animal has, resistance genes, in order to be able to say which drug is best. Wonderful thank you very much.  On what basis should the investigation of the resistance or the sample in general be carried out? There are already a few publications, there are many groups that are working on which genes are responsible for the resistances. There are already a few publications, there are many groups that are now working on which genes are now responsible for the resistance. There is often no change in the genes, but a copy number variation. So these genes are then either multiplied or they are no longer there at all and this leads to this resistance and this is to be investigated on the basis of these scientific publications. And what we also want to do is to use Next Generation Sequencing to examine the entire Leishmania genome, so to speak. So the first approach would be to search specifically for the genes that are in the publications. And we can also look at it again. In other words, we would then also ask the veterinarians again, are these dogs already treated, do you also see resistance to allopurinol, for example, and we can see, yes we also see what is written in the scientific publication, that this and that gene is more common or not. And then we also want to examine the complete genomes of the Leishmania to see if we can find more genes that are relevant. And that would simply make the product more attractive if you don't say, okay, I'm just looking for an allopurinol resistance or only for a Milteforan resistance, but I'll look at everything again and I can then tell you, yes such and such resistances are present and you don't need this and that at all. Perfect, thank you very much. Could you elaborate on how you ultimately want to characterize whether other genes are relevant if they are not yet published? Are there certain patterns that they then practically read out of the publications and then transferred to the rest of the moment, something has just happened to me. I don't see them properly anymore. So we would just take a close look at the whole thing via Next Generation Sequencing.  Yes, of course, because they are often also copy number variations, one would first focus on whether one sees something like this in other genes. But you would also look at variations like these SNPs, for example, to see whether or not you see them clustered in certain genes, in certain resistant Leishmania. And the characterization\n",
            "\n",
            "Using this as context\n",
            "\n",
            "Answer to the following question from a user regarding Leishmania disease project following given guidelines.\n",
            "Question: Are there scientific and/or technical risks involved in implementing the project ? Explain them\n",
            "Guidelines: Explain the engineering, natural, social, or humanities-related barriers that can be identified for the solution approach of your project. Describe the scientific (across all scientific disciplines) and/or technical obstacles, risks, uncertainties, or challenges that could lead to the failure of the project.\n",
            "\n",
            "        Describe how you address the identified risks. Briefly explain milestones and termination criteria. We explicitly emphasize that at this point, no economic and/or financial risks - related to the future product/process - should be mentioned\n",
            "        Try to include following points:\n",
            "        - 3 risks following the above format\n",
            "        \n",
            "Restrict output to ONLY 800 characters\n",
            "\n",
            "Answer:\u001b[0m\n",
            "\n",
            "\u001b[1m> Finished chain.\u001b[0m\n",
            "Three primary scientific and technical risks can be identified for this project:\n",
            "\n",
            "1. Multiple Strains within One Animal: Animals often carry different Leishmania strains, some of which may be resistant while others are not. This may affect the accuracy of the detection of resistance genes. To address this, we aim to develop a methodology capable of mapping all variants.\n",
            "\n",
            "2. Incorrect Publications: The project heavily relies on existing scientific publications to locate resistance genes. If these are incorrect, it could lead to false results and misinterpretation of data. We plan to cross-verify the information from publications with our own research findings.\n",
            "\n",
            "3. High Genomic DNA Background: The presence of too much genomic DNA in the sample could impede the sensitivity of the resistance genes' detection. We aim to adapt our sample preparation to separate parasite DNA and, if necessary, explore cell culturing.\n",
            "Length of response is 923 which is 123 characters above ideal\n",
            "####################################################################################################\n",
            "####################################################################################################\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import json\n",
        "with open('/content/drive/MyDrive/Innoscripta/Advanced/Exp1/data_dump_gptv4.json', 'w') as fout:\n",
        "    json.dump(query_list, fout)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 17
        },
        "outputId": "1ffac560-0ca5-4fc7-966b-1433e10f7415",
        "id": "PM84aA1yFalp"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "# Converting to German and optimising text length"
      ],
      "metadata": {
        "id": "kxh_b_UYE-f0"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "# let's write a prompt for a customer support chatbot that\n",
        "# answer questions using information extracted from our db\n",
        "translate_template = \"\"\"You are a multilingual research document translator, which is able to translate technical documents without altering the underlying importance of technical jargon\n",
        "Use the following background context information on the Leishmania disease research project.\n",
        "\n",
        "Now translate the following technical document from ENGLISH to GERMAN\n",
        "\n",
        "{text_to_translate}\n",
        "\n",
        "Follow the given guidelines\n",
        "Guidelines:Fit the translation response to 800 characters\n",
        "\n",
        "Answer:\"\"\"\n",
        "human_message_prompt = HumanMessagePromptTemplate.from_template(\n",
        "    input_variables=[\"text_to_translate\"],\n",
        "    template=translate_template,\n",
        "    )\n",
        "translate_prompt = ChatPromptTemplate.from_messages([human_message_prompt])"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 17
        },
        "outputId": "93d1f733-3d8a-4145-8195-720370ead385",
        "id": "LCg2tS9BGeRY"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "def llm_translate_pipe(text_to_translate,\n",
        "             gpt_model=\"gpt-3.5-turbo-16k\", max_length=800):\n",
        "\n",
        "  # generate answer\n",
        "  llm = ChatOpenAI(model_name=gpt_model)\n",
        "  chain = LLMChain(llm=llm, prompt=translate_prompt, verbose=True)\n",
        "\n",
        "  response = chain.run(\n",
        "      text_to_translate=text_to_translate,\n",
        "      )\n",
        "\n",
        "  overhead_characters = len(response)- max_length\n",
        "  print(response)\n",
        "  print(\"Length of response is {} which is {} characters above ideal\".format(len(response), overhead_characters))\n",
        "  return response, overhead_characters"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 17
        },
        "outputId": "8bd5e796-3469-4bc2-db6a-c810950c35af",
        "id": "6MM3EOevHiUy"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "#### With GPT-3.5"
      ],
      "metadata": {
        "id": "N6oZsLH5IIpl"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "with open('/content/drive/MyDrive/Innoscripta/Advanced/Exp1/data_dump.json', encoding='utf-8') as data_file:\n",
        "   data_dict = json.loads(data_file.read())"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 17
        },
        "id": "0hFMuAH_IFOl",
        "outputId": "620782e4-8656-4bf3-c7d7-7c49b84aa8a5"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "data_dict[0]"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 257
        },
        "id": "Gd4R3ps3IQPF",
        "outputId": "497e766f-7390-4624-a597-b128d4793604"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "{'query': 'What is the Objective of the project (if applicable, in the context of the cooperative project) ?',\n",
              " 'guidelines': 'Motivation, objectives, and intended results. To what extent does the project aim to expand the state of knowledge/technology or utilize existing scientific, technical, economic, or other relevant findings or approaches\\n\\n        Try to include following points:\\n        - 1 State of the art (Currently/According to the state of the art...)\\n        - 1 Project objective (The goal of the project is...)\\n        - 1 Differentiation from the state of the art (The state of the art is expanded...)\\n        - in terms of..., thereby expanding the knowledge about...\\n        - 1 Project result (The planned outcome/result is...)\\nPlease ensure that the project uses specific technical terminology to describe the innovative core. This is particularly crucial, especially for software projects.\\n        ',\n",
              " 'response': 'The objective of the project is to develop a tool for identifying and characterizing genetic variations, such as single nucleotide polymorphisms (SNPs) and copy number variations (CNVs), in Leishmania samples. Currently, there are no general guidelines on how to explore and interpret the impact of aneuploidy in Leishmania genomes, which makes it difficult for researchers and bioinformaticians to perform their own analyses and interpret results. The project aims to utilize Next Generation Sequencing (NGS) technology to study the entire Leishmania genome and provide valuable insights into the genetic diversities and complexity of the genome. The project will expand the state of knowledge in Leishmania genomics and contribute to the understanding of gene regulation and chromosomal copy number variation. The planned outcome of the project is to provide researchers and veterinarians with a tool that can accurately detect genetic variations in Leishmania and potentially improve the selection of appropriate medications for the treatment of Leishmaniasis.',\n",
              " 'overhead_characters': 263}"
            ]
          },
          "metadata": {},
          "execution_count": 40
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "for i in range(len(query_list)):\n",
        "  print(query_list[i]['response'])\n",
        "  print('*'*100)\n",
        "  translate_response = llm_translate_pipe(\n",
        "            text_to_translate = query_list[i]['response'],\n",
        "             gpt_model=\"gpt-3.5-turbo-16k\")\n",
        "  query_list[i]['translated_text'], query_list[i]['translated_overhead_characters'] = translate_response\n",
        "  print('#'*100)\n",
        "  print('#'*100)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "TjxLJlCqIRqo",
        "outputId": "ce2eaa3b-c220-4ec3-e1f7-2ff2f2a7e043"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "According to the state of the art, Leishmania infection and subsequent resistance development are currently treated using standard medication protocols with no specific genetic-based guidance. The project aims to utilize Next Generation Sequencing (NGS) technology to detect Leishmania and identify specific resistance genes, a novel approach in veterinary medicine. This expands the state of the art by integrating genomic data into treatment strategies, thus enhancing the understanding of Leishmania resistance mechanisms. The planned outcome is a specialized tool for veterinarians, facilitating targeted treatment of Leishmania infections based on the specific resistance genes identified.\n",
            "****************************************************************************************************\n",
            "\n",
            "\n",
            "\u001b[1m> Entering new  chain...\u001b[0m\n",
            "Prompt after formatting:\n",
            "\u001b[32;1m\u001b[1;3mHuman: You are a multilingual research document translator, which is able to translate technical documents without altering the underlying importance of technical jargon\n",
            "Use the following background context information on the Leishmania disease research project.\n",
            "\n",
            "Now translate the following technical document from ENGLISH to GERMAN\n",
            "\n",
            "According to the state of the art, Leishmania infection and subsequent resistance development are currently treated using standard medication protocols with no specific genetic-based guidance. The project aims to utilize Next Generation Sequencing (NGS) technology to detect Leishmania and identify specific resistance genes, a novel approach in veterinary medicine. This expands the state of the art by integrating genomic data into treatment strategies, thus enhancing the understanding of Leishmania resistance mechanisms. The planned outcome is a specialized tool for veterinarians, facilitating targeted treatment of Leishmania infections based on the specific resistance genes identified.\n",
            "\n",
            "Follow the given guidelines\n",
            "Guidelines:Fit the translation response to 800 characters\n",
            "\n",
            "Answer:\u001b[0m\n",
            "\n",
            "\u001b[1m> Finished chain.\u001b[0m\n",
            "Gem dem Stand der Technik werden Leishmanieninfektionen und die anschlieende Resistenzentwicklung derzeit mit Standardmedikationsprotokollen ohne spezifische genetische Leitlinien behandelt. Das Projekt zielt darauf ab, die Next Generation Sequencing (NGS) Technologie zur Detektion von Leishmanien und Identifizierung spezifischer Resistenzgene einzusetzen, ein neuartiger Ansatz in der Veterinrmedizin. Dadurch erweitert sich der Stand der Technik durch die Integration von genomischen Daten in Behandlungsstrategien und verbessert somit das Verstndnis der Leishmanien-Resistenzmechanismen. Das geplante Ergebnis ist ein spezialisiertes Werkzeug fr Tierrzte, das eine gezielte Behandlung von Leishmanieninfektionen auf der Grundlage der identifizierten spezifischen Resistenzgene erleichtert.\n",
            "Length of response is 801 which is 1 characters above ideal\n",
            "####################################################################################################\n",
            "####################################################################################################\n",
            "The project involves various tasks including the next-generation sequencing (NGS) of Leishmania genomes, the identification of genetic variations, and the impact of aneuploidy on genome analyses. Tasks also involve setting up computational environments for genome analyses and characterizing genetic variations among Leishmania samples. The project also focuses on the differentiation of our technologies from existing ones, primarily centered on resistance detection. A novel approach is employed in this regard, extending NGS from basic research to commercial application for the diagnosis of Leishmania resistance.\n",
            "****************************************************************************************************\n",
            "\n",
            "\n",
            "\u001b[1m> Entering new  chain...\u001b[0m\n",
            "Prompt after formatting:\n",
            "\u001b[32;1m\u001b[1;3mHuman: You are a multilingual research document translator, which is able to translate technical documents without altering the underlying importance of technical jargon\n",
            "Use the following background context information on the Leishmania disease research project.\n",
            "\n",
            "Now translate the following technical document from ENGLISH to GERMAN\n",
            "\n",
            "The project involves various tasks including the next-generation sequencing (NGS) of Leishmania genomes, the identification of genetic variations, and the impact of aneuploidy on genome analyses. Tasks also involve setting up computational environments for genome analyses and characterizing genetic variations among Leishmania samples. The project also focuses on the differentiation of our technologies from existing ones, primarily centered on resistance detection. A novel approach is employed in this regard, extending NGS from basic research to commercial application for the diagnosis of Leishmania resistance.\n",
            "\n",
            "Follow the given guidelines\n",
            "Guidelines:Fit the translation response to 800 characters\n",
            "\n",
            "Answer:\u001b[0m\n",
            "\n",
            "\u001b[1m> Finished chain.\u001b[0m\n",
            "Das Projekt umfasst verschiedene Aufgaben, darunter die Next-Generation-Sequenzierung (NGS) von Leishmania-Genomen, die Identifizierung genetischer Variationen und die Auswirkungen von Aneuploidie auf die Genomanalysen. Zu den Aufgaben gehrt auch die Einrichtung von Rechenumgebungen fr Genomanalysen und die Charakterisierung genetischer Variationen bei Leishmania-Proben. Das Projekt konzentriert sich auch auf die Unterscheidung unserer Technologien von bestehenden, insbesondere auf die Resistenzdetektion. In diesem Zusammenhang wird ein neuartiger Ansatz verwendet, der die NGS von der Grundlagenforschung auf die kommerzielle Anwendung zur Diagnose von Leishmania-Resistenz erweitert.\n",
            "Length of response is 693 which is -107 characters above ideal\n",
            "####################################################################################################\n",
            "####################################################################################################\n",
            "Yes, the project aims to develop a novel application of Next Generation Sequencing (NGS) for detecting hereditary diseases in cats, dogs, and horses, focusing primarily on Leishmania disease. This technique represents a significant advancement in the veterinary diagnostics sector. Currently, the state of the art involves the use of individual tests and smaller breed-specific products, without high-throughput technology to study the entire genetic makeup of an animal. The project will enable us to move beyond current limitations by utilizing NGS for comprehensive DNA profiling and specific detection of Leishmania resistance genes directly from animal samples. This novel approach will expand our knowledge and improve animal health management.\n",
            "****************************************************************************************************\n",
            "\n",
            "\n",
            "\u001b[1m> Entering new  chain...\u001b[0m\n",
            "Prompt after formatting:\n",
            "\u001b[32;1m\u001b[1;3mHuman: You are a multilingual research document translator, which is able to translate technical documents without altering the underlying importance of technical jargon\n",
            "Use the following background context information on the Leishmania disease research project.\n",
            "\n",
            "Now translate the following technical document from ENGLISH to GERMAN\n",
            "\n",
            "Yes, the project aims to develop a novel application of Next Generation Sequencing (NGS) for detecting hereditary diseases in cats, dogs, and horses, focusing primarily on Leishmania disease. This technique represents a significant advancement in the veterinary diagnostics sector. Currently, the state of the art involves the use of individual tests and smaller breed-specific products, without high-throughput technology to study the entire genetic makeup of an animal. The project will enable us to move beyond current limitations by utilizing NGS for comprehensive DNA profiling and specific detection of Leishmania resistance genes directly from animal samples. This novel approach will expand our knowledge and improve animal health management.\n",
            "\n",
            "Follow the given guidelines\n",
            "Guidelines:Fit the translation response to 800 characters\n",
            "\n",
            "Answer:\u001b[0m\n",
            "\n",
            "\u001b[1m> Finished chain.\u001b[0m\n",
            "Ja, das Projekt zielt darauf ab, eine neuartige Anwendung der Next Generation Sequencing (NGS) zur Erkennung erblicher Krankheiten bei Katzen, Hunden und Pferden zu entwickeln und konzentriert sich hauptschlich auf die Leishmaniose. Diese Technik stellt einen bedeutenden Fortschritt im Bereich der veterinrmedizinischen Diagnostik dar. Derzeit erfolgt der Stand der Technik durch den Einsatz von Einzeltests und kleineren rassespezifischen Produkten, ohne Hochdurchsatztechnologie, um das gesamte genetische Profil eines Tieres zu untersuchen. Das Projekt wird es uns ermglichen, ber die aktuellen Einschrnkungen hinauszugehen, indem wir NGS zur umfassenden DNA-Profilerstellung und spezifischen Erkennung von Leishmaniose-Resistenzgenen direkt aus Tierproben nutzen. Dieser neuartige Ansatz wird unser Wissen erweitern und die Gesundheitsversorgung von Tieren verbessern.\n",
            "Length of response is 878 which is 78 characters above ideal\n",
            "####################################################################################################\n",
            "####################################################################################################\n",
            "The current technology used in our company primarily involves individual tests and smaller products for breed-specific DNA profiling and parentage analyses. In contrast, the Leishmania disease project introduces the use of Next Generation Sequencing (NGS) for studying the entire genetic makeup of an animal, a novel approach within our operations. The project plans to expand the use of NGS beyond basic research and into commercial applications for detecting hereditary diseases in cats, dogs, and horses. This new methodology will allow for a more comprehensive understanding of animal health, with a focus on larger genetic variants, thereby expanding our existing knowledge base. Such a significant shift from established methods necessitates extensive development and testing, going beyond routine activities in our company.\n",
            "****************************************************************************************************\n",
            "\n",
            "\n",
            "\u001b[1m> Entering new  chain...\u001b[0m\n",
            "Prompt after formatting:\n",
            "\u001b[32;1m\u001b[1;3mHuman: You are a multilingual research document translator, which is able to translate technical documents without altering the underlying importance of technical jargon\n",
            "Use the following background context information on the Leishmania disease research project.\n",
            "\n",
            "Now translate the following technical document from ENGLISH to GERMAN\n",
            "\n",
            "The current technology used in our company primarily involves individual tests and smaller products for breed-specific DNA profiling and parentage analyses. In contrast, the Leishmania disease project introduces the use of Next Generation Sequencing (NGS) for studying the entire genetic makeup of an animal, a novel approach within our operations. The project plans to expand the use of NGS beyond basic research and into commercial applications for detecting hereditary diseases in cats, dogs, and horses. This new methodology will allow for a more comprehensive understanding of animal health, with a focus on larger genetic variants, thereby expanding our existing knowledge base. Such a significant shift from established methods necessitates extensive development and testing, going beyond routine activities in our company.\n",
            "\n",
            "Follow the given guidelines\n",
            "Guidelines:Fit the translation response to 800 characters\n",
            "\n",
            "Answer:\u001b[0m\n",
            "\n",
            "\u001b[1m> Finished chain.\u001b[0m\n",
            "Die aktuelle Technologie, die in unserem Unternehmen verwendet wird, umfasst hauptschlich Einzeltests und kleinere Produkte zur Rassen-spezifischen DNA-Profilierung und Elternschaftsanalysen. Im Gegensatz dazu fhrt das Leishmania-Forschungsprojekt den Einsatz von Next Generation Sequencing (NGS) ein, um das gesamte genetische Profil eines Tieres zu untersuchen, ein neuartiger Ansatz in unserem Betrieb. Das Projekt plant, den Einsatz von NGS ber die Grundlagenforschung hinaus zu erweitern und kommerzielle Anwendungen zur Erkennung erblicher Krankheiten bei Katzen, Hunden und Pferden einzufhren. Diese neue Methodik ermglicht ein umfassenderes Verstndnis der Tiergesundheit mit einem Schwerpunkt auf greren genetischen Varianten und erweitert somit unsere bestehende Wissensbasis. Eine so bedeutende Vernderung etablierter Methoden erfordert umfangreiche Entwicklung und Tests, die ber die routinemigen Aktivitten in unserem Unternehmen hinausgehen.\n",
            "Length of response is 967 which is 167 characters above ideal\n",
            "####################################################################################################\n",
            "####################################################################################################\n",
            "Three primary scientific and technical risks can be identified for this project:\n",
            "\n",
            "1. Multiple Strains within One Animal: Animals often carry different Leishmania strains, some of which may be resistant while others are not. This may affect the accuracy of the detection of resistance genes. To address this, we aim to develop a methodology capable of mapping all variants.\n",
            "\n",
            "2. Incorrect Publications: The project heavily relies on existing scientific publications to locate resistance genes. If these are incorrect, it could lead to false results and misinterpretation of data. We plan to cross-verify the information from publications with our own research findings.\n",
            "\n",
            "3. High Genomic DNA Background: The presence of too much genomic DNA in the sample could impede the sensitivity of the resistance genes' detection. We aim to adapt our sample preparation to separate parasite DNA and, if necessary, explore cell culturing.\n",
            "****************************************************************************************************\n",
            "\n",
            "\n",
            "\u001b[1m> Entering new  chain...\u001b[0m\n",
            "Prompt after formatting:\n",
            "\u001b[32;1m\u001b[1;3mHuman: You are a multilingual research document translator, which is able to translate technical documents without altering the underlying importance of technical jargon\n",
            "Use the following background context information on the Leishmania disease research project.\n",
            "\n",
            "Now translate the following technical document from ENGLISH to GERMAN\n",
            "\n",
            "Three primary scientific and technical risks can be identified for this project:\n",
            "\n",
            "1. Multiple Strains within One Animal: Animals often carry different Leishmania strains, some of which may be resistant while others are not. This may affect the accuracy of the detection of resistance genes. To address this, we aim to develop a methodology capable of mapping all variants.\n",
            "\n",
            "2. Incorrect Publications: The project heavily relies on existing scientific publications to locate resistance genes. If these are incorrect, it could lead to false results and misinterpretation of data. We plan to cross-verify the information from publications with our own research findings.\n",
            "\n",
            "3. High Genomic DNA Background: The presence of too much genomic DNA in the sample could impede the sensitivity of the resistance genes' detection. We aim to adapt our sample preparation to separate parasite DNA and, if necessary, explore cell culturing.\n",
            "\n",
            "Follow the given guidelines\n",
            "Guidelines:Fit the translation response to 800 characters\n",
            "\n",
            "Answer:\u001b[0m\n",
            "\n",
            "\u001b[1m> Finished chain.\u001b[0m\n",
            "Drei Hauptwissenschaftliche und technische Risiken knnen fr dieses Projekt identifiziert werden:\n",
            "\n",
            "1. Mehrere Stmme innerhalb eines Tieres: Tiere tragen oft verschiedene Leishmania-Stmme, von denen einige resistent sein knnen, whrend andere es nicht sind. Dies kann die Genauigkeit der Detektion von Resistenzgenen beeinflussen. Um dies anzugehen, streben wir die Entwicklung einer Methodik an, die in der Lage ist, alle Varianten zu kartieren.\n",
            "\n",
            "2. Falsche Verffentlichungen: Das Projekt sttzt sich stark auf bestehende wissenschaftliche Verffentlichungen, um Resistenzgene zu lokalisieren. Wenn diese falsch sind, knnte dies zu falschen Ergebnissen und einer fehlerhaften Interpretation der Daten fhren. Wir planen, die Informationen aus Verffentlichungen mit unseren eigenen Forschungsergebnissen zu berprfen.\n",
            "\n",
            "3. Hoher genomischer DNA-Hintergrund: Das Vorhandensein von zu viel genomischer DNA in der Probe knnte die Empfindlichkeit der Detektion von Resistenzgenen beeintrchtigen. Wir streben an, unsere Probenprparation anzupassen, um Parasiten-DNA zu separieren und gegebenenfalls Zellkultivierung zu erkunden.\n",
            "Length of response is 1132 which is 332 characters above ideal\n",
            "####################################################################################################\n",
            "####################################################################################################\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import json\n",
        "with open('/content/drive/MyDrive/Innoscripta/Advanced/Exp1/data_dump_translated.json', 'w') as fout:\n",
        "    json.dump(query_list, fout)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 17
        },
        "id": "7TS0-2DbI-2w",
        "outputId": "941c1899-f46d-4a79-b73e-0111baaddbc4"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "#### With GPT-4"
      ],
      "metadata": {
        "id": "Y3wtboTKJTzz"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "with open('/content/drive/MyDrive/Innoscripta/Advanced/Exp1/data_dump_gptv4.json', encoding='utf-8') as data_file:\n",
        "   data_dict = json.loads(data_file.read())"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 17
        },
        "outputId": "309d918e-5942-4dc7-f512-d40e42c9cea4",
        "id": "czFUxWYRJT0F"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "data_dict[0]"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 220
        },
        "outputId": "b86a9eaa-4279-4161-95a5-c167fca728c1",
        "id": "3ySrcIMgJT0G"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "{'query': 'What is the Objective of the project (if applicable, in the context of the cooperative project) ?',\n",
              " 'guidelines': 'Motivation, objectives, and intended results. To what extent does the project aim to expand the state of knowledge/technology or utilize existing scientific, technical, economic, or other relevant findings or approaches\\n\\n        Try to include following points:\\n        - 1 State of the art (Currently/According to the state of the art...)\\n        - 1 Project objective (The goal of the project is...)\\n        - 1 Differentiation from the state of the art (The state of the art is expanded...)\\n        - in terms of..., thereby expanding the knowledge about...\\n        - 1 Project result (The planned outcome/result is...)\\nPlease ensure that the project uses specific technical terminology to describe the innovative core. This is particularly crucial, especially for software projects.\\n        ',\n",
              " 'response': 'According to the state of the art, Leishmania infection and subsequent resistance development are currently treated using standard medication protocols with no specific genetic-based guidance. The project aims to utilize Next Generation Sequencing (NGS) technology to detect Leishmania and identify specific resistance genes, a novel approach in veterinary medicine. This expands the state of the art by integrating genomic data into treatment strategies, thus enhancing the understanding of Leishmania resistance mechanisms. The planned outcome is a specialized tool for veterinarians, facilitating targeted treatment of Leishmania infections based on the specific resistance genes identified.',\n",
              " 'overhead_characters': -106}"
            ]
          },
          "metadata": {},
          "execution_count": 44
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "for i in range(len(query_list)):\n",
        "  print(query_list[i]['response'])\n",
        "  print('*'*100)\n",
        "  translate_response = llm_translate_pipe(\n",
        "            text_to_translate = query_list[i]['response'],\n",
        "             gpt_model=\"gpt-3.5-turbo-16k\")\n",
        "  query_list[i]['translated_text'], query_list[i]['translated_overhead_characters'] = translate_response\n",
        "  print('#'*100)\n",
        "  print('#'*100)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "outputId": "3a0602a8-e97b-4b04-9c7b-bbdccdbf115c",
        "id": "NQMXO_7KJT0G"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "According to the state of the art, Leishmania infection and subsequent resistance development are currently treated using standard medication protocols with no specific genetic-based guidance. The project aims to utilize Next Generation Sequencing (NGS) technology to detect Leishmania and identify specific resistance genes, a novel approach in veterinary medicine. This expands the state of the art by integrating genomic data into treatment strategies, thus enhancing the understanding of Leishmania resistance mechanisms. The planned outcome is a specialized tool for veterinarians, facilitating targeted treatment of Leishmania infections based on the specific resistance genes identified.\n",
            "****************************************************************************************************\n",
            "\n",
            "\n",
            "\u001b[1m> Entering new  chain...\u001b[0m\n",
            "Prompt after formatting:\n",
            "\u001b[32;1m\u001b[1;3mHuman: You are a multilingual research document translator, which is able to translate technical documents without altering the underlying importance of technical jargon\n",
            "Use the following background context information on the Leishmania disease research project.\n",
            "\n",
            "Now translate the following technical document from ENGLISH to GERMAN\n",
            "\n",
            "According to the state of the art, Leishmania infection and subsequent resistance development are currently treated using standard medication protocols with no specific genetic-based guidance. The project aims to utilize Next Generation Sequencing (NGS) technology to detect Leishmania and identify specific resistance genes, a novel approach in veterinary medicine. This expands the state of the art by integrating genomic data into treatment strategies, thus enhancing the understanding of Leishmania resistance mechanisms. The planned outcome is a specialized tool for veterinarians, facilitating targeted treatment of Leishmania infections based on the specific resistance genes identified.\n",
            "\n",
            "Follow the given guidelines\n",
            "Guidelines:Fit the translation response to 800 characters\n",
            "\n",
            "Answer:\u001b[0m\n",
            "\n",
            "\u001b[1m> Finished chain.\u001b[0m\n",
            "Gem dem aktuellen Stand der Technik werden Leishmania-Infektionen und die darauffolgende Resistenzentwicklung derzeit mit standardisierten Medikamentenprotokollen behandelt, ohne spezifische genetische Leitlinien. Das Projekt zielt darauf ab, die Next Generation Sequencing (NGS) Technologie zu nutzen, um Leishmania zu erkennen und spezifische Resistenzgene zu identifizieren - ein neuartiger Ansatz in der Veterinrmedizin. Dadurch erweitert es den Stand der Technik, indem genomische Daten in die Behandlungsstrategien integriert werden und das Verstndnis fr die Leishmania-Resistenzmechanismen verbessert wird. Das geplante Ergebnis ist ein spezialisiertes Werkzeug fr Tierrzte, das eine gezielte Behandlung von Leishmania-Infektionen auf der Grundlage der identifizierten spezifischen Resistenzgene ermglicht.\n",
            "Length of response is 821 which is 21 characters above ideal\n",
            "####################################################################################################\n",
            "####################################################################################################\n",
            "The project involves various tasks including the next-generation sequencing (NGS) of Leishmania genomes, the identification of genetic variations, and the impact of aneuploidy on genome analyses. Tasks also involve setting up computational environments for genome analyses and characterizing genetic variations among Leishmania samples. The project also focuses on the differentiation of our technologies from existing ones, primarily centered on resistance detection. A novel approach is employed in this regard, extending NGS from basic research to commercial application for the diagnosis of Leishmania resistance.\n",
            "****************************************************************************************************\n",
            "\n",
            "\n",
            "\u001b[1m> Entering new  chain...\u001b[0m\n",
            "Prompt after formatting:\n",
            "\u001b[32;1m\u001b[1;3mHuman: You are a multilingual research document translator, which is able to translate technical documents without altering the underlying importance of technical jargon\n",
            "Use the following background context information on the Leishmania disease research project.\n",
            "\n",
            "Now translate the following technical document from ENGLISH to GERMAN\n",
            "\n",
            "The project involves various tasks including the next-generation sequencing (NGS) of Leishmania genomes, the identification of genetic variations, and the impact of aneuploidy on genome analyses. Tasks also involve setting up computational environments for genome analyses and characterizing genetic variations among Leishmania samples. The project also focuses on the differentiation of our technologies from existing ones, primarily centered on resistance detection. A novel approach is employed in this regard, extending NGS from basic research to commercial application for the diagnosis of Leishmania resistance.\n",
            "\n",
            "Follow the given guidelines\n",
            "Guidelines:Fit the translation response to 800 characters\n",
            "\n",
            "Answer:\u001b[0m\n",
            "\n",
            "\u001b[1m> Finished chain.\u001b[0m\n",
            "Das Projekt umfasst verschiedene Aufgaben, einschlielich der Next-Generation-Sequenzierung (NGS) der Leishmania-Genome, der Identifizierung genetischer Variationen und der Auswirkungen von Aneuploidie auf die Genomanalysen. Die Aufgaben beinhalten auch die Einrichtung von Rechenumgebungen fr Genomanalysen und die Charakterisierung genetischer Variationen zwischen Leishmania-Proben. Das Projekt konzentriert sich auch auf die Unterscheidung unserer Technologien von bestehenden, hauptschlich auf die Resistenzerkennung ausgerichtet. In diesem Zusammenhang wird ein neuartiger Ansatz angewendet, der NGS von der Grundlagenforschung auf die kommerzielle Anwendung zur Diagnose von Leishmania-Resistenz erweitert.\n",
            "Length of response is 715 which is -85 characters above ideal\n",
            "####################################################################################################\n",
            "####################################################################################################\n",
            "Yes, the project aims to develop a novel application of Next Generation Sequencing (NGS) for detecting hereditary diseases in cats, dogs, and horses, focusing primarily on Leishmania disease. This technique represents a significant advancement in the veterinary diagnostics sector. Currently, the state of the art involves the use of individual tests and smaller breed-specific products, without high-throughput technology to study the entire genetic makeup of an animal. The project will enable us to move beyond current limitations by utilizing NGS for comprehensive DNA profiling and specific detection of Leishmania resistance genes directly from animal samples. This novel approach will expand our knowledge and improve animal health management.\n",
            "****************************************************************************************************\n",
            "\n",
            "\n",
            "\u001b[1m> Entering new  chain...\u001b[0m\n",
            "Prompt after formatting:\n",
            "\u001b[32;1m\u001b[1;3mHuman: You are a multilingual research document translator, which is able to translate technical documents without altering the underlying importance of technical jargon\n",
            "Use the following background context information on the Leishmania disease research project.\n",
            "\n",
            "Now translate the following technical document from ENGLISH to GERMAN\n",
            "\n",
            "Yes, the project aims to develop a novel application of Next Generation Sequencing (NGS) for detecting hereditary diseases in cats, dogs, and horses, focusing primarily on Leishmania disease. This technique represents a significant advancement in the veterinary diagnostics sector. Currently, the state of the art involves the use of individual tests and smaller breed-specific products, without high-throughput technology to study the entire genetic makeup of an animal. The project will enable us to move beyond current limitations by utilizing NGS for comprehensive DNA profiling and specific detection of Leishmania resistance genes directly from animal samples. This novel approach will expand our knowledge and improve animal health management.\n",
            "\n",
            "Follow the given guidelines\n",
            "Guidelines:Fit the translation response to 800 characters\n",
            "\n",
            "Answer:\u001b[0m\n",
            "\n",
            "\u001b[1m> Finished chain.\u001b[0m\n",
            "Ja, das Projekt zielt darauf ab, eine neuartige Anwendung der Next Generation Sequencing (NGS) zur Erkennung erblicher Krankheiten bei Katzen, Hunden und Pferden zu entwickeln, wobei der Schwerpunkt hauptschlich auf der Leishmaniose liegt. Diese Technik stellt einen bedeutenden Fortschritt im Bereich der veterinrmedizinischen Diagnostik dar. Derzeit erfolgt der Stand der Technik durch den Einsatz einzelner Tests und kleinerer rassespezifischer Produkte, ohne Hochdurchsatztechnologie zur Untersuchung des gesamten genetischen Profils eines Tieres. Das Projekt ermglicht es uns, ber die derzeitigen Einschrnkungen hinauszugehen, indem NGS zur umfassenden DNA-Profilierung und spezifischen Detektion von Leishmaniose-Resistenzgenen direkt aus Tierproben verwendet wird. Dieser neuartige Ansatz wird unser Wissen erweitern und das Management der Tiergesundheit verbessern.\n",
            "Length of response is 878 which is 78 characters above ideal\n",
            "####################################################################################################\n",
            "####################################################################################################\n",
            "The current technology used in our company primarily involves individual tests and smaller products for breed-specific DNA profiling and parentage analyses. In contrast, the Leishmania disease project introduces the use of Next Generation Sequencing (NGS) for studying the entire genetic makeup of an animal, a novel approach within our operations. The project plans to expand the use of NGS beyond basic research and into commercial applications for detecting hereditary diseases in cats, dogs, and horses. This new methodology will allow for a more comprehensive understanding of animal health, with a focus on larger genetic variants, thereby expanding our existing knowledge base. Such a significant shift from established methods necessitates extensive development and testing, going beyond routine activities in our company.\n",
            "****************************************************************************************************\n",
            "\n",
            "\n",
            "\u001b[1m> Entering new  chain...\u001b[0m\n",
            "Prompt after formatting:\n",
            "\u001b[32;1m\u001b[1;3mHuman: You are a multilingual research document translator, which is able to translate technical documents without altering the underlying importance of technical jargon\n",
            "Use the following background context information on the Leishmania disease research project.\n",
            "\n",
            "Now translate the following technical document from ENGLISH to GERMAN\n",
            "\n",
            "The current technology used in our company primarily involves individual tests and smaller products for breed-specific DNA profiling and parentage analyses. In contrast, the Leishmania disease project introduces the use of Next Generation Sequencing (NGS) for studying the entire genetic makeup of an animal, a novel approach within our operations. The project plans to expand the use of NGS beyond basic research and into commercial applications for detecting hereditary diseases in cats, dogs, and horses. This new methodology will allow for a more comprehensive understanding of animal health, with a focus on larger genetic variants, thereby expanding our existing knowledge base. Such a significant shift from established methods necessitates extensive development and testing, going beyond routine activities in our company.\n",
            "\n",
            "Follow the given guidelines\n",
            "Guidelines:Fit the translation response to 800 characters\n",
            "\n",
            "Answer:\u001b[0m\n",
            "\n",
            "\u001b[1m> Finished chain.\u001b[0m\n",
            "Die aktuelle Technologie, die in unserem Unternehmen verwendet wird, umfasst hauptschlich Einzeltests und kleinere Produkte fr die rassespezifische DNA-Profilierung und Elternschaftsanalysen. Im Gegensatz dazu fhrt das Leishmania-Krankheitsprojekt den Einsatz von Next Generation Sequencing (NGS) zur Untersuchung des gesamten genetischen Profils eines Tieres ein, ein neuartiger Ansatz innerhalb unserer Aktivitten. Das Projekt plant, den Einsatz von NGS ber die Grundlagenforschung hinaus auszudehnen und kommerzielle Anwendungen zur Erkennung erblicher Krankheiten bei Katzen, Hunden und Pferden zu entwickeln. Diese neue Methodik ermglicht ein umfassenderes Verstndnis der Tiergesundheit mit Fokus auf grere genetische Varianten und erweitert somit unseren bestehenden Wissensstand. Eine solch bedeutende Vernderung von etablierten Methoden erfordert umfangreiche Entwicklung und Tests, die ber die blichen Aktivitten in unserem Unternehmen hinausgehen.\n",
            "Length of response is 970 which is 170 characters above ideal\n",
            "####################################################################################################\n",
            "####################################################################################################\n",
            "Three primary scientific and technical risks can be identified for this project:\n",
            "\n",
            "1. Multiple Strains within One Animal: Animals often carry different Leishmania strains, some of which may be resistant while others are not. This may affect the accuracy of the detection of resistance genes. To address this, we aim to develop a methodology capable of mapping all variants.\n",
            "\n",
            "2. Incorrect Publications: The project heavily relies on existing scientific publications to locate resistance genes. If these are incorrect, it could lead to false results and misinterpretation of data. We plan to cross-verify the information from publications with our own research findings.\n",
            "\n",
            "3. High Genomic DNA Background: The presence of too much genomic DNA in the sample could impede the sensitivity of the resistance genes' detection. We aim to adapt our sample preparation to separate parasite DNA and, if necessary, explore cell culturing.\n",
            "****************************************************************************************************\n",
            "\n",
            "\n",
            "\u001b[1m> Entering new  chain...\u001b[0m\n",
            "Prompt after formatting:\n",
            "\u001b[32;1m\u001b[1;3mHuman: You are a multilingual research document translator, which is able to translate technical documents without altering the underlying importance of technical jargon\n",
            "Use the following background context information on the Leishmania disease research project.\n",
            "\n",
            "Now translate the following technical document from ENGLISH to GERMAN\n",
            "\n",
            "Three primary scientific and technical risks can be identified for this project:\n",
            "\n",
            "1. Multiple Strains within One Animal: Animals often carry different Leishmania strains, some of which may be resistant while others are not. This may affect the accuracy of the detection of resistance genes. To address this, we aim to develop a methodology capable of mapping all variants.\n",
            "\n",
            "2. Incorrect Publications: The project heavily relies on existing scientific publications to locate resistance genes. If these are incorrect, it could lead to false results and misinterpretation of data. We plan to cross-verify the information from publications with our own research findings.\n",
            "\n",
            "3. High Genomic DNA Background: The presence of too much genomic DNA in the sample could impede the sensitivity of the resistance genes' detection. We aim to adapt our sample preparation to separate parasite DNA and, if necessary, explore cell culturing.\n",
            "\n",
            "Follow the given guidelines\n",
            "Guidelines:Fit the translation response to 800 characters\n",
            "\n",
            "Answer:\u001b[0m\n",
            "\n",
            "\u001b[1m> Finished chain.\u001b[0m\n",
            "Drei primre wissenschaftliche und technische Risiken knnen fr dieses Projekt identifiziert werden:\n",
            "\n",
            "1. Mehrere Stmme in einem Tier: Tiere tragen oft verschiedene Leishmania-Stmme, von denen einige resistent sein knnen, whrend andere es nicht sind. Dies kann die Genauigkeit der Detektion von Resistenzgenen beeinflussen. Um dies zu lsen, streben wir die Entwicklung einer Methodik an, die in der Lage ist, alle Varianten zu kartieren.\n",
            "\n",
            "2. Falsche Verffentlichungen: Das Projekt sttzt sich stark auf vorhandene wissenschaftliche Verffentlichungen, um Resistenzgene zu lokalisieren. Wenn diese falsch sind, kann dies zu falschen Ergebnissen und einer fehlerhaften Interpretation der Daten fhren. Wir planen, die Informationen aus den Verffentlichungen mit unseren eigenen Forschungsergebnissen zu berprfen.\n",
            "\n",
            "3. Hoher genomischer DNA-Hintergrund: Das Vorhandensein von zu viel genomischer DNA in der Probe knnte die Empfindlichkeit der Detektion von Resistenzgenen beeintrchtigen. Wir streben an, unsere Probenvorbereitung anzupassen, um Parasiten-DNA zu separieren und gegebenenfalls Zellkultur zu erforschen.\n",
            "Length of response is 1124 which is 324 characters above ideal\n",
            "####################################################################################################\n",
            "####################################################################################################\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import json\n",
        "with open('/content/drive/MyDrive/Innoscripta/Advanced/Exp1/data_dump_gptv4_translated.json', 'w') as fout:\n",
        "    json.dump(query_list, fout)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 17
        },
        "id": "zKXh1DXOJuDF",
        "outputId": "c1d92576-822d-43d0-e1f3-d80415120507"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "  <style>\n",
              "    pre {\n",
              "        white-space: pre-wrap;\n",
              "    }\n",
              "  </style>\n",
              "  "
            ]
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "EqkNv5jSJ30D"
      },
      "execution_count": null,
      "outputs": []
    }
  ]
}